

IDH1 and *IDH2* Mutations in Gliomas

New England Journal of Medicine

360, 765-773

DOI: 10.1056/nejmoa0808710

Citation Report

#	ARTICLE	IF	CITATIONS
1	Index to Volumes 34, 35 and 36 (1950, 1951 and 1952). Medical Clinics of North America, 1952, 36, 1807-1875.	2.5	0
2	THE POSTOPERATIVE STATUS OF THE DEPENDENT LUNG. The Journal of Thoracic Surgery, 1955, 30, 713-718.	0.7	6
3	Clinical application of the blink reflex with stimulation of the mental nerve in lesions of the inferior alveolar nerve. Neurology, 1994, 44, 2356-2356.	1.1	28
4	AIR DRYERS. , 2000, , 232-241.		1
5	Audio Production and Studio Technology. , 2007, , 375.		0
6	Determinants of $V_{O_2 \max}$ decline with aging: an integrated perspective. Applied Physiology, Nutrition and Metabolism, 2008, 33, 130-140.	1.9	117
7	Genetic Epidemiology of Glioblastoma Multiforme: Confirmatory and New Findings from Analyses of Human Leukocyte Antigen Alleles and Motifs. PLoS ONE, 2009, 4, e7157.	2.5	29
8	<i>IDH1</i> mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology, 2009, 73, 1792-1795.	1.1	176
9	<i>IDH1</i> Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clinical Cancer Research, 2009, 15, 6002-6007.	7.0	604
10	Advances in the genetics of glioblastoma: are we reaching critical mass?. Nature Reviews Neurology, 2009, 5, 419-426.	10.1	105
11	IDH1: function follows form. Science-Business EXchange, 2009, 2, 1749-1749.	0.0	0
12	Anaplastic Glioma: How to Prognosticate Outcome and Choose a Treatment Strategy. Journal of Clinical Oncology, 2009, 27, 5861-5862.	1.6	48
13	Puzzling Patterns of Predisposition. Science, 2009, 324, 192-194.	12.6	55
14	Mutant Metabolic Enzymes Are at the Origin of Gliomas. Cancer Research, 2009, 69, 9157-9159.	0.9	132
15	Isocitrate dehydrogenase mutations in low-grade gliomas. Nature Reviews Neurology, 2009, 5, 303-304.	10.1	5
16	<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas. New England Journal of Medicine, 2009, 360, 2248-2249.	27.0	112
17	Cancer Genomes â€” Continuing Progress. New England Journal of Medicine, 2009, 361, 1111-1112.	27.0	7
18	Hypoxia-induced mediators and neurologic disease. Neurology, 2009, 73, 560-565.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations. PLoS ONE, 2009, 4, e7752.	2.5	450
20	Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. Journal of Cellular and Molecular Medicine, 2009, 13, 4104-4112.	3.6	27
21	Absence of IDH2 codon 172 mutation in common human cancers. International Journal of Cancer, 2009, 125, 2485-2486.	5.1	18
22	The future of neuro-oncology. Acta Neurochirurgica, 2009, 151, 1343-1348.	1.7	4
23	Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathologica, 2009, 117, 653-656.	7.7	71
24	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathologica, 2009, 118, 401-405.	7.7	255
25	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 2009, 118, 469-474.	7.7	1,020
26	Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathologica, 2009, 118, 599-601.	7.7	380
27	Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. Journal of Neuro-Oncology, 2009, 94, 297-297.	2.9	8
28	Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemotherapy and Pharmacology, 2009, 64, 863-866.	2.3	9
29	Analysis of <i>IDH1</i> and <i>IDH2</i> mutations in Japanese glioma patients. Cancer Science, 2009, 100, 1996-1998.	3.9	134
30	Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science, 2009, 100, 2235-2241.	3.9	374
31	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009, 462, 739-744.	27.8	3,315
33	Molecular Epidemiology of Primary Brain Tumors. Neurotherapeutics, 2009, 6, 427-435.	4.4	79
34	Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science, 2009, 324, 1029-1033.	12.6	12,186
35	Genetic signature of adult gliomas and correlation with MRI features. Expert Review of Molecular Diagnostics, 2009, 9, 709-720.	3.1	15
36	Protein Residues That Control the Reaction Trajectory in <i>S</i> -Adenosylmethionine Radical Enzymes: Mutagenesis of Asparagine 153 and Aspartate 155 in <i>Escherichia coli</i> Biotin Synthase. Biochemistry, 2009, 48, 2448-2458.	2.5	21
37	Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers. Cell, 2009, 137, 796-798.	28.9	16

#	ARTICLE	IF	CITATIONS
38	A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and Biophysical Research Communications, 2009, 390, 547-551.	2.1	99
39	Metabolic Enzymes as Oncogenes or Tumor Suppressors. New England Journal of Medicine, 2009, 360, 813-815.	27.0	204
40	Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. New England Journal of Medicine, 2009, 361, 1058-1066.	27.0	2,009
41	Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opinion on Investigational Drugs, 2009, 18, 1061-1083.	4.1	432
42	Glioblastoma multiforme: a review of therapeutic targets. Expert Opinion on Therapeutic Targets, 2009, 13, 701-718.	3.4	138
43	NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 2009, 27, 5874-5880.	1.6	743
44	Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 α . Science, 2009, 324, 261-265.	12.6	1,014
45	Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. British Journal of Neurosurgery, 2009, 23, 351-363.	0.8	48
46	Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations. Cancer Research, 2009, 69, 6660-6667.	0.9	416
47	Cancer genome sequencing: a review. Human Molecular Genetics, 2009, 18, R163-R168.	2.9	185
48	Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. Journal of Clinical Oncology, 2009, 27, 5743-5750.	1.6	534
49	Diagnostic and prognostic markers in gliomas. Current Opinion in Oncology, 2009, 21, 537-542.	2.4	40
50	Combining drugs and radiotherapy: from the bench to the bedside. Current Opinion in Neurology, 2009, 22, 625-632.	3.6	19
51	Classification and management of anaplastic gliomas. Current Opinion in Neurology, 2009, 22, 650-656.	3.6	11
52	Current World Literature. Current Opinion in Neurology, 2009, 22, 681-692.	3.6	0
53	Treatment of recurrent high-grade gliomas. Current Opinion in Neurology, 2009, 22, 657-664.	3.6	30
55	Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. Current Opinion in Neurology, 2009, 22, 619-624.	3.6	8
56	Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1319-1325.	1.7	141

#	ARTICLE	IF	CITATIONS
57	Gliomas: Current Issues in Diagnosis and Treatment. <i>Current Medical Imaging</i> , 2010, 6, 285-294.	0.8	0
58	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. <i>Haematologica</i> , 2010, 95, 1668-1674.	3.5	177
59	Intrathecal Nucleic Acid Injections to Treat Neuropathic Pain. <i>Neurosurgery</i> , 2010, 66, N18-N18.	1.1	0
60	CT Alone May Be Inadequate for Detecting Occult Spinal Injuries. <i>Neurosurgery</i> , 2010, 66, N23-N24.	1.1	0
63	Key Factors Contributing to the Success of Clinician Investigators. <i>Neurosurgery</i> , 2010, 66, N14-N15.	1.1	2
64	Thoughts on Consciousness. <i>Neurosurgery</i> , 2010, 66, N22-N23.	1.1	0
65	A T Cell-Orchestrated Immune Response in the Adult Dorsal Spinal Cord as a Cause of Neuropathic Pain-Like Hypersensitivity After Peripheral Nerve Damage. <i>Neurosurgery</i> , 2010, 66, N24-N25.	1.1	4
66	Glioma Diagnosis: Immunohistochemistry and Beyond. <i>Advances in Anatomic Pathology</i> , 2010, 17, 187-201.	4.3	54
67	Riding the Waves. <i>Neurosurgery</i> , 2010, 66, N15-N16.	1.1	1
68	IDH1 and IDH2 Mutations in Gliomas and the Associated Induction of Hypoxia-Inducible Factor and Production of 2-hydroxyglutarate. <i>Neurosurgery</i> , 2010, 66, N20-N21.	1.1	10
69	Regeneration of Neuromuscular Synapses. <i>Neurosurgery</i> , 2010, 66, N19-N20.	1.1	7
70	Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. <i>Oncology Letters</i> , 2010, 1, 883-884.	1.8	7
71	A Case of Gliomatosis Cerebri Mimicking Limbic Encephalitis: Malignant Transformation to Glioblastoma. <i>Internal Medicine</i> , 2010, 49, 1307-1310.	0.7	24
72	Aberrant Hypermethylation of Non-Promoter Zygote Arrest 1 (Zar1) in Human Brain Tumors. <i>Neurologia Medico-Chirurgica</i> , 2010, 50, 1062-1069.	2.2	17
73	Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. <i>Blood</i> , 2010, 116, 2122-2126.	1.4	345
74	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. <i>Blood</i> , 2010, 115, 2749-2754.	1.4	193
75	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. <i>Blood</i> , 2010, 116, 5486-5496.	1.4	175
76	The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. <i>Blood</i> , 2010, 116, 2779-2782.	1.4	121

#	ARTICLE	IF	CITATIONS
77	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2010, 116, 614-616.	1.4	170
78	A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations. <i>Blood</i> , 2010, 116, 495-496.	1.4	12
79	Forcing Tumor Stem Cells to an End. <i>Neurosurgery</i> , 2010, 66, N17-N18.	1.1	0
80	The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. <i>Advances in Enzyme Regulation</i> , 2010, 50, 44-55.	2.6	69
81	The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes. <i>Science</i> , 2010, 330, 1340-1344.	12.6	1,070
82	The role of mitochondria in pulmonary vascular remodeling. <i>Journal of Molecular Medicine</i> , 2010, 88, 1003-1010.	3.9	94
84	Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. <i>Acta Neuropathologica</i> , 2010, 119, 509-511.	7.7	101
85	The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. <i>Acta Neuropathologica</i> , 2010, 119, 487-494.	7.7	262
86	Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. <i>Acta Neuropathologica</i> , 2010, 119, 501-507.	7.7	108
87	Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. <i>Acta Neuropathologica</i> , 2010, 120, 261-267.	7.7	47
88	Molecular diagnostics of gliomas: state of the art. <i>Acta Neuropathologica</i> , 2010, 120, 567-584.	7.7	243
89	MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 731-743.	7.7	61
90	Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. <i>Acta Neuropathologica</i> , 2010, 120, 719-729.	7.7	255
91	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 707-718.	7.7	719
92	Molecular genetics, imaging and treatment of oligodendroglial tumours. <i>Acta Neurochirurgica</i> , 2010, 152, 1815-1825.	1.7	8
93	The metabolic switch and its regulation in cancer cells. <i>Science China Life Sciences</i> , 2010, 53, 942-958.	4.9	18
94	Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. <i>Targeted Oncology</i> , 2010, 5, 183-191.	3.6	23
95	Molecular markers in gliomas: impact for the clinician. <i>Targeted Oncology</i> , 2010, 5, 201-210.	3.6	21

#	ARTICLE	IF	CITATIONS
96	Newly Diagnosed High-Grade Gliomas. Current Treatment Options in Neurology, 2010, 12, 309-320.	1.8	5
97	Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism. Endocrine, 2010, 38, 397-401.	2.3	9
98	Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Medical Oncology, 2010, 27, 1102-1108.	2.5	38
99	Management of Low-Grade Glioma. Current Neurology and Neuroscience Reports, 2010, 10, 224-231.	4.2	116
100	Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. Journal of Neuro-Oncology, 2010, 99, 209-215.	2.9	65
101	A lower-dose, lower-toxicity cisplatin+etoposide regimen for childhood progressive low-grade glioma. Journal of Neuro-Oncology, 2010, 100, 65-71.	2.9	74
102	Survey of familial glioma and role of germline p16 INK4A /p14 ARF and p53 mutation. Familial Cancer, 2010, 9, 413-421.	1.9	26
103	Neuro-oncology: new hope for patients with gliomas. Lancet Neurology, The, 2010, 9, 17-18.	10.2	2
104	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurology, The, 2010, 9, 717-726.	10.2	251
105	The DNA methylome of glioblastoma multiforme. Neurobiology of Disease, 2010, 39, 40-46.	4.4	50
106	Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas. BMC Cancer, 2010, 10, 454.	2.6	26
107	Multi-site control and regulation of mitochondrial energy production. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 698-709.	1.0	102
108	Metabolic genes in cancer: Their roles in tumor progression and clinical implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 141-152.	7.4	175
109	The "omics" of cancer. Cancer Genetics and Cytogenetics, 2010, 203, 37-42.	1.0	3
110	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17, 98-110.	16.8	6,138
111	IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip. Cancer Cell, 2010, 17, 7-9.	16.8	63
112	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting L-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, 2010, 17, 225-234.	16.8	1,754
113	IDH1 and IDH2: Not Your Typical Oncogenes. Cancer Cell, 2010, 17, 215-216.	16.8	65

#	ARTICLE	IF	CITATIONS
114	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell, 2010, 17, 510-522.	16.8	2,078
115	To Infinium, and Beyond!. Cancer Cell, 2010, 17, 419-420.	16.8	10
116	Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	16.8	2,328
117	The role of p53 in glucose metabolism. Current Opinion in Cell Biology, 2010, 22, 186-191.	5.4	79
118	From Standard Treatment to Personalized Medicine: Role of IDH1 Mutations in Low-Grade Glioma Evolution and Treatment. World Neurosurgery, 2010, 73, 234-236.	1.3	3
119	Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environmental and Molecular Mutagenesis, 2010, 51, 391-405.	2.2	201
120	Integrated genomic profiling identifies candidate genes implicated in glioma genesis and a novel <i>LEO1</i> - <i>SLC12A1</i> fusion gene. Genes Chromosomes and Cancer, 2010, 49, 509-517.	2.8	25
121	Segregation of non-p.R132H mutations in <i>IDH1</i> in distinct molecular subtypes of glioma. Human Mutation, 2010, 31, E1186-E1199.	2.5	90
122	COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Human Mutation, 2010, 31, 1360-1365.	2.5	39
123	Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. International Journal of Cancer, 2010, 126, 2584-2593.	5.1	114
124	Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation. International Journal of Cancer, 2010, 127, 246-247.	5.1	1
125	IDH1 and IDH2 hotspot mutations are not found in canine glioma. International Journal of Cancer, 2010, 127, 245-246.	5.1	29
126	Deregulated signalling networks in human brain tumours. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 476-483.	2.3	31
127	Mutational analysis of <i>FOXL2</i> codon 134 in granulosa cell tumour of ovary and other human cancers. Journal of Pathology, 2010, 221, 147-152.	4.5	122
128	MAPK pathway activation through <i>BRAF</i> gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. Journal of Pathology, 2010, 222, 324-328.	4.5	54
129	The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. Oncogene, 2010, 29, 6138-6148.	5.9	28
130	Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene, 2010, 29, 6409-6417.	5.9	259
131	NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO Journal, 2010, 29, 2659-2674.	7.8	279

#	ARTICLE	IF	CITATIONS
132	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. <i>Leukemia</i> , 2010, 24, 1302-1309.	7.2	300
133	Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. <i>Leukemia</i> , 2010, 24, 1096-1098.	7.2	37
134	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. <i>Leukemia</i> , 2010, 24, 1094-1096.	7.2	225
135	Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. <i>Leukemia</i> , 2010, 24, 909-913.	7.2	87
136	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. <i>Leukemia</i> , 2010, 24, 1128-1138.	7.2	499
137	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. <i>Leukemia</i> , 2010, 24, 1146-1151.	7.2	180
138	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	27.8	2,114
139	Genomics boosts brain-cancer work. <i>Nature</i> , 2010, 463, 278-278.	27.8	12
140	Targeting metabolic transformation for cancer therapy. <i>Nature Reviews Cancer</i> , 2010, 10, 267-277.	28.4	969
141	Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. <i>Nature Reviews Cancer</i> , 2010, 10, 319-331.	28.4	660
142	New cancer targets emerging from studies of the Von Hippelâ€Lindau tumor suppressor protein. <i>Annals of the New York Academy of Sciences</i> , 2010, 1210, 1-7.	3.8	11
143	PCRâ€and Restriction Endonucleaseâ€Based Detection of <i>IDH1</i> Mutations. <i>Brain Pathology</i> , 2010, 20, 298-300.	4.1	58
144	Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas. <i>Brain Pathology</i> , 2010, 20, 539-550.	4.1	324
145	Characterization of R132H Mutationâ€specific IDH1 Antibody Binding in Brain Tumors. <i>Brain Pathology</i> , 2010, 20, 245-254.	4.1	463
146	Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Wellâ€Preserved Histomorphology, Immunohistochemistry and Nucleic Acids. <i>Brain Pathology</i> , 2010, 20, 1010-1020.	4.1	22
147	Polar spongioblastoma: A highâ€grade glioma that does not contain the IDH1 mutation or 1p/19q LOH. <i>Neuropathology</i> , 2010, 30, 547-552.	1.2	2
148	Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. <i>Neuropathology</i> , 2010, 30, 586-596.	1.2	8
149	Les mutations du rÃ©sidu arginine 132 dâ€™IDH1 dans les tumeurs gliales lui confÃ©rent une nouvelle fonction enzymatique. <i>Bulletin Du Cancer</i> , 2010, 97, 289-290.	1.6	0

#	ARTICLE	IF	CITATIONS
150	Oligodendrogliomas. Blue Books of Neurology, 2010, 36, 132-149.	0.1	1
152	Pathology and Molecular Genetics of Common Brain Tumors. Blue Books of Neurology, 2010, 36, 1-36.	0.1	0
153	Génomique des leucémies aiguës myéloïdes de l'adulte. Hematologie, 2010, 16, 9-15.	0.0	0
154	The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmacogenomics and Personalized Medicine, 2010, 3, 111.	0.7	17
155	Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. Journal of Clinical Oncology, 2010, 28, 3061-3068.	1.6	558
156	Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H. Cell Research, 2010, 20, 1188-1200.	12.0	103
157	Prognostic markers in gliomas. Future Oncology, 2010, 6, 733-739.	2.4	17
158	IDH2 Mutations in Patients with -2-Hydroxyglutaric Aciduria. Science, 2010, 330, 336-336.	12.6	177
159	Separating the wheat from the chaff. Neurology, 2010, 74, 1848-1849.	1.1	1
160	Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas. Cancer Research, 2010, 70, 512-519.	0.9	236
161	Epigenetic Downregulation of Mitogen-Activated Protein Kinase Phosphatase MKP-2 Relieves Its Growth Suppressive Activity in Glioma Cells. Cancer Research, 2010, 70, 1689-1699.	0.9	66
162	On Getting There from Here. Science, 2010, 330, 1338-1339.	12.6	104
163	Problems in rare tumor study: a call for papers. Rare Tumors, 2010, 2, 46-47.	0.6	11
164	IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 2348-2355.	1.6	699
165	Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro-Oncology, 2010, 12, 745-755.	1.2	77
166	Update on molecular findings, management and outcome in low-grade gliomas. Nature Reviews Neurology, 2010, 6, 695-701.	10.1	128
167	Genetic variation in pediatric and adult brain tumors. Nature Reviews Neurology, 2010, 6, 653-654.	10.1	5
168	Redefining disease. Clinical Medicine, 2010, 10, 584-594.	1.9	13

#	ARTICLE	IF	CITATIONS
169	<i>IDH1</i> Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?. <i>Oncologist</i> , 2010, 15, 196-199.	3.7	48
170	Malignant Gliomas in Adults. <i>Blue Books of Neurology</i> , 2010, 36, 99-120.	0.1	6
171	Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias. <i>Cancer Research</i> , 2010, 70, 447-452.	0.9	279
172	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. <i>Journal of Experimental Medicine</i> , 2010, 207, 339-344.	8.5	657
173	Metabolism and the leukemic stem cell. <i>Journal of Experimental Medicine</i> , 2010, 207, 677-680.	8.5	70
174	<i>IDH1</i> or <i>IDH2</i> mutations predict longer survival and response to temozolomide in low-grade gliomas. <i>Neurology</i> , 2010, 75, 1560-1566.	1.1	464
175	Association between Epidermal Growth Factor +61 G/A Polymorphism and Glioma Risk in a Chinese Han Population. <i>Journal of International Medical Research</i> , 2010, 38, 1645-1652.	1.0	9
176	Seizures in patients with glioma treated with phenytoin and levetiracetam. <i>Journal of Neurosurgery</i> , 2010, 113, 1176-1181.	1.6	41
177	A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 α . <i>Brain</i> , 2010, 133, 983-995.	7.6	401
178	Identification of several novel non-p.R132 <i>IDH1</i> variants in thyroid carcinomas. <i>European Journal of Endocrinology</i> , 2010, 163, 747-755.	3.7	74
179	Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). <i>Cancer Biology and Therapy</i> , 2010, 10, 582-587.	3.4	79
180	Expression Profiling in Progressive Stages of Fumarate-Hydratase Deficiency: The Contribution of Metabolic Changes to Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 9153-9165.	0.9	63
181	Treatment and management of malignant gliomas. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 75-77.	27.6	24
182	Creation and Validation of a New Animal Model of Intracranial Aneurysms. <i>Neurosurgery</i> , 2010, 66, N16-N17.	1.1	0
183	Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2010, 12, 621-630.	1.2	268
185	Unmasking the multiforme in glioblastoma. <i>Nature Reviews Neurology</i> , 2010, 6, 304-305.	10.1	10
186	Diagnostic and prognostic molecular markers in common adult gliomas. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 637-649.	3.1	5
187	Metabolic Syndromes and Malignant Transformation: Where the Twain Shall Meet. <i>Science Translational Medicine</i> , 2010, 2, 54ps50.	12.4	2

#	ARTICLE	IF	CITATIONS
188	IDH1 mutant structures reveal a mechanism of dominant inhibition. Cell Research, 2010, 20, 1279-1281.	12.0	24
189	Functional genomics to explore cancer cell vulnerabilities. Neurosurgical Focus, 2010, 28, E5.	2.3	7
190	Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1274-1278.	3.6	116
191	Mutations of the Metabolic Genes <i>IDH1</i> , <i>IDH2</i> , and <i>SDHAF2</i> Are Not Major Determinants of the Pseudohypoxic Phenotype of Sporadic Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1469-1472.	3.6	25
193	Oxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration. Current Topics in Microbiology and Immunology, 2010, 345, 71-103.	1.1	21
195	IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications. Haematologica, 2010, 95, 1623-1627.	3.5	23
196	Novel Medical Therapeutics in Glioblastomas, Including Targeted Molecular Therapies, Current and Future Clinical Trials. Neuroimaging Clinics of North America, 2010, 20, 425-448.	1.0	20
198	Nontargeted Elucidation of Metabolic Pathways Using Stable-Isotope Tracers and Mass Spectrometry. Analytical Chemistry, 2010, 82, 6621-6628.	6.5	111
199	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. Future Oncology, 2010, 6, 1407-1414.	2.4	23
200	Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies. Journal of Molecular Diagnostics, 2010, 12, 487-492.	2.8	72
201	Superoxide Dismutase Mimics: Chemistry, Pharmacology, and Therapeutic Potential. Antioxidants and Redox Signaling, 2010, 13, 877-918.	5.4	460
202	The Mitochondrial Proteome and Human Disease. Annual Review of Genomics and Human Genetics, 2010, 11, 25-44.	6.2	497
203	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Molecular Cancer, 2010, 9, 135.	19.2	247
204	Personalized therapies in the cancer "omics" era. Molecular Cancer, 2010, 9, 202.	19.2	52
205	<i>IDH1</i> and <i>IDH2</i> Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With <i>NPM1</i> Mutation Without <i>FLT3</i> Internal Tandem Duplication. Journal of Clinical Oncology, 2010, 28, 3636-3643.	1.6	728
206	Molecular Tools: Biology, Prognosis, and Therapeutic Triage. Neuroimaging Clinics of North America, 2010, 20, 273-282.	1.0	7
207	Impact of <i>IDH1</i> R132 Mutations and an <i>IDH1</i> Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. Journal of Clinical Oncology, 2010, 28, 2356-2364.	1.6	229
208	High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v190-v193.	1.2	262

#	ARTICLE	IF	CITATIONS
209	Prognostic Value of IDH1 Mutations Identified with PCR-RFLP Assay in Glioblastoma Patients. Molecular Diagnosis and Therapy, 2010, 14, 163-169.	3.8	27
210	Ras history. Small GTPases, 2010, 1, 2-27.	1.6	586
211	Mutational Heterogeneity in Human Cancers: Origin and Consequences. Annual Review of Pathology: Mechanisms of Disease, 2010, 5, 51-75.	22.4	210
212	IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine, 2010, 16, 387-397.	6.7	322
216	Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. Current Opinion in Genetics and Development, 2010, 20, 324-329.	3.3	111
217	Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. Current Opinion in Genetics and Development, 2010, 20, 336-341.	3.3	7
218	Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochemical and Biophysical Research Communications, 2010, 393, 555-559.	2.1	122
219	Glioma-derived mutations in IDH: From mechanism to potential therapy. Biochemical and Biophysical Research Communications, 2010, 397, 127-130.	2.1	42
220	IDH1 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications, 2010, 398, 585-587.	2.1	58
221	IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochemical and Biophysical Research Communications, 2010, 402, 378-383.	2.1	38
222	Pheochromocytomas: The (pseudo)-hypoxia hypothesis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 957-968.	4.7	94
223	Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab on A Chip, 2010, 10, 505-511.	6.0	462
224	Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. Cancer Research, 2010, 70, 8981-8987.	0.9	439
225	Peroxisomal localization and function of NADP ⁺ -specific isocitrate dehydrogenases in yeast. Archives of Biochemistry and Biophysics, 2010, 493, 125-134.	3.0	14
226	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	1.6	189
227	All the 1p19q codeleted gliomas are mutated on <i>IDH1</i> or <i>IDH2</i> . Neurology, 2010, 74, 1886-1890.	1.1	240
228	<i>IDH1</i> and <i>IDH2</i> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 2010, 16, 1597-1604.	7.0	364
229	Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer. Journal of Proteome Research, 2010, 9, 6380-6391.	3.7	76

#	ARTICLE	IF	CITATIONS
230	RNAi in Malignant Brain Tumors: Relevance to Molecular and Translational Research. , 2010, , 107-129.		0
231	Molecular Classification of Low-Grade Diffuse Gliomas. American Journal of Pathology, 2010, 177, 2708-2714.	3.8	218
232	Practical molecular diagnostics in neuropathology: making a tough job a little easier. Seminars in Diagnostic Pathology, 2010, 27, 105-113.	1.5	17
233	Somatic Mutations of <i>IDH1</i> and <i>IDH2</i> in the Leukemic Transformation of Myeloproliferative Neoplasms. New England Journal of Medicine, 2010, 362, 369-370.	27.0	268
234	SDHAF2 mutations in familial and sporadic paraganglioma and pheochromocytoma. Lancet Oncology, The, 2010, 11, 366-372.	10.7	256
235	A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples. Journal of Molecular Diagnostics, 2010, 12, 750-756.	2.8	53
236	Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. Journal of the National Cancer Institute, 2010, 102, 932-941.	6.3	448
237	Metabolic Modulation of Glioblastoma with Dichloroacetate. Science Translational Medicine, 2010, 2, 31ra34.	12.4	606
238	Wilms Tumor in a Child with L-2-hydroxyglutaric Aciduria. Pediatric and Developmental Pathology, 2010, 13, 408-411.	1.0	23
239	Astrocytic and Oligodendroglial Tumors. , 2010, , 63-102.		4
240	The expression and significance of IDH1 and p53 in osteosarcoma. Journal of Experimental and Clinical Cancer Research, 2010, 29, 43.	8.6	27
242	Cancer genomics identifies determinants of tumor biology. Genome Biology, 2010, 11, 211.	9.6	17
243	2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas. Expert Review of Neurotherapeutics, 2010, 10, 487-489.	2.8	10
244	Correlation between <i>IDH2</i> mutations and disease status in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 2157-2158.	1.3	1
245	NF- κ B and STAT3 signaling in glioma: targets for future therapies. Expert Review of Neurotherapeutics, 2010, 10, 575-586.	2.8	118
246	IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leukemia and Lymphoma, 2010, 51, 2285-2287.	1.3	7
247	Mutations in <i>CIC</i> and <i>FUBP1</i> Contribute to Human Oligodendroglioma. Science, 2011, 333, 1453-1455.	12.6	485
248	Animal models for glioma drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 1271-1283.	5.0	15

#	ARTICLE	IF	CITATIONS
249	Biology, genetics and imaging of glial cell tumours. British Journal of Radiology, 2011, 84, S90-S106.	2.2	59
250	Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2011, 13, 678-686.	2.8	46
251	Metabolism of glioma and IDH1/IDH2 mutations. Revue Neurologique, 2011, 167, 699-703.	1.5	12
252	Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, 504-515.	1.6	288
253	Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes and Development, 2011, 25, 2436-2452.	5.9	565
255	Histomolecular classification of adult diffuse gliomas: The diagnostic value of immunohistochemical markers. Revue Neurologique, 2011, 167, 683-690.	1.5	26
256	Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research. Neoplasia, 2011, 13, 81-97.	5.3	623
257	52 Chemistry, Biology and Medical Effects of Water-Soluble Metalloporphyrins. Handbook of Porphyrin Science, 2011, , 291-393.	0.8	28
258	A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of α -KG. Biochemistry, 2011, 50, 4804-4812.	2.5	94
259	p53, Aerobic Metabolism, and Cancer. Antioxidants and Redox Signaling, 2011, 15, 1739-1748.	5.4	46
260	Molecular Classification of Gliomas. , 2011, , 9-19.		0
261	Dynamic modeling and analysis of cancer cellular network motifs. Integrative Biology (United) Tj ETQq1 1 0.784314 1.35 BT / Overlock 10 T	1.35	38
263	Metabolomics in Drug Target Discovery. Cold Spring Harbor Symposia on Quantitative Biology, 2011, 76, 235-246.	1.1	75
264	Targeting cancer metabolism: a therapeutic window opens. Nature Reviews Drug Discovery, 2011, 10, 671-684.	46.4	1,227
265	Oncogene addiction in gliomas: Implications for molecular targeted therapy. Journal of Experimental and Clinical Cancer Research, 2011, 30, 58.	8.6	33
266	Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. Journal of Experimental and Clinical Cancer Research, 2011, 30, 76.	8.6	26
267	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics, 2011, 43, 1256-1261.	21.4	488
268	Low-grade gliomas in adults. Journal of Neurosurgery, 2011, 115, 948-965.	1.6	227

#	ARTICLE	IF	CITATIONS
269	Making a Meal of Multiple Mutations in Acute Myeloid Malignancies. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 605-608.	2.8	0
270	Immunoproteomics of HER2-Positive and HER2-Negative Breast Cancer Patients with Positive Lymph Nodes. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 409-418.	2.0	42
271	The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view. <i>Physical Biology</i> , 2011, 8, 015016.	1.8	55
272	Tumors of the Central Nervous System, Volume 2. , 2011, , .		3
273	Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation. <i>American Journal of Pathology</i> , 2011, 178, 1395-1402.	3.8	122
274	Survival of the fittest: metabolic adaptations in cancer. <i>Current Opinion in Genetics and Development</i> , 2011, 21, 59-66.	3.3	23
275	Enzymatic characterization of isocitrate dehydrogenase from an emerging zoonotic pathogen <i>Streptococcus suis</i> . <i>Biochimie</i> , 2011, 93, 1470-1475.	2.6	14
276	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. <i>European Journal of Cancer</i> , 2011, 47, 802-808.	2.8	39
277	Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 608-613.	2.1	46
278	Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. <i>Biochemical and Biophysical Research Communications</i> , 2011, 410, 218-223.	2.1	16
279	Exploring the Genomes of Cancer Cells: Progress and Promise. <i>Science</i> , 2011, 331, 1553-1558.	12.6	606
280	Cancer Cell Metabolism. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2011, 76, 299-311.	1.1	136
281	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1085-1127.	5.4	420
282	5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations. <i>Cancer Research</i> , 2011, 71, 7360-7365.	0.9	400
283	Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. <i>Medical Hypotheses</i> , 2011, 76, 602-603.	1.5	20
284	Revisiting the TCA cycle: signaling to tumor formation. <i>Trends in Molecular Medicine</i> , 2011, 17, 641-649.	6.7	216
285	Mitotic arrest deficient protein MAD2B is overexpressed in human glioma, with depletion enhancing sensitivity to ionizing radiation. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 827-833.	1.5	20
286	Virchow 2011 or How to ID(H) Human Glioblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 4473-4474.	1.6	22

#	ARTICLE	IF	CITATIONS
287	TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation. Cell Stem Cell, 2011, 9, 193-204.	11.1	209
288	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncology, The, 2011, 12, 83-91.	10.7	188
289	Vascular Endothelial Growth Factor +936 C/T Gene Polymorphism and Glioma Risk in a Chinese Han Population. Genetic Testing and Molecular Biomarkers, 2011, 15, 103-106.	0.7	14
290	Unraveling the Genetics of Cancer: Genome Sequencing and Beyond. Annual Review of Genomics and Human Genetics, 2011, 12, 407-430.	6.2	85
291	The Role of IDH1 and IDH2 Mutations in Malignant Gliomas. , 2011, , 47-52.		0
292	Mutations in isocitrate dehydrogenase isoforms 1 and 2 are rare events in primary central nervous system and non-central nervous system diffuse large B cell lymphoma. Basic and Applied Pathology, 2011, 4, 58-62.	0.2	1
293	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research, 2011, 13, 213.	5.0	153
294	Myelodysplastic/myeloproliferative neoplasms. Seminars in Diagnostic Pathology, 2011, 28, 283-297.	1.5	20
295	Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 623-630.	0.8	203
296	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. Hematologie, 2011, 17, 132-144.	0.0	0
297	Title is missing!. , 2011, , xvii-xxiv.		0
298	Biomarkers of Glioma. , 0, , .		3
299	Molecular Hallmarks of Gliomas. , 0, , .		5
300	The Role of Isocitrate Dehydrogenase Mutations in Glioma Brain Tumors. , 0, , .		2
301	Evolvement of Molecular Biomarkers in Targeted Therapy of Malignant Gliomas. , 2011, , .		1
302	Metabolic alterations in cancer cells and therapeutic implications. Chinese Journal of Cancer, 2011, 30, 508-525.	4.9	82
303	Loss of mitochondria in ganglioneuromas. Frontiers in Bioscience - Elite, 2011, E3, 179-186.	1.8	20
304	Childhood Brain Tumors. , 0, , .		0

#	ARTICLE	IF	CITATIONS
305	Genetic Instability in Paediatric and Adult Brain Tumours. , 2011, , .		0
306	Molecular Pathways of Glioblastoma and Glioblastoma Stem Cells. , 0, , .		0
307	Classification of Primary Brain Tumors: Molecular Aspects. , 2011, , .		1
308	The importance of mitochondria in the tumourigenic phenotype: Gliomas as the paradigm (Review). International Journal of Molecular Medicine, 2011, 27, 159-71.	4.0	12
309	Metabolism and Brain Cancer. Clinics, 2011, 66, 33-43.	1.5	96
310	Respiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors. Frontiers in Bioscience - Elite, 2011, E3, 315-325.	1.8	34
311	Emerging Metabolic Targets in Cancer Therapy. Frontiers in Bioscience - Landmark, 2011, 16, 1844.	3.0	70
312	Overview and recent advances in neuropathology. Part 1: Central nervous system tumours. Pathology, 2011, 43, 88-92.	0.6	14
313	BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 2011, 6, e17948.	2.5	268
314	2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations. PLoS ONE, 2011, 6, e16812.	2.5	100
315	Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. PLoS ONE, 2011, 6, e19868.	2.5	71
316	The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. PLoS ONE, 2011, 6, e23332.	2.5	95
317	Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme. PLoS ONE, 2011, 6, e25451.	2.5	239
318	The Accuracy of Survival Time Prediction for Patients with Glioma Is Improved by Measuring Mitotic Spindle Checkpoint Gene Expression. PLoS ONE, 2011, 6, e25631.	2.5	51
319	Genetics of the myeloproliferative neoplasms. Current Opinion in Hematology, 2011, 18, 117-123.	2.5	44
320	Papillary Glioneuronal Tumors. American Journal of Surgical Pathology, 2011, 35, 1794-1805.	3.7	54
321	Clinical trials in neuro-oncology. Current Opinion in Neurology, 2011, 24, 597-598.	3.6	0
322	Single-Copy Gain of Chromosome 1q Is a Negative Prognostic Marker in Pediatric Nonpendymal, Nonpilocytic Gliomas. Neurosurgery, 2011, 68, 206-212.	1.1	21

#	ARTICLE	IF	CITATIONS
323	Supratentorial Primitive Neuroectodermal Tumors of the Central Nervous System in Adults. American Journal of Surgical Pathology, 2011, 35, 573-582.	3.7	27
324	Advances in ultra-high field MRI for the clinical management of patients with brain tumors. Current Opinion in Neurology, 2011, 24, 605-615.	3.6	34
325	Isocitrate dehydrogenase mutations in gliomas. Current Opinion in Neurology, 2011, 24, 648-652.	3.6	75
326	Neuronal-Astrocyte Metabolic Interactions: Understanding the Transition Into Abnormal Astrocytoma Metabolism. Journal of Neuropathology and Experimental Neurology, 2011, 70, 167-176.	1.7	100
327	One Hundred and One Dysembryoplastic Neuroepithelial Tumors: An Adult Epilepsy Series With Immunohistochemical, Molecular Genetic, and Clinical Correlations and a Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2011, 70, 859-878.	1.7	125
328	Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the <i>IDH1-R132H</i> Mutation in Diffuse Glioma Biopsy Specimens. Journal of Neuropathology and Experimental Neurology, 2011, 70, 715-723.	1.7	98
329	Extraventricular neurocytomas: a morphological and histogenetic consideration. A study of six cases. Pathology, 2011, 43, 327-334.	0.6	23
330	Advances in Translational Research in Neuro-oncology. Archives of Neurology, 2011, 68, 303-8.	4.5	4
331	Novel clinical trials in neuro-oncology. Clinical Investigation, 2011, 1, 781-794.	0.0	1
332	IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncology Reports, 2011, 26, 1479-85.	2.6	28
333	Pilocytic Astrocytoma With Histological Malignant Features Without Previous Radiation Therapy -Case Report-. Neurologia Medico-Chirurgica, 2011, 51, 144-147.	2.2	17
334	A glioblastoma arising from the attached region where a meningioma had been totally removed. Neuropathology, 2011, 31, 606-611.	1.2	16
335	Scientific correspondence. Neuropathology and Applied Neurobiology, 2011, 37, 423-427.	3.2	0
336	High incidence of <i>IDH</i> mutations in acute myeloid leukaemia with cuplike nuclei. British Journal of Haematology, 2011, 155, 125-128.	2.5	16
337	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine, 2011, 17, 304-312.	30.7	94
338	Cancer genomics: from discovery science to personalized medicine. Nature Medicine, 2011, 17, 297-303.	30.7	534
339	A close look at cancer. Nature Medicine, 2011, 17, 262-265.	30.7	11
340	Cancer's top papers. Nature Medicine, 2011, 17, 278-279.	30.7	0

#	ARTICLE	IF	CITATIONS
341	Metabolism unhinged: IDH mutations in cancer. <i>Nature Medicine</i> , 2011, 17, 291-293.	30.7	144
342	Regulation of cancer cell metabolism. <i>Nature Reviews Cancer</i> , 2011, 11, 85-95.	28.4	4,100
343	A decade of exploring the cancer epigenome – biological and translational implications. <i>Nature Reviews Cancer</i> , 2011, 11, 726-734.	28.4	2,425
344	Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. <i>Oncogene</i> , 2011, 30, 978-989.	5.9	57
345	Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. <i>Oncogene</i> , 2011, 30, 3813-3820.	5.9	76
346	Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. <i>British Journal of Cancer</i> , 2011, 104, 545-553.	6.4	89
347	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. <i>Leukemia</i> , 2011, 25, 178-181.	7.2	27
348	A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. <i>Leukemia</i> , 2011, 25, 184-186.	7.2	17
349	Charting a course for genomic medicine from base pairs to bedside. <i>Nature</i> , 2011, 470, 204-213.	27.8	823
350	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. <i>Histopathology</i> , 2011, 58, 1167-1172.	2.9	13
351	The Nature and Timing of Specific Copy Number Changes in the Course of Molecular Progression in Diffuse Gliomas: Further Elucidation of Their Genetic ‘Life Story’. <i>Brain Pathology</i> , 2011, 21, 308-320.	4.1	19
352	The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. <i>Brain Pathology</i> , 2011, 21, 74-87.	4.1	150
353	The Use of Global Profiling in Biomarker Development for Gliomas. <i>Brain Pathology</i> , 2011, 21, 88-95.	4.1	19
354	Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas. <i>Brain Pathology</i> , 2011, 21, 564-574.	4.1	55
355	Unraveling the Glioma Epigenome – From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets. <i>Brain Pathology</i> , 2011, 21, 619-632.	4.1	38
356	Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. <i>Neurobiology of Disease</i> , 2011, 44, 84-91.	4.4	98
357	Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges. <i>Seminars in Oncology</i> , 2011, 38, 243-253.	2.2	69
358	IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. <i>Experimental and Molecular Pathology</i> , 2011, 91, 385-393.	2.1	34

#	ARTICLE	IF	CITATIONS
359	Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer, 2011, 11, 325.	2.6	96
360	Genetic insights into OXPHOS defect and its role in cancer. Biochimica Et Biophysica Acta - Bioenergetics, 2011, 1807, 620-625.	1.0	131
361	SDH mutations in cancer. Biochimica Et Biophysica Acta - Bioenergetics, 2011, 1807, 1432-1443.	1.0	327
362	Cell metabolism: An essential link between cell growth and apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 645-654.	4.1	133
363	Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α -Ketoglutarate-Dependent Dioxygenases. Cancer Cell, 2011, 19, 17-30.	16.8	2,340
364	Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain. Cancer Cell, 2011, 19, 305-316.	16.8	249
365	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell, 2011, 20, 11-24.	16.8	1,105
366	Proteomics revisits the cancer metabolome. Expert Review of Proteomics, 2011, 8, 505-533.	3.0	10
367	The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nature Reviews Neuroscience, 2011, 12, 495-508.	10.2	256
368	Predictive and prognostic factors for gliomas. Expert Review of Anticancer Therapy, 2011, 11, 781-789.	2.4	54
369	Molecular Pathogenesis. , 2011, , 27-44.		2
370	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood, 2011, 118, 3932-3941.	1.4	290
371	CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood, 2011, 117, e198-e206.	1.4	143
372	Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Familial Cancer, 2011, 10, 397-411.	1.9	121
373	Mitochondrial Metabolism Inhibitors for Cancer Therapy. Pharmaceutical Research, 2011, 28, 2731-2744.	3.5	45
374	Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. Journal of Neuro-Oncology, 2011, 102, 477-484.	2.9	68
375	Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. Journal of Neuro-Oncology, 2011, 104, 339-349.	2.9	45
376	Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. Journal of Neuro-Oncology, 2011, 105, 219-224.	2.9	36

#	ARTICLE	IF	CITATIONS
377	IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. Journal of Neuro-Oncology, 2011, 105, 345-357.	2.9	86
378	IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. Journal of Neuro-Oncology, 2011, 105, 591-600.	2.9	59
379	Glioblastoma stem cells. Cell and Tissue Research, 2011, 343, 459-465.	2.9	75
380	IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Child's Nervous System, 2011, 27, 87-94.	1.1	152
381	Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathologica, 2011, 121, 241-252.	7.7	124
382	R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 α upregulation in adult glioma. Acta Neuropathologica, 2011, 121, 279-281.	7.7	67
383	Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathologica, 2011, 121, 753-761.	7.7	46
384	High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas. Acta Neuropathologica, 2011, 122, 367-369.	7.7	16
385	High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. Brain Tumor Pathology, 2011, 28, 107-114.	1.7	19
386	Non-promoter hypermethylation of zygote arrest 1 (ZAR1) in human brain tumors. Brain Tumor Pathology, 2011, 28, 199-202.	1.7	7
387	Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathology, 2011, 28, 115-123.	1.7	96
388	Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathology, 2011, 28, 177-183.	1.7	146
389	Loss of heterozygosity analysis in malignant gliomas. Brain Tumor Pathology, 2011, 28, 191-196.	1.7	22
390	New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. Brain Tumor Pathology, 2011, 28, 203-208.	1.7	7
392	Inborn and acquired metabolic defects in cancer. Journal of Molecular Medicine, 2011, 89, 213-220.	3.9	132
393	High-Grade Gliomas. Current Treatment Options in Neurology, 2011, 13, 386-399.	1.8	26
394	The neuropathological spectrum of brain tumours in children and adolescents. Memo - Magazine of European Medical Oncology, 2011, 4, 6-9.	0.5	0
395	Can metabolic plasticity be a cause for cancer? Warburg's "Waddington legacy revisited. Clinical Epigenetics, 2011, 2, 113-122.	4.1	12

#	ARTICLE	IF	CITATIONS
396	Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. <i>Clinical Epigenetics</i> , 2011, 2, 197-212.	4.1	36
397	Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. <i>Tumor Biology</i> , 2011, 32, 325-333.	1.8	25
398	Genomic Profiles of Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 291-297.	4.2	39
399	Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment. <i>Current Oncology Reports</i> , 2011, 13, 26-36.	4.0	5
400	Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. <i>Molecular Cancer</i> , 2011, 10, 17.	19.2	51
401	The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation. <i>Molecular Cancer</i> , 2011, 10, 83.	19.2	49
402	Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?. <i>Radiation Oncology</i> , 2011, 6, 115.	2.7	99
403	MiRNA expression patterns predict survival in glioblastoma. <i>Radiation Oncology</i> , 2011, 6, 153.	2.7	50
404	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. <i>Journal of Pathology</i> , 2011, 224, 334-343.	4.5	834
405	Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. <i>Journal of Pathology</i> , 2011, 225, 4-11.	4.5	225
406	Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. <i>Pediatric Blood and Cancer</i> , 2011, 56, 379-383.	1.5	28
407	Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1. <i>Proteomics</i> , 2011, 11, 4139-4154.	2.2	12
408	IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. <i>Annals of Neurology</i> , 2011, 69, 455-463.	5.3	132
409	NOA05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. <i>Annals of Neurology</i> , 2011, 70, 445-453.	5.3	54
410	Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. <i>American Journal of Hematology</i> , 2011, 86, 393-398.	4.1	23
411	Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. <i>Glia</i> , 2011, 59, 1200-1204.	4.9	44
412	Molecular subclassification of diffuse gliomas: Seeing order in the chaos. <i>Glia</i> , 2011, 59, 1190-1199.	4.9	201
413	Benefits of interferon- γ and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter. <i>Cancer</i> , 2011, 117, 1721-1730.	4.1	85

#	ARTICLE	IF	CITATIONS
414	Alpha-Internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. <i>Cancer</i> , 2011, 117, 3014-3026.	4.1	32
415	Cancer genome variation in children, adolescents, and young adults. <i>Cancer</i> , 2011, 117, 2262-2267.	4.1	4
416	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. <i>International Journal of Cancer</i> , 2011, 128, 1095-1103.	5.1	75
417	Validation of EORTC Prognostic Factors for Adults With Low-Grade Glioma: A Report Using Intergroup 86-72-51. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 218-224.	0.8	118
418	Independent prognostic variables in acute myeloid leukaemia. <i>Blood Reviews</i> , 2011, 25, 39-51.	5.7	93
419	Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?. <i>Clinical Cancer Research</i> , 2011, 17, 4588-4599.	7.0	179
420	Genomic alterations and the pathogenesis of glioblastoma. <i>Cell Cycle</i> , 2011, 10, 1174-1175.	2.6	4
421	Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4482-4490.	1.6	420
422	Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. <i>Leukemia</i> , 2011, 25, 1704-1710.	7.2	73
423	DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma. <i>Journal of the National Cancer Institute</i> , 2011, 103, 143-153.	6.3	224
424	Molecular profile of oligodendrogliomas in young patients. <i>Neuro-Oncology</i> , 2011, 13, 1099-1106.	1.2	43
425	Uncommon Presentations of Uncommon Conditions. <i>Journal of Neuro-Ophthalmology</i> , 2011, 31, 297-298.	0.8	0
426	Genomics of Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 487-491.	2.0	20
427	Characterization of Molecular Genetic Alterations in GBMs Highlights a Distinctive Molecular Profile in Young Adults. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 225-232.	2.1	43
428	Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. <i>Neuro-Oncology</i> , 2011, 13, 1244-1251.	1.2	85
429	Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. <i>Journal of Experimental Medicine</i> , 2011, 208, 313-326.	8.5	639
430	A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas. <i>Clinical Cancer Research</i> , 2011, 17, 317-327.	7.0	73
431	Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. <i>Journal of Clinical Pathology</i> , 2011, 64, 835-844.	2.0	43

#	ARTICLE	IF	CITATIONS
432	<i>ΔNFKBIA</i> Deletion in Glioblastomas. New England Journal of Medicine, 2011, 364, 627-637.	27.0	220
433	Understanding the Enemy. Science Translational Medicine, 2011, 3, 98ps37.	12.4	4
434	Low-grade gliomas in adults. Journal of Neurosurgery, 2011, , 1-18.	1.6	98
435	A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncology, 2011, 7, 873-894.	2.4	12
436	Differential Retinoic Acid Signaling in Tumors of Long- and Short-term Glioblastoma Survivors. Journal of the National Cancer Institute, 2011, 103, 598-601.	6.3	46
437	Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12384-12389.	7.1	40
438	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3270-3275.	7.1	390
439	Next Generation Radiologic-Pathologic Correlation in Oncology: Rad-Path 2.0. American Journal of Roentgenology, 2011, 197, 990-997.	2.2	29
440	Hot spots in dynamic ¹⁸ FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology, 2011, 13, 307-316.	1.2	215
441	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro-Oncology, 2011, 13, 235-241.	1.2	60
442	IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia, 2011, 25, 1570-1577.	7.2	80
443	Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S7685.	1.3	34
444	Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1 ^{R132} Mutation Effects in Human Glioblastoma. Journal of Histochemistry and Cytochemistry, 2011, 59, 489-503.	2.5	29
445	<i>TET2</i> promoter methylation in low-grade diffuse gliomas lacking <i>IDH1/2</i> mutations: Figure 1. Journal of Clinical Pathology, 2011, 64, 850-852.	2.0	65
446	Stem Cells in Brain Tumor Development. Current Topics in Developmental Biology, 2011, 94, 15-44.	2.2	14
447	Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Human Molecular Genetics, 2011, 20, 497-509.	2.9	56
449	The changing face of brain tumours. British Journal of Radiology, 2011, 84, S79-S81.	2.2	0
450	A Sensitive and Specific Diagnostic Panel to Distinguish Diffuse Astrocytoma From Astrocytosis: Chromosome 7 Gain With Mutant Isocitrate Dehydrogenase 1 and p53. Journal of Neuropathology and Experimental Neurology, 2011, 70, 110-115.	1.7	67

#	ARTICLE	IF	CITATIONS
451	Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. British Journal of Cancer, 2011, 105, 1235-1243.	6.4	22
452	Advances in malignant glioma drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 739-753.	5.0	16
453	Novel ways to target brain tumour metabolism. Expert Opinion on Therapeutic Targets, 2011, 15, 1227-1239.	3.4	13
454	Acute Myeloid Leukemia With <i>IDH1</i> or <i>IDH2</i> Mutation. American Journal of Clinical Pathology, 2011, 135, 35-45.	0.7	145
455	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology, 2011, 22, 2616-2624.	1.2	326
456	Autophagy, Stress, and Cancer Metabolism: What Doesn't Kill You Makes You Stronger. Cold Spring Harbor Symposia on Quantitative Biology, 2011, 76, 389-396.	1.1	101
457	Genetic Alterations in Glioma. Cancers, 2011, 3, 1129-1140.	3.7	24
458	Use of in Vivo Two-dimensional MR Spectroscopy to Compare the Biochemistry of the Human Brain to That of Glioblastoma. Radiology, 2011, 259, 540-549.	7.3	36
459	The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma. Japanese Journal of Clinical Oncology, 2011, 41, 190-196.	1.3	11
460	Elevated citrate in pediatric astrocytomas with malignant progression. Neuro-Oncology, 2011, 13, 1107-1117.	1.2	31
461	Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?. Neuro-Oncology, 2011, 13, 1262-1264.	1.2	6
462	Role of isocitrate dehydrogenase in glioma. Expert Review of Neurotherapeutics, 2011, 11, 1399-1409.	2.8	15
463	Aberrant Signaling Pathways in Glioma. Cancers, 2011, 3, 3242-3278.	3.7	178
464	Les tumeurs gliales malignes de l'adulte. , 2011, , 591-612.		0
465	Oncogenic extracellular vesicles in brain tumor progression. Frontiers in Physiology, 2012, 3, 294.	2.8	95
466	Molecular biology of brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 23-34.	1.8	11
467	CD166/Activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro-Oncology, 2012, 14, 1254-1264.	1.2	47
468	TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. International Journal of Cell Biology, 2012, 2012, 1-9.	2.5	133

#	ARTICLE	IF	CITATIONS
469	Interactions between epigenetics and metabolism in cancers. <i>Frontiers in Oncology</i> , 2012, 2, 163.	2.8	67
470	Metabolomic Analysis of Bone Morphogenetic Protein Receptor Type 2 Mutations in Human Pulmonary Endothelium Reveals Widespread Metabolic Reprogramming. <i>Pulmonary Circulation</i> , 2012, 2, 201-213.	1.7	121
471	Clear Cell Tumors of the Central Nervous System: A Case-Based Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 915-926.	2.5	3
472	Quantitative Analysis of Energy Metabolic Pathways in MCF-7 Breast Cancer Cells by Selected Reaction Monitoring Assay. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 422-434.	3.8	82
473	Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers. <i>Cancer Research</i> , 2012, 72, 2428-2439.	0.9	124
474	Novel Delivery Strategies for Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 89-99.	2.0	109
475	Management of Malignant Gliomas and Primary CNS Lymphoma. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2012, 18, 406-415.	0.8	10
476	Molecular predictors of outcome in low-grade glioma. <i>Current Opinion in Neurology</i> , 2012, 25, 767-773.	3.6	54
477	Individualized Targeted Therapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 40-44.	2.0	64
478	Oligodendrogliomas. <i>Current Opinion in Oncology</i> , 2012, 24, 687-693.	2.4	24
479	Pyrosequencing of IDH1 and IDH2 Mutations in Brain Tumors and Non-neoplastic Conditions. <i>Diagnostic Molecular Pathology</i> , 2012, 21, 214-220.	2.1	17
480	Gliosis Versus Glioma?. <i>Advances in Anatomic Pathology</i> , 2012, 19, 239-249.	4.3	40
481	The Molecular Basis for Novel Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 32-39.	2.0	5
482	Biphasic Papillary and Lobular Breast Carcinoma With PIK3CA and IDH1 Mutations. <i>Diagnostic Molecular Pathology</i> , 2012, 21, 221-224.	2.1	13
483	A heterozygous <i>IDH1</i> ^{R132H/WT} mutation induces genome-wide alterations in DNA methylation. <i>Genome Research</i> , 2012, 22, 2339-2355.	5.5	157
484	Cancer-Associated Isocitrate Dehydrogenase Mutations. <i>Oncologist</i> , 2012, 17, 5-8.	3.7	18
485	Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT). <i>Journal of Biological Chemistry</i> , 2012, 287, 42180-42194.	3.4	86
486	Magnetic Resonance of 2-Hydroxyglutarate in <i>IDH1</i> -Mutated Low-Grade Gliomas. <i>Science Translational Medicine</i> , 2012, 4, 116ra5.	12.4	161

#	ARTICLE	IF	CITATIONS
487	The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism. Cancer Research, 2012, 72, 5878-5888.	0.9	147
488	Design and use of biomarkers for the current and future clinical management of brain tumors. Biomarkers in Medicine, 2012, 6, 293-295.	1.4	2
489	Molecular markers in pediatric neuro-oncology. Neuro-Oncology, 2012, 14, iv90-iv99.	1.2	30
490	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro-Oncology, 2012, 14, 1465-1472.	1.2	35
491	Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets. Clinical Cancer Research, 2012, 18, 2768-2779.	7.0	88
492	Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis. Archives of Neurology, 2012, 69, 523.	4.5	148
493	Rare and uncommon genetic variants may hold key to the “missing heritability” in glioma. CNS Oncology, 2012, 1, 109-112.	3.0	1
494	Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?. CNS Oncology, 2012, 1, 137-148.	3.0	6
495	Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas. Current Cancer Drug Targets, 2012, 12, 1016-1031.	1.6	19
496	Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics, 2012, 7, 201-207.	2.7	110
497	Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. Current Cancer Drug Targets, 2012, 12, 197-209.	1.6	196
498	Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics, 2012, 28, 167-175.	4.1	130
499	Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis. Journal of Neurosurgery, 2012, 117, 476-485.	1.6	9
500	Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas. Cancer Biology and Therapy, 2012, 13, 836-839.	3.4	11
501	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 2012, 14, iv100-iv108.	1.2	154
502	An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology, 2012, 14, 184-191.	1.2	145
503	LOW GRADE GLIOMAS. Neuro-Oncology, 2012, 14, i69-i81.	1.2	5
504	HIGH GRADE GLIOMAS. Neuro-Oncology, 2012, 14, i56-i68.	1.2	2

#	ARTICLE	IF	CITATIONS
505	Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies. British Journal of Cancer, 2012, 106, 1816-1825.	6.4	8
506	Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene, 2012, 31, 1995-2006.	5.9	42
507	Differential distribution of CCDC26 glioma-risk alleles in myeloid malignancies with mutant IDH1 compared with their IDH2R140-mutated or IDH-unmutated counterparts. Leukemia, 2012, 26, 1406-1407.	7.2	6
508	Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis. Molecular and Cellular Proteomics, 2012, 11, M111.008821.	3.8	52
509	A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nature Genetics, 2012, 44, 1122-1125.	21.4	131
510	Magnetic Resonance Metabolic Imaging of Glioma. Science Translational Medicine, 2012, 4, 116ps1.	12.4	5
512	Increased Immune Gene Expression and Immune Cell Infiltration in High-Grade Astrocytoma Distinguish Long-Term from Short-Term Survivors. Journal of Immunology, 2012, 189, 1920-1927.	0.8	62
514	Frequent Mutation of Isocitrate Dehydrogenase <i>(IDH)1</i> and <i>IDH2</i> in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist, 2012, 17, 72-79.	3.7	629
515	Moving toward molecular classification of diffuse gliomas in adults. Neurology, 2012, 79, 1917-1926.	1.1	70
516	Promoter Methylation Analysis of IDH Genes in Human Gliomas. Frontiers in Oncology, 2012, 2, 193.	2.8	5
517	Immunohistochemical expression of IDH1 in gliomas: A tissue microarray-based approach. Journal of Cancer Research and Therapeutics, 2012, 8, 598.	0.9	30
518	The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells. International Journal of Cell Biology, 2012, 2012, 1-12.	2.5	89
519	Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events. Journal of Signal Transduction, 2012, 2012, 1-9.	2.0	13
520	The emerging role of fumarate as an oncometabolite. Frontiers in Oncology, 2012, 2, 85.	2.8	140
521	Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors. Cancer Research, 2012, 72, 636-644.	0.9	56
522	An analysis of substitution, deletion and insertion mutations in cancer genes. Nucleic Acids Research, 2012, 40, 6401-6413.	14.5	47
523	Studying a Complex Tumor. Cancer Journal (Sudbury, Mass), 2012, 18, 107-114.	2.0	26
524	Detection of 2-Hydroxyglutarate in <i>IDH</i>-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Science Translational Medicine, 2012, 4, 116ra4.	12.4	367

#	ARTICLE	IF	CITATIONS
525	IDH1 mutation of gliomas with long-term survival analysis. <i>Oncology Reports</i> , 2012, 28, 1639-1644.	2.6	38
526	Lentiviral expression of anti-microRNAs targeting miR-27a inhibits proliferation and invasiveness of U87 glioma cells. <i>Molecular Medicine Reports</i> , 2012, 6, 275-281.	2.4	24
528	Detection of IDH1 R132H Mutation in Acute Myeloid Leukemia by Mutation-specific Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 37-40.	1.2	8
529	Epidermal growth factor receptor. <i>Current Opinion in Neurology</i> , 2012, 25, 774-779.	3.6	79
530	Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review). <i>Oncology Letters</i> , 2012, 3, 7-10.	1.8	2
531	<i>BRAF</i> Duplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 789-795.	1.7	59
532	Cilengitide in bevacizumab-refractory high-grade glioma. <i>Anti-Cancer Drugs</i> , 2012, 23, 749-753.	1.4	2
533	Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. <i>Current Opinion in Oncology</i> , 2012, 24, 83-89.	2.4	52
534	EDL-291, a novel isoquinoline, presents antiglioblastoma effects in vitro and in vivo. <i>Anti-Cancer Drugs</i> , 2012, 23, 494-504.	1.4	3
535	Cerebral Neoplasms in L-2 Hydroxyglutaric Aciduria: 3 New Cases and Meta-Analysis of Literature Data. <i>American Journal of Neuroradiology</i> , 2012, 33, 940-943.	2.4	56
536	Mapping genes for oligodendroglioma. <i>Personalized Medicine</i> , 2012, 9, 311-313.	1.5	0
537	Molecular genetics of acute myeloid leukemia. , 0, , 204-238.		2
538	IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. <i>International Journal of Oncology</i> , 2012, 41, 1325-1336.	3.3	67
539	Glioblastoma with primitive neuroectodermal tumour-like components. <i>Pathology</i> , 2012, 44, 270-273.	0.6	9
540	Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. <i>International Journal of Oncology</i> , 2012, 41, 1029-1035.	3.3	52
542	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2012, 119, 1901-1903.	1.4	435
543	The Application of the Next-Generation Sequencing Technologies in Cancer Research. , 2012, , 227-258.		0
544	Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. <i>International Journal of Oncology</i> , 2012, 40, 2058-62.	3.3	23

#	ARTICLE	IF	CITATIONS
546	Primary brain tumours in adults. Lancet, The, 2012, 379, 1984-1996.	13.7	723
547	How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature, 2012, 491, 364-373.	27.8	800
548	Fluorescence Lifetime Spectroscopy and Imaging in Neurosurgery. IEEE Journal of Selected Topics in Quantum Electronics, 2012, 18, 1465-1477.	2.9	22
549	IDH Mutation Detection in Formalinâ€Fixed Paraffinâ€Embedded Gliomas Using Multiplex PCR and Singleâ€Base Extension. Brain Pathology, 2012, 22, 619-624.	4.1	21
550	Genetically-defined metabolic reprogramming in cancer. Trends in Endocrinology and Metabolism, 2012, 23, 552-559.	7.1	72
551	Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate. Acta Neuropathologica, 2012, 124, 883-891.	7.7	58
552	Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood, 2012, 120, 4649-4652.	1.4	116
553	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. Journal of the National Cancer Institute, 2012, 104, 1458-1469.	6.3	56
554	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-Î² Signaling in Glioblastoma. Cancer Discovery, 2012, 2, 736-749.	9.4	99
555	Immunohistochemical analysisâ€based proteomic subclassification of newly diagnosed glioblastomas. Cancer Science, 2012, 103, 1871-1879.	3.9	42
556	Prospective, high-throughput molecular profiling of human gliomas. Journal of Neuro-Oncology, 2012, 110, 89-98.	2.9	47
557	Genome-wide association study of glioma and meta-analysis. Human Genetics, 2012, 131, 1877-1888.	3.8	222
558	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathologica, 2012, 124, 615-625.	7.7	376
559	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes and Development, 2012, 26, 2038-2049.	5.9	257
560	Reactive Oxygen Species in Cancer Stem Cells. Antioxidants and Redox Signaling, 2012, 16, 1215-1228.	5.4	275
561	Targeting Cancer Metabolism. Clinical Cancer Research, 2012, 18, 5537-5545.	7.0	125
562	<i>IDH1</i> and <i>IDH2</i> Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clinical Cancer Research, 2012, 18, 5562-5571.	7.0	341
563	Nuclear Exclusion of TET1 Is Associated with Loss of 5-Hydroxymethylcytosine in IDH1 Wild-Type Gliomas. American Journal of Pathology, 2012, 181, 675-683.	3.8	98

#	ARTICLE	IF	CITATIONS
564	Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation. <i>Journal of Biological Chemistry</i> , 2012, 287, 14615-14620.	3.4	140
565	IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. <i>Neuropathology</i> , 2012, 32, 30-37.	1.2	18
566	Detection of 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. <i>Journal of Molecular Medicine</i> , 2012, 90, 1161-1171.	3.9	77
567	Malignant transformation in pediatric spinal intramedullary tumors: case-based update. <i>Child's Nervous System</i> , 2012, 28, 1679-1686.	1.1	19
568	Papillary glioneuronal tumor—a rare entity: report of four cases and brief review of literature. <i>Child's Nervous System</i> , 2012, 28, 1897-1904.	1.1	23
569	Molecular markers of glioma: an update on recent progress and perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1971-1981.	2.5	51
570	MR imaging findings of extraventricular neurocytoma: a series of ten patients confirmed by immunohistochemistry of IDH1 gene mutation. <i>Acta Neurochirurgica</i> , 2012, 154, 1973-1980.	1.7	19
571	Anaplastic oligodendroglioma with ganglioglioma-like maturation. <i>Brain Tumor Pathology</i> , 2012, 29, 221-228.	1.7	13
572	Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. <i>Brain Tumor Pathology</i> , 2012, 29, 201-206.	1.7	83
573	Molecular characteristics of glioblastoma with 1p/19q co-deletion. <i>Brain Tumor Pathology</i> , 2012, 29, 148-153.	1.7	27
574	Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. <i>Brain Tumor Pathology</i> , 2012, 29, 183-191.	1.7	9
575	IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. <i>International Journal of Clinical Oncology</i> , 2012, 17, 551-561.	2.2	43
576	IDH1 mutations inhibit multiple α -ketoglutarate-dependent dioxygenase activities in astroglioma. <i>Journal of Neuro-Oncology</i> , 2012, 109, 253-260.	2.9	27
577	Nuclear karyopherin $\alpha 2$: a novel biomarker for infiltrative astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 545-553.	2.9	49
578	Analysis of NADP ⁺ -dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation. <i>Journal of Neuro-Oncology</i> , 2012, 109, 477-484.	2.9	11
579	Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. <i>Journal of Neuro-Oncology</i> , 2012, 110, 205-213.	2.9	32
580	Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 279-285.	2.9	29
581	The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 325-333.	2.9	69

#	ARTICLE	IF	CITATIONS
582	IDH1 Mutations Disrupt Blood, Brain, and Barriers. <i>Cancer Cell</i> , 2012, 22, 285-287.	16.8	11
583	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	16.8	1,551
584	Redox regulation of the epigenetic landscape in Cancer: A role for metabolic reprogramming in remodeling the epigenome. <i>Free Radical Biology and Medicine</i> , 2012, 53, 2178-2187.	2.9	56
585	Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. <i>EMC - Neurologia</i> , 2012, 12, 1-14.	0.0	0
586	Something Old and Something New About Molecular Diagnostics in Gliomas. <i>Surgical Pathology Clinics</i> , 2012, 5, 919-939.	1.7	12
587	IDH Mutations in Human Glioma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 471-480.	1.7	53
588	IDH mutation status in prostate cancer. <i>Oncogene</i> , 2012, 31, 3826-3826.	5.9	59
589	Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: Marker or maker of the diabetic phenotype?. <i>Archives of Physiology and Biochemistry</i> , 2012, 118, 156-189.	2.1	51
590	Alterations of metabolic genes and metabolites in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2012, 23, 370-380.	5.0	100
591	New aspects of the Warburg effect in cancer cell biology. <i>Seminars in Cell and Developmental Biology</i> , 2012, 23, 352-361.	5.0	262
592	IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. <i>Clinical Cancer Research</i> , 2012, 18, 2490-2501.	7.0	127
593	GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct. <i>Hpb</i> , 2012, 14, 677-683.	0.3	48
594	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG <i>in Vivo</i> . <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 850-855.	2.8	175
595	Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2641-2647.	1.6	348
596	Emerging Epigenetic Targets and Therapies in Cancer Medicine. <i>Cancer Discovery</i> , 2012, 2, 405-413.	9.4	106
597	Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 635-642.	2.4	109
598	Nature versus Nurture in Glioblastoma. <i>American Journal of Pathology</i> , 2012, 180, 1768-1771.	3.8	5
599	Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 161-170.	1.3	22

#	ARTICLE	IF	CITATIONS
600	RNA interference targeting cytosolic NADP+-dependent isocitrate dehydrogenase exerts anti-obesity effect in vitro and in vivo. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1181-1188.	3.8	20
601	IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 423, 553-556.	2.1	21
602	Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1 α and β -catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 770-775.	2.8	48
603	Genetically engineered mouse models of diffuse gliomas. <i>Brain Research Bulletin</i> , 2012, 88, 72-79.	3.0	22
604	Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us?. <i>Cell</i> , 2012, 148, 1132-1144.	28.9	684
605	Mitochondria: In Sickness and in Health. <i>Cell</i> , 2012, 148, 1145-1159.	28.9	2,411
606	Metabolic Regulation of Epigenetics. <i>Cell Metabolism</i> , 2012, 16, 9-17.	16.2	568
607	Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. <i>Current Opinion in Genetics and Development</i> , 2012, 22, 45-49.	3.3	43
608	Opening Pandora's Box—the new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. <i>Current Opinion in Genetics and Development</i> , 2012, 22, 3-9.	3.3	34
609	Glioblastoma research 2006–2010: Pattern of citation and systematic review of highly cited articles. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1207-1210.	1.4	12
610	Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. <i>Seminars in Cell and Developmental Biology</i> , 2012, 23, 362-369.	5.0	310
611	Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1247-1266.	4.1	50
612	Gatekeepers of chromatin: Small metabolites elicit big changes in gene expression. <i>Trends in Biochemical Sciences</i> , 2012, 37, 477-483.	7.5	40
613	Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. <i>BMC Cancer</i> , 2012, 12, 375.	2.6	36
614	Genetics of adult glioma. <i>Cancer Genetics</i> , 2012, 205, 613-621.	0.4	737
615	Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 370-384.	7.4	177
616	Enzyme redesign guided by cancer-derived IDH1 mutations. <i>Nature Chemical Biology</i> , 2012, 8, 887-889.	8.0	22
617	The future of glioma treatment: stem cells, nanotechnology and personalized medicine. <i>Future Oncology</i> , 2012, 8, 1149-1156.	2.4	19

#	ARTICLE	IF	CITATIONS
618	Epigenetic Alterations in Glioblastoma Multiforme. , 2012, , 71-90.		1
619	<i>KIAA1549&BRAF</i> Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults. Brain Pathology, 2012, 22, 841-847.	4.1	55
620	Mitochondria and Cancer: A Growing Role in Apoptosis, Cancer Cell Metabolism and Dedifferentiation. Advances in Experimental Medicine and Biology, 2012, 942, 287-308.	1.6	119
621	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
622	Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China. PLoS ONE, 2012, 7, e30339.	2.5	114
623	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature Medicine, 2012, 18, 624-629.	30.7	711
624	Identification of additional IDH mutations associated with oncometabolite R(̂)-2-hydroxyglutarate production. Oncogene, 2012, 31, 2491-2498.	5.9	172
625	Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients. PLoS ONE, 2012, 7, e32764.	2.5	43
626	Glioblastoma cancer stem cells: Basis for a functional hypothesis. Stem Cell Discovery, 2012, 02, 122-131.	0.5	9
627	A Simplified Approach for the Molecular Classification of Glioblastomas. PLoS ONE, 2012, 7, e45475.	2.5	52
628	<i>In Vivo</i> Detection of Brain Krebs Cycle Intermediate by Hyperpolarized Magnetic Resonance. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2108-2113.	4.3	72
629	Overview of Primary Brain Tumors. Hematology/Oncology Clinics of North America, 2012, 26, 715-732.	2.2	29
630	A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 423-433.	7.4	79
631	Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Human Pathology, 2012, 43, 1552-1558.	2.0	211
632	IDH mutations in acute myeloid leukemia. Human Pathology, 2012, 43, 1541-1551.	2.0	103
633	Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Annals of Diagnostic Pathology, 2012, 16, 255-259.	1.3	17
634	Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer. Kaohsiung Journal of Medical Sciences, 2012, 28, 138-144.	1.9	11
635	Biomarker Discovery in Central Nervous System Neoplasms: Past, Present and Future. , 2012, , 107-119.		0

#	ARTICLE	IF	CITATIONS
636	In vivo models of primary brain tumors: pitfalls and perspectives. <i>Neuro-Oncology</i> , 2012, 14, 979-993.	1.2	211
637	IDH1 Mutations in Diffusely Infiltrating Astrocytomas. <i>American Journal of Clinical Pathology</i> , 2012, 138, 177-184.	0.7	31
638	Cancer metabolism: current perspectives and future directions. <i>Cell Death and Disease</i> , 2012, 3, e248-e248.	6.3	327
639	Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas. <i>Current Treatment Options in Oncology</i> , 2012, 13, 417-436.	3.0	25
640	RANK (TNFRSF11A) Is Epigenetically Inactivated and Induces Apoptosis in Gliomas. <i>Neoplasia</i> , 2012, 14, 526-IN12.	5.3	25
644	Low-Grade Gliomas. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 797-809.	2.2	6
645	Advances in Mitochondrial Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2012, , .	1.6	17
648	Systems Metabolic Engineering. , 2012, , .		11
649	Glioblastoma and malignant astrocytoma. , 2012, , 384-407.		3
650	Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma. <i>PLoS ONE</i> , 2012, 7, e41036.	2.5	152
651	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. <i>PLoS ONE</i> , 2012, 7, e41298.	2.5	43
652	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. <i>PLoS ONE</i> , 2012, 7, e45950.	2.5	25
653	EGFR Gene Variants Are Associated with Specific Somatic Aberrations in Glioma. <i>PLoS ONE</i> , 2012, 7, e47929.	2.5	10
654	Histopathology of brain tumors. , 2012, , 138-187.		0
655	Tumors of the Central Nervous System and Intracranial Hypertension and Hypotension. , 2012, , 1246-1257.		0
656	Carbon Source Metabolism and Its Regulation in Cancer Cells. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2012, 22, 17-35.	0.9	53
658	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
659	Glioblastoma: Biology, Genetics, and Behavior. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 102-107.	3.8	11

#	ARTICLE	IF	CITATIONS
661	Establishing the Standard of Care for Patients with Newly Diagnosed and Recurrent Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 112-117.	3.8	0
662	Future Directions in Glioblastoma Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 108-111.	3.8	2
664	Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evidence, 2012, 7, 93.	4.7	39
665	Survival in Patients with Newly Diagnosed Conventional Glioblastoma: A Modified Prognostic Score Based on a Single-Institution Series. Tumori, 2012, 98, 756-761.	1.1	4
666	Molecular biomarkers of glioblastoma: current targets and clinical implications. Current Biomarker Findings, 0, , 63.	0.4	4
667	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.	1.8	532
668	Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF- κ B/MMP-9 pathway. Journal of Pathology, 2012, 226, 534-543.	4.5	33
669	Links between metabolism and cancer. Genes and Development, 2012, 26, 877-890.	5.9	846
670	Expression Pattern and Prognostic Significance of IGFBP Isoforms in Anaplastic Astrocytoma. Pathology and Oncology Research, 2012, 18, 961-967.	1.9	6
671	Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathology, 2012, 29, 131-139.	1.7	115
672	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483, 479-483.	27.8	1,668
673	The mechanisms of IDH mutations in tumorigenesis. Cell Research, 2012, 22, 1102-1104.	12.0	32
674	The cellular origin for malignant glioma and prospects for clinical advancements. Expert Review of Molecular Diagnostics, 2012, 12, 383-394.	3.1	161
675	Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells. Cell, 2012, 149, 36-47.	28.9	528
676	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	27.8	1,693
677	Clinically useful biomarkers in neurooncology. Memo - Magazine of European Medical Oncology, 2012, 5, 201-204.	0.5	1
678	The <i>MET</i> Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. Cancer Research, 2012, 72, 4537-4550.	0.9	120
679	Molecular Biology of Glioma. Advances in Experimental Medicine and Biology, 2012, 746, 2-11.	1.6	58

#	ARTICLE	IF	CITATIONS
680	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	5.9	463
681	Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2012, 5, 5.	17.0	83
682	Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. <i>Leukemia</i> , 2012, 26, 527-529.	7.2	21
683	Systems-Level Analysis of Cancer Metabolism. , 2012, , 349-381.		1
684	Frequent epigenetic inactivation of the chaperone <i>SGNE1</i> in human gliomas. <i>International Journal of Cancer</i> , 2012, 131, 612-622.	5.1	8
685	<i>MGMT</i> CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with <i>IDH1</i> or <i>IDH2</i> mutations. <i>International Journal of Cancer</i> , 2012, 131, 1104-1113.	5.1	78
686	Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. <i>Future Oncology</i> , 2012, 8, 549-558.	2.4	18
687	Hypoxia-driven pathways in bone development, regeneration and disease. <i>Nature Reviews Rheumatology</i> , 2012, 8, 358-366.	8.0	231
688	Inhibition of α -KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. <i>Genes and Development</i> , 2012, 26, 1326-1338.	5.9	855
689	Oligodendroglioma Models. <i>Neuromethods</i> , 2012, , 57-82.	0.3	0
690	DNA hypermethylation and 1p Loss silence <i>NHE4</i> in oligodendroglioma. <i>Annals of Neurology</i> , 2012, 71, 845-849.	5.3	22
691	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. <i>Cancer</i> , 2012, 118, 2665-2673.	4.1	47
692	Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development. <i>Clinical Cancer Research</i> , 2012, 18, 1515-1523.	7.0	41
693	Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy. <i>Advances in Hematology</i> , 2012, 2012, 1-12.	1.0	73
694	Signaling in Control of Cell Growth and Metabolism. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a006783-a006783.	5.5	237
695	Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012, 7, 423-467.	22.4	249
696	Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 81-90.	2.3	13
697	Clinicopathologic and genomic features of gliosarcomas. <i>Journal of Neuro-Oncology</i> , 2012, 107, 643-650.	2.9	48

#	ARTICLE	IF	CITATIONS
698	Recent advances in the molecular understanding of glioblastoma. Journal of Neuro-Oncology, 2012, 108, 11-27.	2.9	358
699	1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. Journal of Neuro-Oncology, 2012, 108, 69-75.	2.9	46
700	Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. Journal of Neuro-Oncology, 2012, 108, 361-373.	2.9	45
701	Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system. Journal of Neuro-Oncology, 2012, 108, 459-468.	2.9	12
702	IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. Journal of Neuro-Oncology, 2012, 108, 403-410.	2.9	101
703	FABP4 is a candidate marker of cerebellar liponeurocytomas. Journal of Neuro-Oncology, 2012, 108, 513-519.	2.9	25
704	No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. Journal of Neuro-Oncology, 2012, 109, 15-22.	2.9	66
705	Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma. Current Neurology and Neuroscience Reports, 2012, 12, 302-307.	4.2	21
706	Recent Innovations in the Management of Low-Grade Gliomas. Current Treatment Options in Neurology, 2012, 14, 369-380.	1.8	3
707	Analysis of Isocitrate Dehydrogenase 1 Mutation in 97 Patients with Glioma. Journal of Molecular Neuroscience, 2012, 47, 442-447.	2.3	9
708	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 2012, 123, 841-852.	7.7	77
709	A huge intraventricular congenital anaplastic astrocytoma: case report with histopathological and genetic consideration. Brain Tumor Pathology, 2012, 29, 107-112.	1.7	5
710	Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathology, 2012, 29, 160-167.	1.7	54
711	Detection of 2- α -Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. Brain Pathology, 2012, 22, 26-31.	4.1	49
712	Molecular lesions in childhood and adult acute megakaryoblastic leukaemia. British Journal of Haematology, 2012, 156, 316-325.	2.5	18
713	IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology, 2012, 60, 363-365.	2.9	60
714	Immunohistochemical analysis of uroplakins, urothelial-specific proteins in sinonasal Schneiderian papillomas. Histopathology, 2012, 60, 365-369.	2.9	0
715	Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell, 2012, 21, 297-308.	16.8	2,617

#	ARTICLE	IF	CITATIONS
716	SnapShot: Glioblastoma Multiforme. Cancer Cell, 2012, 21, 710-710.e1.	16.8	34
717	Reactive oxygen species: Are they important for haematopoiesis?. Critical Reviews in Oncology/Hematology, 2012, 81, 257-274.	4.4	61
718	Targeting cancer metabolism “aiming at a tumour's sweet-spot. Drug Discovery Today, 2012, 17, 232-241.	6.4	145
719	Understanding the central role of citrate in the metabolism of cancer cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 111-116.	7.4	102
720	Clinical Applications of Epigenetic Markers and Epigenetic Profiling in Myeloid Malignancies. Seminars in Oncology, 2012, 39, 109-122.	2.2	45
721	Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: Novel Pathogenetic Lesions. Seminars in Oncology, 2012, 39, 67-73.	2.2	41
722	Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for Tâ€cellâ€mediated immunity. Immunology, 2012, 136, 363-369.	4.4	72
723	<i>IDH2</i> mutations are frequent in Chinese patients with acute myeloid leukemia and associated with <i>NPM1</i> mutations and FABâ€M2 subtype. International Journal of Laboratory Hematology, 2012, 34, 502-509.	1.3	10
724	Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell and Melanoma Research, 2012, 25, 375-383.	3.3	153
725	Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. Journal of Cellular and Molecular Medicine, 2012, 16, 545-554.	3.6	21
726	Pathology of tumours of the central nervous system. Surgery, 2012, 30, 107-115.	0.3	1
727	Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variants. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 729, 1-15.	1.0	75
728	<i>IDH</i> mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Science, 2012, 103, 269-273.	3.9	239
729	Significance of <i>IDH</i> mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Science, 2012, 103, 587-592.	3.9	87
730	Epigenetics and blood disorders. British Journal of Haematology, 2012, 158, 307-322.	2.5	11
731	Insights gained from modelling highâ€grade glioma in the mouse. Neuropathology and Applied Neurobiology, 2012, 38, 254-270.	3.2	19
732	Molecular pathology in adult highâ€grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology, 2012, 38, 271-291.	3.2	97
733	Rosetteâ€forming glioneuronal tumor of the septum pellucidum with extension to the supratentorial ventricles: Rare case with genetic analysis. Neuropathology, 2012, 32, 301-305.	1.2	37

#	ARTICLE	IF	CITATIONS
734	A case of unclassified high-grade glioma with polar spongioblastoma pattern. <i>Neuropathology</i> , 2012, 32, 604-610.	1.2	5
735	The hypermethylation of the O ⁶ -methylguanine-DNA methyltransferase gene promoter in gliomas—correlation with array comparative genome hybridization results and IDH1 mutation. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 20-29.	2.8	13
736	IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. <i>Cancer</i> , 2012, 118, 452-460.	4.1	77
737	Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. <i>Cancer</i> , 2012, 118, 711-721.	4.1	50
738	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. <i>Human Mutation</i> , 2012, 33, 100-103.	2.5	263
739	Metabolism of [¹³ C]glucose in human brain tumors <i>in vivo</i> . <i>NMR in Biomedicine</i> , 2012, 25, 1234-1244.	2.8	282
740	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Annals of Hematology</i> , 2012, 91, 519-525.	1.8	96
741	Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. <i>Journal of Neuro-Oncology</i> , 2012, 107, 1-12.	2.9	47
742	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. <i>Journal of Neuro-Oncology</i> , 2012, 107, 197-205.	2.9	280
743	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2012, 107, 213-221.	2.9	24
744	Lipidized glioblastoma: Pathological and molecular characteristics. <i>Neuropathology</i> , 2013, 33, 87-92.	1.2	5
745	Clinicopathological and genetic characteristics of extraventricular neurocytomas. <i>Neuropathology</i> , 2013, 33, 111-121.	1.2	29
746	Biochemical characterization of NADP ⁺ -dependent isocitrate dehydrogenase from <i>Microcystis aeruginosa</i> PCC7806. <i>Molecular Biology Reports</i> , 2013, 40, 2995-3002.	2.3	11
747	Expression and characterization of a novel isocitrate dehydrogenase from <i>Streptomyces diastaticus</i> No. 7 strain M1033. <i>Molecular Biology Reports</i> , 2013, 40, 1615-1623.	2.3	7
748	Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. <i>Journal of Neuro-Oncology</i> , 2013, 114, 85-91.	2.9	28
749	Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. <i>Journal of Neuro-Oncology</i> , 2013, 113, 251-258.	2.9	32
750	Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. <i>Journal of Neuro-Oncology</i> , 2013, 113, 277-284.	2.9	74
751	GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. <i>Journal of Neuro-Oncology</i> , 2013, 113, 65-74.	2.9	87

#	ARTICLE	IF	CITATIONS
752	Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. Journal of Neuro-Oncology, 2013, 112, 439-448.	2.9	19
753	Gliomatosis cerebri: clinical characteristics, management, and outcomes. Journal of Neuro-Oncology, 2013, 112, 267-275.	2.9	61
754	New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. , 2013, , .		0
756	Cancer Genomics. , 2013, , .		4
757	Applications of Biotechnology in Neurology. , 2013, , .		11
758	Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High-Grade Astrocytomas. Brain Pathology, 2013, 23, 237-243.	4.1	73
759	BCAT1 defines gliomas by IDH status. Nature Medicine, 2013, 19, 816-817.	30.7	17
760	Progress on molecular biomarkers and classification of malignant gliomas. Frontiers of Medicine, 2013, 7, 150-156.	3.4	21
761	Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma. , 2013, , 61-72.		0
762	Molecular Diagnostics for Neurological Disorders. , 2013, , 155-210.		2
763	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	1.6	1
764	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α -KG. Acta Neuropathologica Communications, 2013, 1, 18.	5.2	54
765	The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathologica Communications, 2013, 1, 4.	5.2	40
766	A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. Journal of Neurology, 2013, 260, 1469-1480.	3.6	25
767	Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation. Brain Tumor Pathology, 2013, 30, 175-179.	1.7	8
768	Usefulness of immunohistochemical expression analysis of metabolic-related molecules to differentiate between intracranial neoplastic and non-neoplastic lesions. Brain Tumor Pathology, 2013, 30, 144-150.	1.7	3
769	Primary Tumors of the Nervous System. , 2013, , 1-22.		0
770	Novel Molecular Acquisitions in Leukemias. , 2013, , 453-493.		0

#	ARTICLE	IF	CITATIONS
771	Metabolic Modulation of Epigenetics in Gliomas. Brain Pathology, 2013, 23, 217-221.	4.1	49
772	<sc><i>PDGFRA</i></sc> Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in <sc>IDH</sc>1 Mutant Glioblastoma. Brain Pathology, 2013, 23, 565-573.	4.1	83
773	Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. International Journal of Hematology, 2013, 98, 648-657.	1.6	101
774	DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies. American Journal of Human Genetics, 2013, 93, 439-451.	6.2	67
775	Emerging Concepts in Neuro-Oncology. , 2013, , .		0
776	TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathologica, 2013, 126, 931-937.	7.7	209
778	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. Acta Neuropathologica, 2013, 126, 277-289.	7.7	49
779	Integration of epidemiology, immunobiology, and translational research for brain tumors. Annals of the New York Academy of Sciences, 2013, 1284, 17-23.	3.8	7
780	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nature Neuroscience, 2013, 16, 1373-1382.	14.8	408
781	Current NMR Strategies for Biomarker Discovery. , 2013, , 87-117.		4
782	Glioblastoma management in the temozolomide era: have we improved outcome?. Journal of Neuro-Oncology, 2013, 115, 303-310.	2.9	27
784	A clear picture of renal cell carcinoma. Nature Genetics, 2013, 45, 849-850.	21.4	103
785	2-Hydroxyglutarate as a Magnetic Resonance Biomarker for Glioma Subtyping. Translational Oncology, 2013, 6, 92-98.	3.7	27
786	Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618. Neoplasia, 2013, 15, 1151-IN23.	5.3	67
787	Esami citologico, istologico, immunoistochimico e genetico dei tumori del sistema nervoso centrale. EMC - Neurologia, 2013, 13, 1-26.	0.0	0
788	Central Nervous System Neoplasia: Evidence-Based Medicine, Diagnosis, Treatment, and Complications. , 2013, , 707-728.		0
789	The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro-Oncology, 2013, 15, 1151-1159.	1.2	46
790	Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1480-9.	7.1	37

#	ARTICLE	IF	CITATIONS
791	Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology, 2013, 6, 742-IN34.	3.7	31
792	Cytogenetic and molecular genetic study on granular cell glioblastoma: a case report. Human Pathology, 2013, 44, 282-288.	2.0	14
793	Understanding the Tumor Microenvironment and Radioresistance by Combining Functional Imaging With Global Gene Expression. Seminars in Radiation Oncology, 2013, 23, 296-305.	2.2	16
794	Metabolic targets for cancer therapy. Nature Reviews Drug Discovery, 2013, 12, 829-846.	46.4	592
795	Cancer Genome Landscapes. Science, 2013, 339, 1546-1558.	12.6	6,507
796	Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours. European Journal of Human Genetics, 2013, 21, 1369-1376.	2.8	25
797	Molecular pathways and potential therapeutic targets in glioblastoma multiforme. Expert Review of Anticancer Therapy, 2013, 13, 1307-1318.	2.4	5
798	Tumor Metabolism of Malignant Gliomas. Cancers, 2013, 5, 1469-1484.	3.7	63
799	Is Glioblastoma an Epigenetic Malignancy?. Cancers, 2013, 5, 1120-1139.	3.7	51
800	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics, 2013, 45, 1470-1473.	21.4	564
801	Targeting Cancer Metabolisms. , 2013, , 159-174.		0
802	Perturbations of 5-Hydroxymethylcytosine Patterning in Hematologic Malignancies. Seminars in Hematology, 2013, 50, 61-69.	3.4	14
803	Modulation of oxidative stress as an anticancer strategy. Nature Reviews Drug Discovery, 2013, 12, 931-947.	46.4	2,735
804	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. Journal of Clinical Oncology, 2013, 31, 337-343.	1.6	968
805	The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features. Journal of Neuro-Oncology, 2013, 115, 477-486.	2.9	16
806	Update in the Treatment of High-grade Gliomas. Neurologic Clinics, 2013, 31, 847-867.	1.8	9
807	Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro-Oncology, 2013, 15, 718-726.	1.2	101
808	Epigenetic Regulation of the miR142-3p/Interleukin-6 Circuit in Glioblastoma. Molecular Cell, 2013, 52, 693-706.	9.7	83

#	ARTICLE	IF	CITATIONS
809	IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. <i>Future Oncology</i> , 2013, 9, 1923-1935.	2.4	53
810	Metabolic Mechanisms of Epigenetic Regulation. <i>ACS Chemical Biology</i> , 2013, 8, 2607-2621.	3.4	63
811	IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. <i>Neuro-Oncology</i> , 2013, 15, 1114-1126.	1.2	100
812	Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1021-1048.	2.2	65
813	The biology and clinical impact of genetic lesions in myeloid malignancies. <i>Blood</i> , 2013, 122, 3741-3748.	1.4	47
815	Gene markers in brain tumors: What the epileptologist should know. <i>Epilepsia</i> , 2013, 54, 25-29.	5.1	18
816	Targeting IDH: the next big thing in AML. <i>Blood</i> , 2013, 122, 2770-2771.	1.4	22
818	Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class. <i>Clinical Cancer Research</i> , 2013, 19, 4951-4960.	7.0	182
819	Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas. <i>Brain Tumor Pathology</i> , 2013, 30, 224-232.	1.7	20
820	cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. <i>Journal of Neuro-Oncology</i> , 2013, 115, 249-259.	2.9	28
821	Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 59.	8.6	39
822	Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. <i>Molecular Cancer</i> , 2013, 12, 93.	19.2	63
823	Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. <i>BMC Medical Genomics</i> , 2013, 6, 54.	1.5	34
824	Molecular diagnostics of pancreatic cysts. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 1021-1027.	1.9	8
825	Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. <i>World Journal of Surgical Oncology</i> , 2013, 11, 284.	1.9	22
826	Non-invasive in vivo assessment of IDH1 mutational status in glioma. <i>Nature Communications</i> , 2013, 4, 2429.	12.8	118
827	IDH1 mutation analysis in low cellularity specimen: A limitation of diagnostic accuracy and a proposal for the diagnostic procedure. <i>Pathology Research and Practice</i> , 2013, 209, 284-290.	2.3	8
828	Biology of "cancer metabolic phenotype." , 2013, , 15-138.		2

#	ARTICLE	IF	CITATIONS
829	Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Medicine, 2013, 2, 803-814.	2.8	46
830	Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. Journal of Cellular and Molecular Medicine, 2013, 17, 1218-1235.	3.6	49
831	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell and Melanoma Research, 2013, 26, 852-860.	3.3	48
832	Multi-Specific Monoclonal Antibody MsMab-2 Recognizes IDH1-R132L and IDH2-R172M Mutations. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 32, 377-381.	1.6	20
833	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	7.1	1,202
834	Novel Monoclonal Antibodies GMAb-r1 and LMab-1 Specifically Recognize IDH1-R132G and IDH1-R132L Mutations. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 32, 224-228.	1.6	12
835	Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Genome Medicine, 2013, 5, 66.	8.2	23
836	Current and future directions for Phase II trials in high-grade glioma. Expert Review of Neurotherapeutics, 2013, 13, 369-387.	2.8	4
838	Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells. Cancer Science, 2013, 104, 143-148.	3.9	16
839	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nature Reviews Clinical Oncology, 2013, 10, 14-26.	27.6	281
840	Genetic profiling in acute myeloid leukaemia - where are we and what is its role in patient management. British Journal of Haematology, 2013, 160, 303-320.	2.5	47
841	The Definition of Primary and Secondary Glioblastoma. Clinical Cancer Research, 2013, 19, 764-772.	7.0	819
842	Expanding the spectrum of IDH1 mutations in gliomas. Modern Pathology, 2013, 26, 619-625.	5.5	37
843	Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas. Cancer Research, 2013, 73, 496-501.	0.9	108
844	Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies. Archivum Immunologiae Et Therapiae Experimentalis, 2013, 61, 25-41.	2.3	191
845	Toward personalized cancer nanomedicine - past, present, and future. Integrative Biology (United Kingdom), 2013, 4, 1-14.	1.3	41
846	Mitoplasticity: Adaptation Biology of the Mitochondrion to the Cellular Redox State in Physiology and Carcinogenesis. Antioxidants and Redox Signaling, 2013, 18, 808-849.	5.4	40
847	Epigenetic therapy of hematological malignancies: where are we now?. Therapeutic Advances in Hematology, 2013, 4, 81-91.	2.5	23

#	ARTICLE	IF	CITATIONS
848	Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping. Brain Tumor Pathology, 2013, 30, 45-49.	1.7	9
849	Clinicopathological features of human brainstem gliomas. Brain Tumor Pathology, 2013, 30, 1-7.	1.7	20
850	Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Letters, 2013, 331, 139-146.	7.2	228
851	The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization. Journal of Biological Chemistry, 2013, 288, 3804-3815.	3.4	141
852	IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncology, 2013, 15, 469-479.	1.2	158
853	Analysis of 60 Reported Glioma Risk <sc>SNP</sc>s Replicates Published <sc>GWAS</sc> Findings but Fails to Replicate Associations From Published Candidateâ€Gene Studies. Genetic Epidemiology, 2013, 37, 222-228.	1.3	47
854	Mitochondrial Dysfunction in Gliomas. Seminars in Pediatric Neurology, 2013, 20, 216-227.	2.0	27
855	The Role of MGMT Testing in Clinical Practice. Journal of Molecular Diagnostics, 2013, 15, 539-555.	2.8	57
856	Cancer and the Reemerging Role of Metabolism. World Neurosurgery, 2013, 79, 410-411.	1.3	0
857	R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations. American Journal of Pathology, 2013, 182, 1494-1500.	3.8	60
858	Analysis of the raw serum peptidomic pattern in glioma patients. Clinica Chimica Acta, 2013, 425, 221-226.	1.1	9
859	A case of oligodendroglioma with prominent neuronal differentiation. Human Pathology, 2013, 44, 2353-2359.	2.0	10
860	NADP+-dependent IDH1R132 mutation and its relevance for glioma patient survival. Medical Hypotheses, 2013, 80, 728-731.	1.5	29
861	Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. Neurology, 2013, 81, 1515-1522.	1.1	211
862	The molecular biology of WHO Grade II gliomas. Neurosurgical Focus, 2013, 34, E1.	2.3	16
863	Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases. Clinical Neurology and Neurosurgery, 2013, 115, 323-328.	1.4	9
864	Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochemical and Biophysical Research Communications, 2013, 432, 40-45.	2.1	25
865	Multicentric oligodendroglioma: Case report and review of the literature. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 480-482.	2.0	8

#	ARTICLE	IF	CITATIONS
866	Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 49-59.	7.4	18
867	Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation. <i>Biochemical and Biophysical Research Communications</i> , 2013, 433, 374-378.	2.1	14
868	Oncology Scanâ€”Low-Grade Gliomas: Predicting and Changing Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 234-236.	0.8	4
869	A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. <i>Biochemical and Biophysical Research Communications</i> , 2013, 432, 564-567.	2.1	16
870	Mutational landscape of AML with normal cytogenetics: Biological and clinical implications. <i>Blood Reviews</i> , 2013, 27, 13-22.	5.7	95
871	Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials. <i>Current Oncology Reports</i> , 2013, 15, 56-63.	4.0	32
872	Success at Last: A Molecular Factor That Informs Treatment. <i>Current Oncology Reports</i> , 2013, 15, 47-55.	4.0	6
873	On the Pathway to Success: Defining Subtypes of Gliomas for Better Treatment Selection and Refining the Meaning of Success. <i>Current Oncology Reports</i> , 2013, 15, 24-26.	4.0	1
874	Tumor Prognostic Factors and the Challenge of Developing Predictive Factors. <i>Current Oncology Reports</i> , 2013, 15, 33-46.	4.0	1
875	Molecular diagnostics in paediatric glial tumours. <i>Lancet Oncology</i> , The, 2013, 14, e19-e27.	10.7	8
876	Adult Cerebellar Glioblastoma: Understanding Survival and Prognostic Factors Using a Population-Based Database from 1973 to 2009. <i>World Neurosurgery</i> , 2013, 80, e237-e243.	1.3	51
877	Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant <sc>H</sc>istone 3 Tail. <i>Brain Pathology</i> , 2013, 23, 210-216.	4.1	74
878	A comprehensive analysis of 41 patients with rosette-forming glioneuronal tumors of the fourth ventricle. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 335-341.	1.5	46
879	Surgical resection of malignant gliomasâ€”role in optimizing patient outcome. <i>Nature Reviews Neurology</i> , 2013, 9, 141-151.	10.1	133
880	Chemical approaches to study metabolic networks. <i>Pflugers Archiv European Journal of Physiology</i> , 2013, 465, 427-440.	2.8	13
881	MicroRNA-183 upregulates HIF-1Î± by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells. <i>Journal of Neuro-Oncology</i> , 2013, 111, 273-283.	2.9	82
882	Anaplastic Oligodendroglioma: Advances and Treatment Options. <i>Current Treatment Options in Neurology</i> , 2013, 15, 289-301.	1.8	10
883	<i><sc>MET</sc></i> Gain in Diffuse Astrocytomas is Associated with Poorer Outcome. <i>Brain Pathology</i> , 2013, 23, 13-18.	4.1	37

#	ARTICLE	IF	CITATIONS
884	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. <i>Neuro-Oncology</i> , 2013, 15, 57-68.	1.2	128
885	Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. <i>British Journal of Radiology</i> , 2013, 86, 20120414.	2.2	106
886	Impact of Genetic Targets on Primary Brain Tumor Therapy: What's Ready for Prime Time?. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 267-289.	1.6	11
887	Classification of Gliomas. , 2013, , 3-20.		2
888	SnapShot: Cancer Metabolism Pathways. <i>Cell Metabolism</i> , 2013, 17, 466-466.e2.	16.2	43
889	Epigenomics: Sequencing the Methylome. <i>Methods in Molecular Biology</i> , 2013, 973, 39-54.	0.9	3
890	Genetic and epigenetic alterations of myeloproliferative disorders. <i>International Journal of Hematology</i> , 2013, 97, 183-197.	1.6	60
891	How Molecular Testing Can Help (and Hurt) in the Workup of Gliomas. <i>American Journal of Clinical Pathology</i> , 2013, 139, 275-288.	0.7	6
892	Lessons from the Cancer Genome. <i>Cell</i> , 2013, 153, 17-37.	28.9	1,133
893	The Molecular Biology of Diffuse Low-Grade Gliomas. , 2013, , 99-115.		0
894	Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. <i>Nature Genetics</i> , 2013, 45, 602-612.	21.4	704
895	Targeting apoptosis pathways in glioblastoma. <i>Cancer Letters</i> , 2013, 332, 335-345.	7.2	60
896	Clinicopathological Features and Molecular Analysis of Primary Glioblastomas in Moroccan Patients. <i>Journal of Molecular Neuroscience</i> , 2013, 49, 567-573.	2.3	9
897	A comparative study of short- and long-TE ¹ H MRS at 3 T for <i>in vivo</i> detection of 2-hydroxyglutarate in brain tumors. <i>NMR in Biomedicine</i> , 2013, 26, 1242-1250.	2.8	73
898	What do we know about IDH1/2 mutations so far, and how do we use it?. <i>Acta Neuropathologica</i> , 2013, 125, 621-636.	7.7	133
899	IDH1 and IDH2 Mutations in Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 345.	4.2	469
900	Anaplastic Astrocytoma. <i>Current Treatment Options in Neurology</i> , 2013, 15, 302-315.	1.8	8
901	Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. <i>Cancer Gene Therapy</i> , 2013, 20, 211-221.	4.6	58

#	ARTICLE	IF	CITATIONS
902	Pyruvate Kinase M2 Expression, but Not Pyruvate Kinase Activity, Is Up-Regulated in a Grade-Specific Manner in Human Glioma. PLoS ONE, 2013, 8, e57610.	2.5	77
903	Genomic sequencing in cancer. Cancer Letters, 2013, 340, 161-170.	7.2	28
904	Prognostic impact of the isocitrate dehydrogenase 1 single nucleotide polymorphism rs11554137 in malignant gliomas. Cancer, 2013, 119, 806-813.	4.1	26
905	Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression. Advances in Immunology, 2013, 117, 1-38.	2.2	27
906	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science, 2013, 340, 626-630.	12.6	1,014
907	Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. ACS Medicinal Chemistry Letters, 2013, 4, 542-546.	2.8	70
908	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer and Metastasis Reviews, 2013, 32, 479-492.	5.9	46
909	Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nature Reviews Cancer, 2013, 13, 497-510.	28.4	490
910	Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis. Modern Pathology, 2013, 26, 1492-1497.	5.5	65
911	Cancer metabolism: Key players in metabolic reprogramming. Cancer Science, 2013, 104, 275-281.	3.9	210
912	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathologica, 2013, 125, 659-669.	7.7	250
913	Subgrouping of gliomas on the basis of genetic profiles. Brain Tumor Pathology, 2013, 30, 203-208.	1.7	29
914	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	21.4	394
915	Autophagy and Prostate Cancer Therapeutics. , 2013, , 497-518.		4
917	Diagnostic and prognostic markers in gliomas – an update. British Journal of Neurosurgery, 2013, 27, 311-315.	0.8	12
918	IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker. British Journal of Neurosurgery, 2013, 27, 442-445.	0.8	15
919	5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics and Chromatin, 2013, 6, 10.	3.9	157
920	Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism. Biochemistry, 2013, 52, 4563-4577.	2.5	69

#	ARTICLE	IF	CITATIONS
921	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. <i>Nature Medicine</i> , 2013, 19, 901-908.	30.7	388
922	A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities. <i>Free Radical Biology and Medicine</i> , 2013, 63, 446-456.	2.9	225
923	Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma. <i>NeuroMolecular Medicine</i> , 2013, 15, 420-434.	3.4	34
924	Inhibition of DNA methyltransferases and histone deacetylases induces astrocytic differentiation of neural progenitors. <i>Stem Cell Research</i> , 2013, 11, 574-586.	0.7	23
925	Molecular cytogenetics: recent developments and applications in cancer. <i>Clinical Genetics</i> , 2013, 84, 315-325.	2.0	26
926	Expression of R132H Mutational IDH1 in Human U87 Glioblastoma Cells Affects the SREBP1a Pathway and Induces Cellular Proliferation. <i>Journal of Molecular Neuroscience</i> , 2013, 50, 165-171.	2.3	16
927	Glioblastoma cancer stem cells – From concept to clinical application. <i>Cancer Letters</i> , 2013, 338, 32-40.	7.2	67
928	Releasing the Block: Setting Differentiation Free with Mutant IDH Inhibitors. <i>Cancer Cell</i> , 2013, 23, 570-572.	16.8	21
929	Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma – molecular testing procedures under scrutiny. , 2013, 32, 82-83.		4
930	Whole-Genome Sequencing. , 2013, , 87-93.		2
931	Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation. <i>Cancer Letters</i> , 2013, 328, 297-306.	7.2	21
932	Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2013, 115, 333-341.	2.9	24
933	Metabolic alteration in tumorigenesis. <i>Science China Life Sciences</i> , 2013, 56, 1067-1075.	4.9	19
935	Infratentorial low-grade oligoastrocytoma with aggressive clinical behavior in an adult: a case report with genetic characterization. <i>Brain Tumor Pathology</i> , 2013, 30, 99-103.	1.7	2
936	Gliomas of the posterior fossa in adults. <i>Journal of Neuro-Oncology</i> , 2013, 115, 401-409.	2.9	8
937	Proteomics analysis of tumor microenvironment: Implications of metabolic and oxidative stresses in tumorigenesis. <i>Mass Spectrometry Reviews</i> , 2013, 32, 267-311.	5.4	15
938	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , 2013, 15, 1017-1026.	1.2	78
939	Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 1319-1323.	1.8	8

#	ARTICLE	IF	CITATIONS
940	A glioblastoma neurosphere line with alternative lengthening of telomeres. <i>Acta Neuropathologica</i> , 2013, 126, 607-608.	7.7	9
941	Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1416-1425.	4.9	62
942	The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment. <i>Aging Cell</i> , 2013, 12, 733-741.	6.7	19
943	Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice. <i>Neuro-Oncology</i> , 2013, 15, 1278-1288.	1.2	18
944	Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. <i>Oncogene</i> , 2013, 32, 3091-3100.	5.9	324
947	Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 298-306.	1.7	51
948	Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. <i>Nature Communications</i> , 2013, 4, 1822.	12.8	98
949	Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th Annual Frye-Halloran Brain Tumor Symposium. <i>Neurosurgical Focus</i> , 2013, 34, E9.	2.3	10
950	Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. <i>Modern Pathology</i> , 2013, 26, 315-326.	5.5	48
951	5-hydroxymethylcytosine profiling as an indicator of cellular state. <i>Epigenomics</i> , 2013, 5, 655-669.	2.1	52
952	Isocitrate dehydrogenase 1: what it means to the neurosurgeon. <i>Journal of Neurosurgery</i> , 2013, 118, 1176-1180.	1.6	20
953	Relationship between cognitive function and prognosis in glioblastoma. <i>CNS Oncology</i> , 2013, 2, 195-201.	3.0	24
955	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). <i>Neuro-Oncology</i> , 2013, 15, 112-121.	1.2	31
956	Promoter Hypermethylation of the <i>EMP3</i> Gene in a Series of 229 Human Gliomas. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	15
957	What a difference a hydroxyl makes: mutant IDH, (<i>R</i>)-2-hydroxyglutarate, and cancer. <i>Genes and Development</i> , 2013, 27, 836-852.	5.9	491
958	Novel cases of D-2-hydroxyglutaric aciduria with <i>IDH1</i> or <i>IDH2</i> mosaic mutations identified by amplicon deep sequencing. <i>Journal of Medical Genetics</i> , 2013, 50, 754-759.	3.2	19
959	The Upper Midwest Health Study: gliomas and occupational exposure to chlorinated solvents. <i>Occupational and Environmental Medicine</i> , 2013, 70, 73-80.	2.8	16
960	Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013030.	1.3	3

#	ARTICLE	IF	CITATIONS
962	Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells. International Journal of Cell Biology, 2013, 2013, 1-13.	2.5	57
963	Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro-Oncology, 2013, 15, 535-541.	1.2	38
964	Multi-study Integration of Brain Cancer Transcriptomes Reveals Organ-Level Molecular Signatures. PLoS Computational Biology, 2013, 9, e1003148.	3.2	16
965	Ionizing Radiation in Glioblastoma Initiating Cells. Frontiers in Oncology, 2013, 3, 74.	2.8	27
966	Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro-Oncology, 2013, 15, 682-690.	1.2	26
967	Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro-Oncology, 2013, 15, 542-547.	1.2	48
968	Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas. ISRN Oncology, 2013, 2013, 1-13.	2.1	20
969	Brain Tumors and Gliomas. , 2013, , 749-764.		0
970	The molecular landscape of diffuse glioma and prospects for biomarker development. Expert Opinion on Medical Diagnostics, 2013, 7, 573-587.	1.6	9
971	Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients. Journal of Immunotherapy, 2013, 36, 152-157.	2.4	111
972	A Novel COLD-PCR/FMCA Assay Enhances the Detection of Low-abundance IDH1 Mutations in Gliomas. Diagnostic Molecular Pathology, 2013, 22, 28-34.	2.1	13
973	Morphologic Characteristics and Immunohistochemical Profile of Diffuse Intrinsic Pontine Gliomas. American Journal of Surgical Pathology, 2013, 37, 1357-1364.	3.7	55
974	The Molecular Pathology of Primary Brain Tumors. , 2013, 18, 210-220.		0
975	Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors. Advances in Anatomic Pathology, 2013, 20, 32-38.	4.3	73
976	Molecular biomarkers in pediatric glial tumors. Current Opinion in Oncology, 2013, 25, 665-673.	2.4	14
977	Glioblastoma With Oligodendroglioma Component. , 2013, 18, 231-236.		1
978	The metabolism of lymphomas. Current Opinion in Hematology, 2013, 20, 345-354.	2.5	19
979	Silencing a Metabolic Oncogene. Science, 2013, 340, 558-559.	12.6	11

#	ARTICLE	IF	CITATIONS
980	Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. <i>Neuro-Oncology</i> , 2013, 15, 1041-1047.	1.2	42
981	Evolutionary etiology of high-grade astrocytomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17933-17938.	7.1	35
982	Induction of sarcomas by mutant IDH2. <i>Genes and Development</i> , 2013, 27, 1986-1998.	5.9	135
983	Molecular prognostic factors in glioblastoma: state of the art and future challenges. <i>CNS Oncology</i> , 2013, 2, 495-510.	3.0	9
984	From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. <i>Neurosurgical Focus</i> , 2013, 34, E2.	2.3	59
985	Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 5146-5157.	7.0	157
986	<i>BRAF</i> V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults. <i>Journal of Clinical Oncology</i> , 2013, 31, e233-e236.	1.6	67
987	Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. <i>Neuro-Oncology</i> , 2013, 15, 972-978.	1.2	37
988	The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms. <i>Frontiers in Oncology</i> , 2013, 3, 169.	2.8	44
989	Applications of metabolomics in cancer research. <i>Journal of Carcinogenesis</i> , 2013, 12, 9.	2.5	83
990	Immunohistochemical Classification of Primary and Secondary Glioblastomas. <i>Korean Journal of Pathology</i> , 2013, 47, 541.	1.3	21
991	Mitochondrial Dysfunction in Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 292.	2.8	382
992	PKM2, a Central Point of Regulation in Cancer Metabolism. <i>International Journal of Cell Biology</i> , 2013, 2013, 1-11.	2.5	188
993	Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (<i>IDH1</i>) mutation in a patient with Ollier disease: evidence for a causal relationship. <i>Histopathology</i> , 2013, 62, 667-670.	2.9	13
994	Pediatric glioblastoma with oligodendroglioma component: Aggressive clinical phenotype with distinct molecular characteristics. <i>Neuropathology</i> , 2013, 33, 652-657.	1.2	5
995	A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy. <i>Neuropathology</i> , 2013, 33, 576-581.	1.2	20
996	Anti-cancer Drug Development: Computational Strategies to Identify and Target Proteins Involved in Cancer Metabolism. <i>Current Pharmaceutical Design</i> , 2013, 19, 532-577.	1.9	30
997	1p/19q testing has no significance in the workup of glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2013, 39, 706-717.	3.2	43

#	ARTICLE	IF	CITATIONS
998	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1028-1035.	1.3	30
999	Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities. <i>Cancer Discovery</i> , 2013, 3, 730-741.	9.4	371
1000	Comparative Expression Analysis Reveals Lineage Relationships between Human and Murine Gliomas and a Dominance of Glial Signatures during Tumor Propagation <i>In Vitro</i> . <i>Cancer Research</i> , 2013, 73, 5834-5844.	0.9	28
1001	Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5136-5145.	7.0	37
1002	Mitochondrial genome instability resulting from SUV3 haploinsufficiency leads to tumorigenesis and shortened lifespan. <i>Oncogene</i> , 2013, 32, 1193-1201.	5.9	37
1003	MAPping the genomic landscape of low-grade pediatric gliomas. <i>Nature Genetics</i> , 2013, 45, 847-849.	21.4	5
1004	Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. <i>Genes and Development</i> , 2013, 27, 1974-1985.	5.9	165
1005	BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e109.	5.1	284
1006	Three different brain tumours evolving from a common origin. <i>Oncogenesis</i> , 2013, 2, e41-e41.	4.9	9
1007	Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. <i>CNS Oncology</i> , 2013, 2, 351-358.	3.0	10
1008	Epigenetic pathways and glioblastoma treatment. <i>Epigenetics</i> , 2013, 8, 785-795.	2.7	54
1009	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013, 15, 242-250.	1.2	83
1011	Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas <i>BRAF</i> ^{V600E} Mutation and Expression. <i>Brain Pathology</i> , 2013, 23, 574-583.	4.1	167
1012	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. <i>Blood</i> , 2013, 122, 2877-2887.	1.4	186
1013	Controversies in the Treatment of Elderly Patients With Newly Diagnosed Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1165-1173.	4.9	23
1015	Diffuse Leptomeningeal Neuroepithelial Tumor. <i>American Journal of Surgical Pathology</i> , 2013, 37, 763-771.	3.7	73
1016	Cavity Volume Dynamics After Resection of Brain Metastases and Timing of Postresection Cavity Stereotactic Radiosurgery. <i>Neurosurgery</i> , 2013, 72, 180-185.	1.1	95
1017	<i>PDGFRA</i> Gain in Low-Grade Diffuse Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 61-66.	1.7	13

#	ARTICLE	IF	CITATIONS
1018	Glioblastoma with Oligodendroglioma Component (<scp>GBM</scp>â€œ<scp>O</scp>): Molecular Genetic and Clinical Characteristics. Brain Pathology, 2013, 23, 454-461.	4.1	47
1019	Surgical Management of Adult Intrinsic Brainstem Tumors. Neurosurgery, 2013, 60, 131-138.	1.1	12
1020	Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations. American Journal of Surgical Pathology, 2013, 37, 787-795.	3.7	92
1021	Neuro-oncologic Applications of Exosomes, Microvesicles, and Other Nano-Sized Extracellular Particles. Neurosurgery, 2013, 72, 501-510.	1.1	35
1022	Differentiating Diffuse World Health Organization Grade II and IV Astrocytomas With Ex Vivo Magnetic Resonance Spectroscopy. Neurosurgery, 2013, 72, 186-195.	1.1	19
1023	Imaging Genomic Mapping in Glioblastoma. Neurosurgery, 2013, 60, 126-130.	1.1	27
1024	Current Knowledge and Treatment Strategies for Grade II Gliomas. Neurologia Medico-Chirurgica, 2013, 53, 429-437.	2.2	6
1025	An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells. Neurologia Medico-Chirurgica, 2013, 53, 645-654.	2.2	11
1026	Establishment of a Multi-Specific Monoclonal Antibody MsMab-1 Recognizing Both IDH1 and IDH2 Mutations. Tohoku Journal of Experimental Medicine, 2013, 230, 103-109.	1.2	27
1028	Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights. , 2013, , .		0
1029	Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. Journal of Clinical Investigation, 2013, 123, 3659-3663.	8.2	147
1030	High-Grade Glioma: Refined Diagnostics Steering Stratified Therapy. Case Reports in Oncology, 2013, 6, 387-390.	0.7	1
1031	Isocitrate Dehydrogenase from Streptococcus mutans: Biochemical Properties and Evaluation of a Putative Phosphorylation Site at Ser102. PLoS ONE, 2013, 8, e58918.	2.5	12
1032	A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. PLoS ONE, 2013, 8, e59773.	2.5	39
1033	Integrated Analysis of Mismatch Repair System in Malignant Astrocytomas. PLoS ONE, 2013, 8, e76401.	2.5	22
1034	Novel CIC Point Mutations and an Exon-Spanning, Homozygous Deletion Identified in Oligodendroglial Tumors by a Comprehensive Genomic Approach Including Transcriptome Sequencing. PLoS ONE, 2013, 8, e76623.	2.5	16
1035	Tumor versus Stromal Cells in Cultureâ€”Survival of the Fittest?. PLoS ONE, 2013, 8, e81183.	2.5	5
1036	Alterations of 5-Hydroxymethylcytosine in Human Cancers. Cancers, 2013, 5, 786-814.	3.7	46

#	ARTICLE	IF	CITATIONS
1037	Angiocentric glioma: the infiltrative glioma with ependymal differentiation. Turk Patoloji Dergisi, 2013, 33, 251-255.	0.3	5
1038	The Significance of IDH1 Mutations in Tumor-Associated Seizure in 60 Chinese Patients with Low-Grade Gliomas. Scientific World Journal, The, 2013, 2013, 1-4.	2.1	19
1039	Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. OncoTargets and Therapy, 2013, 6, 1363.	2.0	127
1040	The Distribution and Significance of IDH Mutations in Gliomas. , 0, , .		5
1041	The molecular basis of acute myeloid leukemia. , 0, , 751-768.		0
1042	Pediatric solid tumors: embryonal cell oncogenesis. , 0, , 826-835.		0
1043	Current NMR strategies for biomarker discovery. , 2013, , 103-131.		1
1044	Genetic Profiling: Searching for Novel Genetic Aberrations in Glioblastoma. , 0, , .		0
1045	Gliomas Biology: Angiogenesis and Invasion. , 2013, , .		2
1046	Chromosomal Analysis: Clinical Applicability to Brain Cancers. , 2013, , .		1
1047	Association of loss of heterozygosity with shorter survival in primary glioblastoma patients. Polish Journal of Pathology, 2013, 4, 268-275.	0.3	12
1048	Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer. Current Metabolomics, 2014, 2, 53-69.	0.5	28
1049	Surgical Pathology of Neoplasms of the Central Nervous System. , 2014, , 3592-3606.		0
1050	BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells. PLoS ONE, 2014, 9, e102438.	2.5	54
1051	DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide. PLoS ONE, 2014, 9, e104455.	2.5	22
1052	Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia. BioMed Research International, 2014, 2014, 1-5.	1.9	26
1053	Treatment options and outcomes for glioblastoma in the elderly patient. Clinical Interventions in Aging, 2014, 9, 357.	2.9	92
1054	Molecular, histopathological, and genomic variants of glioblastoma. Frontiers in Bioscience - Landmark, 2014, 19, 1065.	3.0	17

#	ARTICLE	IF	CITATIONS
1055	Most frequent molecular and immunohistochemical markers present in selected types of brain tumors. General Physiology and Biophysics, 2014, 33, 259-279.	0.9	8
1056	Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment. Frontiers in Oncology, 2014, 4, 47.	2.8	36
1057	The genetic landscape of anaplastic astrocytoma. Oncotarget, 2014, 5, 1452-1457.	1.8	69
1058	Complex role of HIF in cancer: the known, the unknown, and the unexpected. Hypoxia (Auckland, N Z), 2014, 2, 59.	1.9	11
1059	Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. ImmunoTargets and Therapy, 2014, 3, 55.	5.8	5
1060	Brain stem cells as the cell of origin in glioma. World Journal of Stem Cells, 2014, 6, 43.	2.8	70
1061	Immunohistochemistry and Brain Tumors. , 2014, , 679-683.		0
1062	Novel Treatment Targets in Sarcoma: More Than Just the GIST. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e488-e495.	3.8	7
1063	A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3538-3543.	7.1	93
1064	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncology, 2014, 16, 414-420.	1.2	82
1065	Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status. Translational Oncology, 2014, 7, 712-719.	3.7	13
1066	Antiangiogenic therapy for high-grade glioma. The Cochrane Library, 2014, , CD008218.	2.8	84
1067	Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Review of Molecular Diagnostics, 2014, 14, 439-452.	3.1	69
1068	In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cellular and Molecular Life Sciences, 2014, 71, 4007-4026.	5.4	42
1069	Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region. BMC Cancer, 2014, 14, 641.	2.6	20
1070	The orthotopic xenotransplant of human glioblastoma successfully recapitulates glioblastoma-microenvironment interactions in a non-immunosuppressed mouse model. BMC Cancer, 2014, 14, 923.	2.6	31
1071	Determination of Phosphate-activated Glutaminase Activity and Its Kinetics in Mouse Tissues using Metabolic Mapping (Quantitative Enzyme Histochemistry). Journal of Histochemistry and Cytochemistry, 2014, 62, 813-826.	2.5	35
1072	Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathologica Communications, 2014, 2, 158.	5.2	48

#	ARTICLE	IF	CITATIONS
1073	Somatic mutations of amino acid metabolism-related genes in gastric and colorectal cancers and their regional heterogeneity - a short report. Cellular Oncology (Dordrecht), 2014, 37, 455-461.	4.4	14
1074	IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma. Cancer Research, 2014, 74, 4898-4907.	0.9	78
1075	Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma. Cancer Research, 2014, 74, 4247-4257.	0.9	77
1076	Metabolic circuits in neural stem cells. Cellular and Molecular Life Sciences, 2014, 71, 4221-4241.	5.4	53
1077	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-Oncology, 2014, 16, viii7-viii13.	1.2	85
1078	Modeling mayhem: predicting invasion and proliferation kinetics in IDH1 mutant glioblastoma with mathematical models. Neuro-Oncology, 2014, 16, 763-764.	1.2	1
1079	Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells. Oncology Letters, 2014, 7, 651-657.	1.8	9
1080	Genetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer. Frontiers in Oncology, 2014, 4, 200.	2.8	19
1081	STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. Cancers, 2014, 6, 376-395.	3.7	97
1082	Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas". Neuro-Oncology, 2014, 16, 891-892.	1.2	0
1084	Glioblastoma occurring after the surgical resection of a craniopharyngioma. British Journal of Neurosurgery, 2014, 28, 284-286.	0.8	2
1085	Emerging Insights into Barriers to Effective Brain Tumor Therapeutics. Frontiers in Oncology, 2014, 4, 126.	2.8	127
1086	Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncology Letters, 2014, 7, 1895-1902.	1.8	143
1087	Glioblastoma multiforme: State of the art and future therapeutics. , 2014, 5, 64.		223
1088	Achievement of three year remission in a case of aggressive glioblastoma using a multidisciplinary treatment strategy: A case report. Oncology Letters, 2014, 7, 1608-1612.	1.8	1
1089	<i>IDH</i> Mutations: Genotype-Phenotype Correlation and Prognostic Impact. BioMed Research International, 2014, 2014, 1-7.	1.9	27
1090	<i>IDH1</i>/<i>IDH2</i> but Not <i>TP53</i> Mutations Predict Prognosis in Bulgarian Glioblastoma Patients. BioMed Research International, 2014, 2014, 1-9.	1.9	37
1091	RAPID IDH1 GENE MUTATION ANALYSIS FOR INTRAOPERATIVE PATHOLOGICAL DIAGNOSIS. Neuro-Oncology, 2014, 16, iii47-iii47.	1.2	1

#	ARTICLE	IF	CITATIONS
1092	Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review). <i>Oncology Letters</i> , 2014, 8, 1409-1421.	1.8	62
1093	Genomic landscape of glioblastoma and the potential clinical utility. <i>CNS Oncology</i> , 2014, 3, 169-172.	3.0	0
1094	Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature. <i>Experimental Hematology and Oncology</i> , 2014, 3, 29.	5.0	3
1095	Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors. <i>Neuro-Oncology</i> , 2014, 16, 320-322.	1.2	5
1096	Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5630-5640.	7.0	124
1097	Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. <i>Pediatric Research</i> , 2014, 75, 205-209.	2.3	70
1098	Molecular and cellular heterogeneity: the hallmark of glioblastoma. <i>Neurosurgical Focus</i> , 2014, 37, E11.	2.3	147
1099	Mitochondrial Retrograde Signaling Mediated by UCP2 Inhibits Cancer Cell Proliferation and Tumorigenesis. <i>Cancer Research</i> , 2014, 74, 3971-3982.	0.9	73
1100	Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. <i>Epigenetics</i> , 2014, 9, 1454-1460.	2.7	20
1101	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. <i>Nature Communications</i> , 2014, 5, 5694.	12.8	295
1102	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014, 16, 1630-1638.	1.2	77
1103	Characterization of metabolites in infiltrating gliomas using <i>ex vivo</i> ¹ H high-resolution magic angle spinning spectroscopy. <i>NMR in Biomedicine</i> , 2014, 27, 578-593.	2.8	49
1104	Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. <i>Neurosurgical Focus</i> , 2014, 37, E13.	2.3	48
1105	IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. <i>Epilepsia</i> , 2014, 55, 1438-1443.	5.1	66
1106	Elevated expression of fatty acid synthase and nuclear localization of carnitine palmitoyltransferase _{1C} are common among human gliomas. <i>Neuropathology</i> , 2014, 34, 465-474.	1.2	26
1107	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. <i>Acta Neuropathologica</i> , 2014, 128, 615-627.	7.7	49
1108	IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. <i>American Journal of Hematology</i> , 2014, 89, 137-144.	4.1	76
1109	High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii93-iii101.	1.2	532

#	ARTICLE	IF	CITATIONS
1110	<scp><i>TET2</i></scp> as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Science, 2014, 105, 1093-1099.	3.9	89
1111	<scp>IDH</scp>2 and <scp>TP</scp>53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome. Cancer Science, 2014, 105, 359-362.	3.9	25
1112	Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. Cancer Science, 2014, 105, 744-748.	3.9	37
1113	Low-Grade Gliomas. Oncologist, 2014, 19, 403-413.	3.7	192
1114	In Vivo Modeling of Malignant Glioma. Advances in Cancer Research, 2014, 121, 261-330.	5.0	21
1115	5-Hydroxymethylcytosine and disease. Mutation Research - Reviews in Mutation Research, 2014, 762, 167-175.	5.5	44
1116	Beating the odds: extreme long-term survival with glioblastoma. Neuro-Oncology, 2014, 16, 1159-1160.	1.2	63
1117	Assessment and treatment relevance in elderly glioblastoma patients. Neuro-Oncology, 2014, 16, 1459-1468.	1.2	34
1118	Computer-extracted MR imaging features are associated with survival in glioblastoma patients. Journal of Neuro-Oncology, 2014, 120, 483-488.	2.9	32
1119	Mutational profiling of kinases in glioblastoma. BMC Cancer, 2014, 14, 718.	2.6	50
1120	Ultrastructural characterization of primary cilia in pathologically characterized human glioblastoma multiforme (GBM) tumors. BMC Clinical Pathology, 2014, 14, 40.	1.8	46
1121	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105Câ€™%>â€™%T have a prognostic value in acute myeloid leukemia. Biomarker Research, 2014, 2, 18.	6.8	36
1122	A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathologica Communications, 2014, 2, 58.	5.2	37
1123	Dynamic evolution of clonal epialleles revealed by methclone. Genome Biology, 2014, 15, 472.	8.8	67
1124	TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL. Neuro-Oncology, 2014, 16, iii5-iii6.	1.2	8
1125	Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro-Oncology, 2014, 16, 1244-1254.	1.2	47
1126	Molecular Genetics of Gliomas. Cancer Journal (Sudbury, Mass), 2014, 20, 66-72.	2.0	93
1127	The impact of extent of resection on malignant transformation of pure oligodendrogliomas. Journal of Neurosurgery, 2014, 120, 309-314.	1.6	69

#	ARTICLE	IF	CITATIONS
1128	Genetics of Myeloproliferative Neoplasms. Cancer Journal (Sudbury, Mass), 2014, 20, 61-65.	2.0	48
1129	Isocitrate dehydrogenase mutations in chondrosarcoma. Current Opinion in Oncology, 2014, 26, 403-407.	2.4	9
1130	Isocitrate Dehydrogenase-1 Is Mutated in Inflammatory Bowel Disease-associated Intestinal Adenocarcinoma With Low-grade Tubuloglandular Histology but Not in Sporadic Intestinal Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1147-1156.	3.7	32
1131	Alterations of the <i>RRAS</i> and <i>ERCC1</i> Genes at 19q13 in Gemistocytic Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2014, 73, 908-915.	1.7	7
1132	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology, 2014, 16, 81-91.	1.2	370
1133	Emerging drugs for biliary cancer. Expert Opinion on Emerging Drugs, 2014, 19, 11-24.	2.4	6
1134	Glucose Metabolism and the Antioxidative Defense System in Cancer Cells: Options for the Application of ROS-based Anticancer Drugs. Cancer Drug Discovery and Development, 2014, , 109-130.	0.4	0
1135	Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance. Cancer Research, 2014, 74, 4836-4844.	0.9	65
1136	Cancer cell metabolism as new targets for novel designed therapies. Future Medicinal Chemistry, 2014, 6, 1791-1810.	2.3	22
1137	Tumor Metabolome Targeting and Drug Development. Cancer Drug Discovery and Development, 2014, , .	0.4	0
1138	<i>IDH</i> Mutation in Glioma. JAMA Neurology, 2014, 71, 1319.	9.0	176
1139	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490.	5.9	70
1140	Emerging Therapies for Glioblastoma. JAMA Neurology, 2014, 71, 1437.	9.0	148
1141	Genomic Characterization of Acute Leukemias. Medical Principles and Practice, 2014, 23, 487-506.	2.4	23
1142	Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology, 2014, 30, 295-302.	2.3	42
1143	Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 284-287.	1.2	12
1144	An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients. Molecular Diagnosis and Therapy, 2014, 18, 45-53.	3.8	21
1145	Glioblastoma: From Molecular Pathology to Targeted Treatment. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 1-25.	22.4	427

#	ARTICLE	IF	CITATIONS
1146	Rare insights into cancer biology. <i>Oncogene</i> , 2014, 33, 2547-2556.	5.9	74
1147	Brain and Spinal Cord. , 2014, , 1384-1426.		0
1148	Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?. <i>Acta Neuropathologica Communications</i> , 2014, 2, 6.	5.2	19
1149	Genetic and pathologic evolution of early secondary gliosarcoma. <i>Brain Tumor Pathology</i> , 2014, 31, 40-46.	1.7	10
1150	Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution. <i>Journal of Neuro-Oncology</i> , 2014, 116, 395-404.	2.9	13
1151	Incidence and prognostic value of multiple gene promoter methylations in gliomas. <i>Journal of Neuro-Oncology</i> , 2014, 116, 349-356.	2.9	19
1152	An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. <i>Neurological Sciences</i> , 2014, 35, 839-845.	1.9	55
1153	Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 400-408.	1.2	13
1154	Branched-chain amino acid metabolism: from rare Mendelian diseases to more common disorders. <i>Human Molecular Genetics</i> , 2014, 23, R1-R8.	2.9	234
1155	Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. <i>Nature Communications</i> , 2014, 5, 3128.	12.8	438
1156	Transcriptional diversity of long-term glioblastoma survivors. <i>Neuro-Oncology</i> , 2014, 16, 1186-1195.	1.2	69
1157	Metabolic requirements for the maintenance of self-renewing stem cells. <i>Nature Reviews Molecular Cell Biology</i> , 2014, 15, 243-256.	37.0	848
1158	Decision Tools for Radiation Oncology. <i>Medical Radiology</i> , 2014, , .	0.1	2
1159	Current concepts in clinical radiation oncology. <i>Radiation and Environmental Biophysics</i> , 2014, 53, 1-29.	1.4	143
1160	Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3 β . <i>Molecular Biology Reports</i> , 2014, 41, 3907-3913.	2.3	15
1161	Analysis of KIAA1549 and BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. <i>Journal of Neuro-Oncology</i> , 2014, 117, 235-242.	2.9	31
1162	3D cell culture systems modeling tumor growth determinants in cancer target discovery. <i>Advanced Drug Delivery Reviews</i> , 2014, 69-70, 29-41.	13.7	369
1163	Unsuspected task for an old team: Succinate, fumarate and other Krebs cycle acids in metabolic remodeling. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2014, 1837, 1330-1337.	1.0	66

#	ARTICLE	IF	CITATIONS
1164	Targeting glucose metabolism in patients with cancer. <i>Cancer</i> , 2014, 120, 774-780.	4.1	87
1165	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>International Journal of Cancer</i> , 2014, 135, 1822-1831.	5.1	117
1166	Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 66-74.	7.4	39
1167	Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. <i>Tumor Biology</i> , 2014, 35, 5911-5920.	1.8	95
1168	Targeting Metabolic Changes in Cancer: Novel Therapeutic Approaches. <i>Annual Review of Medicine</i> , 2014, 65, 157-170.	12.2	54
1169	A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor. <i>Cancer Discovery</i> , 2014, 4, 828-839.	9.4	70
1170	Mitochondrial pathology: stress signals from the energy factory. <i>Trends in Molecular Medicine</i> , 2014, 20, 282-292.	6.7	121
1171	Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. <i>Cancer</i> , 2014, 120, 2440-2447.	4.1	39
1172	Deregulation of cell signaling in cancer. <i>FEBS Letters</i> , 2014, 588, 2558-2570.	2.8	103
1173	Using the molecular classification of glioblastoma to inform personalized treatment. <i>Journal of Pathology</i> , 2014, 232, 165-177.	4.5	214
1174	Performance of Common Analysis Methods for Detecting Low-Frequency Single Nucleotide Variants in Targeted Next-Generation Sequence Data. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 75-88.	2.8	124
1175	Molecular Testing in Cancer. , 2014, , .		2
1176	Prostate Cancer Genomics as a Driver of Personalized Medicine. , 2014, , 233-245.		1
1177	Key determinants of short-term and long-term glioblastoma survival: A 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital. <i>Clinical Neurology and Neurosurgery</i> , 2014, 120, 103-112.	1.4	42
1178	Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. <i>Neuro-Oncology</i> , 2014, 16, 914-923.	1.2	69
1179	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 2898-2909.	7.0	146
1180	The epidemiology of glioma in adults: a "state of the science" review. <i>Neuro-Oncology</i> , 2014, 16, 896-913.	1.2	1,586
1181	An overview of current and future treatment options for chondrosarcoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 217-227.	0.8	4

#	ARTICLE	IF	CITATIONS
1182	Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. <i>Acta Neurochirurgica</i> , 2014, 156, 1427-1440.	1.7	51
1183	Current and Investigational Drug Strategies for Glioblastoma. <i>Clinical Oncology</i> , 2014, 26, 419-430.	1.4	31
1184	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 294-307.	7.4	45
1185	Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. <i>Leukemia Research</i> , 2014, 38, 649-659.	0.8	38
1186	Exploiting extension bias in polymerase chain reaction to improve primer specificity in ensembles of nearly identical <sc>DNA</sc> templates. <i>Environmental Microbiology</i> , 2014, 16, 1354-1365.	3.8	72
1187	Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. <i>The Cochrane Library</i> , 2014, , CD007104.	2.8	20
1188	DNA Sequencing of Cancer: What Have We Learned?. <i>Annual Review of Medicine</i> , 2014, 65, 63-79.	12.2	41
1189	Pathogenesis and Molecular Biology of a Transmissible Tumor in the Tasmanian Devil. <i>Annual Review of Animal Biosciences</i> , 2014, 2, 165-187.	7.4	21
1190	Cysteine Catabolism: A Novel Metabolic Pathway Contributing to Glioblastoma Growth. <i>Cancer Research</i> , 2014, 74, 787-796.	0.9	116
1191	Lactate dehydrogenase A silencing in IDH mutant gliomas. <i>Neuro-Oncology</i> , 2014, 16, 686-695.	1.2	162
1192	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. <i>Nature Reviews Cancer</i> , 2014, 14, 92-107.	28.4	469
1193	Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 45-51.	2.5	57
1194	Genetic Variants in Genes of Tricarboxylic Acid Cycle Key Enzymes Predict Postsurgical Overall Survival of Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 4300-4307.	1.5	5
1195	Epigenetic Changes in Gliomas. , 2014, , 23-45.		0
1196	Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. , 2014, , 47-75.		2
1198	Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians. <i>CNS Drugs</i> , 2014, 28, 1127-1137.	5.9	10
1199	<i><sc>IDH</sc>1</i> and <i><sc>IDH</sc>2</i> mutations confer an adverse effect in patients with acute myeloid leukemia lacking the <i><sc>NPM</sc>1</i> mutation. <i>European Journal of Haematology</i> , 2014, 92, 471-477.	2.2	40
1200	Oncogenic Signaling Is Dominant to Cell of Origin and Dictates Astrocytic or Oligodendroglial Tumor Development from Oligodendrocyte Precursor Cells. <i>Journal of Neuroscience</i> , 2014, 34, 14644-14651.	3.6	42

#	ARTICLE	IF	CITATIONS
1201	<i>TP53</i> Promoter Methylation in Primary Glioblastoma: Relationship with <i>TP53</i> mRNA and Protein Expression and Mutation Status. <i>DNA and Cell Biology</i> , 2014, 33, 217-226.	1.9	23
1202	Immunotherapy for Brain Cancer: Recent Progress and Future Promise. <i>Clinical Cancer Research</i> , 2014, 20, 3651-3659.	7.0	92
1203	Hominoid-specific enzyme GLUD2 promotes growth of <i>IDH1</i> ^{<i>R132H</i>} glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14217-14222.	7.1	87
1204	Facing the Future of Brain Tumor Clinical Research. <i>Clinical Cancer Research</i> , 2014, 20, 5591-5600.	7.0	4
1205	Supratentorial cortical ependymoma: Case series and review of the literature. <i>Neuropathology</i> , 2014, 34, 243-252.	1.2	31
1206	Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective. <i>Journal of Neuro-Oncology</i> , 2014, 119, 481-490.	2.9	20
1207	Diagnostic and prognostic value of preoperative combined GFAP, IGFBP2, and YKL40 plasma levels in patients with glioblastoma. <i>Cancer</i> , 2014, 120, 3972-3980.	4.1	69
1208	Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8307-8318.	6.4	48
1209	Supratentorial Low-Grade Diffuse Astrocytoma: Medical Management. <i>Seminars in Oncology</i> , 2014, 41, 446-457.	2.2	12
1210	Genetic Markers in Adult High-Grade Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 235-239.	2.2	2
1211	Section III: Molecular diagnostics in neuro-oncology. <i>Current Problems in Cancer</i> , 2014, 38, 175-179.	2.0	6
1212	Anatomical localization of p53 mutated tumors: A radiographic study of human glioblastomas. <i>Journal of the Neurological Sciences</i> , 2014, 346, 94-98.	0.6	8
1213	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. <i>Neuro-Oncology</i> , 2014, 16, 1263-1273.	1.2	159
1214	Extracellular vesicles as a platform for “liquid biopsy” in glioblastoma patients. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 819-825.	3.1	104
1215	Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme. <i>Cancer Letters</i> , 2014, 353, 41-51.	7.2	13
1216	Human <i>Brat</i> Ortholog <i>TRIM3</i> Is a Tumor Suppressor That Regulates Asymmetric Cell Division in Glioblastoma. <i>Cancer Research</i> , 2014, 74, 4536-4548.	0.9	90
1217	Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism. <i>Chemistry and Biology</i> , 2014, 21, 1143-1161.	6.0	39
1218	A Prognostic Model Based on Preoperative MRI Predicts Overall Survival in Patients with Diffuse Gliomas. <i>American Journal of Neuroradiology</i> , 2014, 35, 1096-1102.	2.4	58

#	ARTICLE	IF	CITATIONS
1219	Mitochondrial substrates in cancer: Drivers or passengers?. Mitochondrion, 2014, 19, 8-19.	3.4	14
1220	KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas. Journal of Clinical Neuroscience, 2014, 21, 1719-1724.	1.5	9
1221	Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. Journal of Biological Chemistry, 2014, 289, 23318-23328.	3.4	81
1222	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. Neuro-Oncology, 2014, 16, 173-178.	1.2	23
1223	p75 Neurotrophin Receptor Cleavage by $\hat{1}\pm$ - and $\hat{1}^3$ -Secretases Is Required for Neurotrophin-mediated Proliferation of Brain Tumor-initiating Cells. Journal of Biological Chemistry, 2014, 289, 8067-8085.	3.4	57
1224	IDH1 regulates phospholipid metabolism in developing astrocytes. Neuroscience Letters, 2014, 582, 87-92.	2.1	7
1225	Glioma di alto grado: astrocitoma anaplastico e glioblastoma. EMC - Neurologia, 2014, 14, 1-10.	0.0	0
1226	Therapeutic potential of targeting glucose metabolism in glioma stem cells. Expert Opinion on Therapeutic Targets, 2014, 18, 1233-1236.	3.4	23
1227	<i>Isocitrate dehydrogenase 1</i> and <i>2</i> mutations in gliomas. Journal of Neuroscience Research, 2014, 92, 1611-1620.	2.9	18
1228	Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1985-1996.	2.5	933
1229	The impact of TP53 and RAS mutations on cerebellar glioblastomas. Experimental and Molecular Pathology, 2014, 97, 202-207.	2.1	16
1230	RNA-seq of 272 gliomas revealed a novel, recurrent <i>PTPRZ1-MET</i> fusion transcript in secondary glioblastomas. Genome Research, 2014, 24, 1765-1773.	5.5	316
1231	ATP-Dependent Lon Protease Controls Tumor Bioenergetics by Reprogramming Mitochondrial Activity. Cell Reports, 2014, 8, 542-556.	6.4	186
1232	Emerging approaches to target tumor metabolism. Current Opinion in Pharmacology, 2014, 17, 22-29.	3.5	18
1233	The role of mutation of metabolism-related genes in genomic hypermethylation. Biochemical and Biophysical Research Communications, 2014, 455, 16-23.	2.1	25
1234	Mitochondrial dysfunction in cancer chemoresistance. Biochemical Pharmacology, 2014, 92, 62-72.	4.4	73
1235	Immunohistochemical evaluation of ⁶ O ⁶ -methylguanine DNA methyltransferase (<i>MGMT</i>) expression in 117 cases of glioblastoma. Neuropathology, 2014, 34, 268-276.	1.2	18
1236	Regulation of the pentose phosphate pathway in cancer. Protein and Cell, 2014, 5, 592-602.	11.0	363

#	ARTICLE	IF	CITATIONS
1237	Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas. <i>BMC Cancer</i> , 2014, 14, 506.	2.6	20
1238	Defects in mitochondrial metabolism and cancer. <i>Cancer & Metabolism</i> , 2014, 2, 10.	5.0	208
1239	Molecular Neuro-oncology and the Challenge of the Blood-Brain Barrier. <i>Seminars in Oncology</i> , 2014, 41, 438-445.	2.2	12
1240	Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. <i>Nature Reviews Cancer</i> , 2014, 14, 651-661.	28.4	241
1241	Circulating glioma biomarkers. <i>Neuro-Oncology</i> , 2015, 17, 343-60.	1.2	73
1242	A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. <i>Acta Neuropathologica</i> , 2014, 128, 39-54.	7.7	139
1243	The role of 5-hydroxymethylcytosine in human cancer. <i>Cell and Tissue Research</i> , 2014, 356, 631-641.	2.9	87
1244	Leukemia-like onset of bone marrow metastasis from anaplastic oligodendroglioma after 17 years of dormancy: an autopsy case report. <i>Brain Tumor Pathology</i> , 2014, 31, 131-136.	1.7	6
1245	Differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma: a case report of an elderly man. <i>Brain Tumor Pathology</i> , 2014, 31, 118-123.	1.7	4
1246	The role of neuropathology in the management of progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 118, 461-478.	2.9	10
1247	Interactions among mitochondrial proteins altered in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 118, 247-256.	2.9	57
1248	Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. <i>Journal of Neuro-Oncology</i> , 2014, 118, 405-412.	2.9	28
1249	The proteomic response in glioblastoma in young patients. <i>Journal of Neuro-Oncology</i> , 2014, 119, 79-89.	2.9	14
1250	Cancer: pathological nuclear reprogramming?. <i>Nature Reviews Cancer</i> , 2014, 14, 568-573.	28.4	70
1251	D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 19.	5.2	72
1252	IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism. <i>Cancer Research</i> , 2014, 74, 3317-3331.	0.9	224
1253	Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 119, 429-435.	2.9	29
1254	Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer. <i>Journal of Biomolecular Screening</i> , 2014, 19, 1193-1200.	2.6	27

#	ARTICLE	IF	CITATIONS
1255	Melanoma epigenetics: novel mechanisms, markers, and medicines. <i>Laboratory Investigation</i> , 2014, 94, 822-838.	3.7	69
1256	BMP Signaling Induces Astrocytic Differentiation of Clinically Derived Oligodendroglioma Propagating Cells. <i>Molecular Cancer Research</i> , 2014, 12, 283-294.	3.4	21
1257	Medical therapy of gliomas. <i>Journal of Neuro-Oncology</i> , 2014, 119, 503-512.	2.9	15
1258	The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014, 120, 85-93.	2.9	30
1259	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	7.7	176
1260	Role of Surgical Resection in Low- and High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2014, 16, 284.	1.8	134
1261	Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation. <i>NeuroMolecular Medicine</i> , 2014, 16, 70-82.	3.4	78
1262	MicroRNA Expression Signatures and Their Correlation with Clinicopathological Features in Glioblastoma Multiforme. <i>NeuroMolecular Medicine</i> , 2014, 16, 565-577.	3.4	37
1263	MicroRNA Expression Signatures Determine Prognosis and Survival in Glioblastoma Multiforme—a Systematic Overview. <i>Molecular Neurobiology</i> , 2014, 50, 896-913.	4.0	53
1264	Driver mutations of cancer epigenomes. <i>Protein and Cell</i> , 2014, 5, 265-296.	11.0	139
1265	High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells. <i>BMC Genomics</i> , 2014, 15, 158.	2.8	16
1266	Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. <i>BMC Medical Genomics</i> , 2014, 7, 30.	1.5	60
1267	Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways. <i>Archives of Biochemistry and Biophysics</i> , 2014, 545, 69-73.	3.0	42
1268	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH1</i> . <i>Journal of Clinical Oncology</i> , 2014, 32, 783-790.	1.6	356
1269	Tackling the cancer stem cells — what challenges do they pose?. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 497-512.	46.4	831
1270	Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astroglomas? A Retrospective Study of 112 Cases. <i>American Journal of Neuroradiology</i> , 2014, 35, 920-927.	2.4	58
1271	Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11121-11126.	7.1	230
1272	Role of somatic cancer mutations in human protein lysine methyltransferases. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 366-379.	7.4	34

#	ARTICLE	IF	CITATIONS
1273	Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma. Cancer Research, 2014, 74, 4622-4637.	0.9	123
1274	e-Driver: a novel method to identify protein regions driving cancer. Bioinformatics, 2014, 30, 3109-3114.	4.1	116
1275	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathologica, 2014, 128, 551-559.	7.7	268
1276	Principles of Surgery for Malignant Astrocytomas. Seminars in Oncology, 2014, 41, 523-531.	2.2	4
1277	Therapeutic Decision Making in Patients with Newly Diagnosed Low Grade Glioma. Current Treatment Options in Oncology, 2014, 15, 529-538.	3.0	17
1278	Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1. Journal of Biological Chemistry, 2014, 289, 13717-13725.	3.4	78
1279	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics, 2014, 46, 726-730.	21.4	148
1280	Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3ÅT: A phantom study. Physica Medica, 2014, 30, 702-707.	0.7	22
1281	Mitochondrial 2-hydroxyglutarate metabolism. Mitochondrion, 2014, 19, 275-281.	3.4	38
1282	Parallel evolution of <i>IDH2</i> gene in cetaceans, primates and bats. FEBS Letters, 2014, 588, 450-454.	2.8	3
1283	Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling. Journal of Neuro-Oncology, 2014, 119, 243-251.	2.9	6
1284	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	27.8	613
1285	Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. Neuro-Oncology, 2014, 16, 779-786.	1.2	77
1286	Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance. Molecular Cell, 2014, 54, 716-727.	9.7	771
1287	Nicotinamide Nucleotide Transhydrogenase (Nnt) Links the Substrate Requirement in Brain Mitochondria for Hydrogen Peroxide Removal to the Thioredoxin/Peroxiredoxin (Trx/Prx) System. Journal of Biological Chemistry, 2014, 289, 15611-15620.	3.4	72
1288	Glial Progenitors as Targets for Transformation in Glioma. Advances in Cancer Research, 2014, 121, 1-65.	5.0	38
1289	Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia. Cancer Discovery, 2014, 4, 348-361.	9.4	135
1290	Erlotinib: early clinical development in brain cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1027-1037.	4.1	17

#	ARTICLE	IF	CITATIONS
1291	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. <i>Leukemia</i> , 2014, 28, 1774-1783.	7.2	225
1292	Krebs cycle intermediates regulate DNA and histone methylation: Epigenetic impact on the aging process. <i>Ageing Research Reviews</i> , 2014, 16, 45-65.	10.9	95
1293	Mitochondria: The Anti- cancer Target for the Third Millennium. , 2014, , .		3
1294	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 326-341.	7.4	118
1295	Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer. <i>Gene</i> , 2014, 546, 263-270.	2.2	22
1296	Current Concepts in the Surgical Management of Glioma Patients. <i>Clinical Oncology</i> , 2014, 26, 385-394.	1.4	29
1297	Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades Iâ€“III. <i>Molecular Oncology</i> , 2014, 8, 417-430.	4.6	96
1298	Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 1261-1267.	2.1	11
1299	Protein lysine acetylation guards metabolic homeostasis to fight against cancer. <i>Oncogene</i> , 2014, 33, 2279-2285.	5.9	35
1300	Identification of a NFKBIA polymorphism associated with lower NFKBIA protein levels and poor survival outcomes in patients with glioblastoma multiforme. <i>International Journal of Molecular Medicine</i> , 2014, 34, 1233-1240.	4.0	12
1301	Emerging treatment strategies for glioblastoma multiforme. <i>EMBO Molecular Medicine</i> , 2014, 6, 1359-1370.	6.9	280
1302	Characterizing DNA methylation alterations from The Cancer Genome Atlas. <i>Journal of Clinical Investigation</i> , 2014, 124, 17-23.	8.2	162
1303	Harnessing the potential of epigenetic therapy to target solid tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 56-63.	8.2	130
1304	Genetics and epigenetics of gliomas. <i>Swiss Medical Weekly</i> , 2014, 144, w14018.	1.6	7
1306	Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-Î²B activation in a hypoxia-inducible factor 1-Î± dependent manner. <i>Molecular Medicine Reports</i> , 2014, 9, 1799-1805.	2.4	27
1307	Recent developments in myelodysplastic syndromes. <i>Blood</i> , 2014, 124, 2793-2803.	1.4	147
1308	Pregnenolone, a cholesterol metabolite, induces glioma cell apoptosis via activating extrinsic and intrinsic apoptotic pathways. <i>Oncology Letters</i> , 2014, 8, 645-650.	1.8	17
1309	Clinical Discussion of the Management of Anaplastic Oligodendroglioma/Oligoastrocytoma (Both) Tj ETQq1 1 0.784314 rgBT /Overlook 665-672.	4.9	11

#	ARTICLE	IF	CITATIONS
1310	The Comprehensive Neuro-Oncology Data Repository (CONDR). <i>Neurosurgery</i> , 2014, 74, 88-98.	1.1	8
1311	Evolution of Malignant Glioma Treatment. <i>Neurosurgery</i> , 2014, 61, 74-83.	1.1	18
1312	Cystic Glioblastoma. <i>Neurosurgery</i> , 2014, 74, 71-76.	1.1	21
1313	IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a. <i>Molecular Medicine Reports</i> , 2015, 12, 6695-6701.	2.4	13
1314	Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. <i>Cell Reports</i> , 2015, 13, 2353-2361.	6.4	153
1315	Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma. <i>Clinical Neurology and Neurosurgery</i> , 2015, 138, 37-44.	1.4	30
1316	The mitochondrial proteome and human disease. <i>Pathology</i> , 2015, 47, S28.	0.6	0
1317	Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 95-105.	3.0	32
1318	Dynamic ¹⁸ F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. <i>International Journal of Cancer</i> , 2015, 136, 2132-2145.	5.1	68
1319	Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis. <i>Molecular Medicine Reports</i> , 2015, 11, 2548-2554.	2.4	54
1320	IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. <i>Scientific Reports</i> , 2015, 5, 16238.	3.3	259
1321	Autoantibody Profiling of Glioma Serum Samples to Identify Biomarkers Using Human Proteome Arrays. <i>Scientific Reports</i> , 2015, 5, 13895.	3.3	43
1322	Glioma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15017.	30.5	718
1323	Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing. <i>Molecular Medicine Reports</i> , 2015, 12, 4376-4381.	2.4	9
1325	IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2015, 126, 1741-1752.	1.4	184
1326	Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in <i>Drosophila</i> . <i>Blood</i> , 2015, 125, 336-345.	1.4	25
1327	MiR-181a regulates lipid metabolism via IDH1. <i>Scientific Reports</i> , 2015, 5, 8801.	3.3	53
1328	Pathology and Genetics of Diffuse Gliomas in Adults. <i>Neurologia Medico-Chirurgica</i> , 2015, 55, 28-37.	2.2	16

#	ARTICLE	IF	CITATIONS
1329	A new functional classification system (FGA/B) with prognostic value for glioma patients. Scientific Reports, 2015, 5, 12373.	3.3	7
1330	Overexpression of isocitrate dehydrogenase-1R132H enhances the proliferation of A172 glioma cells via aerobic glycolysis. Molecular Medicine Reports, 2015, 11, 3715-3721.	2.4	11
1331	Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Cancer Control, 2015, 22, 200-205.	1.8	10
1332	PO69THE IMPACT OF MGMT METHYLATION AND IDH-1 MUTATION ON LONG TERM OUTCOME FOR GLIOBLASTOMA TREATED WITH CHEMORADIOTHERAPY. Neuro-Oncology, 2015, 17, viii12.5-viii12.	1.2	0
1333	<i>CDKN2A</i> Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2015, 74, 442-452.	1.7	144
1334	Genetic variations in genes of metabolic enzymes predict postoperative prognosis of patients with colorectal cancer. Molecular Cancer, 2015, 14, 171.	19.2	12
1335	2â€Hydroxyglutarate: D/Riving Pathology in gLiomaS. Brain Pathology, 2015, 25, 760-768.	4.1	11
1336	<i><sc>IDH2</sc></i> mutation in gliomas including novel mutation. Neuropathology, 2015, 35, 236-244.	1.2	19
1337	TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion. Journal of Hematology and Oncology, 2015, 8, 89.	17.0	30
1338	HOT mutation screening in human glioblastomas. Future Science OA, 2015, 1, .	1.9	1
1339	Genetic and epigenetic characterization of lowâ€grade gliomas reveals frequent methylation of the <i><sc>M</sc>LH3</i> gene. Genes Chromosomes and Cancer, 2015, 54, 655-667.	2.8	8
1340	Intratumor heterogeneity and transcriptional profiling in glioblastoma: translational opportunities. Future Neurology, 2015, 10, 369-381.	0.5	1
1341	Magnetic Resonance (MR) Metabolic Imaging in Glioma. Brain Pathology, 2015, 25, 769-780.	4.1	37
1342	Predictors of preoperative and early postoperative seizures in patients with intraâ€axial primary and metastatic brain tumors: A retrospective observational single center study. Annals of Neurology, 2015, 78, 917-928.	5.3	60
1343	Imaging Genomics in Gliomas. Cancer Journal (Sudbury, Mass), 2015, 21, 225-234.	2.0	22
1344	Immunohistochemical profiles of I<sc>DH</sc>1, <sc>MGMT</sc> and <sc>P</sc>53: Practical significance for prognostication of patients with diffuse gliomas. Neuropathology, 2015, 35, 324-335.	1.2	52
1345	Novel Approaches to Imaging Tumor Metabolism. Cancer Journal (Sudbury, Mass), 2015, 21, 165-173.	2.0	27
1346	Low-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2015, 21, 345-354.	0.8	17

#	ARTICLE	IF	CITATIONS
1347	Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas. Neurosurgery, 2015, 62, 166-170.	1.1	2
1348	Chordoid Gliomas of the Third Ventricle Share TTF-1 Expression With Organum Vasculosum of the Lamina Terminalis. American Journal of Surgical Pathology, 2015, 39, 948-956.	3.7	52
1349	Imaging Genomics of Glioblastoma. Topics in Magnetic Resonance Imaging, 2015, 24, 155-163.	1.2	14
1351	The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e648-e655.	3.8	13
1352	Pathology and Molecular Classification. , 2015, , .		0
1353	34. Supratentorial Hemispheric Gliomas. , 2015, , .		0
1354	IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil. Genetics and Molecular Research, 2015, 14, 6533-6542.	0.2	4
1355	Application of Volumetric Analysis to Glioblastomas: a Correlation Study on the Status of the Isocitrate Dehydrogenase Mutation. Investigative Magnetic Resonance Imaging, 2015, 19, 218.	0.4	0
1356	DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer. Epigenetic Diagnosis & Therapy, 2015, 1, 49-59.	0.1	0
1357	EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arquivos De Neuro-Psiquiatria, 2015, 73, 561-568.	0.8	17
1358	Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Oncotarget, 2015, 6, 13579-13590.	1.8	21
1359	IDH1 Mutation in Gliomas in Mosul City - Iraq. Open Access Macedonian Journal of Medical Sciences, 2015, 3, 250-255.	0.2	3
1360	Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. Oncotarget, 2015, 6, 20266-20277.	1.8	38
1361	Modern Brain Tumor Imaging. Brain Tumor Research and Treatment, 2015, 3, 8.	1.0	157
1362	Functions of TET Proteins in Hematopoietic Transformation. Molecules and Cells, 2015, 38, 925-935.	2.6	21
1363	Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information. Metabolites, 2015, 5, 502-520.	2.9	63
1364	Cancer Metabolism and Drug Resistance. Metabolites, 2015, 5, 571-600.	2.9	130
1365	Brain Tumor Immunotherapy: What have We Learned so Far?. Frontiers in Oncology, 2015, 5, 98.	2.8	28

#	ARTICLE	IF	CITATIONS
1366	Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2015, 5, 147.	2.8	91
1367	Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. <i>Clinical Pharmacology: Advances and Applications</i> , 2015, 7, 57.	1.2	12
1368	Proportional Upregulation of CD97 Isoforms in Glioblastoma and Glioblastoma-Derived Brain Tumor Initiating Cells. <i>PLoS ONE</i> , 2015, 10, e0111532.	2.5	19
1369	Metabolic Reprogramming in Mutant IDH1 Glioma Cells. <i>PLoS ONE</i> , 2015, 10, e0118781.	2.5	67
1370	LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation. <i>PLoS ONE</i> , 2015, 10, e0119781.	2.5	40
1371	Radiological and Pathological Features Associated with IDH1-R132H Mutation Status and Early Mortality in Newly Diagnosed Anaplastic Astrocytic Tumours. <i>PLoS ONE</i> , 2015, 10, e0123890.	2.5	24
1372	Polymorphisms in Genes of Tricarboxylic Acid Cycle Key Enzymes Are Associated with Early Recurrence of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0124471.	2.5	5
1373	Molecular Heterogeneity in a Patient-Derived Glioblastoma Xenoline Is Regulated by Different Cancer Stem Cell Populations. <i>PLoS ONE</i> , 2015, 10, e0125838.	2.5	25
1374	Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma. <i>PLoS ONE</i> , 2015, 10, e0127471.	2.5	27
1375	International Differences in Treatment and Clinical Outcomes for High Grade Glioma. <i>PLoS ONE</i> , 2015, 10, e0129602.	2.5	11
1376	IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. <i>PLoS ONE</i> , 2015, 10, e0130596.	2.5	54
1377	Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes. <i>PLoS ONE</i> , 2015, 10, e0131998.	2.5	55
1378	Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. <i>PLoS ONE</i> , 2015, 10, e0133813.	2.5	88
1379	Cancer Metabolism: A Modeling Perspective. <i>Frontiers in Physiology</i> , 2015, 6, 382.	2.8	58
1381	Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	50
1382	Congenital Oligodendroglioma: Clinicopathologic and Molecular Assessment with Review of the Literature. <i>Case Reports in Pathology</i> , 2015, 2015, 1-4.	0.3	4
1383	Combination genetic signature stratifies lower-grade gliomas better than histological grade. <i>Oncotarget</i> , 2015, 6, 20885-20901.	1.8	42
1384	Brain Tumor Metabolism “Unraveling Its Role in Finding New Therapeutic Targets. , 0, , .		2

#	ARTICLE	IF	CITATIONS
1386	Combined Cataract Extraction and Vitrectomy for Macula-sparing Retinal Detachment: Visual Outcomes and Complications. Korean Journal of Ophthalmology: KJO, 2015, 29, 147.	1.1	3
1387	Isocitrate dehydrogenase mutations: new opportunities for translational research. BMB Reports, 2015, 48, 266-270.	2.4	9
1388	A Metabolic Phenotype Based on Mitochondrial Ribosomal Protein Expression as a Predictor of Lymph Node Metastasis in Papillary Thyroid Carcinoma. Medicine (United States), 2015, 94, e380.	1.0	22
1389	The Evolving Molecular Genetics of Low-grade Glioma. Advances in Anatomic Pathology, 2015, 22, 94-101.	4.3	89
1390	Imaging Tumor Metabolism Using In Vivo Magnetic Resonance Spectroscopy. Cancer Journal (Sudbury,) 2015, 21, 100-107.	2.0	31
1391	Mutant <i>IDH1</i> is sufficient to initiate enchondromatosis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2829-2834.	7.1	115
1392	Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. European Journal of Neurology, 2015, 22, 348-354.	3.3	48
1393	Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma. Journal of Clinical Neuroscience, 2015, 22, 1219-1226.	1.5	41
1394	Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets. Cancers, 2015, 7, 538-555.	3.7	103
1395	Malignant Glioma: Viewpoint on Chemotherapy. , 2015, , 279-293.		0
1396	Genomic Applications in Brain Tumors. , 2015, , 321-339.		0
1398	IDH1, a CHOP and C/EBP β -responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis. Cancer Letters, 2015, 365, 201-210.	7.2	43
1399	Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 165-171.	3.4	44
1400	Targeting Mitochondria: A Powerhouse Approach to Cancer Treatment. , 2015, , 263-276.		1
1401	Genome-Based Multi-targeting of Cancer: Hype or Hope?. , 2015, , 19-56.		4
1402	Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 809-827.	7.7	162
1403	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	7.7	74
1404	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	7.7	272

#	ARTICLE	IF	CITATIONS
1405	Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 789-808.	7.7	45
1406	MRI findings and pathological features in early-stage glioblastoma. Journal of Neuro-Oncology, 2015, 123, 289-297.	2.9	49
1407	5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genetics, 2015, 208, 167-177.	0.4	77
1408	Extracranial growth of glioblastoma multiforme. Journal of Clinical Neuroscience, 2015, 22, 1521-1523.	1.5	25
1409	How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutation Research - Reviews in Mutation Research, 2015, 764, 16-30.	5.5	158
1410	Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping. Expert Review of Anticancer Therapy, 2015, 15, 1-3.	2.4	19
1411	Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma. Journal of Clinical Oncology, 2015, 33, e27-e31.	1.6	18
1412	TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Research, 2015, 75, 2833-2843.	0.9	80
1413	Upfront chemotherapy and subsequent resection for molecularly defined gliomas. Journal of Neuro-Oncology, 2015, 124, 127-135.	2.9	18
1414	Brain Tumor Stem Cells. Molecular Pathology Library, 2015, , 23-34.	0.1	1
1416	Biomarker-driven diagnosis of diffuse gliomas. Molecular Aspects of Medicine, 2015, 45, 87-96.	6.4	71
1417	Decreased Expression of miR-15b in Human Gliomas Is Associated with Poor Prognosis. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 169-173.	1.0	25
1418	Immunotherapy for malignant glioma. , 2015, 6, 68.		36
1419	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. Expert Opinion on Therapeutic Targets, 2015, 19, 1187-1202.	3.4	16
1420	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathology and Applied Neurobiology, 2015, 41, 694-720.	3.2	83
1421	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	16.8	327
1422	Bevacizumab and other novel therapies for recurrent oligodendroglial tumors. CNS Oncology, 2015, 4, 333-339.	3.0	4
1423	Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Science Signaling, 2015, 8, ra125.	3.6	52

#	ARTICLE	IF	CITATIONS
1424	Advances in the treatment of newly diagnosed glioblastoma. BMC Medicine, 2015, 13, 293.	5.5	36
1425	Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 tesla for characterization of differences in metabolite levels. Journal of Magnetic Resonance Imaging, 2015, 41, 1332-1341.	3.4	44
1426	Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia, 2015, 29, 2134-2142.	7.2	77
1428	Unravelling tumour heterogeneityâ€™implications for therapy. Nature Reviews Clinical Oncology, 2015, 12, 69-70.	27.6	89
1429	EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. British Journal of Neurosurgery, 2015, 29, 23-29.	0.8	35
1430	Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas. Cancer Letters, 2015, 357, 566-574.	7.2	25
1431	Targeting respiratory complex I to prevent the Warburg effect. International Journal of Biochemistry and Cell Biology, 2015, 63, 41-45.	2.8	28
1433	Pediatric High-Grade Gliomas and DIPG. Molecular Pathology Library, 2015, , 95-104.	0.1	0
1434	TET Family Proteins: Oxidation Activity, Interacting Molecules, and Functions in Diseases. Chemical Reviews, 2015, 115, 2225-2239.	47.7	89
1435	Mitochondrial dependency in progression of acute myeloid leukemia. Mitochondrion, 2015, 21, 41-48.	3.4	57
1436	Practical Molecular Pathologic Diagnosis of Infiltrating Gliomas. Surgical Pathology Clinics, 2015, 8, 49-61.	1.7	3
1437	5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 144-154.	7.4	69
1438	Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development. Cold Spring Harbor Perspectives in Biology, 2015, 7, a020610.	5.5	163
1439	Glioblastoma. , 2015, , 909-917.		6
1440	Genomic discoveries in adult astrocytoma. Current Opinion in Genetics and Development, 2015, 30, 17-24.	3.3	17
1441	Famine versus feast: understanding the metabolism of tumors in vivo. Trends in Biochemical Sciences, 2015, 40, 130-140.	7.5	150
1442	<sc>FOXO</sc> s support the metabolic requirements of normal and tumor cells by promoting <sc>IDH</sc> 1 expression. EMBO Reports, 2015, 16, 456-466.	4.5	38
1443	Pleomorphic Xanthoastrocytoma: Natural History and Longâ€™Term Followâ€™Up. Brain Pathology, 2015, 25, 575-586.	4.1	188

#	ARTICLE	IF	CITATIONS
1444	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015, 17, 854-861.	1.2	335
1445	Multi-Targeted Approach to Treatment of Cancer. , 2015, , .		1
1446	Survival and low-grade glioma: the emergence of genetic information. <i>Neurosurgical Focus</i> , 2015, 38, E6.	2.3	358
1447	Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. <i>Human Pathology</i> , 2015, 46, 322-326.	2.0	8
1448	Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2015, 122, 317-323.	1.6	9
1449	Metabolomic comparison between cells overexpressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. <i>Journal of Neurochemistry</i> , 2015, 132, 183-193.	3.9	16
1450	Clinical impact of molecular biomarkers in gliomas. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 437-444.	1.5	57
1451	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. <i>Nature Medicine</i> , 2015, 21, 178-184.	30.7	459
1452	Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 286-291.	1.4	18
1453	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. , 2015, 151, 16-31.		205
1454	Robustness of Equations that Define Molecular Subtypes of Glioblastoma Tumors Based on Five Transcripts Measured by RT-PCR. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 41-51.	2.0	2
1455	Rom1 is associated with ROS production and cellular growth in human gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 121, 73-81.	2.9	19
1456	Cancer metabolomics in basic science perspective. <i>Archives of Pharmacal Research</i> , 2015, 38, 372-380.	6.3	24
1457	Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. <i>Tumor Biology</i> , 2015, 36, 655-662.	1.8	117
1459	When cancer and immunology meet. <i>Immunological Reviews</i> , 2015, 263, 2-5.	6.0	0
1460	Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas. <i>Brain Tumor Pathology</i> , 2015, 32, 169-175.	1.7	10
1461	Multinodular and vacuolating neuronal tumor of the cerebrum. <i>Brain Tumor Pathology</i> , 2015, 32, 131-136.	1.7	42
1462	Biomarkers for glioma immunotherapy: the next generation. <i>Journal of Neuro-Oncology</i> , 2015, 123, 359-372.	2.9	23

#	ARTICLE	IF	CITATIONS
1463	Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. <i>Neurosurgical Focus</i> , 2015, 38, E2.	2.3	42
1464	Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. <i>Journal of Neuro-Oncology</i> , 2015, 121, 141-150.	2.9	92
1465	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. <i>Acta Neuropathologica</i> , 2015, 129, 669-678.	7.7	277
1466	Glioblastoma antigen discoveryâ€”foundations for immunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 347-358.	2.9	7
1467	A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. <i>Cell Reports</i> , 2015, 11, 1809-1821.	6.4	82
1468	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
1469	Metabolic dysregulation in monogenic disorders and cancer â€” finding method in madness. <i>Nature Reviews Cancer</i> , 2015, 15, 440-448.	28.4	89
1470	Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. <i>British Journal of Radiology</i> , 2015, 88, 20150354.	2.2	53
1471	Molecularly based management of gliomas in clinical practice. <i>Neurological Sciences</i> , 2015, 36, 1551-1557.	1.9	7
1472	Conditions for ¹³ C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas. <i>Analytical Biochemistry</i> , 2015, 481, 4-6.	2.4	10
1473	Surgical treatment of cervical disc protrusion causing intracranial hypotension following chiropractic manipulation. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1523-1525.	1.5	8
1474	DNA copy number analysis of Grade IIâ€”III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. <i>Acta Neuropathologica Communications</i> , 2015, 3, 34.	5.2	64
1475	Input of molecular analysis in medical management of primary brain tumor patients. <i>Revue Neurologique</i> , 2015, 171, 457-465.	1.5	2
1476	Phase II study of PX-866 in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1270-4.	1.2	77
1477	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. <i>Nature Genetics</i> , 2015, 47, 996-1002.	21.4	348
1478	Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. <i>Experimental Hematology</i> , 2015, 43, 609-624.	0.4	47
1479	IDH1, lipid metabolism and cancer: Shedding new light on old ideas. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 1781-1785.	2.4	33
1480	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015, 130, 407-417.	7.7	237

#	ARTICLE	IF	CITATIONS
1481	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. <i>Molecular Cell</i> , 2015, 59, 345-358.	9.7	125
1482	Enigmas of IDH mutations in hematology/oncology. <i>Experimental Hematology</i> , 2015, 43, 685-697.	0.4	22
1483	Multicentric Low-Grade Gliomas. <i>World Neurosurgery</i> , 2015, 84, 1045-1050.	1.3	5
1484	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. <i>Cell Metabolism</i> , 2015, 22, 508-515.	16.2	190
1485	Genetic architecture of colorectal cancer. <i>Gut</i> , 2015, 64, 1623-1636.	12.1	152
1486	Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 550-555.	0.4	30
1487	The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. <i>Human Pathology</i> , 2015, 46, 1626-1632.	2.0	88
1489	Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP+/NADPH ratio. <i>Cell Death and Differentiation</i> , 2015, 22, 1837-1845.	11.2	85
1490	Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 274-307.	4.4	9
1491	Pheochromocytoma: Gasping for Air. <i>Hormones and Cancer</i> , 2015, 6, 191-205.	4.9	26
1492	Applicable advances in the molecular pathology of glioblastoma. <i>Brain Tumor Pathology</i> , 2015, 32, 153-162.	1.7	12
1493	Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?. <i>Seminars in Radiation Oncology</i> , 2015, 25, 203-209.	2.2	12
1494	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	27.0	2,582
1495	Isocitrate Dehydrogenase (IDH) Mutation in Gliomas. , 2015, , 441-458.		0
1496	Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 124, 197-205.	2.9	15
1497	Accurate Computation of Survival Statistics in Genome-Wide Studies. <i>PLoS Computational Biology</i> , 2015, 11, e1004071.	3.2	24
1498	RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies. <i>Molecular BioSystems</i> , 2015, 11, 2635-2657.	2.9	7
1499	Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK). <i>Molecular Biology of the Cell</i> , 2015, 26, 430-439.	2.1	54

#	ARTICLE	IF	CITATIONS
1500	Molecular profiling of gliomas: potential therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 955-962.	2.4	22
1501	Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas. <i>Biomedical Reports</i> , 2015, 3, 33-37.	2.0	15
1502	Toward precision medicine in glioblastoma: the promise and the challenges. <i>Neuro-Oncology</i> , 2015, 17, 1051-1063.	1.2	178
1503	A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. <i>Experimental and Molecular Pathology</i> , 2015, 98, 568-573.	2.1	14
1504	Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. <i>Clinical Cancer Research</i> , 2015, 21, 286-294.	7.0	92
1505	FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 193-199.	3.4	37
1506	Mouse models of glioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 619-626.	1.5	64
1507	Organ-Specific Cancer Metabolism and Its Potential for Therapy. <i>Handbook of Experimental Pharmacology</i> , 2015, 233, 321-353.	1.8	86
1508	A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 785-799.	1.5	33
1509	Adapting the drivers to the road: a new strategy for cancer evolution?. <i>Annals of Oncology</i> , 2015, 26, 827-829.	1.2	5
1511	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015, 129, 585-596.	7.7	272
1512	Dynamic study of methionine positron emission tomography in patients with glioblastoma with oligodendroglial components. <i>Brain Tumor Pathology</i> , 2015, 32, 253-260.	1.7	4
1513	HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. <i>Journal of Neuro-Oncology</i> , 2015, 122, 303-312.	2.9	36
1514	Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma. <i>BMC Genomics</i> , 2015, 16, S1.	2.8	35
1515	TET proteins and the control of cytosine demethylation in cancer. <i>Genome Medicine</i> , 2015, 7, 9.	8.2	176
1516	Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 4.	5.2	100
1517	Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating β -oxygenation pathway in colorectal cancer. <i>International Journal of Oncology</i> , 2015, 46, 1181-1191.	3.3	17
1518	Modular Synthesis of Cell-Permeating 2-Ketoglutarate Esters. <i>Organic Letters</i> , 2015, 17, 2326-2329.	4.6	17

#	ARTICLE	IF	CITATIONS
1519	Molecular and Genomic Alterations in Glioblastoma Multiforme. American Journal of Pathology, 2015, 185, 1820-1833.	3.8	141
1520	Markers for bone sarcomas. , 2015, , 273-285.		2
1521	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	6.1	86
1522	Anaplastic glioma: current treatment and management. Expert Review of Neurotherapeutics, 2015, 15, 601-620.	2.8	21
1523	Mitochondrial control by DRP1 in brain tumor initiating cells. Nature Neuroscience, 2015, 18, 501-510.	14.8	306
1524	Viral Pseudo-Enzymes Activate RIG-I via Deamidation to Evade Cytokine Production. Molecular Cell, 2015, 58, 134-146.	9.7	66
1525	Metabolic consequences of oncogenic IDH mutations. , 2015, 152, 54-62.		125
1526	Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 829-848.	7.7	503
1527	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
1528	Oncometabolites: tailoring our genes. FEBS Journal, 2015, 282, 2796-2805.	4.7	112
1529	Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis. Advances in Anatomic Pathology, 2015, 22, 50-58.	4.3	78
1530	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. Journal of Neuro-Oncology, 2015, 123, 373-383.	2.9	14
1531	IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia. Cancer Research, 2015, 75, 2005-2016.	0.9	48
1532	Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. American Journal of Surgical Pathology, 2015, 39, 454-461.	3.7	25
1533	Potentially Modifiable Risk Factors For Acute Kidney Injury After Surgery on The Thoracic Aorta. Medicine (United States), 2015, 94, e273.	1.0	54
1534	Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. Journal of Neuro-Oncology, 2015, 122, 529-537.	2.9	12
1535	Malignant Transformation of Low-Grade Gliomas in Children: Lessons Learned From Rare Medical Events. Journal of Clinical Oncology, 2015, 33, 978-979.	1.6	9
1536	Hypoxia-inducible factors in cancer stem cells and inflammation. Trends in Pharmacological Sciences, 2015, 36, 374-383.	8.7	96

#	ARTICLE	IF	CITATIONS
1537	Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. <i>Neuro-Oncology</i> , 2015, 17, 1231-1240.	1.2	102
1538	A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 636-642.	2.1	4
1539	Mutational landscape and clonal architecture in grade II and III gliomas. <i>Nature Genetics</i> , 2015, 47, 458-468.	21.4	729
1540	Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification. <i>Seminars in Radiation Oncology</i> , 2015, 25, 155-163.	2.2	62
1541	Identification of novel hereditary cancer genes by whole exome sequencing. <i>Cancer Letters</i> , 2015, 369, 274-288.	7.2	31
1542	Emerging circulating biomarkers in glioblastoma: promises and challenges. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1311-1323.	3.1	60
1543	IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status. <i>Radiotherapy and Oncology</i> , 2015, 116, 381-387.	0.6	33
1544	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. <i>Journal of Neuro-Oncology</i> , 2015, 125, 401-410.	2.9	59
1545	Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML. <i>Annals of Hematology</i> , 2015, 94, 1991-2001.	1.8	3
1546	MicroRNA as potential biomarkers in Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 237-248.	2.9	47
1547	Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. <i>Science Translational Medicine</i> , 2015, 7, 303ra138.	12.4	227
1548	The <i>cpk</i> model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F492-F498.	2.7	33
1549	BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1685-1690.	1.0	28
1550	Early cognitive function tests predict early progression in glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 137-143.	1.6	14
1551	Mapping p53 Mutations in Low-Grade Glioma: A Voxel-Based Neuroimaging Analysis. <i>American Journal of Neuroradiology</i> , 2015, 36, 70-76.	2.4	26
1552	The role of neuropathology in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 531-549.	2.9	120
1553	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59.	4.1	49
1554	Predictors of survival and effect of short (40Gy) or standard-course (60Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015, 125, 359-367.	2.9	42

#	ARTICLE	IF	CITATIONS
1555	Epigenetic-based therapy: From single- to multi-target approaches. International Journal of Biochemistry and Cell Biology, 2015, 69, 121-131.	2.8	40
1556	Targeting cancer epigenetics: Linking basic biology to clinical medicine. Advanced Drug Delivery Reviews, 2015, 95, 56-64.	13.7	34
1557	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Journal of Neuro-Oncology, 2015, 124, 413-420.	2.9	27
1558	Case-Based Review: newly diagnosed glioblastoma. Neuro-Oncology Practice, 2015, 2, 106-121.	1.6	13
1559	The mitochondrial side of epigenetics. Physiological Genomics, 2015, 47, 299-307.	2.3	72
1560	Next-generation sequencing to guide cancer therapy. Genome Medicine, 2015, 7, 80.	8.2	251
1561	Absence of EGFR, ERBB2 and ERBB4 mutation homologous to the oncogenic ERBB3 Val-104 mutation in colorectal cancers. Apmis, 2015, 123, 87-88.	2.0	0
1562	IC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Annals of Neurology, 2015, 78, 355-374.	5.3	71
1563	Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. Journal of Neuro-Oncology, 2015, 124, 385-392.	2.9	6
1564	A high-sensitive HMAb-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Biochemical and Biophysical Research Communications, 2015, 466, 733-739.	2.1	13
1565	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist, 2015, 20, 1019-1027.	3.7	112
1566	D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. Cell Death and Disease, 2015, 6, e1704-e1704.	6.3	27
1567	The functional relevance of somatic synonymous mutations in melanoma and other cancers. Pigment Cell and Melanoma Research, 2015, 28, 673-684.	3.3	47
1568	Evaluation of a ring enhancing lesion. BMJ, The, 2015, 351, h5033.	6.0	0
1569	Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. Neuro-Oncology, 2015, 17, 1525-1537.	1.2	75
1570	IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. Journal of Neuro-Oncology, 2015, 124, 493-500.	2.9	9
1571	TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications, 2015, 6, 7207.	12.8	42
1572	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	2.8	31

#	ARTICLE	IF	CITATIONS
1573	Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. Journal of Medicinal Chemistry, 2015, 58, 6899-6908.	6.4	63
1574	Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell, 2015, 28, 318-328.	16.8	242
1575	Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Research, 2015, 75, 4790-4802.	0.9	127
1576	Central Nervous System Tumors. , 2015, , 537-565.		0
1577	Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncology, 2015, 1, 662.	7.1	68
1578	Research into cancer metabolomics: Towards a clinical metamorphosis. Seminars in Cell and Developmental Biology, 2015, 43, 52-64.	5.0	36
1579	IDH1 mutation-associated long non-coding RNA expression profile changes in glioma. Journal of Neuro-Oncology, 2015, 125, 253-263.	2.9	16
1580	Structure, regulation, and function of TET family proteins. , 2015, , 379-395.		4
1581	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncology, 2015, 4, 287-294.	3.0	48
1582	NADP+IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. Molecular Cell, 2015, 60, 661-675.	9.7	175
1583	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. Archives of Pathology and Laboratory Medicine, 2015, 139, 1087-1093.	2.5	13
1584	Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. Neuroradiology, 2015, 57, 1111-1120.	2.2	9
1585	Epigenetic Reprogramming in Cancer. Epigenetics and Human Health, 2015, , 193-223.	0.2	4
1587	Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule. Journal of Biological Chemistry, 2015, 290, 762-774.	3.4	111
1588	Neuroimaging and Genetic Influence in Treating Brain Neoplasms. Neuroimaging Clinics of North America, 2015, 25, 121-140.	1.0	5
1589	Angiotensin-converting enzyme insertion/deletion gene polymorphisms is associated with risk of glioma in a Chinese population. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 443-447.	1.7	9
1590	Epigenetic Mechanisms in Cellular Reprogramming. Epigenetics and Human Health, 2015, , .	0.2	2
1591	Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genetics in Medicine, 2015, 17, 610-620.	2.4	91

#	ARTICLE	IF	CITATIONS
1592	Emerging Interplay of Genetics and Epigenetics in Gliomas: A New Hope for Targeted Therapy. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 14-22.	2.0	12
1593	Peptide vaccines for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 123, 433-440.	2.9	41
1594	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146.	7.7	378
1595	Glioma Biology and Molecular Markers. <i>Cancer Treatment and Research</i> , 2015, 163, 15-30.	0.5	161
1596	TET proteins and 5methylcytosine oxidation in hematological cancers. <i>Immunological Reviews</i> , 2015, 263, 6-21.	6.0	158
1597	Epigenetics in T-cell acute lymphoblastic leukemia. <i>Immunological Reviews</i> , 2015, 263, 50-67.	6.0	61
1598	The role of mutations in epigenetic regulators in myeloid malignancies. <i>Immunological Reviews</i> , 2015, 263, 22-35.	6.0	46
1599	Molecular Genetic Biomarkers in Myeloid Malignancies. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 594-601.	2.5	14
1601	Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. <i>Brain Pathology</i> , 2015, 25, 418-428.	4.1	8
1602	ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/ β 2-catenin activity. <i>Cancer Letters</i> , 2015, 357, 404-411.	7.2	35
1603	Imaging Genomics of Glioblastoma. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 141-153.	1.0	37
1604	IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients. <i>Epilepsy Research</i> , 2015, 109, 100-105.	1.6	58
1605	Current Understanding and Treatment of Gliomas. <i>Cancer Treatment and Research</i> , 2015, , .	0.5	11
1606	Methionine and cystine double deprivation stress suppresses glioma proliferation via inducing ROS/autophagy. <i>Toxicology Letters</i> , 2015, 232, 349-355.	0.8	41
1607	Deregulated proliferation and differentiation in brain tumors. <i>Cell and Tissue Research</i> , 2015, 359, 225-254.	2.9	28
1608	Successive distinct high-grade gliomas in L-hydroxyglutaric aciduria. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 273-277.	3.6	20
1609	Cancer cell metabolism and the modulating effects of nitric oxide. <i>Free Radical Biology and Medicine</i> , 2015, 79, 324-336.	2.9	86
1610	Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity. <i>Cancer Letters</i> , 2015, 356, 217-223.	7.2	97

#	ARTICLE	IF	CITATIONS
1611	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 85-94.	1.6	107
1612	Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. <i>Oncogene</i> , 2015, 34, 2125-2137.	5.9	24
1613	Epigenetics and cancer metabolism. <i>Cancer Letters</i> , 2015, 356, 309-314.	7.2	90
1614	IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. <i>Gene</i> , 2015, 554, 81-86.	2.2	24
1615	Mitochondrial energy metabolism and apoptosis regulation in glioblastoma. <i>Brain Research</i> , 2015, 1595, 127-142.	2.2	30
1616	Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. <i>Brain Tumor Pathology</i> , 2015, 32, 3-11.	1.7	62
1617	Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite <scp>d</scp>-2-Hydroxyglutarate. <i>ACS Chemical Biology</i> , 2015, 10, 510-516.	3.4	152
1618	IDH1/2 mutation detection in gliomas. <i>Brain Tumor Pathology</i> , 2015, 32, 79-89.	1.7	44
1619	Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications. <i>Leukemia</i> , 2015, 29, 269-278.	7.2	38
1620	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. <i>Modern Pathology</i> , 2015, 28, 177-186.	5.5	107
1621	Molecular Genetics of Glioblastomas. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 97-103.	1.0	7
1622	Epigenetics and Cancer. , 2015, , 67-78.e3.		0
1623	Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. <i>Cancer</i> , 2015, 121, 502-516.	4.1	120
1624	Investigational cancer drugs targeting cell metabolism in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 79-94.	4.1	58
1625	Genomic Applications in Pathology. , 2015, , .		1
1626	Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. <i>Brain Tumor Pathology</i> , 2015, 32, 22-30.	1.7	65
1627	Genetic Alterations of Glioblastoma. , 0, , .		2
1628	Oligoastrocytoma: A Vanishing Tumor Entity. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1630	Molecular Advances in Glioblastoma Neuropathology. , 0, , .		3
1632	Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. <i>Oncotarget</i> , 2016, 7, 45005-45014.	1.8	10
1633	The Story of Glioblastoma: History and Modern Correlates. , 2016, , 1-9.		0
1634	Brain Tumors: Epidemiology and Current Trends in Treatment. <i>Journal of Brain Tumors & Neurooncology</i> , 2016, 01, .	0.1	6
1635	Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis. <i>Frontiers in Oncology</i> , 2016, 6, 211.	2.8	7
1636	Glioblastoma stem cells: a therapeutic challenge. <i>Turkish Journal of Biology</i> , 2016, 40, 990-997.	0.8	0
1637	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 75-81.	3.8	17
1638	Hallmarks of glioblastoma: a systematic review. <i>ESMO Open</i> , 2016, 1, e000144.	4.5	122
1639	Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art. <i>BioMed Research International</i> , 2016, 2016, 1-11.	1.9	50
1640	Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets. <i>Stem Cells International</i> , 2016, 2016, 1-20.	2.5	91
1641	A Genomic Study of DNA Alteration Events Caused by Ionizing Radiation in Human Embryonic Stem Cells via Next-Generation Sequencing. <i>Stem Cells International</i> , 2016, 2016, 1-7.	2.5	3
1642	17 Tumor genomicsGenomicsOn the Horizon: Tumor Genomics. , 2016, , .		0
1643	<i>In-Vivo</i> Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. <i>Korean Journal of Radiology</i> , 2016, 17, 620.	3.4	31
1644	Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. <i>Oncotarget</i> , 2016, 7, 21763-21774.	1.8	80
1645	Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation. <i>Frontiers in Oncology</i> , 2016, 6, 16.	2.8	60
1646	Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique. <i>Frontiers in Oncology</i> , 2016, 6, 46.	2.8	6
1647	ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 984.	4.1	104
1648	ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1276.	4.1	27

#	ARTICLE	IF	CITATIONS
1649	Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. International Journal of Molecular Sciences, 2016, 17, 1876.	4.1	11
1650	Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla. Journal of Translational Medicine, 2016, 14, 274.	4.4	35
1651	Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data. PLoS ONE, 2016, 11, e0160489.	2.5	39
1652	Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines. PLoS ONE, 2016, 11, e0168728.	2.5	4
1653	Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. Journal of Korean Medical Science, 2016, 31, 1208.	2.5	56
1654	IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. Journal of Blood Medicine, 2016, Volume 7, 171-180.	1.7	176
1655	Evolving Molecular Genetics of Glioblastoma. Chinese Medical Journal, 2016, 129, 464-471.	2.3	41
1656	Frameshift mutations of OGDH, PPAT and PCCA genes in gastric and colorectal cancers. Neoplasma, 2016, 63, 681-686.	1.6	12
1657	IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC. PLoS ONE, 2016, 11, e0161261.	2.5	16
1658	Immunotherapy for gliomas. , 0, , 91-120.		0
1659	Neuropathology of gliomas. , 0, , 146-168.		0
1660	Chemotherapy for gliomas. , 0, , 76-90.		0
1661	Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. Brain Pathology, 2016, 26, 206-214.	4.1	25
1662	Clinical ramifications of "genomic staging" of low-grade gliomas. Journal of Neuro-Oncology, 2016, 129, 195-199.	2.9	11
1663	Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Journal of Neuro-Oncology, 2016, 129, 505-514.	2.9	116
1664	Detection of Human Brain Tumor Infiltration With Quantitative Stimulated Raman Scattering Microscopy. Neurosurgery, 2016, 78, N9-N11.	1.1	7
1665	Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. Journal of Pediatric Hematology/Oncology, 2016, 38, 249-260.	0.6	26
1666	Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase. International Journal of Hematology, 2016, 104, 491-501.	1.6	10

#	ARTICLE	IF	CITATIONS
1667	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. <i>International Journal of Cancer</i> , 2016, 139, 424-432.	5.1	18
1668	Metabolic, autophagic, and mitophagic activities in cancer initiation and progression. <i>Biomedical Journal</i> , 2016, 39, 98-106.	3.1	23
1669	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. <i>Cancer</i> , 2016, 122, 2206-2215.	4.1	77
1670	MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 823-833.	3.4	36
1671	Current status of biomarker research in neurology. <i>EPMA Journal</i> , 2016, 7, 14.	6.1	36
1672	2-Hydroxy-Glutarate 3-Dimensional Functional Spectroscopy in the Evaluation of Isocitrate Dehydrogenase-Mutant Glioma Response to Therapy. <i>Neurosurgery</i> , 2016, 78, N9.	1.1	2
1673	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. <i>Neuro-Oncology</i> , 2016, 18, now100.	1.2	30
1674	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. <i>Neuro-Oncology</i> , 2016, 18, 1357-1366.	1.2	116
1675	Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 169-176.	2.8	3
1676	Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. <i>Brain Pathology</i> , 2016, 26, 517-522.	4.1	63
1677	Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. <i>Histopathology</i> , 2016, 69, 260-267.	2.9	54
1678	Adult Diffuse Astrocytoma in the Medulla Oblongata: Molecular Biological Analyses Including H3F3A Mutation of Histone H3.3. <i>NMC Case Report Journal</i> , 2016, 3, 29-33.	0.5	2
1679	Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. <i>Neurologia Medico-Chirurgica</i> , 2016, 56, 170-179.	2.2	18
1680	Visualization of heterogeneity and regional grading of gliomas by multiple features using magnetic resonance-based clustered images. <i>Scientific Reports</i> , 2016, 6, 30344.	3.3	14
1681	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
1682	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. <i>Neuro-Oncology</i> , 2017, 19, now236.	1.2	39
1683	Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma. <i>Scientific Reports</i> , 2016, 6, 35142.	3.3	52
1684	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 15084-15089.	7.1	96

#	ARTICLE	IF	CITATIONS
1685	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. <i>Cancer Research</i> , 2016, 76, 7118-7129.	0.9	99
1686	Current management of low-grade gliomas. <i>Current Opinion in Neurology</i> , 2016, 29, 782-788.	3.6	26
1687	World Health Organization grade II astrocytomas consist of genetically distinct tumor lineages. <i>Cancer Science</i> , 2016, 107, 1159-1164.	3.9	21
1688	Genetics of glioma. , 0, , 1-23.		1
1689	Beyond the Oncogene Revolution: Four New Ways to Combat Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 85-92.	1.1	6
1690	SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. <i>EBioMedicine</i> , 2016, 13, 80-89.	6.1	43
1691	Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. <i>Journal of Hematology and Oncology</i> , 2016, 9, 49.	17.0	124
1692	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 681-691.	4.4	46
1693	Detecting isocitrate dehydrogenase gene mutations in oligodendroglial tumors using diffusion tensor imaging metrics and their correlations with proliferation and microvascular density. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 45-54.	3.4	28
1695	Role of mitochondrial dysfunction in cancer progression. <i>Experimental Biology and Medicine</i> , 2016, 241, 1281-1295.	2.4	212
1696	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. <i>European Journal of Medicinal Chemistry</i> , 2016, 119, 218-230.	5.5	13
1697	Oncometabolites: Unconventional triggers of oncogenic signalling cascades. <i>Free Radical Biology and Medicine</i> , 2016, 100, 175-181.	2.9	137
1698	High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. <i>World Neurosurgery</i> , 2016, 91, 518-523.e1.	1.3	2
1699	Further understanding of the pathology of glioma: implications for the clinic. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1055-1065.	2.8	32
1700	Investigational new drugs for brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 937-956.	4.1	16
1701	Abundance of LRP12 C-rs9694676 allelic promoter variant in epilepsy-associated gangliogliomas. <i>Life Sciences</i> , 2016, 155, 70-75.	4.3	5
1702	Elevation of Urinary 2-Hydroxyglutarate in <i>IDH</i> -Mutant Glioma. <i>Oncologist</i> , 2016, 21, 214-219.	3.7	33
1703	Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas. <i>Medicine (United States)</i> , 2016, 95, e2583.	1.0	99

#	ARTICLE	IF	CITATIONS
1704	Role of rare germline copy number variation in melanoma-prone patients. <i>Future Oncology</i> , 2016, 12, 1345-1357.	2.4	8
1705	Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2016, 77, 195-200.	0.8	12
1706	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 151, 278-287.e6.	1.3	147
1707	A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. <i>Pituitary</i> , 2016, 19, 407-414.	2.9	12
1708	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. <i>Leukemia</i> , 2016, 30, 1708-1715.	7.2	38
1709	Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. <i>Neuro-Oncology</i> , 2016, 18, now090.	1.2	56
1710	Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. <i>Cancer Cell</i> , 2016, 29, 737-750.	16.8	50
1711	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	7.2	448
1712	Maximizing safe resection of low- and high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 269-282.	2.9	330
1713	Molecular classification of gliomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 97-120.	1.8	90
1714	Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1. <i>Molecular BioSystems</i> , 2016, 12, 2276-2287.	2.9	92
1715	Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. <i>Blood</i> , 2016, 128, 1226-1233.	1.4	185
1716	An update on the epigenetics of glioblastomas. <i>Epigenomics</i> , 2016, 8, 1289-1305.	2.1	19
1717	IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 117-120.	1.5	21
1719	Immunohistochemistry using monoclonal antibody MsMab2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma. <i>Pathology International</i> , 2016, 66, 578-582.	1.3	3
1720	MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. <i>Computational and Structural Biotechnology Journal</i> , 2016, 14, 223-233.	4.1	62
1721	Interrogating Metabolism in Brain Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 687-703.	1.1	17
1722	Hyperpolarized ¹³ C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. <i>NeuroImage: Clinical</i> , 2016, 12, 180-189.	2.7	57

#	ARTICLE	IF	CITATIONS
1723	Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis. <i>Pathology Research and Practice</i> , 2016, 212, 838-841.	2.3	0
1724	Actionable Molecular Biomarkers in Primary Brain Tumors. <i>Trends in Cancer</i> , 2016, 2, 338-349.	7.4	41
1725	High-Grade Gliomas. , 2016, , 469-482.e4.		1
1726	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532.	10.7	396
1727	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. <i>Acta Neuropathologica Communications</i> , 2016, 4, 79.	5.2	189
1728	Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With <i>IDH</i>-Mutant Glioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4030-4039.	1.6	157
1729	Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis. <i>Cancer Cell</i> , 2016, 30, 578-594.	16.8	122
1730	An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. <i>Science and Technology of Advanced Materials</i> , 2016, 17, 618-625.	6.1	12
1731	Mutant IDH1 and thrombosis in gliomas. <i>Acta Neuropathologica</i> , 2016, 132, 917-930.	7.7	130
1732	Transcription factors as readers and effectors of DNA methylation. <i>Nature Reviews Genetics</i> , 2016, 17, 551-565.	16.3	482
1733	In Vivo Determination of Mitochondrial Function Using Luciferase-Expressing <i>Caenorhabditis elegans</i>: Contribution of Oxidative Phosphorylation, Glycolysis, and Fatty Acid Oxidation to Toxicant-Induced Dysfunction. <i>Current Protocols in Toxicology</i> / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2016, 69, 25.8.1-25.8.22.	1.1	25
1734	Astrocytic gliomas WHO grades II and III. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 345-360.	1.8	11
1735	Emerging biological therapies for the treatment of myelodysplastic syndromes. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 283-300.	2.4	15
1736	Magnetic Resonance Spectroscopy. , 2016, , 327-334.		1
1737	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. <i>Current Treatment Options in Oncology</i> , 2016, 17, 51.	3.0	32
1738	Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 457-473.	1.7	42
1739	Molecular Pathology. <i>Surgical Pathology Clinics</i> , 2016, 9, 489-521.	1.7	3
1740	Concepts in glioma immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1269-1275.	4.2	52

#	ARTICLE	IF	CITATIONS
1741	Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. <i>Cell Reports</i> , 2016, 16, 1604-1613.	6.4	47
1742	Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic <i>IDH1</i> . <i>Molecular and Cellular Biology</i> , 2016, 36, 2384-2395.	2.3	25
1743	Mitochondrial metabolic remodeling in response to genetic and environmental perturbations. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2016, 8, 272-285.	6.6	17
1744	<i>RUNX3</i> is downregulated in glioma by Myc-regulated miR-4295. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 518-525.	3.6	16
1745	Sequencing Structural Variants in Cancer for Precision Therapeutics. <i>Trends in Genetics</i> , 2016, 32, 530-542.	6.7	86
1746	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , 2016, 132, 625-634.	7.7	85
1747	Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India. <i>Translational Oncology</i> , 2016, 9, 371-376.	3.7	11
1748	Fractional Anisotropy Correlates with Overall Survival in Glioblastoma. <i>World Neurosurgery</i> , 2016, 95, 525-534.e1.	1.3	6
1749	ZEB1 expression is increased in IDH1-mutant lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 130, 111-122.	2.9	14
1750	Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. <i>Neuro-Oncology</i> , 2016, 18, 1656-1663.	1.2	110
1751	A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a <i>Drosophila</i> hydroxyglutaric aciduria type II mouse model. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 807-820.	3.6	11
1752	Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 944-949.	2.8	21
1754	Putamen involvement and survival outcomes in patients with insular low-grade gliomas. <i>Journal of Neurosurgery</i> , 2016, 126, 1788-1794.	1.6	22
1755	Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1. <i>Biochemical and Biophysical Research Communications</i> , 2016, 478, 1274-1279.	2.1	4
1756	Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. <i>Surgical Pathology Clinics</i> , 2016, 9, 379-390.	1.7	4
1757	The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. <i>Acta Neurochirurgica</i> , 2016, 158, 1943-1953.	1.7	37
1758	Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?. <i>Cancer Research</i> , 2016, 76, 5195-5200.	0.9	41
1759	Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. <i>Molecular Cancer Research</i> , 2016, 14, 976-983.	3.4	84

#	ARTICLE	IF	CITATIONS
1760	Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma. Brain Tumor Pathology, 2016, 33, 248-254.	1.7	6
1761	Metabolic control of epigenetics in cancer. Nature Reviews Cancer, 2016, 16, 694-707.	28.4	317
1762	miR-148b-3p inhibits malignant biological behaviors of human glioma cells induced by high HOTAIR expression. Oncology Letters, 2016, 12, 879-886.	1.8	45
1763	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	4.6	64
1764	Oncogene-Directed Alterations in Cancer Cell Metabolism. Trends in Cancer, 2016, 2, 365-377.	7.4	136
1765	Genomic Landscape of Brain Tumors. , 2016, , 653-663.		0
1766	Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opinion on Investigational Drugs, 2016, 25, 1007-1009.	4.1	2
1767	Recent advances and future of immunotherapy for glioblastoma. Expert Opinion on Biological Therapy, 2016, 16, 1245-1264.	3.1	57
1768	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004â€“2012, varying). Journal of Neuro-Oncology, 2016, 130, 31-42.	2.9	35
1769	Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nature Reviews Clinical Oncology, 2016, 13, 725-739.	27.6	88
1770	Mutant IDH1 Expression Drives <i>TERT</i> Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Research, 2016, 76, 6680-6689.	0.9	55
1771	Acute myeloid leukaemia. Nature Reviews Disease Primers, 2016, 2, 16010.	30.5	277
1772	Low-grade epilepsy-associated neuroepithelial tumours â€” the 2016 WHO classification. Nature Reviews Neurology, 2016, 12, 732-740.	10.1	113
1773	Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. Human Molecular Genetics, 2016, 25, 3524-3538.	2.9	8
1774	5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. Scientific Reports, 2016, 6, 20882.	3.3	29
1775	Fundamentals of cancer metabolism. Science Advances, 2016, 2, e1600200.	10.3	2,039
1776	An expression based REST signature predicts patient survival and therapeutic response for glioblastoma multiforme. Scientific Reports, 2016, 6, 34556.	3.3	14
1777	Emerging targeted therapies for glioma. Expert Opinion on Emerging Drugs, 2016, 21, 441-452.	2.4	45

#	ARTICLE	IF	CITATIONS
1778	Tissue mechanics promote IDH1-dependent HIF1 α -tenascin C feedback to regulate glioblastoma aggression. <i>Nature Cell Biology</i> , 2016, 18, 1336-1345.	10.3	259
1779	Papilloedema secondary to oligodendroglioma. <i>Australasian journal of optometry</i> , The, 2016, 99, 507-517.	1.3	2
1780	Quantitative Analysis of the Cellular Microenvironment of Glioblastoma to Develop Predictive Statistical Models of Overall Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 1110-1123.	1.7	17
1781	The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. <i>Nature Communications</i> , 2016, 7, 12700.	12.8	134
1782	IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients. <i>Pathology</i> , 2016, 48, 675-683.	0.6	26
1783	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. <i>Neuro-Oncology</i> , 2016, 18, v1-v75.	1.2	995
1785	Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study. <i>Neurosurgery</i> , 2017, 80, 590-601.	1.1	34
1786	Molecular imaging of 1p/19q deletion in oligodendroglial tumours with ¹¹ C-methionine positron emission tomography. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1016-1021.	1.9	32
1788	Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. <i>Current Opinion in Oncology</i> , 2016, 28, 494-501.	2.4	62
1789	Combined ∞ infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma Harboring IDH1 R132H and BRAF V600E Mutations. <i>American Journal of Surgical Pathology</i> , 2016, 40, 279-284.	3.7	14
1791	Genomic Characterization of Isocitrate Dehydrogenase-1 α Mutant Glioma Malignant Progression. <i>Neurosurgery</i> , 2016, 78, N8-N9.	1.1	0
1792	Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 147-154.	2.9	36
1793	Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 1285-1306.	8.5	118
1794	DNA repair mechanisms and their clinical impact in glioblastoma. <i>Mutation Research - Reviews in Mutation Research</i> , 2016, 769, 19-35.	5.5	128
1795	Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis. <i>ACS Chemical Biology</i> , 2016, 11, 2420-2427.	3.4	37
1796	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. <i>Public Health Genomics</i> , 2016, 19, 170-177.	1.0	2
1798	Anaplastic astrocytoma. <i>CNS Oncology</i> , 2016, 5, 145-157.	3.0	51
1799	Immunotherapy in glioblastoma: emerging options in precision medicine. <i>CNS Oncology</i> , 2016, 5, 175-186.	3.0	11

#	ARTICLE	IF	CITATIONS
1800	Mutational status of IDH1 in uveal melanoma. <i>Experimental and Molecular Pathology</i> , 2016, 100, 476-481.	2.1	6
1801	A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. <i>Clinical and Translational Medicine</i> , 2016, 5, 3.	4.0	65
1802	Characteristics of gliomas in patients with somatic IDH mosaicism. <i>Acta Neuropathologica Communications</i> , 2016, 4, 31.	5.2	29
1803	Diffusion Magnetic Resonance Imaging in Brain Tumors. , 2016, , 273-300.		0
1804	Cancer metabolism as a central driving force of glioma pathogenesis. <i>Brain Tumor Pathology</i> , 2016, 33, 161-168.	1.7	38
1805	Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. <i>Clinical Cancer Research</i> , 2016, 22, 6256-6265.	7.0	43
1806	Give it or take it: the flux of oneâ€carbon in cancer cells. <i>FEBS Journal</i> , 2016, 283, 3695-3704.	4.7	34
1807	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. <i>Acta Neuropathologica</i> , 2016, 131, 833-845.	7.7	288
1808	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 15.	4.2	23
1809	Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv409.	6.3	31
1810	Current status of publicly available sarcoma cell lines for use in proteomic studies. <i>Expert Review of Proteomics</i> , 2016, 13, 227-240.	3.0	7
1811	Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. <i>Expert Review of Hematology</i> , 2016, 9, 447-469.	2.2	12
1812	Computational Identification of Tumor Anatomic Location Associated with Survival in 2 Large Cohorts of Human Primary Glioblastomas. <i>American Journal of Neuroradiology</i> , 2016, 37, 621-628.	2.4	27
1813	IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2016, 127, 363-372.	2.9	48
1814	Search for new loci and low-frequency variants influencing glioma risk by exome-array analysis. <i>European Journal of Human Genetics</i> , 2016, 24, 717-724.	2.8	8
1815	Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era. <i>Journal of Clinical Neuroscience</i> , 2016, 24, 105-111.	1.5	35
1816	Has the survival of patients with glioblastoma changed over the years?. <i>British Journal of Cancer</i> , 2016, 114, 146-150.	6.4	54
1817	Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1349-1363.	5.4	101

#	ARTICLE	IF	CITATIONS
1818	Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 127, 23-32.	2.9	13
1819	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.8	289
1820	Superior Efficacy of Gross Total Resection in Anaplastic Astrocytoma Patients Relative to Glioblastoma Patients. <i>World Neurosurgery</i> , 2016, 90, 186-193.	1.3	13
1821	Public Databases. , 2016, , 53-58.		0
1822	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 497-521.	22.4	37
1823	Magnetic resonance analysis of malignant transformation in recurrent glioma. <i>Neuro-Oncology</i> , 2016, 18, 1169-1179.	1.2	28
1824	IDH mutations in cancer and progress toward development of targeted therapeutics. <i>Annals of Oncology</i> , 2016, 27, 599-608.	1.2	367
1825	Molecular Subtypes of <i>KIT/PDGFRα</i> Wild-Type Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2016, 2, 922.	7.1	291
1826	Distinctive Genetic Profile With <i>IDH1</i> , <i>TP53</i> , and <i>MLH1</i> Mutations in a Radiation-Induced Anaplastic Astrocytoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 179-179.	1.5	1
1827	Rare glial tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 399-415.	1.8	10
1828	In Unraveling a Novel Mechanism Behind Cancer Cells, Researchers Report a Potential New Approach to Blocking Gliomas. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2016, 16, 1.	0.0	3
1829	Genotyping low-grade gliomas among Hispanics. <i>Neuro-Oncology Practice</i> , 2016, 3, 164-172.	1.6	4
1831	Development of Glioblastoma after Treatment of Brain Abscess. <i>World Neurosurgery</i> , 2016, 88, 686.e19-686.e25.	1.3	2
1832	Prioritization schema for immunotherapy clinical trials in glioblastoma. <i>Oncolimmunology</i> , 2016, 5, e1145332.	4.6	13
1833	Bringing IDH into the Fold. <i>Cancer Cell</i> , 2016, 29, 139-140.	16.8	2
1834	Genetic risk variants in the <i>CDKN2A/B</i> , <i>RTEL1</i> and <i>EGFR</i> genes are associated with somatic biomarkers in glioma. <i>Journal of Neuro-Oncology</i> , 2016, 127, 483-492.	2.9	29
1835	R132H mutation in <i>IDH1</i> gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/ β -catenin signaling. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 73, 72-81.	2.8	56
1836	How I treat glioblastoma in older patients. <i>Journal of Geriatric Oncology</i> , 2016, 7, 1-6.	1.0	6

#	ARTICLE	IF	CITATIONS
1837	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016, 164, 550-563.	28.9	1,695
1838	Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1837-1842.	7.0	165
1839	A simplified approach for molecular classification of glioblastomas (GBMs): experience from a tertiary care center in India. <i>Brain Tumor Pathology</i> , 2016, 33, 183-190.	1.7	7
1840	Next-generation sequencing of central nervous systems tumors: the future of personalized patient management. <i>Neuro-Oncology</i> , 2016, 18, 308-310.	1.2	6
1841	Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer. <i>Cancer Research</i> , 2016, 76, 1714-1723.	0.9	68
1842	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
1843	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. <i>Expert Review of Hematology</i> , 2016, 9, 433-445.	2.2	9
1844	Central Nervous System: Progress of Today and a Preview of Tomorrow. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 425-427.	0.8	3
1846	Understanding inherited genetic risk of adult glioma – a review. <i>Neuro-Oncology Practice</i> , 2016, 3, 10-16.	1.6	62
1847	Epidemiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 3-18.	1.8	15
1848	Classification based on mutations of <i>TERT</i> promoter and <i>IDH</i> characterizes subtypes in grade II/III gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1099-1108.	1.2	93
1849	Seizures and gliomas – towards a single therapeutic approach. <i>Nature Reviews Neurology</i> , 2016, 12, 204-216.	10.1	147
1850	Advances in Therapeutic Cancer Vaccines. <i>Advances in Immunology</i> , 2016, 130, 191-249.	2.2	88
1851	Prospective of curcumin, a pleiotropic signalling molecule from <i>Curcuma longa</i> in the treatment of Glioblastoma. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 23-35.	5.5	59
1852	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. <i>Neuro-Oncology</i> , 2016, 18, 283-290.	1.2	161
1853	Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. <i>Journal of Biological Chemistry</i> , 2016, 291, 4256-4265.	3.4	234
1854	ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma (retracted). <i>CNS Oncology</i> , 2016, 5, 11-26.	3.0	21
1855	An epigenetic gateway to brain tumor cell identity. <i>Nature Neuroscience</i> , 2016, 19, 10-19.	14.8	76

#	ARTICLE	IF	CITATIONS
1856	Oncogene brought into the loop. <i>Nature</i> , 2016, 529, 34-35.	27.8	6
1857	Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of <i>IDH</i> Mutation Status and Tumor Progression. <i>American Journal of Neuroradiology</i> , 2016, 37, 66-73.	2.4	56
1858	The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival. <i>Carcinogenesis</i> , 2016, 37, 169-176.	2.8	14
1859	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 4-18.	1.7	81
1860	Glioblastomas with <i>IDH1/2</i> mutations have a short clinical history and have a favorable clinical outcome. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 31-39.	1.3	15
1861	Update on Brain Tumors: New Developments in Neuro-oncologic Diagnosis and Treatment, and Impact on Rehabilitation Strategies. <i>PM and R</i> , 2016, 8, 678-689.	1.6	14
1862	Molecular Pathways: <i>IDH2</i> Mutations "Co-opting Cellular Metabolism for Malignant Transformation. <i>Clinical Cancer Research</i> , 2016, 22, 16-19.	7.0	38
1863	Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application. <i>Journal of Neurosurgery</i> , 2016, 124, 1611-1618.	1.6	8
1864	Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. <i>Journal of Neurosurgery</i> , 2016, 125, 7-16.	1.6	20
1865	Immunotherapy for cancer in the central nervous system: Current and future directions. <i>Oncolmmunology</i> , 2016, 5, e1082027.	4.6	72
1866	RHOA mutation may be associated with diffuse-type gastric cancer progression, but is it gain or loss?. <i>Gastric Cancer</i> , 2016, 19, 326-328.	5.3	8
1867	Myocyte enhancer factor 2D promotes tumorigenicity in malignant glioma cells. <i>Tumor Biology</i> , 2016, 37, 601-610.	1.8	5
1868	Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. <i>Advances and Technical Standards in Neurosurgery</i> , 2016, , 91-108.	0.5	37
1869	Treatment Response Assessment in <i>IDH</i> -Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	7.0	127
1870	Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. <i>European Radiology</i> , 2016, 26, 1705-1715.	4.5	54
1871	<i>In Vivo</i> Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of <i>SDH</i> Mutations in Paraganglioma. <i>Clinical Cancer Research</i> , 2016, 22, 1120-1129.	7.0	54
1872	BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. <i>Brain Tumor Pathology</i> , 2016, 33, 40-49.	1.7	30
1873	Malignant gliomas: old and new systemic treatment approaches. <i>Radiology and Oncology</i> , 2016, 50, 129-138.	1.7	25

#	ARTICLE	IF	CITATIONS
1874	Protein species and moonlighting proteins: Very small changes in a protein's covalent structure can change its biochemical function. <i>Journal of Proteomics</i> , 2016, 134, 19-24.	2.4	59
1875	Low Grade Gliomas in Children. <i>Journal of Child Neurology</i> , 2016, 31, 517-522.	1.4	41
1876	Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. <i>Neurosurgical Review</i> , 2016, 39, 37-46.	2.4	45
1877	Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549â€“BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 89-100.	2.5	46
1878	Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. <i>Neuro-Oncology</i> , 2016, 18, 160-172.	1.2	214
1879	Isocitrate dehydrogenase mutations in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 16-26.	1.2	221
1880	Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population. <i>Molecular Neurobiology</i> , 2017, 54, 2381-2394.	4.0	13
1881	In vivo detection of 2â€“hydroxyglutarate in brain tumors by optimized pointâ€“resolved spectroscopy (PRESS) at 7T. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 936-944.	3.0	40
1882	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. <i>European Radiology</i> , 2017, 27, 1556-1567.	4.5	26
1883	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 109-117.	1.2	211
1884	An IDH1-mutated primary gliosarcoma: case report. <i>Journal of Neurosurgery</i> , 2017, 126, 476-480.	1.6	5
1885	ACTC1 as an invasion and prognosis marker in glioma. <i>Journal of Neurosurgery</i> , 2017, 126, 467-475.	1.6	40
1886	The Promoting Effect of Radiation on Glucose Metabolism in Breast Cancer Cells under the Treatment of Cobalt Chloride. <i>Pathology and Oncology Research</i> , 2017, 23, 47-53.	1.9	9
1887	Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. <i>Molecular Cell</i> , 2017, 65, 323-335.	9.7	120
1888	Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 873-882.	2.5	7
1889	(Pro)renin receptor is crucial for glioma development via the Wnt/ β 2-catenin signaling pathway. <i>Journal of Neurosurgery</i> , 2017, 127, 819-828.	1.6	43
1890	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 20-34.	4.4	105
1891	Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study. <i>Journal of Neuro-Oncology</i> , 2017, 132, 55-62.	2.9	26

#	ARTICLE	IF	CITATIONS
1892	Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide. <i>Journal of Neuro-Oncology</i> , 2017, 132, 287-294.	2.9	12
1893	Point mutation (R153H or R153C) in <i>Escherichia coli</i> isocitrate dehydrogenase: Biochemical characterization and functional implication. <i>Journal of Basic Microbiology</i> , 2017, 57, 41-49.	3.3	1
1894	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. <i>Leukemia</i> , 2017, 31, 2020-2028.	7.2	97
1895	Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity. <i>Structure</i> , 2017, 25, 506-513.	3.3	53
1896	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. <i>Molecular Cancer Research</i> , 2017, 15, 507-520.	3.4	41
1897	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	420
1898	Targeted Therapy of IDH1-Mutated Tumors. , 2017, , 151-161.		0
1899	Glioma: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 263-282.	7.7	223
1900	Immunotherapy for High-Grade Gliomas. , 2017, , 177-192.		0
1901	Radiation Therapy for Malignant Gliomas: Current Options. , 2017, , 217-231.		3
1902	Glioblastoma. , 2017, , 265-288.		11
1903	Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. <i>Oncogene</i> , 2017, 36, 3359-3374.	5.9	219
1904	Insular primary glioblastomas with IDH mutations: Clinical and biological specificities. <i>Neuropathology</i> , 2017, 37, 200-206.	1.2	12
1905	Molecular mechanisms involved in gliomagenesis. <i>Brain Tumor Pathology</i> , 2017, 34, 1-7.	1.7	18
1906	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , 2017, 133, 629-644.	7.7	146
1907	Genetic alterations in Krebs cycle and its impact on cancer pathogenesis. <i>Biochimie</i> , 2017, 135, 164-172.	2.6	80
1908	A chemical probe toolbox for dissecting the cancer epigenome. <i>Nature Reviews Cancer</i> , 2017, 17, 160-183.	28.4	76
1909	Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation. <i>Molecular Carcinogenesis</i> , 2017, 56, 1837-1850.	2.7	17

#	ARTICLE	IF	CITATIONS
1910	Prognostic value of survivin and DNA topoisomerase II \pm in diffuse and anaplastic astrocytomas. Pathology Research and Practice, 2017, 213, 339-347.	2.3	2
1911	Molecular markers in glioma. Journal of Neuro-Oncology, 2017, 134, 505-512.	2.9	279
1912	Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Cancer Research, 2017, 77, 1709-1718.	0.9	159
1913	Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. Journal of Clinical Neuroscience, 2017, 39, 170-175.	1.5	32
1914	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Current Neurology and Neuroscience Reports, 2017, 17, 19.	4.2	87
1915	Marked for death: targeting epigenetic changes in cancer. Nature Reviews Drug Discovery, 2017, 16, 241-263.	46.4	244
1916	IDH mutation assessment of glioma using texture features of multimodal MR images. Proceedings of SPIE, 2017, , .	0.8	5
1917	Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma. Radiation Oncology, 2017, 12, 46.	2.7	9
1918	Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics, 2017, 14, 284-297.	4.4	471
1919	Glutaminolysis: A Hallmark of Cancer Metabolism. Annual Review of Biomedical Engineering, 2017, 19, 163-194.	12.3	528
1920	Asperspiropene A, a novel fungal metabolite as an inhibitor of cancer-associated mutant isocitrate dehydrogenase 1. Organic Chemistry Frontiers, 2017, 4, 1137-1144.	4.5	16
1921	Brain Gliomas in the Elderly. , 2017, , 119-140.		0
1922	Mitochondria and Epigenetics â€“ Crosstalk in Homeostasis and Stress. Trends in Cell Biology, 2017, 27, 453-463.	7.9	256
1923	Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor. World Neurosurgery, 2017, 102, 49-55.	1.3	7
1924	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations. Cancer Discovery, 2017, 7, 478-493.	9.4	350
1925	DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Clinical Epigenetics, 2017, 9, 32.	4.1	22
1927	IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation. Cell Reports, 2017, 19, 389-400.	6.4	24
1928	Targeting the immune system in glioblastoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 121-131.	0.7	0

#	ARTICLE	IF	CITATIONS
1929	Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience. Archives of Pathology and Laboratory Medicine, 2017, 141, 355-365.	2.5	2
1930	High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Experimental and Molecular Medicine, 2017, 49, e317-e317.	7.7	37
1932	Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. Journal of Neuro-Oncology, 2017, 133, 183-192.	2.9	30
1933	Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?. Journal of Neuropathology and Experimental Neurology, 2017, 76, 342-346.	1.7	24
1934	Isocitrate dehydrogenase mutations. Neurology, 2017, 88, 1782-1783.	1.1	1
1935	Volumetric Analysis of Extent of Resection, Survival, and Surgical Outcomes for Insular Gliomas. World Neurosurgery, 2017, 103, 265-274.	1.3	46
1936	Applied Cancer Immunogenomics. Cancer Journal (Sudbury, Mass), 2017, 23, 125-130.	2.0	16
1938	Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews Neurology, 2017, 13, 363-374.	10.1	125
1940	The role of 5-hydroxymethylcytosine in development, aging and age-related diseases. Ageing Research Reviews, 2017, 37, 28-38.	10.9	69
1941	Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. Journal of Pathology, 2017, 242, 400-408.	4.5	83
1942	Mitochondrial determinants of cancer health disparities. Seminars in Cancer Biology, 2017, 47, 125-146.	9.6	68
1943	Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging. American Journal of Neuroradiology, 2017, 38, 1138-1144.	2.4	103
1944	Key rates for the grades and transformation ability of glioma: model simulations and clinical cases. Journal of Neuro-Oncology, 2017, 133, 377-388.	2.9	5
1945	Metabolic reprogramming and epithelial-mesenchymal transition in cancer. FEBS Journal, 2017, 284, 3132-3144.	4.7	230
1946	Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group. Neurologia Medico-Chirurgica, 2017, 57, 17-27.	2.2	8
1947	Recent advances in subtyping tumors of the central nervous system using molecular data. Expert Review of Molecular Diagnostics, 2017, 17, 83-94.	3.1	10
1948	Dynamic RNA Modifications in Gene Expression Regulation. Cell, 2017, 169, 1187-1200.	28.9	2,222
1949	Metabolomic signature of brain cancer. Molecular Carcinogenesis, 2017, 56, 2355-2371.	2.7	86

#	ARTICLE	IF	CITATIONS
1950	Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. <i>Neuro-Oncology</i> , 2017, 19, 1008-1010.	1.2	12
1951	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD ⁺ Depletionâ€‘Mediated Cytotoxicity. <i>Cancer Research</i> , 2017, 77, 4102-4115.	0.9	74
1952	Surgical Management of Incidental Gliomas. <i>Neurosurgery Clinics of North America</i> , 2017, 28, 397-406.	1.7	11
1953	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. <i>Clinical Cancer Research</i> , 2017, 23, e83-e90.	7.0	122
1954	Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. <i>Journal of Neuro-Oncology</i> , 2017, 134, 65-74.	2.9	46
1956	Current and upcoming mitochondrial targets for cancer therapy. <i>Seminars in Cancer Biology</i> , 2017, 47, 154-167.	9.6	41
1957	IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI. <i>Neuroradiology</i> , 2017, 59, 555-562.	2.2	36
1958	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade IIâ€‘III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 134, 177-188.	2.9	118
1959	Adult IDH wild-type lower-grade gliomas should be further stratified. <i>Neuro-Oncology</i> , 2017, 19, 1327-1337.	1.2	177
1960	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. <i>Acta Neuropathologica Communications</i> , 2017, 5, 39.	5.2	110
1961	Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 133, 107-118.	2.9	10
1962	Constitutional abnormalities of <i>IDH1</i> combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26647.	1.5	9
1963	A Comprehensive Review of Genomics and Noncoding RNA in Gliomas. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 3-14.	1.2	18
1964	2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter. <i>Cell Reports</i> , 2017, 19, 1846-1857.	6.4	50
1965	Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. <i>Human Pathology</i> , 2017, 65, 239-246.	2.0	50
1966	Glioblastoma targeted therapy: updated approaches from recent biological insights. <i>Annals of Oncology</i> , 2017, 28, 1457-1472.	1.2	314
1967	Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 179-188.	1.7	23
1968	Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. <i>Neuro-Oncology</i> , 2017, 19, 736-738.	1.2	20

#	ARTICLE	IF	CITATIONS
1969	Diffuse intrinsic pontine gliomas—current management and new biologic insights. Is there a glimmer of hope?. <i>Neuro-Oncology</i> , 2017, 19, 1025-1034.	1.2	91
1970	IDH1 mutant negative ganglioglioma progression to gliosarcoma. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2017, 9, 41-44.	0.3	0
1971	Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency. <i>Journal of Biological Chemistry</i> , 2017, 292, 7971-7983.	3.4	40
1972	Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. <i>Scientific Reports</i> , 2017, 7, 44792.	3.3	63
1973	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <i>Nature Genetics</i> , 2017, 49, 789-794.	21.4	259
1974	Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. <i>Nature Neuroscience</i> , 2017, 20, 661-673.	14.8	153
1975	Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. <i>Annual Review of Biochemistry</i> , 2017, 86, 305-331.	11.1	161
1976	Tumor Vaccines for Malignant Gliomas. <i>Neurotherapeutics</i> , 2017, 14, 345-357.	4.4	41
1977	A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. <i>Brain Tumor Pathology</i> , 2017, 34, 91-97.	1.7	16
1978	A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment. <i>Brain Tumor Pathology</i> , 2017, 34, 51-61.	1.7	46
1979	Evaluation of Magnetoparticles Conjugated with New Angiogenesis Peptides in Intracranial Glioma Tumors by MRI. <i>Applied Biochemistry and Biotechnology</i> , 2017, 183, 265-279.	2.9	13
1980	Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. <i>Radiotherapy and Oncology</i> , 2017, 123, 106-111.	0.6	32
1981	Molecular mechanisms and therapeutic targets in pediatric brain tumors. <i>Science Signaling</i> , 2017, 10, .	3.6	53
1982	Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. , 2017, 177, 123-128.		23
1983	Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents. <i>Annual Review of Cancer Biology</i> , 2017, 1, 379-401.	4.5	14
1984	The Effect of Molecular Diagnostics on the Treatment of Glioma. <i>Current Oncology Reports</i> , 2017, 19, 26.	4.0	40
1985	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	10.7	586
1986	Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients. <i>BMC Medicine</i> , 2017, 15, 56.	5.5	49

#	ARTICLE	IF	CITATIONS
1987	Oncometabolites <scp>d</scp>- and <scp>l</scp>-2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions. Chemical Research in Toxicology, 2017, 30, 1102-1110.	3.3	62
1988	The transcription factor PPAR α is overexpressed and is associated with a favourable prognosis in <scp>IDH</scp>-wildtype primary glioblastoma. Histopathology, 2017, 70, 1030-1043.	2.9	19
1989	Metabolic Reprogramming in Brain Tumors. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 515-545.	22.4	82
1990	Advances in the molecular genetics of gliomas â€” implications for classification and therapy. Nature Reviews Clinical Oncology, 2017, 14, 434-452.	27.6	497
1991	1D-spectral editing and 2D multispectral inÂvivo 1 H-MRS and 1 H-MRSI - Methods and applications. Analytical Biochemistry, 2017, 529, 48-64.	2.4	45
1992	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Research, 2017, 77, 960-970.	0.9	78
1993	Integrating genomic information and signaling dynamics for efficient cancer therapy. Current Opinion in Systems Biology, 2017, 1, 38-43.	2.6	1
1994	Mutations in MDH2, Encoding a Krebs Cycle Enzyme, Cause Early-Onset Severe Encephalopathy. American Journal of Human Genetics, 2017, 100, 151-159.	6.2	63
1995	MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motility. Translational Oncology, 2017, 10, 70-79.	3.7	6
1997	Metabolic synthetic lethality in cancer therapy. Biochimica Et Biophysica Acta - Bioenergetics, 2017, 1858, 723-731.	1.0	50
1998	Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type. Oncology Reports, 2017, 38, 2394-2400.	2.6	5
1999	A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit. Scientific Reports, 2017, 7, 13853.	3.3	34
2000	CATNON interim results: another triumph of upfront chemotherapy in glioma. Neuro-Oncology, 2017, 19, 1287-1288.	1.2	1
2001	H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. Cancer Cell, 2017, 32, 684-700.e9.	16.8	192
2002	A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma. Journal of Genetics and Genomics, 2017, 44, 519-530.	3.9	29
2003	Long term oncologic surveillance in Maffucci syndrome: A case report. Journal of Oncological Science, 2017, 3, 140-144.	0.1	9
2004	Isocitrate dehydrogenaseâ€”mutant glioma: Evolving clinical and therapeutic implications. Cancer, 2017, 123, 4535-4546.	4.1	103
2005	Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. Cell Reports, 2017, 21, 1267-1280.	6.4	95

#	ARTICLE	IF	CITATIONS
2006	Absolute Neurocritical Care Review. , 2017, , .		0
2007	Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. Scientific Reports, 2017, 7, 12758.	3.3	59
2008	The promises of immunotherapy in gliomas. Current Opinion in Neurology, 2017, 30, 650-658.	3.6	16
2009	Recent Advances for Targeted Therapies in Glioblastoma. Current Cancer Research, 2017, , 91-115.	0.2	0
2011	Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chemical Biology, 2017, 24, 1075-1091.	5.2	38
2012	Targeting Metabolism for Cancer Therapy. Cell Chemical Biology, 2017, 24, 1161-1180.	5.2	677
2013	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroupsâ€”A meta-analysis of aggregate data. Critical Reviews in Oncology/Hematology, 2017, 120, 1-9.	4.4	44
2014	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. Radiographics, 2017, 37, 2164-2180.	3.3	105
2015	Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5262-5266.	2.2	10
2016	Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas. Scientific Reports, 2017, 7, 13396.	3.3	57
2017	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. Cancer, 2017, 123, 3628-3637.	4.1	57
2018	The impact of cellular metabolism on chromatin dynamics and epigenetics. Nature Cell Biology, 2017, 19, 1298-1306.	10.3	369
2019	Altered metabolic landscape in <scp>IDH</scp> â€”mutant gliomasÂaffects phospholipid, energy, and oxidative stress pathways. EMBO Molecular Medicine, 2017, 9, 1681-1695.	6.9	111
2020	Capillary electrophoresis â€” Mass spectrometry metabolomics analysis revealed enrichment of hypotaurine in rat glioma tissues. Analytical Biochemistry, 2017, 537, 1-7.	2.4	14
2021	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. OMICS A Journal of Integrative Biology, 2017, 21, 429-439.	2.0	15
2022	Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. BioDrugs, 2017, 31, 379-392.	4.6	8
2023	Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report. Molecular and Clinical Oncology, 2017, 6, 321-326.	1.0	5
2024	Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature, 2017, 549, 476-481.	27.8	398

#	ARTICLE	IF	CITATIONS
2025	Mutational analysis using Sanger and next generation sequencing in sporadic spindle cell hemangiomas: A study of 19 cases. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 855-860.	2.8	16
2026	IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 135, 273-284.	2.9	20
2027	Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma. <i>Scientific Reports</i> , 2017, 7, 11568.	3.3	16
2028	Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10743-10748.	7.1	109
2029	Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1116-1121.	2.8	84
2030	Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation. <i>World Neurosurgery</i> , 2017, 108, 991.e13-991.e16.	1.3	16
2031	If it is Not a Glioblastoma, Then What is it? A Differential Diagnostic Review. <i>Advances in Anatomic Pathology</i> , 2017, 24, 379-391.	4.3	13
2032	Applications of high-resolution magic angle spinning MRS in biomedical studies II—Human diseases. <i>NMR in Biomedicine</i> , 2017, 30, e3784.	2.8	27
2033	The Roles of DNA Methylation in the Stages of Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 257-261.	2.0	51
2034	Isomers Identification of 2-hydroxyglutarate acid disodium salt (2HG) by Terahertz Time-domain Spectroscopy. <i>Scientific Reports</i> , 2017, 7, 12166.	3.3	36
2035	Molecular Pathology of Glioblastoma- An Update. <i>Current Cancer Research</i> , 2017, , 19-55.	0.2	0
2036	Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. <i>Journal of Neuro-Oncology</i> , 2017, 135, 601-609.	2.9	75
2037	Paradoxical prognostic impact of <i>TERT</i> promoter mutations in gliomas depends on different histological and genetic backgrounds. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 790-797.	3.9	17
2038	Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1031-1040.	5.0	38
2039	Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APT _w) MRI. <i>Magnetic Resonance in Medicine</i> , 2017, 78, 1100-1109.	3.0	126
2040	Imaging Correlates of Adult Glioma Genotypes. <i>Radiology</i> , 2017, 284, 316-331.	7.3	160
2041	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. <i>Journal of Neuro-Oncology</i> , 2017, 135, 183-192.	2.9	138
2042	Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. <i>Scientific Reports</i> , 2017, 7, 5467.	3.3	219

#	ARTICLE	IF	CITATIONS
2043	Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas. <i>Journal of Neuro-Oncology</i> , 2017, 133, 399-407.	2.9	5
2044	Letter: A Role for Wild-Type Isocitrate Dehydrogenase 1 in Gliomagenesis. <i>Neurosurgery</i> , 2017, 81, E56-E57.	1.1	0
2045	Measurement of Oncometabolites d-2-Hydroxyglutaric Acid and l-2-Hydroxyglutaric Acid. <i>Methods in Molecular Biology</i> , 2017, 1633, 219-234.	0.9	7
2046	Metabolic regulation of glioma stem-like cells in the tumor micro-environment. <i>Cancer Letters</i> , 2017, 408, 174-181.	7.2	25
2047	Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma. <i>Oncology Letters</i> , 2017, 14, 47-54.	1.8	19
2048	Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies. <i>Current Cancer Research</i> , 2017, , 219-240.	0.2	4
2049	Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. <i>Trends in Cell Biology</i> , 2017, 27, 738-752.	7.9	99
2050	CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS. <i>Revista Médica Clínica Las Condes</i> , 2017, 28, 343-351.	0.2	6
2051	Epigenetic plasticity and the hallmarks of cancer. <i>Science</i> , 2017, 357, .	12.6	920
2052	T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. <i>Clinical Cancer Research</i> , 2017, 23, 6078-6085.	7.0	285
2053	Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care. <i>Npj Precision Oncology</i> , 2017, 1, 22.	5.4	127
2054	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. <i>Oncolmunology</i> , 2017, 6, e1328339.	4.6	114
2055	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. <i>Journal of Neuro-Oncology</i> , 2017, 135, 245-254.	2.9	17
2057	Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. <i>Medicine (United States)</i> , 2017, 96, e7422.	1.0	39
2058	Cell Signaling Pathways in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 15-26.	1.2	5
2059	Interrogating IDH Mutation in Brain Tumor. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 27-32.	1.2	5
2060	Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma. <i>Oncology Letters</i> , 2017, 14, 2427-2431.	1.8	12
2061	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017, 390, 1645-1653.	13.7	307

#	ARTICLE	IF	CITATIONS
2062	Benefit with adjuvant chemotherapy in anaplastic astrocytoma. <i>Lancet</i> , The, 2017, 390, 1625-1626.	13.7	3
2063	Tumor Syndromes That Include Bone Tumors. <i>Surgical Pathology Clinics</i> , 2017, 10, 749-764.	1.7	6
2064	Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers. <i>Brain Tumor Pathology</i> , 2017, 34, 149-154.	1.7	12
2065	PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma. <i>Scientific Reports</i> , 2017, 7, 7391.	3.3	8
2067	Diffuse glioma “ Rare homozygous <i>IDH</i> point mutation, is it an oncogenetic mechanism?. <i>Neuropathology</i> , 2017, 37, 582-585.	1.2	6
2068	Genetic factors affecting intraoperative 5-aminolevulinic acid-induced fluorescence of diffuse gliomas. <i>Radiology and Oncology</i> , 2017, 51, 142-150.	1.7	21
2069	Allosteric inhibitor remotely modulates the conformation of the orthosteric pockets in mutant IDH2/R140Q. <i>Scientific Reports</i> , 2017, 7, 16458.	3.3	18
2070	The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1633-1645.	2.5	30
2071	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017, 21, 2183-2197.	6.4	56
2072	Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 856-868.e5.	16.8	121
2073	LRIG proteins in glioma: Functional roles, molecular mechanisms, and potential clinical implications. <i>Journal of the Neurological Sciences</i> , 2017, 383, 56-60.	0.6	13
2074	IDH1 status is significantly different between high-grade thalamic and superficial gliomas. <i>Cancer Biomarkers</i> , 2017, 20, 183-189.	1.7	2
2075	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1331-1345.	4.9	160
2076	Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas. <i>Journal of Neuro-Oncology</i> , 2017, 135, 443-452.	2.9	29
2077	Comprehensive Analysis of Short-, Medium-, and Long-Chain Acyl-Coenzyme A by Online Two-Dimensional Liquid Chromatography/Mass Spectrometry. <i>Analytical Chemistry</i> , 2017, 89, 12902-12908.	6.5	25
2078	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	2.9	21
2079	High expression of TIG3 predicts poor survival in patients with primary glioblastoma. <i>Tumor Biology</i> , 2017, 39, 101042831771213.	1.8	2
2081	Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. <i>Nature Communications</i> , 2017, 8, 15987.	12.8	53

#	ARTICLE	IF	CITATIONS
2082	Recent developments in predictive biomarkers of pediatric glioma. <i>Oncology Letters</i> , 2017, 14, 497-500.	1.8	1
2083	Commentary on “Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813” <i>Neuro-Oncology</i> , 2017, 19, 738-739.	1.2	1
2084	Characterization of gliomas: from morphology to molecules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 257-269.	2.8	86
2085	Surgical Considerations in the Optimal Management of Patients with Malignant Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2017, 18, 46.	3.0	7
2086	Pediatric High Grade Glioma. <i>Current Cancer Research</i> , 2017, , 241-266.	0.2	1
2087	Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort. <i>World Neurosurgery</i> , 2017, 106, 165-173.	1.3	28
2088	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. <i>Neuro-Oncology</i> , 2017, 19, 1640-1650.	1.2	54
2089	IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. <i>Clinical Sarcoma Research</i> , 2017, 7, 8.	2.3	50
2090	Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?. <i>Targeted Oncology</i> , 2017, 12, 413-447.	3.6	19
2092	Adipocytokines, Energy Balance, and Cancer. <i>Energy Balance and Cancer</i> , 2017, , .	0.2	4
2093	Classification of adult diffuse gliomas by molecular markers—a short review with historical footnote. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 2-6.	1.3	10
2094	Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters. <i>Journal of Neuro-Oncology</i> , 2017, 131, 403-412.	2.9	22
2095	Neomorphic mutations create therapeutic challenges in cancer. <i>Oncogene</i> , 2017, 36, 1607-1618.	5.9	24
2097	Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 39-56.	3.8	23
2098	Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study. <i>Radiology</i> , 2017, 283, 215-221.	7.3	50
2099	Glioblastoma Secondary to Meningioma: A Case Report and Literature Review. <i>World Neurosurgery</i> , 2017, 98, 881.e9-881.e13.	1.3	6
2100	Glutamate and α -ketoglutarate: key players in glioma metabolism. <i>Amino Acids</i> , 2017, 49, 21-32.	2.7	89
2101	Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. <i>Journal of Neuro-Oncology</i> , 2017, 131, 213-222.	2.9	22

#	ARTICLE	IF	CITATIONS
2102	Apelin and Cancer. Energy Balance and Cancer, 2017, , 137-160.	0.2	3
2103	Poor Prognosis and Challenging Treatment of Optic Nerve Malignant Gliomas: Literature Review and Case Report Series. World Neurosurgery, 2017, 97, 751.e1-751.e6.	1.3	25
2104	Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo. Magnetic Resonance in Medicine, 2017, 78, 40-48.	3.0	28
2105	Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert Review of Vaccines, 2017, 16, 27-36.	4.4	33
2106	Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma. Pathobiology, 2017, 84, 99-107.	3.8	17
2107	Analyzing Tumor Metabolism In Vivo. Annual Review of Cancer Biology, 2017, 1, 99-117.	4.5	33
2108	Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. Journal of Neurosurgery, 2017, 126, 1448-1460.	1.6	65
2109	Metabolic interactions with cancer epigenetics. Molecular Aspects of Medicine, 2017, 54, 50-57.	6.4	40
2110	Pathology and Molecular Pathology of Brain Cancer. , 2017, , 291-311.		2
2111	A new functional <i>IDH2</i> genetic variant is associated with the risk of lung cancer. Molecular Carcinogenesis, 2017, 56, 1082-1087.	2.7	7
2112	IDH1 mutation diminishes aggressive phenotype in glioma stem cells. International Journal of Oncology, 2018, 52, 270-278.	3.3	16
2113	IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas. Neurosurgery, 2017, 64, 134-138.	1.1	27
2115	EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients. Journal of Molecular Cell Biology, 2017, 9, 477-488.	3.3	48
2116	CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncology, 2017, 19, v1-v88.	1.2	1,236
2117	Targeting Neoantigens in Glioblastoma. Neurosurgery, 2017, 64, 165-176.	1.1	24
2118	BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients. Scientific Reports, 2017, 7, 17740.	3.3	20
2119	The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. Neurologia Medico-Chirurgica, 2017, 57, 301-311.	2.2	196
2120	Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells (Review). Biomedical Reports, 2018, 8, 3-10.	2.0	54

#	ARTICLE	IF	CITATIONS
2121	<i>BICD1</i> expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas. <i>Oncotarget</i> , 2017, 8, 113766-113791.	1.8	9
2122	Subcutaneous Dissemination in Highly Aggressive Intracranial Glioblastoma: Case Report and Literature Review. <i>Brazilian Neurosurgery</i> , 2017, 36, 47-53.	0.1	0
2123	Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. <i>Oncotarget</i> , 2017, 8, 15071-15084.	1.8	13
2124	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 480-494.	3.8	9
2125	Beyond Alkylating Agents for Gliomas: <i>Quo Vadimus</i> ?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 175-186.	3.8	6
2126	Epigenetic dysregulation in brain tumors and neurodevelopment. , 2017, , 261-276.		0
2127	Role of Pathologist in Driver of Treatment of CNS Tumors. , 2017, , .		0
2128	Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma. <i>Frontiers in Pharmacology</i> , 2017, 8, 652.	3.5	15
2129	Long non-coding RNA PAR5 inhibits the proliferation and progression of glioma through interaction with EZH2. <i>Oncology Reports</i> , 2017, 38, 3177-3186.	2.6	18
2130	Advances in Brain Tumor Surgery for Glioblastoma in Adults. <i>Brain Sciences</i> , 2017, 7, 166.	2.3	213
2131	Molecular and Genetic Determinants of Glioma Cell Invasion. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2609.	4.1	28
2132	Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2732.	4.1	26
2133	Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas. <i>Metabolites</i> , 2017, 7, 29.	2.9	48
2134	Cancer as a Paradigm for Translational and Clinical Biomedical Research. , 2017, , 587-607.		0
2135	Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-27.	0.8	78
2136	MiR-200c Inhibits the Tumor Progression of Glioma via Targeting Moesin. <i>Theranostics</i> , 2017, 7, 1663-1673.	10.0	40
2137	Transcriptional Regulation of Telomerase Reverse Transcriptase (TERT) by MYC. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 1.	3.7	94
2138	Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1201.	4.1	14

#	ARTICLE	IF	CITATIONS
2139	CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression. <i>Frontiers in Immunology</i> , 2017, 8, 1451.	4.8	47
2140	Improved Pathologic Diagnosisâ€”Forecasting the Future in Glioblastoma. <i>Frontiers in Neurology</i> , 2017, 8, 707.	2.4	3
2141	Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. <i>Frontiers in Oncology</i> , 2017, 7, 40.	2.8	101
2142	Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma. <i>Frontiers in Oncology</i> , 2017, 7, 45.	2.8	45
2143	Cancer: Untethering Mitochondria from the Endoplasmic Reticulum?. <i>Frontiers in Oncology</i> , 2017, 7, 105.	2.8	39
2144	Peptide-Specific Vaccines. , 2017, , 213-226.		1
2145	Advances in Immunotherapy for Glioblastoma Multiforme. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	2.2	73
2146	Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	239
2147	Chimeric Antigen Receptor Therapy of Brain Tumors. , 2017, , 337-365.		0
2148	IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours. <i>Journal of Cancer</i> , 2017, 8, 2704-2712.	2.5	10
2149	IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. <i>PLoS ONE</i> , 2017, 12, e0169038.	2.5	34
2150	Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps. <i>PLoS ONE</i> , 2017, 12, e0174620.	2.5	39
2151	TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 155.	8.6	68
2152	Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. <i>Cell and Bioscience</i> , 2017, 7, 37.	4.8	69
2153	Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. <i>Acta Neuropathologica Communications</i> , 2017, 5, 78.	5.2	48
2154	Expression of HLA-DR genes in gliomas: correlation with clinicopathological features and prognosis. <i>Chinese Neurosurgical Journal</i> , 2017, 3, .	0.9	10
2155	Molecular Testing in Acute Myeloid Leukemia. , 2017, , 419-434.		0
2156	Mutating Our Understanding of Brain Tumors and Seizures: Entrez IDH. <i>Epilepsy Currents</i> , 2017, 17, 365-367.	0.8	1

#	ARTICLE	IF	CITATIONS
2157	Racial disparity in metabolic regulation of cancer. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 1221-1246.	3.0	5
2158	Tumor-Specific Mutations in Gliomas and Their Implications for Immunotherapy. , 2017, , 83-107.		0
2159	SETMAR isoforms in glioblastoma: A matter of protein stability. <i>Oncotarget</i> , 2017, 8, 9835-9848.	1.8	13
2160	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. <i>Journal of Clinical Investigation</i> , 2017, 127, 1425-1437.	8.2	334
2161	Treatment and Outcomes for Glioblastoma in Elderly Compared with Non-elderly Patients: A Population-Based Study. <i>Current Oncology</i> , 2017, 24, 92-98.	2.2	48
2162	Estudio de mutaciones en los genes IDH1 e IDH2 en una muestra de gliomas de población colombiana. <i>Biomedica</i> , 2018, 38, 93-99.	0.7	3
2163	Insights From Molecular Profiling of Adult Glioma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2386-2393.	1.6	53
2164	Treatment of Glioblastoma. <i>Journal of Oncology Practice</i> , 2017, 13, 629-638.	2.5	94
2165	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	1.6	561
2166	Immunotherapy for Brain Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2450-2456.	1.6	112
2167	Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. <i>Oncotarget</i> , 2017, 8, 80124-80138.	1.8	33
2168	Brain Tumors: Challenges and Opportunities to Cure. <i>Journal of Clinical Oncology</i> , 2017, 35, 2343-2345.	1.6	18
2170	Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. <i>Journal of Clinical Investigation</i> , 2017, 127, 1856-1872.	8.2	100
2171	Summary of the WHO Revised 4th Edition for CNS Tumours. <i>Japanese Journal of Neurosurgery</i> , 2017, 26, 644-649.	0.0	0
2172	Genetic and immune features of resectable malignant brainstem gliomas. <i>Oncotarget</i> , 2017, 8, 82571-82582.	1.8	12
2173	Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. <i>Oncotarget</i> , 2017, 8, 44015-44031.	1.8	69
2174	Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. <i>Acta Neuropathologica</i> , 2018, 135, 743-755.	7.7	42
2175	Mutant Isocitrate Dehydrogenase 1 Disrupts PKM2-Catenin-BRG1 Transcriptional Network-Driven CD47 Expression. <i>Molecular and Cellular Biology</i> , 2018, 38, .	2.3	33

#	ARTICLE	IF	CITATIONS
2176	IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. <i>Neuro-Oncology</i> , 2018, 20, 716-718.	1.2	8
2177	Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 71-80.	1.7	19
2178	Females have the survival advantage in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 576-577.	1.2	122
2179	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	1.3	4
2180	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. <i>Advances in Anatomic Pathology</i> , 2018, 25, 143-171.	4.3	31
2181	Obesity, Metabolic Syndrome, and Breast Cancer: From Prevention to Intervention. <i>Current Surgery Reports</i> , 2018, 6, 1.	0.9	18
2182	MR Elastography Analysis of Glioma Stiffness and IDH1-Mutation Status. <i>American Journal of Neuroradiology</i> , 2018, 39, 31-36.	2.4	70
2183	Deep learning with convolutional neural network in radiology. <i>Japanese Journal of Radiology</i> , 2018, 36, 257-272.	2.4	243
2184	Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas. <i>Clinical Nuclear Medicine</i> , 2018, 43, 311-316.	1.3	12
2185	D-2-hydroxyglutarate interferes with HIF-1 α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. <i>Oncolmmunology</i> , 2018, 7, e1445454.	4.6	97
2186	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	7.7	298
2187	Medicinal Plants as Novel Promising Therapeutics for Neuroprotection and Neuroregeneration. , 2018, , 437-453.		4
2188	Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1067-1075.	3.7	52
2189	New Age Herbals. , 2018, , .		7
2190	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	12.8	106
2191	Quo Vadisâ€Do Immunotherapies Have a Role in Glioblastoma?. <i>Current Treatment Options in Neurology</i> , 2018, 20, 14.	1.8	22
2192	Reduced hydroxymethylation characterizes medulloblastoma while TET and IDH genes are differentially expressed within molecular subgroups. <i>Journal of Neuro-Oncology</i> , 2018, 139, 33-42.	2.9	8
2193	Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. <i>Medical Oncology</i> , 2018, 35, 60.	2.5	14

#	ARTICLE	IF	CITATIONS
2194	Butyrate Inhibits Indices of Colorectal Carcinogenesis via Enhancing α -Ketoglutarate-Dependent DNA Demethylation of Mismatch Repair Genes. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1700932.	3.3	25
2195	Reconstructing the molecular life history of gliomas. <i>Acta Neuropathologica</i> , 2018, 135, 649-670.	7.7	61
2196	Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. <i>Neuro-Oncology</i> , 2018, 20, 1197-1206.	1.2	27
2197	Tumor growth dynamics in serially-imaged low-grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2018, 139, 167-175.	2.9	20
2198	Microfluidics in Malignant Glioma Research and Precision Medicine. <i>Advanced Biology</i> , 2018, 2, 1700221.	3.0	25
2199	Association between mutant IDHs and tumorigenesis in gliomas. <i>Medical Molecular Morphology</i> , 2018, 51, 194-198.	1.0	9
2200	Increased <i>HOXA5</i> expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. <i>Genes and Development</i> , 2018, 32, 512-523.	5.9	40
2201	Cerebellar high-grade astrocytoma with <i>IDH</i> mutations in the elderly: A report of two cases. <i>Neuropathology</i> , 2018, 38, 411-416.	1.2	5
2202	Oncogenic MicroRNA-20a is downregulated by the HIF-1/c-MYC pathway in IDH1 R132H-mutant glioma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 882-888.	2.1	13
2203	A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. <i>Cell Reports</i> , 2018, 23, 637-651.	6.4	137
2204	Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. <i>Journal of Experimental Medicine</i> , 2018, 215, 963-983.	8.5	36
2205	Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 138, 241-250.	2.9	9
2207	Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes. <i>World Neurosurgery</i> , 2018, 112, e407-e414.	1.3	13
2208	Pathology and Genetics of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 31, 1-37.	1.3	19
2209	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , 2018, 31, 168-179.	1.3	2
2210	A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors. <i>Journal of Biological Chemistry</i> , 2018, 293, 3421-3435.	3.4	25
2211	Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. <i>Oncolimmunology</i> , 2018, 7, e1434466.	4.6	53
2212	IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 55, 76-82.	2.0	38

#	ARTICLE	IF	CITATIONS
2213	Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. <i>Neuro-Oncology</i> , 2018, 20, 942-953.	1.2	31
2214	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	1.2	130
2215	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	1.2	119
2216	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	2.0	60
2217	Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer. <i>International Journal of Cancer</i> , 2018, 143, 396-407.	5.1	57
2218	5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. <i>Acta Neuropathologica</i> , 2018, 135, 617-634.	7.7	15
2219	Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1262-1271.	1.2	31
2220	Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge. <i>Cancer Science</i> , 2018, 109, 560-571.	3.9	156
2221	Extent of BOLD Vascular Dysregulation Is Greater in Diffuse Gliomas without Isocitrate Dehydrogenase 1 R132H Mutation. <i>Radiology</i> , 2018, 287, 965-972.	7.3	15
2222	LncRNA IDH1-AS1 links the functions of c-Myc and HIF1 α via IDH1 to regulate the Warburg effect. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1465-E1474.	7.1	93
2224	Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 916-926.	3.4	89
2225	Metabolomic Analysis of Glioma Cells Using Nanoflow Liquid Chromatography-Tandem Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2018, 1741, 125-134.	0.9	8
2226	Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. <i>Trends in Cancer</i> , 2018, 4, 151-165.	7.4	160
2227	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 694-699.	2.2	18
2228	Genome-Wide Association Studies in Glioma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 418-428.	2.5	34
2229	Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 307-313.	2.9	13
2230	Neoplasia in Three Aye-Ayes (<i>Daubentonia madagascariensis</i>). <i>Journal of Comparative Pathology</i> , 2018, 159, 16-20.	0.4	2
2231	IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1705-1715.	7.0	80

#	ARTICLE	IF	CITATIONS
2232	An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants. <i>Biomolecular Detection and Quantification</i> , 2018, 15, 6-12.	7.0	36
2233	Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification. <i>Scientific Reports</i> , 2018, 8, 777.	3.3	26
2234	Wild-type and mutated IDH1/2 enzymes and therapy responses. <i>Oncogene</i> , 2018, 37, 1949-1960.	5.9	169
2235	Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning Protection. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1154-1164.	6.1	29
2236	MRI radiomics analysis of molecular alterations in low-grade gliomas. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2018, 13, 563-571.	2.8	72
2237	IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. <i>Epilepsy and Behavior</i> , 2018, 78, 30-36.	1.7	26
2238	Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. <i>Cell Reports</i> , 2018, 22, 512-522.	6.4	74
2239	A novel ex vivo method for measuring whole brain metabolism in model systems. <i>Journal of Neuroscience Methods</i> , 2018, 296, 32-43.	2.5	25
2240	2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 469-474.	0.9	10
2241	Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. <i>Acta Neuropathologica</i> , 2018, 135, 285-298.	7.7	10
2242	R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes. <i>Veterinary Research Communications</i> , 2018, 42, 49-56.	1.6	6
2243	Immunotherapy of Gliomas. , 2018, , 657-664.		0
2244	MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. <i>American Journal of Roentgenology</i> , 2018, 210, 621-628.	2.2	75
2245	Management and Outcomes in the Oldest-Old Population with Glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 199-205.	0.5	10
2246	Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma. <i>Journal of Neurosurgery</i> , 2018, 129, 1446-1455.	1.6	22
2247	A comparison of 2-hydroxyglutarate detection at 3 and 7ÂT with longâ€TE semiâ€LASER. <i>NMR in Biomedicine</i> , 2018, 31, e3886.	2.8	25
2248	Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma. <i>CNS Oncology</i> , 2018, 7, 41-50.	3.0	10
2249	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 472-483.	1.2	42

#	ARTICLE	IF	CITATIONS
2250	Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2018, 137, 395-407.	2.9	42
2251	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	1.2	92
2252	Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2018, 20, 907-916.	1.2	72
2253	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-“mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91.	2.8	28
2254	Isocitrate dehydrogenase 1“snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability. <i>Breast Cancer Research</i> , 2018, 20, 25.	5.0	31
2255	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 21.	5.2	28
2256	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 877-882.	2.2	26
2257	Mechanism of N6-methyladenosine modification and its emerging role in cancer. , 2018, 189, 173-183.		31
2258	Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups. <i>BMC Cancer</i> , 2018, 18, 399.	2.6	15
2259	Steroids from <i>Ganoderma sinense</i> as new natural inhibitors of cancer-associated mutant IDH1. <i>Bioorganic Chemistry</i> , 2018, 79, 89-97.	4.1	13
2260	Assessing the predictability of <i>IDH</i> mutation and <i>MGMT</i> methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. <i>Neuro-Oncology</i> , 2018, 20, 1661-1671.	1.2	119
2261	Brain tumors “ other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.8	2
2262	Mutant IDH1 Promotes Glioma Formation InÂVivo. <i>Cell Reports</i> , 2018, 23, 1553-1564.	6.4	91
2263	Synthesis and Evaluation of a ¹⁸F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 606-611.	2.8	17
2264	Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. <i>European Radiology</i> , 2018, 28, 4350-4361.	4.5	63
2265	Repurposing drugs for glioblastoma: From bench to bedside. <i>Cancer Letters</i> , 2018, 428, 173-183.	7.2	47
2266	Applications of metabolomics to study cancer metabolism. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 2-14.	7.4	129
2267	Non“small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. <i>Human Pathology</i> , 2018, 78, 138-143.	2.0	21

#	ARTICLE	IF	CITATIONS
2268	Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade IV astrocytic brain tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1227-1237.	2.5	15
2269	Far Upstream Element-Binding Protein 1 Regulates LSD1 Alternative Splicing to Promote Terminal Differentiation of Neural Progenitors. <i>Stem Cell Reports</i> , 2018, 10, 1208-1221.	4.8	28
2270	Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002246.	1.2	5
2271	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation. <i>Molecular Cancer Research</i> , 2018, 16, 947-960.	3.4	8
2272	Mitochondria Remodeling in Cancer. , 2018, , 153-191.		0
2273	Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1037-1047.	2.5	18
2274	Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas. <i>IEEE Transactions on Medical Imaging</i> , 2018, 37, 1775-1787.	8.9	25
2275	Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis. <i>Cell Reports</i> , 2018, 22, 3107-3114.	6.4	64
2276	Current Clinical State of Advanced Magnetic Resonance Imaging for Brain Tumor Diagnosis and Follow Up. <i>Seminars in Roentgenology</i> , 2018, 53, 45-61.	0.6	10
2277	Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. <i>European Radiology</i> , 2018, 28, 3779-3788.	4.5	58
2278	Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients. <i>Scientific Reports</i> , 2018, 8, 4459.	3.3	9
2279	Radiomics, Metabolic, and Molecular MRI for Brain Tumors. <i>Seminars in Neurology</i> , 2018, 38, 032-040.	1.4	19
2280	Origin of Gliomas. <i>Seminars in Neurology</i> , 2018, 38, 005-010.	1.4	52
2281	Concepts for Immunotherapies in Gliomas. <i>Seminars in Neurology</i> , 2018, 38, 062-072.	1.4	26
2282	What's New in Grade II and Grade III Gliomas?. <i>Seminars in Neurology</i> , 2018, 38, 041-049.	1.4	1
2283	New Directions in the Treatment of Glioblastoma. <i>Seminars in Neurology</i> , 2018, 38, 050-061.	1.4	33
2284	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. <i>Seminars in Neurology</i> , 2018, 38, 019-023.	1.4	30
2285	Bivalent Chromatin Domains in Glioblastoma Reveal a Subtype-Specific Signature of Glioma Stem Cells. <i>Cancer Research</i> , 2018, 78, 2463-2474.	0.9	40

#	ARTICLE	IF	CITATIONS
2286	Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase- <i>mutant</i> glioma. <i>Journal of Neurosurgery</i> , 2018, 130, 56-66.	1.6	14
2287	Impairment of astrocytic glutaminolysis in glutaric aciduria type I. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 91-99.	3.6	9
2288	Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of <i>IDH1</i> -Mutation and 1p/19q-Codeletion Status in World Health Organization Grade II Gliomas. <i>American Journal of Neuroradiology</i> , 2018, 39, 693-698.	2.4	56
2289	MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. <i>Future Oncology</i> , 2018, 14, 699-707.	2.4	29
2290	Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 249-253.	3.4	18
2291	Comprehensive genetic characterization of rosette-forming glioneuronal tumors: independent component analysis by tissue microdissection. <i>Brain Pathology</i> , 2018, 28, 87-93.	4.1	19
2292	Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. <i>Journal of Neurosurgery</i> , 2018, 128, 1076-1083.	1.6	38
2293	Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. <i>Journal of Neurosurgery</i> , 2018, 128, 391-398.	1.6	62
2294	Cysteinyl Leukotriene Receptor Antagonists Inhibit Migration, Invasion, and Expression of MMP-2/9 in Human Glioblastoma. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 559-573.	3.3	27
2295	Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 23-37.	3.2	42
2296	The emerging role and targetability of the TCA cycle in cancer metabolism. <i>Protein and Cell</i> , 2018, 9, 216-237.	11.0	345
2297	The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas. <i>Neurosurgery</i> , 2018, 82, 808-814.	1.1	50
2298	Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features. <i>European Radiology</i> , 2018, 28, 159-169.	4.5	10
2299	Mechanisms regulating immune surveillance of cellular stress in cancer. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 225-240.	5.4	22
2300	Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 101-107.	1.2	16
2301	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 66-77.	1.2	225
2302	Multi-pronged proteomic analysis to study the glioma pathobiology using cerebrospinal fluid samples. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700056.	1.6	15
2303	Low FoxG1 and high Olig2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)- <i>mutant</i> gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 207-223.	3.2	10

#	ARTICLE	IF	CITATIONS
2304	Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. <i>Neuro-Oncology</i> , 2018, 20, 608-620.	1.2	194
2305	EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 743-752.	1.2	210
2306	Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors. <i>Child's Nervous System</i> , 2018, 34, 107-116.	1.1	14
2307	Vaccination in the immunotherapy of glioblastoma. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 255-268.	3.3	50
2308	The trans-laminar terminalis approach reduces mortalities associated with chordoid glioma resections: A case report and a review of 20 years of literature. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 43-55.	1.5	9
2309	Survival patterns of oligoastrocytoma patients: A surveillance, epidemiology and end results (SEER) based analysis. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2018, 11, 70-75.	0.3	3
2310	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 632-641.	1.2	33
2311	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	7.0	68
2312	Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis. <i>Seminars in Cancer Biology</i> , 2018, 51, 89-100.	9.6	21
2313	Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. <i>Neurosurgical Review</i> , 2018, 41, 621-628.	2.4	22
2314	Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. <i>ACS Chemical Neuroscience</i> , 2018, 9, 130-137.	3.5	17
2315	Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2018, 10, e1406.	6.6	70
2316	Targeting Epigenetics in Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 187-207.	9.4	185
2317	Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. <i>Neurosurgical Review</i> , 2018, 41, 641-647.	2.4	18
2318	Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1851-1861.	3.0	30
2319	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. , 2018, 182, 70-79.		25
2320	Biomarkers and therapeutic advances in glioblastoma multiforme. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 40-51.	1.1	120
2321	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 1-9.	1.7	12

#	ARTICLE	IF	CITATIONS
2322	Neurological update: gliomas and other primary brain tumours in adults. Journal of Neurology, 2018, 265, 717-727.	3.6	24
2323	Bioinformatic analysis of gene expression and methylation regulation in glioblastoma. Journal of Neuro-Oncology, 2018, 136, 495-503.	2.9	38
2324	Glioma epigenetics: From subclassification to novel treatment options. Seminars in Cancer Biology, 2018, 51, 50-58.	9.6	377
2325	Residual Convolutional Neural Network for the Determination of <i>IDH</i> Status in Low- and High-Grade Gliomas from MR Imaging. Clinical Cancer Research, 2018, 24, 1073-1081.	7.0	297
2326	Astrocytic and Oligodendroglial Tumors. , 2018, , 91-123.		1
2327	Nondiffuse Astrocytoma Variants. , 2018, , 125-143.		0
2328	Reverse engineering the cancer metabolic network using flux analysis to understand drivers of human disease. Metabolic Engineering, 2018, 45, 95-108.	7.0	36
2329	Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report. Cellular Oncology (Dordrecht), 2018, 41, 213-221.	4.4	11
2330	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. Cancer Research, 2018, 78, 36-50.	0.9	35
2331	Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. Journal of Neuro-Oncology, 2018, 136, 453-461.	2.9	34
2332	Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. American Journal of Surgical Pathology, 2018, 42, 569-577.	3.7	9
2333	Prediction of<i>IDH1</i>-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas. American Journal of Neuroradiology, 2018, 39, 37-42.	2.4	111
2334	Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. , 2018, 184, 13-41.		230
2335	Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2. Chemical Biology and Drug Design, 2018, 91, 1087-1093.	3.2	6
2336	Clinical neuropathology of brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 477-534.	1.8	6
2337	Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. Pediatric Neurosurgery, 2018, 53, 24-35.	0.7	19
2338	<scp>WHO</scp> 2016 Classification of gliomas. Neuropathology and Applied Neurobiology, 2018, 44, 139-150.	3.2	612
2339	The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 240-252.	0.6	3

#	ARTICLE	IF	CITATIONS
2340	Glioblastoma: new therapeutic strategies to address cellular and genomic complexity. Oncotarget, 2018, 9, 9540-9554.	1.8	60
2341	Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. JCO Precision Oncology, 2018, 2, 1-6.	3.0	2
2342	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 148-157.	3.8	2
2343	The Role of Astrocytes in Tumor Growth and Progression. , 0, , .		6
2344	Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. Journal of Pathology and Translational Medicine, 2018, 52, 28-36.	1.1	3
2345	Glioblastoma: Pathology and Genetics. , 2018, , .		0
2346	The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas. Wspolczesna Onkologia, 2018, 22, 215-222.	1.4	23
2347	Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas. Current Opinion in Neurology, 2018, 31, 727-732.	3.6	6
2348	Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis. ASN Neuro, 2018, 10, 175909141881826.	2.7	80
2349	IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas. Medicine (United States), 2018, 97, e13675.	1.0	11
2350	PET imaging in glioma. Nuclear Medicine Communications, 2018, 39, 1064-1080.	1.1	13
2351	Detection of IDH1 and IDH2 Mutation in Formalin-fixed Paraffin-embedded Gliomas Using Allele-specific COLD-PCR and Probe Melting Curve Analysis. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, e93-e100.	1.2	1
2352	Glioblastoma multiforme presenting as postpartum depression: a case report. Journal of Medical Case Reports, 2018, 12, 374.	0.8	4
2353	Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation. Journal of Veterinary Medical Science, 2018, 80, 85-91.	0.9	0
2354	Genetics of Glioblastoma in Moroccan population: Review of literature. IBRO Reports, 2018, 5, 133-136.	0.3	1
2355	A New Insight into the Development of Novel Anti-Cancer Drugs that Improve the Expression of Mitochondrial Function-Associated Genes. , 2018, , .		0
2356	Survivorship in Neuro-Oncology: Improving Care by Advancing Science. Neuro-Oncology, 2018, 20, NP-NP.	1.2	0
2357	Biological role of metabolic reprogramming of cancer cells during epithelialâ€mesenchymal transition (Review). Oncology Reports, 2019, 41, 727-741.	2.6	15

#	ARTICLE	IF	CITATIONS
2358	Updates in prognostic markers for gliomas. <i>Neuro-Oncology</i> , 2018, 20, vii17-vii26.	1.2	78
2359	IDH1: Linking Metabolism and Epigenetics. <i>Frontiers in Genetics</i> , 2018, 9, 493.	2.3	53
2360	Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. <i>Seminars in Oncology Nursing</i> , 2018, 34, 430-442.	1.5	5
2361	Surgery and Evidence-based Treatments in Patients with Newly Diagnosed High-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 443-453.	1.5	13
2362	Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. <i>Scientific Reports</i> , 2018, 8, 14965.	3.3	6
2363	Astrocytic Tumors. <i>Essentials in Cytopathology Series</i> , 2018, , 79-117.	0.1	2
2364	Oligodendroglial Tumors. <i>Essentials in Cytopathology Series</i> , 2018, , 119-128.	0.1	1
2365	Association analysis of RTEL1 variants with risk of adult gliomas in a Korean population. <i>PLoS ONE</i> , 2018, 13, e0207660.	2.5	8
2366	MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 991-1000.	1.6	51
2367	The clinical use of IDH1 and IDH2 mutations in gliomas. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1041-1051.	3.1	34
2368	IDH2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2018, , .	0.1	0
2369	The Influence of Metabolism on Drug Response in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 500.	2.8	182
2370	Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. <i>Npj Precision Oncology</i> , 2018, 2, 24.	5.4	32
2371	Nanotechnology for treatment of glioblastoma multiforme. <i>Journal of Translational Internal Medicine</i> , 2018, 6, 128-133.	2.5	56
2372	Evidence-based Treatment for Low-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 465-471.	1.5	6
2373	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies (Review). <i>Biomedical Reports</i> , 2018, 10, 3-9.	2.0	7
2374	Spectral Comparison of Pass-By Traffic Noise. , 2018, , .		2
2375	Global DNA methylation synergistically regulates the nuclear and mitochondrial genomes in glioblastoma cells. <i>Nucleic Acids Research</i> , 2018, 46, 5977-5995.	14.5	40

#	ARTICLE	IF	CITATIONS
2376	ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2Q607R. <i>Cancer Cell International</i> , 2018, 18, 196.	4.1	19
2377	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. <i>Cell Death and Disease</i> , 2018, 9, 1190.	6.3	42
2379	IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. <i>Oncotarget</i> , 2018, 9, 16462-16476.	1.8	17
2380	Evidence-based Therapy and Problem of Glioblastoma. <i>Japanese Journal of Neurosurgery</i> , 2018, 27, 91-98.	0.0	0
2381	Cyclin F-Dependent Degradation of RBPJ Inhibits IDH1R132H-Mediated Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 6386-6398.	0.9	24
2382	Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants. <i>Biochemical Journal</i> , 2018, 475, 3221-3238.	3.7	10
2383	900MHz 1H-/13C-NMR analysis of 2-hydroxyglutarate and other brain metabolites in human brain tumor tissue extracts. <i>PLoS ONE</i> , 2018, 13, e0203379.	2.5	8
2384	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the <sc>BET</sc> inhibitor <sc>JQ</sc>1. <i>Cancer Science</i> , 2018, 109, 3602-3610.	3.9	17
2385	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. <i>Neuro-Oncology</i> , 2018, 20, iv1-iv86.	1.2	1,624
2386	Epigenetic Targeting of Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 448.	2.8	82
2387	Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives. <i>World Neurosurgery</i> , 2018, 120, 302-315.	1.3	29
2388	Involvement of an Orphan Transporter, SLC22A18, in Cell Growth and Drug Resistance of Human Breast Cancer MCF7 Cells. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 3163-3170.	3.3	12
2389	Promising vaccines for treating glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1159-1170.	3.1	8
2390	Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes. <i>Scientific Reports</i> , 2018, 8, 14275.	3.3	9
2391	Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 421-436.	2.0	9
2392	cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. <i>Acta Neuropathologica</i> , 2018, 136, 805-810.	7.7	599
2393	VDAC2 interacts with PFKP to regulate glucose metabolism and phenotypic reprogramming of glioma stem cells. <i>Cell Death and Disease</i> , 2018, 9, 988.	6.3	48
2394	Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3325.	4.1	46

#	ARTICLE	IF	CITATIONS
2395	Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Journal of Biological Chemistry, 2018, 293, 20051-20061.	3.4	11
2396	Methylation dependent down-regulation of GOS2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma. PLoS ONE, 2018, 13, e0206552.	2.5	8
2397	Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells. Cell Reports, 2018, 25, 1018-1026.e4.	6.4	56
2398	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	9.4	138
2399	Tumours of the central nervous system. Surgery, 2018, 36, 630-636.	0.3	0
2400	Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis. World Neurosurgery, 2018, 120, e818-e854.	1.3	9
2401	BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study. World Neurosurgery, 2018, 120, e1225-e1233.	1.3	16
2402	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Medical Sciences (Basel, Switzerland), 2018, 6, 85.	2.9	9
2403	Diagnostic moléculaire des gliomes diffus. Revue Francophone Des Laboratoires, 2018, 2018, 61-67.	0.0	1
2404	Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas. International Journal of Molecular Sciences, 2018, 19, 3353.	4.1	25
2405	PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. Nature Communications, 2018, 9, 4552.	12.8	72
2406	Potent immunosuppressive effects of the oncometabolite <i>R</i> -2-hydroxyglutarate. OncoImmunology, 2018, 7, e1528815.	4.6	16
2407	Isocitrate Dehydrogenase 1 Expression in Canine Gliomas. Journal of Comparative Pathology, 2018, 165, 33-39.	0.4	7
2408	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Frontiers in Genetics, 2018, 9, 427.	2.3	88
2409	Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. Radiotherapy and Oncology, 2018, 129, 347-351.	0.6	18
2410	Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma. NeuroMolecular Medicine, 2018, 20, 452-474.	3.4	18
2411	Study of Histomolecular Classification of Glioma-Integrating Histology and Molecular Analysis in the Diagnosis of Brain Tumors. Indian Journal of Neurosurgery, 2018, 07, 129-134.	0.2	1
2412	C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1024-1028.	0.8	18

#	ARTICLE	IF	CITATIONS
2413	Drug Repurposing of Metabolic Agents in Malignant Glioma. International Journal of Molecular Sciences, 2018, 19, 2768.	4.1	27
2414	Association between IDH1/2 mutations and brain glioma grade. Oncology Letters, 2018, 16, 5405-5409.	1.8	31
2415	Using genomics to guide treatment for glioblastoma. Pharmacogenomics, 2018, 19, 1217-1229.	1.3	10
2416	Modulation of mitochondrial DNA copy number in a model of glioblastoma induces changes to DNA methylation and gene expression of the nuclear genome in tumours. Epigenetics and Chromatin, 2018, 11, 53.	3.9	30
2417	Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathologica Communications, 2018, 6, 89.	5.2	12
2418	IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. Journal of Cancer, 2018, 9, 998-1005.	2.5	50

2419

#	ARTICLE	IF	CITATIONS
2431	IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy. <i>Journal of Neuro-Oncology</i> , 2018, 139, 261-268.	2.9	35
2432	Machine learning: a useful radiological adjunct in determination of a newly diagnosed glioma's grade and IDH status. <i>Journal of Neuro-Oncology</i> , 2018, 139, 491-499.	2.9	30
2433	Neurosciences Continuing Education: An Adult With New-Onset Seizures. <i>Journal of Neuroscience Nursing</i> , 2018, 50, 100-101.	1.1	0
2434	Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 804-814.	2.5	22
2435	Heterozygous IDH1R132H/WT created by "single base editing" inhibits human astroglial cell growth by downregulating YAP. <i>Oncogene</i> , 2018, 37, 5160-5174.	5.9	27
2436	Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8981-9003.	6.4	23
2437	IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1505-1516.	1.2	52
2438	Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation. <i>World Neurosurgery</i> , 2018, 116, 316-321.	1.3	1
2439	Improved grading of IDH-mutated astrocytic gliomas. <i>Nature Reviews Neurology</i> , 2018, 14, 383-384.	10.1	2
2440	Expression of Oligodendrocyte Precursor Cell Markers in Canine Oligodendrogliomas. <i>Veterinary Pathology</i> , 2018, 55, 634-644.	1.7	19
2441	Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 642-645.	4.9	9
2442	The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review. <i>Clinical Neurology and Neurosurgery</i> , 2018, 170, 120-126.	1.4	26
2443	Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. <i>Clinical Oncology</i> , 2018, 30, 556-562.	1.4	6
2444	Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases. <i>Journal of Molecular Biology</i> , 2018, 430, 3081-3092.	4.2	43
2445	Analysis of CARD10 and CARD11 somatic mutations in patients with ovarian endometriosis. <i>Oncology Letters</i> , 2018, 16, 491-496.	1.8	7
2446	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , 2018, 14, 1559-1567.	2.4	17
2447	The Heterogeneity of Cancer Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	1.6	7
2448	The Multifaceted Metabolism of Glioblastoma. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1063, 59-72.	1.6	23

#	ARTICLE	IF	CITATIONS
2449	An Overview of Molecular Genetics of Brain Tumors. , 2018, , 249-255.		1
2450	Molecular Treatment of High-Grade Gliomas. , 2018, , 419-437.		0
2451	Chemotherapy of Pediatric High-Grade Gliomas. , 2018, , 557-568.		0
2452	The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Therapeutic Advances in Hematology, 2018, 9, 163-173.	2.5	50
2453	Glutamine Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2018, 1063, 13-32.	1.6	153
2454	Genomics of Peritoneal Malignancies. Surgical Oncology Clinics of North America, 2018, 27, 463-475.	1.5	14
2455	Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). Journal of Neuro-Oncology, 2018, 140, 75-82.	2.9	31
2456	Features of diffuse gliomas that are misdiagnosed on initial neuroimaging: a case control study. Journal of Neuro-Oncology, 2018, 140, 107-113.	2.9	6
2457	Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. Current Treatment Options in Oncology, 2018, 19, 41.	3.0	8
2458	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. Disease Markers, 2018, 2018, 1-8.	1.3	9
2459	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. World Neurosurgery, 2018, 116, 495-504.	1.3	13
2460	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurologic Clinics, 2018, 36, 421-437.	1.8	9
2461	IDH1 Δ mutant cancer cells are sensitive to cisplatin and an IDH1 Δ mutant inhibitor counteracts this sensitivity. FASEB Journal, 2018, 32, 6344-6352.	0.5	28
2462	Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. BMC Gastroenterology, 2018, 18, 94.	2.0	6
2463	Multimodal 3D DenseNet for IDH Genotype Prediction in Gliomas. Genes, 2018, 9, 382.	2.4	91
2464	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	16.8	623
2465	Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas. BMC Cancer, 2018, 18, 664.	2.6	14
2466	Clinical significance of FBXO17 gene expression in high-grade glioma. BMC Cancer, 2018, 18, 773.	2.6	9

#	ARTICLE	IF	CITATIONS
2467	Enasidenib. Recent Results in Cancer Research, 2018, 212, 187-197.	1.8	4
2469	Higher Plasma Fibrinogen Levels are Associated with Malignant Phenotype and Worse Survival in Patients with Glioblastomas. Journal of Cancer, 2018, 9, 2024-2029.	2.5	6
2470	Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. World Neurosurgery, 2018, 116, 505-517.	1.3	105
2471	Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer. Current Topics in Medicinal Chemistry, 2018, 18, 494-504.	2.1	180
2472	Long non-coding RNA SNHG12 promotes the proliferation and migration of glioma cells by binding to HuR. International Journal of Oncology, 2018, 53, 1374-1384.	3.3	30
2473	Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report. Frontiers in Neurology, 2018, 9, 398.	2.4	10
2474	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. Frontiers in Molecular Neuroscience, 2018, 11, 82.	2.9	61
2475	The Role of Mitochondrial H ⁺ -ATP Synthase in Cancer. Frontiers in Oncology, 2018, 8, 53.	2.8	58
2476	Machine learning classifies cancer. Nature, 2018, 555, 446-447.	27.8	64
2477	Metabolic Alterations in Cancer Cells and the Emerging Role of Oncometabolites as Drivers of Neoplastic Change. Antioxidants, 2018, 7, 16.	5.1	27
2478	Chaperonology: The Third Eye on Brain Gliomas. Brain Sciences, 2018, 8, 110.	2.3	14
2479	Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. Cancers, 2018, 10, 49.	3.7	31
2480	Highlighting the need for reliable clinical trials in glioblastoma. Expert Review of Anticancer Therapy, 2018, 18, 1031-1040.	2.4	12
2481	Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment. International Journal of Molecular Sciences, 2018, 19, 1115.	4.1	72
2482	Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. International Journal of Molecular Sciences, 2018, 19, 1765.	4.1	44
2483	Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence. Journal of Pathology, 2018, 246, 205-216.	4.5	53
2484	The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRIâ€ derived and clinical features, predict adult primary glioblastoma survival. Cancer Medicine, 2018, 7, 3704-3712.	2.8	22
2485	Brain tumor related-epilepsy. Neurologia I Neurochirurgia Polska, 2018, 52, 436-447.	1.2	29

#	ARTICLE	IF	CITATIONS
2486	Clinical and immunological correlates of long term survival in glioblastoma. Wspolczesna Onkologia, 2018, 2018, 81-85.	1.4	15
2487	Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas. PLoS ONE, 2018, 13, e0199379.	2.5	19
2488	Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315. Journal of Medicinal Chemistry, 2018, 61, 6647-6657.	6.4	34
2489	Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations. Histopathology, 2018, 73, 963-968.	2.9	15
2490	D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells. Clinical Cancer Research, 2018, 24, 5381-5391.	7.0	55
2491	Magnetic resonance imaging of cancer metabolism with hyperpolarized 13C-labeled cell metabolites. Current Opinion in Chemical Biology, 2018, 45, 187-194.	6.1	40
2492	Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. Journal of Neuroinflammation, 2018, 15, 145.	7.2	15
2493	Hydrogel-Based Drug Delivery Nanosystems for the Treatment of Brain Tumors. Gels, 2018, 4, 62.	4.5	79
2494	Comparison of glioblastoma (GBM) molecular classification methods. Seminars in Cancer Biology, 2018, 53, 201-211.	9.6	125
2495	Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget, 2018, 9, 20134-20155.	1.8	46
2496	Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers, 2018, 10, 187.	3.7	27
2497	The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. Trends in Cancer, 2018, 4, 523-536.	7.4	36
2498	Over-Expressed FEZF1 Predicts a Poor Prognosis in Glioma and Promotes Glioma Cell Malignant Biological Properties by Regulating Akt-ERK Pathway. Journal of Molecular Neuroscience, 2018, 65, 411-419.	2.3	14
2499	Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. Cancer Letters, 2018, 429, 1-10.	7.2	14
2500	Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. Journal of Neuropathology and Experimental Neurology, 2018, 77, 437-442.	1.7	72
2501	Preoperative Two-Dimensional Size of Glioblastoma is Associated with Patient Survival. World Neurosurgery, 2018, 115, e448-e463.	1.3	14
2502	Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. American Journal of Neuroradiology, 2018, 39, 1201-1207.	2.4	323
2504	Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. Scientific Reports, 2018, 8, 7373.	3.3	6

#	ARTICLE	IF	CITATIONS
2505	Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 542-548.	1.7	34
2506	Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?. <i>Neuroradiology</i> , 2018, 60, 1043-1051.	2.2	15
2507	CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high-grade glioma. <i>Oncology Reports</i> , 2018, 40, 2036-2046.	2.6	25
2508	Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. <i>Cancer Letters</i> , 2018, 435, 92-100.	7.2	279
2509	IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. <i>PLoS ONE</i> , 2018, 13, e0199737.	2.5	4
2510	Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2912-2917.	2.1	51
2511	Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6433-6446.	7.0	54
2512	3-(7-azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase inhibitors: Design, synthesis, and biological evaluation. <i>Archiv Der Pharmazie</i> , 2018, 351, e1800039.	4.1	7
2513	Treatment of glioblastoma in adults. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879045.	3.5	117
2514	Personalized therapeutic delivery in the neurosurgical operating room. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 8846-8848.	7.1	2
2515	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018, 140, 559-568.	2.9	9
2516	Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics. <i>Journal of Neuro-Oncology</i> , 2018, 139, 633-642.	2.9	26
2517	Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives. <i>Oral Oncology</i> , 2018, 83, 1-10.	1.5	15
2518	Pediatric low-grade gliomas can be molecularly stratified for risk. <i>Acta Neuropathologica</i> , 2018, 136, 641-655.	7.7	36
2519	Age and surgical outcome of low-grade glioma in Sweden. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 359-368.	2.1	27
2520	Simultaneous Supratentorial and Infratentorial Pilocytic Astrocytomas in an Adult Patient with Concurrent Neurofibromatosis Type 1 and HIV Infection. <i>World Neurosurgery</i> , 2018, 117, 172-177.	1.3	6
2521	Alterations of the levels of primary antioxidant enzymes in different grades of human astrocytoma tissues. <i>Free Radical Research</i> , 2018, 52, 856-871.	3.3	5
2522	Cerebrospinal fluid biomarkers of malignancies located in the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 139-169.	1.8	16

#	ARTICLE	IF	CITATIONS
2523	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. <i>Neurologia Medico-Chirurgica</i> , 2018, 58, 290-295.	2.2	29
2524	Molecular pathway activation “ New type of biomarkers for tumor morphology and personalized selection of target drugs. <i>Seminars in Cancer Biology</i> , 2018, 53, 110-124.	9.6	101
2525	Over-expression of lysyl oxidase is associated with poor prognosis and response to therapy of patients with lower grade gliomas. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 619-627.	2.1	8
2526	Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. <i>Neuro-Oncology</i> , 2019, 21, 274-284.	1.2	30
2527	Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. <i>Neurosurgery</i> , 2019, 85, 335-342.	1.1	7
2528	Isocitrate dehydrogenase “mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress. <i>FASEB Journal</i> , 2019, 33, 557-571.	0.5	33
2529	Genetic and epigenetic determinants of AML pathogenesis. <i>Seminars in Hematology</i> , 2019, 56, 84-89.	3.4	65
2530	Use of metformin and survival of patients with high-grade glioma. <i>International Journal of Cancer</i> , 2019, 144, 273-280.	5.1	48
2531	Retrochiasmal Disorders. , 2019, , 293-339.		1
2532	Exosomes and their implications in central nervous system tumor biology. <i>Progress in Neurobiology</i> , 2019, 172, 71-83.	5.7	26
2533	Identification of Local Clusters of Mutation Hotspots in Cancer-Related Genes and Their Biological Relevance. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2019, 16, 1656-1662.	3.0	11
2534	<i>DNMT3A</i> co-mutation in an <i>IDH1</i> -mutant glioblastoma. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004119.	1.2	6
2535	Pan-Cancer and Single-Cell Modeling of Genomic Alterations Through Gene Expression. <i>Frontiers in Genetics</i> , 2019, 10, 671.	2.3	22
2536	Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma. <i>Oncotarget</i> , 2019, 10, 3129-3143.	1.8	71
2537	Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. <i>Nature Reviews Materials</i> , 2019, 4, 651-668.	48.7	103
2538	Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2019, 9, 768.	2.8	72
2540	The epigenomic impact of methylation in metabolic dysfunction and cancer. , 2019, , 67-83.		1
2541	Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment. <i>Journal of Clinical Neuroscience</i> , 2019, 68, 45-50.	1.5	0

#	ARTICLE	IF	CITATIONS
2542	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. , 2019, , .		0
2543	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. Expert Review of Neurotherapeutics, 2019, 19, 663-677.	2.8	3
2544	Deconvolution and network analysis of IDH-mutant lower grade glioma predict recurrence and indicate therapeutic targets. Epigenomics, 2019, 11, 1323-1333.	2.1	8
2545	Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry. Scientific Reports, 2019, 9, 11238.	3.3	8
2546	Toward Single-Organelle Lipidomics in Live Cells. Analytical Chemistry, 2019, 91, 11380-11387.	6.5	20
2547	Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications. International Journal of Molecular Sciences, 2019, 20, 3478.	4.1	35
2548	Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor. Frontiers in Oncology, 2019, 9, 307.	2.8	19
2549	RELB: A novel prognostic marker for glioblastoma as identified by populationâ€based analysis. Oncology Letters, 2019, 18, 386-394.	1.8	7
2550	31 gene expressionâ€based signatures serve as indicators of prognosis for patients with glioma. Oncology Letters, 2019, 18, 291-297.	1.8	1
2551	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nature Reviews Cancer, 2019, 19, 420-438.	28.4	98
2552	Comparative proteogenomic characterization of glioblastoma. CNS Oncology, 2019, 8, CNS37.	3.0	20
2553	Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of Î²-oxidation Due to Carnitine Deficiency. Scientific Reports, 2019, 9, 9787.	3.3	23
2554	PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Scientific Reports, 2019, 9, 10521.	3.3	36
2555	Quantitative proteomics reveals reduction of endocytic machinery components in gliomas. EBioMedicine, 2019, 46, 32-41.	6.1	26
2556	The Systemic Treatment of Glioma. , 2019, , .		0
2557	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neuro-Oncology Advances, 2019, 1, vdz015.	0.7	22
2558	Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Acta Neuropathologica Communications, 2019, 7, 121.	5.2	16
2559	Oncometabolites: A new insight for oncology. Molecular Genetics & Genomic Medicine, 2019, 7, e873.	1.2	34

#	ARTICLE	IF	CITATIONS
2560	Infratentorial Glioblastoma Metastasis to Bone. World Neurosurgery, 2019, 131, 90-94.	1.3	13
2561	Defining Protein Pattern Differences Among Molecular Subtypes of Diffuse Gliomas Using Mass Spectrometry*[S]. Molecular and Cellular Proteomics, 2019, 18, 2029-2043.	3.8	19
2562	Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype. American Journal of Neuroradiology, 2019, 40, 1149-1155.	2.4	63
2563	Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms. Cancers, 2019, 11, 889.	3.7	17
2564	Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma. Cancer, 2019, 125, 3457-3466.	4.1	3
2565	The role of biomarkers in the diagnosis and treatment of oligodendrogliomas. , 2019, , 109-115.		1
2566	Pathology of pediatric oligodendroglioma. , 2019, , 129-135.		0
2567	Molecular Therapy for Oligodendrogliomas. , 2019, , 359-366.		0
2568	Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985395.	3.2	45
2569	Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas. Cancer Immunology Research, 2019, 7, 1401-1411.	3.4	35
2570	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	1.2	49
2571	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Journal of Neuro-Oncology, 2019, 144, 205-210.	2.9	24
2572	LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas. Frontiers in Oncology, 2019, 9, 1083.	2.8	16
2573	Prognostic Roles of Central Carbon Metabolism-Associated Genes in Patients With Low-Grade Glioma. Frontiers in Genetics, 2019, 10, 831.	2.3	2
2574	Friend or foe-IDH1 mutations in glioma 10 years on. Carcinogenesis, 2019, 40, 1299-1307.	2.8	58
2576	Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomarker Research, 2019, 7, 22.	6.8	73
2577	Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features. Scientific Reports, 2019, 9, 16058.	3.3	33
2578	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro-Oncology, 2019, 21, v1-v100.	1.2	1,735

#	ARTICLE	IF	CITATIONS
2579	Metabolic dependencies and vulnerabilities in leukemia. <i>Genes and Development</i> , 2019, 33, 1460-1474.	5.9	63
2580	Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients. <i>Journal of Cancer</i> , 2019, 10, 5536-5548.	2.5	10
2581	Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment. <i>Trends in Cancer</i> , 2019, 5, 693-703.	7.4	90
2582	IDH-1 polymorphisms in pilocytic astrocytomas. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151411.	1.3	2
2583	Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas. <i>Cancers</i> , 2019, 11, 1616.	3.7	17
2584	Glutamine Metabolism in Brain Tumors. <i>Cancers</i> , 2019, 11, 1628.	3.7	53
2585	Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 200.	4.1	30
2586	Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma. <i>Molecules</i> , 2019, 24, 3046.	3.8	5
2587	History and progress of hypotheses and clinical trials for Alzheimer's disease. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 29.	17.1	370
2588	Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance. <i>Cancers</i> , 2019, 11, 1231.	3.7	90
2589	Enrichment of Aldolase C Correlates with Low Non-Mutated IDH1 Expression and Predicts a Favorable Prognosis in Glioblastomas. <i>Cancers</i> , 2019, 11, 1238.	3.7	11
2590	Multiparametric and multiregional diffusion features help predict molecule information, grade and survival in lower-grade gliomas: a feasibility study. <i>British Journal of Radiology</i> , 2019, 92, 20190324.	2.2	1
2591	Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz008.	0.7	27
2592	Cross-Modality Augmentation of Brain Mr Images Using a Novel Pairwise Generative Adversarial Network for Enhanced Glioma Classification. , 2019, , .		18
2593	A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM. <i>Frontiers in Genetics</i> , 2019, 10, 906.	2.3	39
2594	The current state of immunotherapy for gliomas: an eye toward the future. <i>Journal of Neurosurgery</i> , 2019, 131, 657-666.	1.6	79
2595	Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. <i>Cancers</i> , 2019, 11, 1279.	3.7	23
2596	Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production. <i>Oncotarget</i> , 2019, 10, 2675-2692.	1.8	13

#	ARTICLE	IF	CITATIONS
2598	Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 751-765.	1.4	105
2599	CircFOXO3 promotes glioblastoma progression by acting as a competing endogenous RNA for NFAT5. <i>Neuro-Oncology</i> , 2019, 21, 1284-1296.	1.2	78
2600	Detection of chromosome-mediated tet(X4)-carrying <i>Aeromonas caviae</i> in a sewage sample from a chicken farm. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3628-3630.	3.0	27
2601	Finding a four-leaf clover—identifying long-term survivors in IDH-wildtype glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1352-1353.	1.2	7
2602	Special issue on hypoxia. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-3.	7.7	2
2603	Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111694.	5.5	9
2605	Warburg and Krebs and related effects in cancer. <i>Expert Reviews in Molecular Medicine</i> , 2019, 21, e4.	3.9	22
2606	Associations of PCK1 promoter hypomethylation and PCK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis. <i>Cancer Communications</i> , 2019, 39, 1-17.	9.2	23
2607	Novel management of glioma by molecular therapies, a review article. <i>European Journal of Translational Myology</i> , 2019, 29, 8209.	1.7	12
2608	Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 145, 321-328.	2.9	7
2609	Emerging Applications of Artificial Intelligence in Neuro-Oncology. <i>Radiology</i> , 2019, 290, 607-618.	7.3	159
2610	Prognostic factors associated with survival in patients with anaplastic oligodendroglioma. <i>PLoS ONE</i> , 2019, 14, e0211513.	2.5	15
2611	Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy. <i>Biosensors</i> , 2019, 9, 5.	4.7	11
2612	Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2019, 40, 426-432.	2.4	49
2613	Treatment of WHO Grade 2 and 3 Gliomas With Potentially Favorable Survival: Is Monotherapy Obsolete?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 533-536.	0.8	3
2614	Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2019, 9, 41.	2.8	109
2615	A Review on a Deep Learning Perspective in Brain Cancer Classification. <i>Cancers</i> , 2019, 11, 111.	3.7	253
2616	Accelerated progression of IDH mutant glioma after first recurrence. <i>Neuro-Oncology</i> , 2019, 21, 669-677.	1.2	38

#	ARTICLE	IF	CITATIONS
2617	Malignant Intramedullary Spinal Cord Tumors. , 2019, , 337-364.		1
2618	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 272-280.	1.8	6
2619	MRI texture analysis based on 3D tumor measurement reflects the IDH1 mutations in gliomas “ A preliminary study. European Journal of Radiology, 2019, 112, 169-179.	2.6	29
2620	Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer. Analytical and Bioanalytical Chemistry, 2019, 411, 1503-1508.	3.7	18
2621	Basic Gene Expression Characteristics of Glioma Stem Cells and Human Glioblastoma. Anticancer Research, 2019, 39, 597-607.	1.1	14
2622	PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. Oncoimmunology, 2019, 8, e1541535.	4.6	32
2623	Commentary: Radiological Characteristics and Natural History of Adult IDH-Wild-Type Astrocytomas With TERT Promoter Mutations. Neurosurgery, 2019, 85, E459-E460.	1.1	2
2624	<p>Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients</p>. Cancer Management and Research, 2019, Volume 11, 3227-3236.	1.9	17
2625	<p>Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis</p>. Cancer Management and Research, 2019, Volume 11, 3139-3152.	1.9	22
2626	Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Frontiers in Oncology, 2019, 9, 417.	2.8	183
2627	Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Science Advances, 2019, 5, eaaw4543.	10.3	98
2628	Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer & Metabolism, 2019, 7, 4.	5.0	18
2629	<p>Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma</p>. Cancer Management and Research, 2019, Volume 11, 3765-3777.	1.9	5
2630	Single nucleotide editing: From principle, optimization to application. Human Mutation, 2019, 40, 2171-2183.	2.5	7
2631	Angiogenin Upregulation Independently Predicts Unfavorable Overall Survival in Proneural Subtype of Glioblastoma. Technology in Cancer Research and Treatment, 2019, 18, 153303381984663.	1.9	3
2632	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.5	4
2633	Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma. Academic Pathology, 2019, 6, 2374289519848353.	1.1	21
2634	Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging. Cancers, 2019, 11, 829.	3.7	75

#	ARTICLE	IF	CITATIONS
2635	Abundance of d-2-hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1-expressing cells. <i>FEBS Letters</i> , 2019, 593, 2177-2193.	2.8	11
2636	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. <i>Cancer Treatment and Research</i> , 2019, 178, 81-108.	0.5	2
2637	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-17.	7.7	118
2638	Genetic and molecular epidemiology of adult diffuse glioma. <i>Nature Reviews Neurology</i> , 2019, 15, 405-417.	10.1	437
2639	Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. <i>Acta Neuropathologica Communications</i> , 2019, 7, 99.	5.2	32
2640	Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. <i>Scientific Reports</i> , 2019, 9, 8946.	3.3	44
2641	IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 625-636.	2.8	8
2642	Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: A comprehensive review. <i>Oncotarget</i> , 2019, 10, 3952-3977.	1.8	21
2643	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 865.	3.7	22
2644	Radioterapia dei tumori cerebrali primitivi dell'adulto. <i>EMC - Neurologia</i> , 2019, 19, 1-11.	0.0	0
2645	Etiological and Epidemiological Aspects. , 2019, , 91-109.		0
2646	Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients. , 2019, , 717-728.		0
2647	Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. <i>European Radiology</i> , 2019, 29, 6643-6652.	4.5	45
2648	Serine/threonine/tyrosine-interacting-like protein 1 (STYXL1), a pseudo phosphatase, promotes oncogenesis in glioma. <i>Biochemical and Biophysical Research Communications</i> , 2019, 515, 241-247.	2.1	10
2649	DNA methylation-based classification of sinonasal undifferentiated carcinoma. <i>Modern Pathology</i> , 2019, 32, 1447-1459.	5.5	82
2650	Molecular pathology of tumors of the central nervous system. <i>Annals of Oncology</i> , 2019, 30, 1265-1278.	1.2	129
2651	Integrated analysis of 34 microarray datasets reveals CBX3 as a diagnostic and prognostic biomarker in glioblastoma. <i>Journal of Translational Medicine</i> , 2019, 17, 179.	4.4	36
2652	Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3229-3236.	3.0	11

#	ARTICLE	IF	CITATIONS
2653	Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network. <i>Neuro-Oncology</i> , 2019, 21, 1197-1209.	1.2	80
2654	IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2679.	4.1	14
2655	<i>Tumor Biology.</i> , 2019, , 143-152.		0
2656	Total copy number variation as a prognostic factor in adult astrocytoma subtypes. <i>Acta Neuropathologica Communications</i> , 2019, 7, 92.	5.2	48
2657	Glioma Stem Cellâ€“Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling. <i>Cancer Discovery</i> , 2019, 9, 1248-1267.	9.4	120
2658	Current Applications of Diffusion Tensor Imaging and Tractography in Intracranial Tumor Resection. <i>Frontiers in Oncology</i> , 2019, 9, 426.	2.8	54
2659	Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6575-6596.	6.4	25
2660	Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 451-462.	1.6	36
2661	Prognosis and management of gliosarcoma patients: A review of literature. <i>Clinical Neurology and Neurosurgery</i> , 2019, 182, 98-103.	1.4	11
2662	Magnetic resonance diffusion-tensor imaging metrics in High Grade Gliomas: Correlation with IDH1 gene status in WHO 2016 era. <i>European Journal of Radiology</i> , 2019, 116, 174-179.	2.6	4
2663	Malignant Transformation of a Rosette-Forming Glioneuronal Tumor with IDH1 Mutation: A Case Report and Literature Review. <i>World Neurosurgery: X</i> , 2019, 2, 100006.	1.1	10
2664	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	1.2	28
2665	Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 211-224.	3.3	11
2666	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 411-420.	3.8	16
2667	Pheochromocytomas and Paragangliomas: Bypassing Cellular Respiration. <i>Cancers</i> , 2019, 11, 683.	3.7	22
2668	Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 1710-1720.	3.4	36
2669	Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis. <i>Clinical Science</i> , 2019, 133, 1167-1184.	4.3	37
2670	A 4â€“gene panel predicting the survival of patients with glioblastoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16037-16043.	2.6	30

#	ARTICLE	IF	CITATIONS
2671	IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region. <i>Acta Radiologica</i> , 2019, 60, 1663-1672.	1.1	19
2672	Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifer among Patient Populations. <i>Scientific Reports</i> , 2019, 9, 7442.	3.3	43
2673	PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2019, 7, 66.	5.2	26
2674	Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 133-145.	3.8	65
2675	The Development of a Personalised Training Framework: Implementation of Emerging Technologies for Performance. <i>Journal of Functional Morphology and Kinesiology</i> , 2019, 4, 25.	2.4	14
2676	Targeted Therapies for the Treatment of Glioblastoma in Adults. <i>Current Oncology Reports</i> , 2019, 21, 61.	4.0	15
2677	Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations. <i>Scientific Reports</i> , 2019, 9, 7436.	3.3	7
2678	Animal models of primary brain tumors. , 2019, , 149-195.		0
2679	Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy. <i>Blood Cells, Molecules, and Diseases</i> , 2019, 77, 88-94.	1.4	3
2680	Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation. <i>Journal of Geriatric Oncology</i> , 2019, 10, 770-778.	1.0	10
2681	The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF- κ B pathway. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1292-1302.	6.1	46
2682	Joint bioinformatics analysis of underlying potential functions of hsa-let-7b-5p and core genes in human glioma. <i>Journal of Translational Medicine</i> , 2019, 17, 129.	4.4	55
2683	<p>The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2215-2224.	2.0	10
2684	Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours. <i>Journal of Neuro-Oncology</i> , 2019, 143, 187-196.	2.9	12
2685	DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. <i>DNA Repair</i> , 2019, 78, 128-141.	2.8	89
2686	Epilepsy Associated with Glioma. , 2019, , 561-569.		0
2687	Epilepsy Associated with Ganglioglioma, Dysembryoplastic Neuroepithelial Tumor, and Related Tumors. , 2019, , 570-580.		0
2688	Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. <i>Journal of Neuro-Oncology</i> , 2019, 143, 515-523.	2.9	11

#	ARTICLE	IF	CITATIONS
2689	Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 633-640.	1.7	19
2690	Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 845-854.	3.1	17
2691	The French glioblastoma biobank (FGB): a national clinicobiological database. <i>Journal of Translational Medicine</i> , 2019, 17, 133.	4.4	19
2692	Role of Metabolic Reprogramming in Epithelialâ€“Mesenchymal Transition (EMT). <i>International Journal of Molecular Sciences</i> , 2019, 20, 2042.	4.1	93
2693	Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 501-507.	1.7	15
2694	ATRX immunohistochemistry can help refine â€“not elsewhere classifiedâ€™ categorisation for grade II/III gliomas. <i>British Journal of Neurosurgery</i> , 2019, 33, 536-540.	0.8	1
2695	A prognostic signature based on three nonâ€“codingRNAs for prediction of the overall survival of glioma patients. <i>FEBS Open Bio</i> , 2019, 9, 682-692.	2.3	5
2696	The role of microglia and P2X7 receptors in gliomas. <i>Journal of Neuroimmunology</i> , 2019, 332, 138-146.	2.3	29
2697	Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?. <i>Neurochemical Research</i> , 2019, 44, 2392-2404.	3.3	33
2698	Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy. <i>Cancers</i> , 2019, 11, 563.	3.7	38
2699	Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 722-725.	1.2	16
2700	Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients. <i>Journal of Child Neurology</i> , 2019, 34, 394-401.	1.4	2
2701	IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108774.	5.6	12
2702	Metabolic reprogramming links chronic intestinal inflammation and the oncogenic transformation in colorectal tumorigenesis. <i>Cancer Letters</i> , 2019, 450, 123-131.	7.2	12
2703	Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. <i>Nature Medicine</i> , 2019, 25, 403-418.	30.7	297
2704	Molecular responses to immune checkpoint blockade in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 359-361.	30.7	35
2705	MicroRNAs, Hypoxia and the Stem-Like State as Contributors to Cancer Aggressiveness. <i>Frontiers in Genetics</i> , 2019, 10, 125.	2.3	42
2706	Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. <i>Brain Tumor Pathology</i> , 2019, 36, 56-62.	1.7	15

#	ARTICLE	IF	CITATIONS
2707	Integrated phenotypeâ€“genotype approach in diagnosis and classification of common central nervous system tumours. <i>Histopathology</i> , 2019, 75, 299-311.	2.9	13
2708	The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. <i>BMC Cancer</i> , 2019, 19, 190.	2.6	2
2709	Pathology of Primary Brain Tumorsâ€“Gliomas. , 2019, , 121-137.		2
2710	Tumor Genetics and Their Outcomes on Surgery and Survival. , 2019, , 191-203.		0
2711	D-2-Hydroxyglutarate and L-2-Hydroxyglutarate Inhibit IL-12 Secretion by Human Monocyte-Derived Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 742.	4.1	16
2712	Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 425-441.	27.6	452
2713	Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 876-883.	3.9	27
2714	Hypoxia/pseudohypoxiaâ€“mediated activation of hypoxiaâ€“inducible factorâ€“1 β in cancer. <i>Cancer Science</i> , 2019, 110, 1510-1517.	3.9	143
2715	The Genetic Landscape of Human Glioblastoma and Matched Primary Cancer Stem Cells Reveals Intratumour Similarity and Intertumour Heterogeneity. <i>Stem Cells International</i> , 2019, 2019, 1-12.	2.5	29
2716	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	2.8	32
2717	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. <i>Cancer Discovery</i> , 2019, 9, 756-777.	9.4	18
2718	High Beclin-1 and ARID1A expression correlates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study. <i>BMC Cancer</i> , 2019, 19, 213.	2.6	17
2719	Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data. <i>World Neurosurgery</i> , 2019, 125, e688-e696.	1.3	31
2720	Wholeâ€“exome sequencing revealed mutational profiles of giant cell glioblastomas. <i>Brain Pathology</i> , 2019, 29, 782-792.	4.1	11
2721	Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging in glioblastoma multiforme. <i>Radiation Oncology</i> , 2019, 14, 37.	2.7	5
2722	Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins. <i>Molecules</i> , 2019, 24, 968.	3.8	72
2723	Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. <i>Leukemia and Lymphoma</i> , 2019, 60, 2635-2645.	1.3	6
2724	Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. <i>Diagnostic Pathology</i> , 2019, 14, 29.	2.0	40

#	ARTICLE	IF	CITATIONS
2725	Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381982839.	1.9	5
2726	3D-QSAR, molecular docking and molecular dynamics simulations study of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives to explore the structure requirements of mutant IDH1 inhibitors. <i>Journal of Molecular Structure</i> , 2019, 1189, 187-202.	3.6	7
2727	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019, 21, 837-853.	1.2	66
2728	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	7.0	26
2729	Prospective Clinical Sequencing of Adult Glioma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 991-1000.	4.1	15
2730	Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. <i>Radiation Oncology</i> , 2019, 14, 51.	2.7	38
2731	Prognostic Role of Chicken Ovalbumin Upstream Promoter Transcription Factor II in Isocitrate Dehydrogenase-Mutant Glioma with 1p19q Co-Deletion. <i>Journal of Molecular Neuroscience</i> , 2019, 68, 234-242.	2.3	4
2732	Overview of DNA methylation in adult diffuse gliomas. <i>Brain Tumor Pathology</i> , 2019, 36, 84-91.	1.7	45
2733	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1071-1090.	8.5	89
2734	Developmental origins and oncogenic pathways in malignant brain tumors. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2019, 8, e342.	5.9	35
2735	Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research. <i>American Journal of Neuroradiology</i> , 2019, 40, 758-765.	2.4	87
2736	Basics of Brain Tumor Biology for Clinicians. , 2019, , 7-19.		0
2737	Comparison of Biomarker Assays for <i>EGFR</i> : Implications for Precision Medicine in Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 3259-3265.	7.0	24
2738	Genetic association study of promoter variation rs3761549 in the <i>FOXP3</i> gene of Iranian patients diagnosed with brain tumour. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 11915-11920.	2.6	3
2739	Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 543-550.	2.5	76
2740	ZEB1 Is a Transcription Factor That Is Prognostic and Predictive in Diffuse Gliomas. <i>Frontiers in Neurology</i> , 2019, 9, 1199.	2.4	9
2741	Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1759-1777.	5.4	147
2742	DNA demethylation is associated with malignant progression of lower-grade gliomas. <i>Scientific Reports</i> , 2019, 9, 1903.	3.3	31

#	ARTICLE	IF	CITATIONS
2743	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. <i>Nature Medicine</i> , 2019, 25, 470-476.	30.7	459
2744	Biomarkers in tumors of the central nervous system – a review. <i>Apmis</i> , 2019, 127, 265-287.	2.0	9
2745	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4202-4210.	7.0	207
2746	The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 200.	3.5	82
2747	Practice-changing developments in neuro-oncology: embracing heterogeneity. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641982768.	3.5	1
2748	Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3. <i>PLoS ONE</i> , 2019, 14, e0212581.	2.5	33
2749	Understanding cognitive functioning in glioma patients: The relevance of IDH1 mutation status and functional connectivity. <i>Brain and Behavior</i> , 2019, 9, e01204.	2.2	42
2750	Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. <i>European Radiology</i> , 2019, 29, 4957-4967.	4.5	64
2751	Machine Learning Versus Logistic Regression Methods for 2-Year Mortality Prognostication in a Small, Heterogeneous Glioma Database. <i>World Neurosurgery</i> : X, 2019, 2, 100012.	1.1	52
2752	Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 3366-3373.	7.0	17
2753	Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. <i>Journal of Neuro-Oncology</i> , 2019, 142, 511-520.	2.9	9
2754	IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	169
2755	Targeting IDH1-Mutated Malignancies with NRF2 Blockade. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1033-1041.	6.3	61
2756	Dynamic in vitro models for tumor tissue engineering. <i>Cancer Letters</i> , 2019, 449, 178-185.	7.2	14
2757	Validation of a Mathematical Procedure for the Cobb Angle Assessment Based on Photogrammetry. <i>Journal of Chiropractic Medicine</i> , 2019, 18, 270-277.	0.7	5
2758	The DNA methylation landscape in cancer. <i>Essays in Biochemistry</i> , 2019, 63, 797-811.	4.7	169
2759	Prognostic value of VEGFR2 immunoexpression in glioblastoma. <i>Journal of Solid Tumors</i> , 2019, 10, 1.	0.1	0
2760	Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas. <i>Chinese Medical Journal</i> , 2019, 132, 2920-2926.	2.3	8

#	ARTICLE	IF	CITATIONS
2761	Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. <i>Oncologist</i> , 2019, 24, 664-670.	3.7	3
2762	Malignant Gliomas: Simplifying the Complexity. <i>Cancer Discovery</i> , 2019, 9, 1650-1652.	9.4	9
2763	Multi-path convolutional neural network for glioblastoma survival group prediction with point mutations and demographic features. , 2019, , .		0
2764	Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy. <i>Clinical and Translational Immunology</i> , 2019, 8, e01088.	3.8	10
2767	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. <i>Scientific Reports</i> , 2019, 9, 16830.	3.3	29
2768	The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A ¹¹ C-MET PET Study. <i>Molecular Imaging</i> , 2019, 18, 153601211989408.	1.4	3
2769	Adjuvant therapy and molecular profiling for inoperable gliomas. , 2019, , 193-208.		0
2770	Radiogenomics of Oncology. <i>Advances in Clinical Radiology</i> , 2019, 1, 71-82.	0.2	0
2771	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. <i>Cancers</i> , 2019, 11, 2028.	3.7	23
2772	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	2.8	10
2773	Feature engineering applied to intraoperative <i>in vivo</i> Raman spectroscopy sheds light on molecular processes in brain cancer: a retrospective study of 65 patients. <i>Analyst</i> , The, 2019, 144, 6517-6532.	3.5	24
2774	<p>Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy<p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10263-10273.	2.0	25
2775	Novel IDH1-Targeted Glioma Therapies. <i>CNS Drugs</i> , 2019, 33, 1155-1166.	5.9	52
2776	Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1151.	2.8	63
2779	Sanbo Scoring System, Based on Age and Pre-treatment Hematological Markers, is a Non-invasive and Independent Prognostic Predictor for Patients with Primary Glioblastomas: A Retrospective Multicenter Study. <i>Journal of Cancer</i> , 2019, 10, 5654-5660.	2.5	4
2780	Brain Tumors of Glial Origin. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1190, 281-297.	1.6	19
2781	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
2782	The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. <i>Annual Review of Genetics</i> , 2019, 53, 483-503.	7.6	22

#	ARTICLE	IF	CITATIONS
2783	Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. PLoS ONE, 2019, 14, e0225599.	2.5	17
2784	Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma. Cancers, 2019, 11, 1895.	3.7	17
2785	Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses. Frontiers in Oncology, 2019, 9, 1433.	2.8	16
2786	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. PLoS ONE, 2019, 14, e0219724.	2.5	25
2787	EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study. BMC Cancer, 2019, 19, 1184.	2.6	34
2788	The Translational Status of Cancer Liquid Biopsies. Regenerative Engineering and Translational Medicine, 2021, 7, 312-352.	2.9	39
2789	Neurological malignancies in neurofibromatosis type 1. Current Opinion in Oncology, 2019, 31, 554-561.	2.4	5
2790	Updates in the Neuroimaging and WHO Classification of Primary CNS Gliomas. Topics in Magnetic Resonance Imaging, 2019, 28, 73-84.	1.2	2
2791	New metabolic imaging tools in neuro-oncology. Current Opinion in Neurology, 2019, 32, 872-877.	3.6	5
2792	Targeting DNA repair in gliomas. Current Opinion in Neurology, 2019, 32, 878-885.	3.6	11
2793	CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Molecular Cancer Research, 2019, 17, 2042-2050.	3.4	15
2794	Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. Acta Neuropathologica Communications, 2019, 7, 201.	5.2	13
2795	Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status. Cancers, 2019, 11, 1918.	3.7	24
2796	Genomic Landscape of Intramedullary Spinal Cord Gliomas. Scientific Reports, 2019, 9, 18722.	3.3	28
2797	3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo. Magnetic Resonance in Medicine, 2019, 81, 795-802.	3.0	9
2798	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 205-215.	5.5	22
2799	Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis. Histopathology, 2019, 74, 350-354.	2.9	4
2800	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro-Oncology, 2019, 21, 189-200.	1.2	49

#	ARTICLE	IF	CITATIONS
2801	Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 589-603.	3.0	9
2802	An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 88-99.	2.8	67
2803	Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry. <i>Laboratory Investigation</i> , 2019, 99, 588-598.	3.7	16
2804	The R132H mutation in <scp>IDH</scp>1 promotes the recruitment of <scp>NK</scp> cells through <scp>CX</scp>3<scp>CL</scp>1/<scp>CX</scp>3<scp>CR</scp>1 chemotaxis and is correlated with a better prognosis in gliomas. <i>Immunology and Cell Biology</i> , 2019, 97, 457-469.	2.3	48
2805	Attenuation of Tumor Suppressive Function of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma. <i>Neoplasia</i> , 2019, 21, 106-116.	5.3	26
2806	shRNA-mediated PPAR γ knockdown in human glioma stem cells reduces <i>in vitro</i> proliferation and inhibits orthotopic xenograft tumour growth. <i>Journal of Pathology</i> , 2019, 247, 422-434.	4.5	13
2807	Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis. <i>Journal of Neuro-Oncology</i> , 2019, 142, 253-261.	2.9	13
2808	Transcriptional and epigenetic mechanisms underlying astrocyte identity. <i>Progress in Neurobiology</i> , 2019, 174, 36-52.	5.7	26
2809	Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation. <i>Journal of Proteome Research</i> , 2019, 18, 960-969.	3.7	56
2810	Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	230
2811	The added prognostic value of radiological phenotype combined with clinical features and molecular subtype in anaplastic gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 142, 129-138.	2.9	9
2812	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-“mutant Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 1261-1271.	7.0	50
2813	Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies. <i>Journal of Clinical Pathology</i> , 2019, 72, 271-280.	2.0	27
2814	Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 337-347.	1.2	25
2815	Brain T1 ρ -mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study. <i>Journal of Neuro-Oncology</i> , 2019, 141, 245-252.	2.9	9
2816	Impact of Multifocality and Molecular Markers on Survival of Glioblastoma. <i>World Neurosurgery</i> , 2019, 122, e461-e466.	1.3	21
2817	Altered cancer metabolism in mechanisms of immunotherapy resistance. , 2019, 195, 162-171.		97
2818	Commentary: Radiological Characteristics and Natural History of Adult IDH-Wild-Type Astrocytomas With TERT Promoter Mutations. <i>Neurosurgery</i> , 2019, 85, E457-E458.	1.1	0

#	ARTICLE	IF	CITATIONS
2819	Isocitrate dehydrogenase 1 and 2 mutations, 2-oxoglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 541-549.	4.1	23
2820	Management of low-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2019, 6, 249-258.	1.6	52
2821	Chemotherapy Treatment and Trials in Low-Grade Gliomas. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 103-109.	1.7	15
2822	Molecular Pathogenesis of Low-Grade Glioma. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 17-25.	1.7	31
2823	Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. <i>Journal of Clinical Neuroscience</i> , 2019, 59, 68-74.	1.5	4
2824	Radiation-induced genomic instability, epigenetic mechanisms and the mitochondria: a dysfunctional ménage à trois?. <i>International Journal of Radiation Biology</i> , 2019, 95, 516-525.	1.8	21
2825	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. <i>Blood</i> , 2019, 133, 156-167.	1.4	40
2826	Evidence for Improving Outcome Through Extent of Resection. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 85-93.	1.7	42
2827	Epidemiology and Molecular Epidemiology. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 1-16.	1.7	30
2828	Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis. <i>Journal of Neuro-Oncology</i> , 2019, 141, 289-301.	2.9	11
2829	The Misclassification of Diffuse Gliomas: Rates and Outcomes. <i>Clinical Cancer Research</i> , 2019, 25, 2656-2663.	7.0	42
2830	Metabolic reprogramming in the pathogenesis of glioma: Update. <i>Neuropathology</i> , 2019, 39, 3-13.	1.2	38
2831	Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-oxoglutarate with ¹ H-MRS. <i>NMR in Biomedicine</i> , 2019, 32, e4027.	2.8	13
2832	Coupling Krebs cycle metabolites to signalling in immunity and cancer. <i>Nature Metabolism</i> , 2019, 1, 16-33.	11.9	260
2833	Cancer metabolism in a snapshot: MRS(I). <i>NMR in Biomedicine</i> , 2019, 32, e4054.	2.8	17
2834	Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. <i>Neurotherapeutics</i> , 2019, 16, 319-347.	4.4	32
2835	Loss of GINS2 inhibits cell proliferation and tumorigenesis in human gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 273-287.	3.9	22
2836	Sensitive and rapid detection of <i>TERT</i> promoter and <i>IDH</i> mutations in diffuse gliomas. <i>Neuro-Oncology</i> , 2019, 21, 440-450.	1.2	27

#	ARTICLE	IF	CITATIONS
2837	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <i>Neuro-Oncology</i> , 2019, 21, 14-25.	1.2	69
2838	Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes. <i>Gene</i> , 2019, 685, 85-95.	2.2	10
2839	Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 348-356.	2.5	5
2840	Predicting Glioblastoma Response to Bevacizumab Through MRI Biomarkers of the Tumor Microenvironment. <i>Molecular Imaging and Biology</i> , 2019, 21, 747-757.	2.6	11
2841	Integrated profiling identifies caveolin-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 343-354.	3.9	21
2842	Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic. <i>Cancer Reports</i> , 2019, 2, e1131.	1.4	8
2843	Integrated molecular characterization of IDH-mutant glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 108-118.	3.2	68
2844	The molecular landscape of glioma in patients with Neurofibromatosis 1. <i>Nature Medicine</i> , 2019, 25, 176-187.	30.7	145
2845	Drak/STK17A Drives Neoplastic Glial Proliferation through Modulation of MRLC Signaling. <i>Cancer Research</i> , 2019, 79, 1085-1097.	0.9	15
2846	Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 11.	2.5	4
2847	Glioblastoma Therapy in the Age of Molecular Medicine. <i>Trends in Cancer</i> , 2019, 5, 46-65.	7.4	68
2848	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	1.2	25
2849	miR-145 is a potential biomarker for predicting clinical outcome in glioblastomas. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8016-8020.	2.6	3
2850	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 57-64.	1.7	8
2851	Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wildtype lower-grade glioma: the need to further stratify this tumor entity – a meta-analysis. <i>European Journal of Neurology</i> , 2019, 26, 379-387.	3.3	18
2852	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. <i>Oncologist</i> , 2019, 24, 402-413.	3.7	3
2853	Deciphering the metabolic role of AMPK in cancer multi-drug resistance. <i>Seminars in Cancer Biology</i> , 2019, 56, 56-71.	9.6	25
2854	IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract. <i>Human Pathology</i> , 2019, 84, 183-191.	2.0	35

#	ARTICLE	IF	CITATIONS
2855	It's complicatedâ€¦ m6A-dependent regulation of gene expression in cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 382-393.	1.9	31
2856	Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 747-759.	7.0	35
2857	Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2019, 58, 130-141.	9.6	49
2858	Dynamic and reversible RNA N^6 -methyladenosine methylation. <i>Wiley Interdisciplinary Reviews RNA</i> , 2019, 10, e1507.	6.4	31
2859	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105.	1.2	100
2860	In vivo Metabolic Profiles as Determined by ^{31}P and short TE ^1H MR-Spectroscopy. <i>Clinical Neuroradiology</i> , 2019, 29, 27-36.	1.9	14
2861	Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas. <i>Neurosurgical Review</i> , 2019, 42, 433-441.	2.4	19
2862	Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas. <i>Journal of Neurosurgery</i> , 2019, 130, 1289-1298.	1.6	25
2863	Malignancy Index Using Intraoperative Flow Cytometry is a Valuable Prognostic Factor for Glioblastoma Treated With Radiotherapy and Concomitant Temozolomide. <i>Neurosurgery</i> , 2019, 84, 662-672.	1.1	20
2864	The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[^{18}F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study. <i>Journal of Neurosurgery</i> , 2018, 130, 1-14.	1.6	9
2865	Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans. <i>Xenobiotica</i> , 2019, 49, 200-210.	1.1	12
2866	Mitochondria as playmakers of apoptosis, autophagy and senescence. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 139-153.	5.0	305
2867	Succinate Dehydrogenaseâ€“Deficient Gastrointestinal Stromal Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 655-660.	2.5	47
2868	The multifaceted contribution of α -ketoglutarate to tumor progression: An opportunity to exploit?. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 26-33.	5.0	50
2869	Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 31-39.	2.0	6
2870	Cancer Metabolism. , 2020, , 127-138.e4.		3
2871	Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. <i>Autophagy</i> , 2020, 16, 106-122.	9.1	91
2872	IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis. <i>Neurosurgical Review</i> , 2020, 43, 383-395.	2.4	30

#	ARTICLE	IF	CITATIONS
2873	Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectroscopy in Neurodiagnostics. <i>World Neurosurgery</i> , 2020, 133, e421-e427.	1.3	16
2874	Risks and Benefits of Glioblastoma Resection in Older Adults: A Retrospective Austrian Multicenter Study. <i>World Neurosurgery</i> , 2020, 133, e583-e591.	1.3	8
2875	Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2020, 81, 064-070.	0.8	38
2876	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209.	7.7	83
2877	Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 419-427.	7.0	60
2878	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
2879	Mitochondrial Dysfunction and Morphological Abnormality in Keloid Fibroblasts. <i>Advances in Wound Care</i> , 2020, 9, 539-552.	5.1	9
2880	Prognostic Markers Identification in Glioma by Gene Expression Profile Analysis. <i>Journal of Computational Biology</i> , 2020, 27, 81-90.	1.6	19
2881	To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma. <i>Cellular and Molecular Neurobiology</i> , 2020, 40, 53-63.	3.3	22
2882	Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 480-492.	1.2	31
2884	Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy. <i>Neurosurgical Review</i> , 2020, 43, 1583-1593.	2.4	11
2885	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. <i>Immunobiology</i> , 2020, 225, 151853.	1.9	50
2886	Identification of IDH and TERTp mutation status using ¹ H-MRS in 112 hemispheric diffuse gliomas. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1799-1809.	3.4	17
2887	11 Long noncoding RNA UCA1 functions as miR-135a sponge to promote the epithelial to mesenchymal transition in glioma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2447-2457.	2.6	10
2888	In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. <i>Neurological Sciences</i> , 2020, 41, 347-355.	1.9	12
2889	Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2. <i>Cancer Medicine</i> , 2020, 9, 1069-1078.	2.8	18
2890	Oncometabolites in renal cancer. <i>Nature Reviews Nephrology</i> , 2020, 16, 156-172.	9.6	113
2891	An Update on Neurofibromatosis Type 1-Associated Gliomas. <i>Cancers</i> , 2020, 12, 114.	3.7	50

#	ARTICLE	IF	CITATIONS
2892	Molecular Classification of Diffuse Gliomas. Canadian Journal of Neurological Sciences, 2020, 47, 464-473.	0.5	5
2893	Is There an Independent Role of TERT and NF1 in High Grade Gliomas?. Translational Oncology, 2020, 13, 346-354.	3.7	11
2894	A Multiple-Instance Learning-Based Convolutional Neural Network Model to Detect the <i>IDH1</i> Mutation in the Histopathology Images of Glioma Tissues. Journal of Computational Biology, 2020, 27, 1264-1272.	1.6	20
2895	Whole-Brain MR Spectroscopy Imaging of Brain Tumor Metabolites. Radiology, 2020, 294, 598-599.	7.3	5
2896	CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell International, 2020, 20, 7.	4.1	74
2897	Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common <i>TET2</i> mutant progenitor cell. Journal of Pathology, 2020, 250, 346-357.	4.5	50
2898	Identification of miRNA signatures in serum exosomes as a potential biomarker after radiotherapy treatment in glioma patients. Annals of Diagnostic Pathology, 2020, 44, 151436.	1.3	27
2899	Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/ β -Catenin Signaling in IDH1-mutant Gliomas. Translational Oncology, 2020, 13, 125-134.	3.7	15
2900	Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity. Biochemistry, 2020, 59, 479-490.	2.5	4
2901	2-Hydroxyglutarate in Cancer Cells. Antioxidants and Redox Signaling, 2020, 33, 903-926.	5.4	68
2903	Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/ β -catenin signalling. Brain, 2020, 143, 512-530.	7.6	96
2904	A molecularly distinct subset of glioblastoma requires serum-containing media to establish sustainable bona fide glioblastoma stem cell cultures. Glia, 2020, 68, 1228-1240.	4.9	12
2905	EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?. Journal of Neuro-Oncology, 2020, 146, 275-284.	2.9	16
2906	Twenty Metabolic Genes Based Signature Predicts Survival of Glioma Patients. Journal of Cancer, 2020, 11, 441-449.	2.5	3
2907	The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity. Antioxidants and Redox Signaling, 2020, 32, 834-852.	5.4	40
2908	TGF β -induced β -site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF κ B signalling pathway in human gliomas. Molecular Oncology, 2020, 14, 407-425.	4.6	14
2909	Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. Neurologic Clinics, 2020, 38, 95-113.	1.8	21
2910	Targeting Cell Metabolism as Cancer Therapy. Antioxidants and Redox Signaling, 2020, 32, 285-308.	5.4	32

#	ARTICLE	IF	CITATIONS
2911	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. <i>Brain Pathology</i> , 2020, 30, 541-553.	4.1	73
2912	A double surrogate approach for the quantitation of 2-Hydroxyglutarate – An oncometabolite in human brain tumors via LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 179, 112916.	2.8	14
2913	Cancer of the Central Nervous System. , 2020, , 906-967.e12.		9
2914	Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center. <i>Journal of Cancer</i> , 2020, 11, 1371-1382.	2.5	12
2915	Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGF β 1/p-Smad2/3 signaling. <i>Cancer Letters</i> , 2020, 472, 151-164.	7.2	43
2916	Nitric oxide and tumor metabolic reprogramming. <i>Biochemical Pharmacology</i> , 2020, 176, 113769.	4.4	31
2917	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126825.	2.2	13
2918	Blockade of Glutathione Metabolism in <i>IDH1</i>-Mutated Glioma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 221-230.	4.1	55
2919	Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. <i>Cancer Medicine</i> , 2020, 9, 1263-1275.	2.8	11
2920	Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status. <i>Neuroradiology</i> , 2020, 62, 319-326.	2.2	28
2921	New aspects of amino acid metabolism in cancer. <i>British Journal of Cancer</i> , 2020, 122, 150-156.	6.4	250
2922	Altered cellular metabolism in gliomas – an emerging landscape of actionable co-dependency targets. <i>Nature Reviews Cancer</i> , 2020, 20, 57-70.	28.4	187
2923	Impact of the 2016 World Health Organization Classification of Tumours of the Central Nervous System: an Irish experience. <i>Irish Journal of Medical Science</i> , 2020, 189, 799-803.	1.5	3
2924	Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. <i>Paediatric Drugs</i> , 2020, 22, 45-54.	3.1	7
2925	A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 375-383.	4.1	27
2926	Diffuse gliomas in patients aged 55%years or over: A suggestion for <i>IDH</i> mutation testing. <i>Neuropathology</i> , 2020, 40, 68-74.	1.2	23
2927	REVIEW: MR elastography of brain tumors. <i>NeuroImage: Clinical</i> , 2020, 25, 102109.	2.7	65
2928	Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis. <i>Carcinogenesis</i> , 2020, 41, 743-750.	2.8	17

#	ARTICLE	IF	CITATIONS
2929	Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System. <i>Advances in Anatomic Pathology</i> , 2020, 27, 206-219.	4.3	7
2930	Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion. <i>Cancers</i> , 2020, 12, 13.	3.7	22
2931	ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. <i>Pharmaceutics</i> , 2020, 12, 20.	4.5	80
2932	Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. <i>Journal of Genetics and Genomics</i> , 2020, 47, 69-83.	3.9	124
2933	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.	5.5	35
2934	Global Trends in Survival From Astrocytic Tumors in Adolescents and Young Adults: A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa049.	2.9	5
2935	Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa126.	0.7	27
2936	Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 841-847.	3.0	4
2937	Personalized Multimodal Demarcation of Peritumoral Tissue in Glioma. <i>JCO Precision Oncology</i> , 2020, 4, 1128-1140.	3.0	6
2938	A system-level approach identifies HIF-2 α as a critical regulator of chondrosarcoma progression. <i>Nature Communications</i> , 2020, 11, 5023.	12.8	14
2939	(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2842.	3.7	6
2941	Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples. <i>International Immunopharmacology</i> , 2020, 88, 106894.	3.8	2
2942	Apoptosis related microRNAs and MGMT in glioblastoma cell lines submitted to treatments with ionizing radiation and temozolomide. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 714-719.	0.6	3
2943	Exploration into biomarker potential of region-specific brain gene co-expression networks. <i>Scientific Reports</i> , 2020, 10, 17089.	3.3	4
2944	A machine learning analysis of a “normal-like” IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets. <i>BMC Medicine</i> , 2020, 18, 280.	5.5	8
2945	High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. <i>NeuroImage: Clinical</i> , 2020, 28, 102433.	2.7	37
2946	IFI30 expression is an independent unfavourable prognostic factor in glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12433-12443.	3.6	15
2947	Non-Coding RNAs in Brain Tumors, the Contribution of lncRNAs, circRNAs, and snoRNAs to Cancer Development—Their Diagnostic and Therapeutic Potential. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7001.	4.1	29

#	ARTICLE	IF	CITATIONS
2948	The Janus-like role of proline metabolism in cancer. <i>Cell Death Discovery</i> , 2020, 6, 104.	4.7	65
2949	Cancer prognosis prediction using somatic point mutation and copy number variation data: a comparison of gene-level and pathway-based models. <i>BMC Bioinformatics</i> , 2020, 21, 467.	2.6	7
2950	Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients. <i>BMC Cancer</i> , 2020, 20, 931.	2.6	4
2951	Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma. <i>Microorganisms</i> , 2020, 8, 1471.	3.6	16
2952	Peptide-lipid nanoconstructs act site-specifically towards glioblastoma growth impairment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 155, 177-189.	4.3	13
2953	Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review. <i>Current Oncology Reports</i> , 2020, 22, 120.	4.0	13
2954	Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. <i>Human Pathology</i> , 2020, 106, 45-53.	2.0	13
2955	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1037-1048.	2.4	8
2956	The IMPACT of Molecular Grading of Gliomas on Contemporary Clinical Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 859-862.	0.8	1
2957	Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa053.	0.7	13
2958	Comprehensive analysis of potential prognostic biomarker in gliomas. <i>Library Hi Tech</i> , 2020, 38, 783-797.	5.1	1
2959	Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 843-854.	1.7	32
2960	Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas. <i>American Journal of Neuroradiology</i> , 2020, 41, 1414-1422.	2.4	7
2961	The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. <i>Cancers</i> , 2020, 12, 1831.	3.7	29
2962	A Review of Radiomics and Deep Predictive Modeling in Glioma Characterization. <i>Academic Radiology</i> , 2021, 28, 1599-1621.	2.5	45
2963	Anaplastic Astrocytoma: State of the art and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103062.	4.4	13
2964	A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas. <i>Scientific Reports</i> , 2020, 10, 11852.	3.3	41
2965	Proteins inform survival-based differences in patients with glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa039.	0.7	3

#	ARTICLE	IF	CITATIONS
2966	Cancer Predisposition Syndromes Associated With Pediatric High-Grade Gliomas. <i>Frontiers in Pediatrics</i> , 2020, 8, 561487.	1.9	8
2970	The cohesive parametric high-fidelity-generalized-method-of-cells micromechanical model. <i>International Journal of Solids and Structures</i> , 2020, 206, 183-197.	2.7	5
2971	Ellipsoidal inhomogeneity in elliptically orthotropic elastic solid. <i>International Journal of Solids and Structures</i> , 2020, 206, 282-291.	2.7	5
2972	Gerotechnology for Older Adults With Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2650-2670.	2.8	66
2973	Riesgo de trombosis en pacientes con β^2 -talasemia. <i>Revista Clinica Espanola</i> , 2020, 220, 186-187.	0.6	0
2975	Association of cagA+ <i>Helicobacter pylori</i> strains with high urease activity and dyspepsia in Mexican adults. <i>Revista De Gastroenterolog�a De M�xico (English Edition)</i> , 2020, 85, 404-409.	0.2	1
2976	71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results. <i>Annals of Oncology</i> , 2020, 31, S1446-S1447.	1.2	13
2977	98P Low prognostic nutritional index is independently associated with poorer survival in patients receiving immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2020, 31, S1457.	1.2	0
2978	A discussion of the paper "Cemdata18: A chemical thermodynamic database for hydrated Portland cements and alkali-activated materials". <i>Cement and Concrete Research</i> , 2020, 138, 106224.	11.0	1
2979	Utilising an Accelerated Delphi Process to Develop Guidance and Protocols for Telepresence Applications in Remote Robotic Surgery Training. <i>European Urology Open Science</i> , 2020, 22, 23-33.	0.4	13
2980	The Acceptability of Tools for the Data Marketplace among Firms Using Market Research Online Communities. <i>Procedia Computer Science</i> , 2020, 176, 1613-1620.	2.0	4
2981	The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2020, 150, 143-164.	2.9	9
2982	Arthroscopic Lysis of Adhesions With Manipulation for Management of Late-Presenting Stiffness After Total Knee Arthroplasty. <i>Arthroplasty Today</i> , 2020, 6, 761-765.	1.6	7
2983	A 69-Year-Old Man With Chronic Cough and Recurrent Pneumonia. <i>Chest</i> , 2020, 158, e283-e287.	0.8	0
2984	Using citizen science to understand the prerequisites for physical activity among adolescents in low socioeconomic status neighborhoods - The NESLA study. <i>Health and Place</i> , 2020, 65, 102387.	3.3	18
2985	Using Virtual Reality to Examine Emotional Hotspots and Intrusions in the Trauma Film Paradigm. <i>Journal of Applied Research in Memory and Cognition</i> , 2020, 9, 370-380.	1.1	5
2986	Miastenia gravis ocular y factores asociados al desarrollo de una generalizaci�n secundaria: descripci�n de una serie espa�ola. <i>Neurolog�a</i> , 2023, 38, 229-235.	0.7	0
2987	Assessment of metals pollution in sediments and tailings of Klein Aub and Oamites mine sites, Namibia. <i>Environmental Advances</i> , 2020, 2, 100006.	4.8	18

#	ARTICLE	IF	CITATIONS
2988	Deformation heterogeneity in laser-welded Eurofer. Fusion Engineering and Design, 2020, 161, 111860.	1.9	5
2989	AM repair of 100 million turbine blades. Metal Powder Report, 2020, 75, 381.	0.1	0
2990	Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases. Scientific Reports, 2020, 10, 20162.	3.3	10
2991	Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning. Cancers, 2020, 12, 3406.	3.7	17
2992	Big ear keloid response to PDL laser. Medicina Clínica, 2021, 157, 217.	0.6	0
2993	A new method of interface tension measurement of a magnetic fluid drop. MethodsX, 2020, 7, 101152.	1.6	2
2994	On the non-existence of negative weight derivations of the new moduli algebras of singularities. Journal of Algebra, 2020, 564, 199-246.	0.7	11
2995	Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma. Cell Death and Disease, 2020, 11, 998.	6.3	19
2996	Maladies neuromusculaires. Perfectionnement En PÃ©diatrie, 2020, 3, eS5-eS6.	0.0	0
2997	Pourquoi et comment traiter lâ€™hyperesthésie dentinaire. Actualites Pharmaceutiques, 2020, 59, 52-56.	0.0	0
2998	Upscaled DEM-CFD model for vibrated fluidized bed based on particle-scale similarities. Advanced Powder Technology, 2020, 31, 4598-4618.	4.1	26
2999	Acute myocardial infarction complicating Russell's viper bite, a case report. Atherosclerosis, 2020, 315, e241.	0.8	0
3000	Facing the test of time: a service evaluation of maxillofacial trauma management over 5 years. British Journal of Oral and Maxillofacial Surgery, 2020, 58, e188.	0.8	0
3001	Temporomandibular joint dysfunction: relationship between mental health and MRI findings. British Journal of Oral and Maxillofacial Surgery, 2020, 58, e224.	0.8	0
3002	Pressure Injuries Among Critical Care Patients. Critical Care Nursing Clinics of North America, 2020, 32, 573-587.	0.8	3
3003	Oxidation and corrosion protection of ZG12Cr9Mo1Co1NiVNbNB (CB2) ferritic stainless steel by inorganic composite coatings at 650°C. Corrosion Science, 2020, 177, 109000.	6.6	9
3004	Intermittent disturbance benefits colony size, biomass and dominance of Microcystis in Lake Taihu under field simulation condition. Harmful Algae, 2020, 99, 101909.	4.8	18
3005	Cardiac sarcoidosis as an incidental finding: A case report. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 783-787.	1.6	0

#	ARTICLE	IF	CITATIONS
3006	Highly efficient ~3.4Å ^{1/4} m emission of Er ³⁺ -doped TeO ₂ based glasses via resonant energy transfer and multi-phonon relaxation processes. Optical Materials, 2020, 108, 110387.	3.6	13
3010	Three-dimensional (3D) vascular cell culture model for disease modeling and screening therapies. Atherosclerosis, 2020, 315, e32.	0.8	0
3011	Î²B kinase 2 (IKK2) is not essential for platelet activation. Atherosclerosis, 2020, 315, e93.	0.8	0
3012	Aronia melanocarpa anthocyanin extracts are an effective regulator of suppressor of cytokine signaling 3-dependent insulin resistance in HepG2 and C2C12 cells. Journal of Functional Foods, 2020, 75, 104258.	3.4	13
3013	Essential anatomy for total mesorectal excision and lateral lymph node dissection, in both trans-abdominal and trans-anal perspective. Journal of the Royal College of Surgeons of Edinburgh, 2021, 19, e462-e474.	1.8	6
3015	Primary intraosseous carcinoma arising in dentigerous cyst: Case report. International Journal of Surgery Case Reports, 2020, 76, 530-533.	0.6	5
3016	A Lesson From the COVID-19 Pandemic:ÂPreparing Future HealthÂCare Professionals. Journal of Emergency Medicine, 2020, 59, 718-719.	0.7	3
3017	15261 Lack of tuberculosis reactivation in 12,319 patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab: An ad hoc analysis of pooled safety data from 28 clinical trials. Journal of the American Academy of Dermatology, 2020, 83, AB33.	1.2	0
3018	16003 Orally administered EDP1815, a monoclonal strain of Prevotella histicola, has potent systemic anti-inflammatory effects. Journal of the American Academy of Dermatology, 2020, 83, AB52.	1.2	2
3019	13396 Public social media consultations for skin conditions: An online survey. Journal of the American Academy of Dermatology, 2020, 83, AB119.	1.2	0
3020	15396 Factors affecting patient preferences between teledermatology and traditional face-to-face dermatology encounters. Journal of the American Academy of Dermatology, 2020, 83, AB149.	1.2	0
3022	Work-family spillover stress predicts health outcomes across two decades. Social Science and Medicine, 2020, 265, 113516.	3.8	12
3023	Immunological classification of gliomas based on immunogenomic profiling. Journal of Neuroinflammation, 2020, 17, 360.	7.2	17
3024	Epidemiology, pathophysiology and classification. , 2020, , .		0
3025	Role of tyrosine phosphorylation in modulating cancer cell metabolism. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188442.	7.4	33
3026	Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients. Surgical Oncology, 2020, 35, 515-519.	1.6	4
3027	Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Contrast Media and Molecular Imaging, 2020, 2020, 1-11.	0.8	3
3028	IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. Cancers, 2020, 12, 3310.	3.7	25

#	ARTICLE	IF	CITATIONS
3029	A study of the mechanical properties and appearance of efflorescence in paving bricks under different curing environments. Construction and Building Materials, 2020, 265, 120148.	7.2	5
3030	Polyurethane film prepared from ball-milled algal polyol particle and activated carbon filler for NH ₃ -N removal. Heliyon, 2020, 6, e04590.	3.2	31
3031	Natural capital protection indicators: Measuring performance in achieving the Sustainable Development Goals for green growth transition. Environmental and Sustainability Indicators, 2020, 8, 100069.	3.3	22
3032	Surgeons and the Opioid Crisis. Journal of the American College of Surgeons, 2020, 231, 648-649.	0.5	0
3033	Perforating foreign body causing incomplete facial paralysis. Trauma Case Reports, 2020, 30, 100370.	0.4	0
3034	Antihypertensive drugs. Side Effects of Drugs Annual, 2020, , 215-226.	0.6	1
3035	COMPARATIVE ASSESSMENT OF INTIMA-MEDIA THICKNESS OF CAROTID ARTERY IN PATIENTS WITH BEHCETÄ™S DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS. Chest, 2020, 157, A48.	0.8	0
3036	Extracellular Protein Radical Formation Increases After Damage to Articular Cartilage. Free Radical Biology and Medicine, 2020, 159, S106.	2.9	0
3037	Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering. Genome Medicine, 2020, 12, 110.	8.2	22
3038	Increased M1 Macrophages Infiltration Correlated With Poor Survival Outcomes and Radiation Response in Gliomas. Dose-Response, 2020, 18, 155932582096499.	1.6	5
3039	Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment. Pan African Medical Journal, 2020, 36, 309.	0.8	7
3040	Conceptualizing grade inflation. Economics of Education Review, 2020, 78, 102037.	1.4	2
3041	Investigar colaborando o colaborar para investigar en enfermerÄa intensiva. EnfermerÄa Intensiva, 2020, 31, 161-163.	0.6	0
3042	Examining mediators of change in wellbeing, stress, and depression in a blended, Internet-based, ACT intervention for university students. Internet Interventions, 2020, 22, 100343.	2.7	10
3043	Reply. Journal of Vascular Surgery, 2020, 72, 2216.	1.1	0
3045	An efficient stress intensity factor evaluation method for interacting arbitrary shaped 3D cracks. Theoretical and Applied Fracture Mechanics, 2020, 109, 102767.	4.7	7
3046	Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. Frontiers in Cell and Developmental Biology, 2020, 8, 580464.	3.7	8
3047	Ancient burial hints at modern bias. New Scientist, 2020, 248, 22.	0.0	0

#	ARTICLE	IF	CITATIONS
3048	45. Identification of predicted neoantigen vaccine candidates in follicular lymphoma patients. <i>Cancer Genetics</i> , 2020, 244, 17.	0.4	0
3049	Prrx1 Fibroblasts Represent a Pro-fibrotic Lineage in the Mouse Ventral Dermis. <i>Cell Reports</i> , 2020, 33, 108356.	6.4	44
3050	Interaction of super-critical CO2 with mudrocks: Impact on composition and mechanical properties. <i>International Journal of Greenhouse Gas Control</i> , 2020, 102, 103163.	4.6	10
3051	The Great escape? A liberal perspective on assisted suicide for prisoners. <i>Ethics, Medicine and Public Health</i> , 2020, 15, 100566.	0.9	1
3052	Effects of different light sources used for dental operating microscope illumination on the visual function of operators. <i>Journal of Oral Biosciences</i> , 2020, 62, 363-371.	2.2	1
3053	Tailoring NMR experiments for structural characterization of amorphous biological solids: A practical guide. <i>Solid State Nuclear Magnetic Resonance</i> , 2020, 109, 101686.	2.3	20
3055	First-principles study on stability, electronic and optical properties of Janus-functionalized ZnO monolayer and bilayer for optoelectronic device. <i>Vacuum</i> , 2020, 181, 109749.	3.5	6
3056	Aims and Scope of the Volume. , 2020, , ix.		0
3057	Discretization of the system of equations for fluid flow through porous media. <i>Developments in Petroleum Science</i> , 2020, 70, 261-272.	0.2	0
3058	Sukano adds impact modifier masterbatch to portfolio for recycled PET. <i>Additives for Polymers</i> , 2020, 2020, 4-5.	0.0	0
3059	Bacteriophage biocontrol to fight <i>Listeria</i> outbreaks in seafood. <i>Food and Chemical Toxicology</i> , 2020, 145, 111682.	3.6	10
3060	Sliver defect formation in single crystal Ni-based superalloy castings. <i>Materials and Design</i> , 2020, 196, 109138.	7.0	21
3062	Neutrophil-lymphocyte index as prognostic factor for overall survival and disease-free survival in breast cancer patients. <i>Revista De Senologia Y Patologia Mamaria</i> , 2020, 33, 137-144.	0.1	0
3063	Metastatic breast cancer: Is systemic therapy the only effective treatment?. <i>Revista De Senologia Y Patologia Mamaria</i> , 2020, 33, 169.	0.1	0
3064	Occurrence of Glioma in Pregnant Patients: An Institutional Case Series and Review of the Literature. <i>Anticancer Research</i> , 2020, 40, 3453-3457.	1.1	6
3065	Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581.	7.7	45
3066	Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era. <i>Cancer Gene Therapy</i> , 2020, 28, 971-983.	4.6	6
3067	Prognostic Nomograms for Primary High-Grade Glioma Patients in Adult: A Retrospective Study Based on the SEER Database. <i>BioMed Research International</i> , 2020, 2020, 1-19.	1.9	9

#	ARTICLE	IF	CITATIONS
3068	Deep semi-supervised learning for brain tumor classification. BMC Medical Imaging, 2020, 20, 87.	2.7	43
3069	Isocitrate dehydrogenase variants in cancer – Cellular consequences and therapeutic opportunities. Current Opinion in Chemical Biology, 2020, 57, 122-134.	6.1	35
3070	Glioma induced alterations in fecal short-chain fatty acids and neurotransmitters. CNS Oncology, 2020, 9, CNS57.	3.0	19
3071	Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology, 2020, 38, 3407-3417.	1.6	107
3072	Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile. Current Opinion in Neurology, 2020, 33, 413-421.	3.6	11
3073	Educational Case: Pilocytic Astrocytoma With Atypical Features. Academic Pathology, 2020, 7, 237428952091249.	1.1	2
3074	The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma. Frontiers in Oncology, 2020, 10, 1087.	2.8	22
3075	Optimized Protocol for the In Situ Derivatization of Glutathione with N-Ethylmaleimide in Cultured Cells and the Simultaneous Determination of Glutathione/Glutathione Disulfide Ratio by HPLC-UV-QTOF-MS. Metabolites, 2020, 10, 292.	2.9	15
3076	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clinical Cancer Research, 2020, 26, 5297-5303.	7.0	67
3077	The Prognostic Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas. Journal of Neuroimaging, 2020, 30, 901-909.	2.0	7
3078	Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients. Cancers, 2020, 12, 1958.	3.7	21
3079	Ivosenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study. CNS Oncology, 2020, 9, CNS62.	3.0	21
3080	Chitosan-Based Non-viral Gene and Drug Delivery Systems for Brain Cancer. Frontiers in Neurology, 2020, 11, 740.	2.4	33
3081	Ketogenic Diet for Malignant Gliomas: a Review. Current Nutrition Reports, 2020, 9, 258-263.	4.3	11
3082	Genes and proteins associated with the risk for cancer-associated thrombosis. Thrombosis Research, 2020, 191, S43-S49.	1.7	6
3083	Correlation of preoperative seizures with a wide range of tumor molecular markers in gliomas: An analysis of 442 glioma patients from China. Epilepsy Research, 2020, 166, 106430.	1.6	8
3084	Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas. European Radiology, 2020, 30, 6464-6474.	4.5	8
3085	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. European Journal of Cancer, 2020, 137, 10-17.	2.8	25

#	ARTICLE	IF	CITATIONS
3086	Gene of the month: IDH1. Journal of Clinical Pathology, 2020, 73, 611-615.	2.0	8
3087	The Emerging Role of Extracellular Vesicles in the Glioma Microenvironment: Biogenesis and Clinical Relevance. Cancers, 2020, 12, 1964.	3.7	19
3088	Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. Journal of Neuro-Oncology, 2020, 149, 55-64.	2.9	19
3089	Mapping and Quantification of Non-Coding RNA Originating from the rDNA in Human Glioma Cells. Cancers, 2020, 12, 2090.	3.7	7
3090	The importance of IDH1, ATRX and WT-1 mutations in glioblastoma. Polish Journal of Pathology, 2020, 71, 127-137.	0.3	8
3091	Ethnic delineation of primary glioblastoma genome. Cancer Medicine, 2020, 9, 7352-7359.	2.8	6
3092	Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. European Radiology, 2020, 30, 6475-6484.	4.5	29
3093	A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165916.	3.8	46
3094	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma. Frontiers in Oncology, 2020, 10, 573800.	2.8	9
3095	A Practical Overview on the Molecular Biology of Meningioma. Current Neurology and Neuroscience Reports, 2020, 20, 62.	4.2	17
3096	Outstanding dispersion of CeO2 on reduced graphene oxide. Implications for highly dispersed Pd catalysts. Diamond and Related Materials, 2020, 109, 108061.	3.9	2
3097	Clinical and Molecular Characterization of Incidentally Discovered Lower-Grade Gliomas with Enrichment of Aerobic Respiration. OncoTargets and Therapy, 2020, Volume 13, 9533-9542.	2.0	8
3098	Identification of Prognostic Model and Biomarkers for Cancer Stem Cell Characteristics in Glioblastoma by Network Analysis of Multi-Omics Data and Stemness Indices. Frontiers in Cell and Developmental Biology, 2020, 8, 558961.	3.7	30
3099	Identification of novel tumor suppressors for pancreatic cancer initiation and progression from normal human pancreatic acinar cells. European Journal of Cancer, 2020, 138, S29-S30.	2.8	1
3100	Effect of Yoga and Ergonomic Interventions on Stress and AROM for Employees in Sedentary Work Environments. Archives of Physical Medicine and Rehabilitation, 2020, 101, e56-e57.	0.9	0
3101	Rasch Analysis of the PROMIS Self-Efficacy for Managing Symptoms in Individuals With Chronic Diseases. Archives of Physical Medicine and Rehabilitation, 2020, 101, e61.	0.9	0
3102	Striding Through Summer: Improvements in Gait and Function following a Gait Camp. Archives of Physical Medicine and Rehabilitation, 2020, 101, e102.	0.9	0
3103	Probability pooling for dependent agents in collective learning. Artificial Intelligence, 2020, 288, 103371.	5.8	1

#	ARTICLE	IF	CITATIONS
3104	A new graphical approach for simultaneous targeting and design of mass exchange networks. Computers and Chemical Engineering, 2020, 142, 107061.	3.8	15
3105	Proprioception but not cardiac interoception is related to the rubber hand illusion. Cortex, 2020, 132, 361-373.	2.4	36
3106	16 - Urine Cytokine Levels and Albuminuria Progression Over 2 Years in Youth With Type 2 Diabetes. Canadian Journal of Diabetes, 2020, 44, S7.	0.8	0
3108	Understanding the role of Ca segregation on thermal stability, electrical resistivity and mechanical strength of nanostructured aluminum. Materials Science & Engineering A: Structural Materials: Properties, Microstructure and Processing, 2020, 798, 140108.	5.6	20
3109	Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). Anticancer Research, 2020, 40, 4929-4935.	1.1	3
3110	FGFR3 \rightarrow 37 \rightarrow 9 promotes tumor progression via the phosphorylation and destabilization of ten-eleven translocation-2 in human hepatocellular carcinoma. Cell Death and Disease, 2020, 11, 903.	6.3	16
3111	IDH-wildtype secondary glioblastoma arising in IDH-mutant diffuse astrocytoma: a case report. British Journal of Neurosurgery, 2020, , 1-4.	0.8	0
3112	HGF/MET Signaling in Malignant Brain Tumors. International Journal of Molecular Sciences, 2020, 21, 7546.	4.1	21
3113	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 429-438.	0.7	2
3114	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013 \rightarrow 2017. Neuro-Oncology, 2020, 22, iv1-iv96.	1.2	1,175
3115	Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. Cancer & Metabolism, 2020, 8, 23.	5.0	14
3116	Microglia-Centered Combinatorial Strategies Against Glioblastoma. Frontiers in Immunology, 2020, 11, 571951.	4.8	17
3117	5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids. Surgical Oncology, 2020, 35, 484-490.	1.6	8
3118	Clinical Management of Diffuse Low-Grade Gliomas. Cancers, 2020, 12, 3008.	3.7	44
3119	Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma. Frontiers in Oncology, 2020, 10, 1514.	2.8	6
3120	The Prognostic Significance of \rightarrow RB and PI3K Pathway Alterations in IDH-Mutant Grade II/III Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1019-1023.	1.7	3
3121	Elevated plasma 20S proteasome chymotrypsin-like activity is correlated with IL-8 levels and associated with an increased risk of death in glial brain tumor patients. PLoS ONE, 2020, 15, e0238406.	2.5	6
3122	Is DNA Methylation a Ray of Sunshine in Predicting Meningioma Prognosis?. Frontiers in Oncology, 2020, 10, 1323.	2.8	9

#	ARTICLE	IF	CITATIONS
3123	Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1031-1037.	1.7	15
3124	Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication. BioMed Research International, 2020, 2020, 1-23.	1.9	7
3125	Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. Frontiers in Molecular Biosciences, 2020, 7, 562798.	3.5	85
3126	Case 16 Glioma”Surgical Treatment. , 2020, , .		0
3127	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	1.6	2
3128	Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma. Oncogene, 2020, 39, 6340-6353.	5.9	19
3129	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Frontiers in Molecular Biosciences, 2020, 7, 172.	3.5	25
3130	Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 2020, 19, 776-800.	46.4	264
3131	Radioresistance in Glioblastoma and the Development of Radiosensitizers. Cancers, 2020, 12, 2511.	3.7	77
3132	Teleological Role of L-2-Hydroxyglutarate Dehydrogenase in the Kidney. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	8
3133	Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study. International Journal of Molecular Sciences, 2020, 21, 6716.	4.1	13
3134	The evolving metabolic landscape of chromatin biology and epigenetics. Nature Reviews Genetics, 2020, 21, 737-753.	16.3	255
3135	Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma. Frontiers in Oncology, 2020, 10, 1119.	2.8	25
3136	Mitochondria as a target in cancer treatment. MedComm, 2020, 1, 129-139.	7.2	57
3137	MIR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR. Oncogene, 2020, 39, 6190-6202.	5.9	24
3138	Establishment of age group classification for risk stratification in glioma patients. BMC Neurology, 2020, 20, 310.	1.8	59
3139	New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. Oncogenesis, 2020, 9, 73.	4.9	14
3140	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepevec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. Clinical Cancer Research, 2020, 26, 6176-6186.	7.0	13

#	ARTICLE	IF	CITATIONS
3141	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. <i>Biomedicines</i> , 2020, 8, 294.	3.2	39
3142	Glioma and temozolomide induced alterations in gut microbiome. <i>Scientific Reports</i> , 2020, 10, 21002.	3.3	38
3143	Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma. <i>Frontiers in Neurology</i> , 2020, 11, 573264.	2.4	11
3144	Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study. <i>Journal of Clinical Neuroscience</i> , 2020, 82, 122-127.	1.5	2
3145	A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 591352.	2.8	3
3146	Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma. <i>Cancers</i> , 2020, 12, 3825.	3.7	33
3147	Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres. <i>Journal of Translational Medicine</i> , 2020, 18, 482.	4.4	4
3148	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa142.	0.7	35
3149	Prise en charge de l'allergie chez les patients asthmatiques s'Ã©valuent. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S423-2S433.	0.0	0
3150	Comparative analysis of transcriptomic profile, histology, and IDH mutation for classification of gliomas. <i>Scientific Reports</i> , 2020, 10, 20651.	3.3	6
3151	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. <i>Current Opinion in Neurology</i> , 2020, 33, 707-715.	3.6	8
3152	Interrogation of IDH1 Status in Gliomas by Fourier Transform Infrared Spectroscopy. <i>Cancers</i> , 2020, 12, 3682.	3.7	12
3153	Clinicopathological and Prognostic Roles of STAT3 and Its Phosphorylation in Glioma. <i>Disease Markers</i> , 2020, 2020, 1-11.	1.3	6
3154	A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma. <i>Frontiers in Oncology</i> , 2020, 10, 605737.	2.8	13
3156	Linder hypothesis revisited: Does it hold for services trade?. <i>Economics Letters</i> , 2020, 195, 109469.	1.9	8
3157	Observations of internal tides off the coast of Shandong Peninsula, China. <i>Estuarine, Coastal and Shelf Science</i> , 2020, 245, 106944.	2.1	6
3159	Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. <i>Acta Neuropathologica Communications</i> , 2020, 8, 182.	5.2	11
3161	Safety and efficacy of apraglutide in patients with short bowel syndrome intestinal failure: a double-blind, crossover, randomized, placebo-controlled, phase 2 trial. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 436.	1.2	0

#	ARTICLE	IF	CITATIONS
3162	Systemic Allergic Contact Dermatitis Due to a GORE CARDIOFORM Septal Occluder Device. JACC: Case Reports, 2020, 2, 1867-1871.	0.6	6
3163	177: Evidence-Based Hypofractionated Radiotherapy Uptake in Europe: An Explorative Giro-Hero Analysis. Radiotherapy and Oncology, 2020, 150, S76.	0.6	0
3164	Malnutrition in hospitalized patients with SARS-CoV-2 infection. Clinical Nutrition ESPEN, 2020, 40, 448-449.	1.2	1
3165	Lower basal net protein breakdown is linked to more impaired muscle quality, physical activity level, lung function, and protein intake in COPD patients and sedentary control subjects. Clinical Nutrition ESPEN, 2020, 40, 449-450.	1.2	0
3166	Older patients (50+ Y) declining participation in a randomized controlled nutritional trial have higher risk of readmissions. Clinical Nutrition ESPEN, 2020, 40, 465.	1.2	0
3167	How to establish increased protein intake in a blended lifestyle intervention in community-dwelling older adults? Subgroup-analysis of the vitamin rct. Clinical Nutrition ESPEN, 2020, 40, 500.	1.2	0
3168	Nutrition status and physical development of children with chronic kidney disease C3-C5. Clinical Nutrition ESPEN, 2020, 40, 520-521.	1.2	1
3169	Associations between dietary patterns and insulin resistance in patients with obstructive sleep apnea.. Clinical Nutrition ESPEN, 2020, 40, 535.	1.2	0
3170	Periodontal tissue loss and visceral fat levels in renal transplant recipients - are they related?. Clinical Nutrition ESPEN, 2020, 40, 542.	1.2	0
3171	Home-delivered between-meal snacks for fragile elderly people. Clinical Nutrition ESPEN, 2020, 40, 590-591.	1.2	0
3172	Comparing dietary intake at cancer diagnosis to recommendations and actual need. Clinical Nutrition ESPEN, 2020, 40, 664.	1.2	0
3173	Calf circumference as an indicator for muscle mass in evaluating sarcopenia. Clinical Nutrition ESPEN, 2020, 40, 680-681.	1.2	0
3174	Description, prediction and causation: Methodological challenges of studying child and adolescent development. Developmental Cognitive Neuroscience, 2020, 46, 100867.	4.0	32
3175	Effectiveness of physical exercise toward decreased fatigue in cervical cancer. Enfermer�a Cl�nica, 2020, 30, 127-131.	0.3	1
3177	Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging. Frontiers in Immunology, 2020, 11, 592389.	4.8	23
3180	ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Research, 2020, 182, 104922.	4.1	24
3181	Maternal separation induces retinal and peripheral blood mononuclear cell alterations across the lifespan of female rats. Brain Research, 2020, 1749, 147117.	2.2	4
3183	Laboratory biomarkers associated with COVID-19 severity and management. Clinical Immunology, 2020, 221, 108614.	3.2	56

#	ARTICLE	IF	CITATIONS
3184	Boride formation behaviour and their effect on tensile ductility in cast TiAl-based alloys. <i>Materials and Design</i> , 2020, 195, 109064.	7.0	20
3185	Manejo del ictus agudo. Tratamientos y cuidados específicos de enfermería en la Unidad de Ictus. <i>Neurología</i> , 2023, 38, 419-426.	0.7	1
3186	Recent advances in fructose intake and risk of hyperuricemia. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110795.	5.6	58
3187	Effect of chemical structure on complexation efficiency of aromatic drugs with cyclodextrins: The example of dibenzazepine derivatives. <i>Carbohydrate Polymers</i> , 2020, 250, 116957.	10.2	5
3188	An unconditionally stable space-time FE method for the Korteweg-de Vries equation. <i>Computer Methods in Applied Mechanics and Engineering</i> , 2020, 371, 113297.	6.6	4
3189	Strength and plasticity of amorphous ceramics with self-patterned nano-heterogeneities. <i>International Journal of Plasticity</i> , 2020, 134, 102837.	8.8	19
3190	Tomographic imaging of two-phase flow. <i>International Journal of Advanced Nuclear Reactor Design and Technology</i> , 2020, 2, 86-92.	1.3	5
3191	Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death. <i>Toxicology in Vitro</i> , 2020, 69, 104992.	2.4	3
3193	Response to Letter to the Editor on “Diagnostic Utility of Platelet Count/Lymphocyte Count Ratio and Platelet Count/Mean Platelet Volume Ratio in Periprosthetic Joint Infection After Total Knee Arthroplasty”. <i>Journal of Arthroplasty</i> , 2020, 35, 3782-3783.	3.1	12
3194	Surgery during the COVID-19 pandemic. <i>Lancet, The</i> , 2020, 396, e77.	13.7	2
3197	232 National Cost Savings, Length of Stay Reduction and Preventable Cancer from Expanded Use of Point-of-Care Ultrasound for Small Bowel Obstruction. <i>Annals of Emergency Medicine</i> , 2020, 76, S90.	0.6	0
3198	388 Patient-Provided Medication List Verification in the Emergency Department: Improving Compliance and Enhancing Teamwork. <i>Annals of Emergency Medicine</i> , 2020, 76, S149.	0.6	0
3199	Changes in Wnt-Dependent Neuronal Morphology Underlie the Anatomical Diversification of Neocortical Homologs in Amniotes. <i>Cell Reports</i> , 2020, 31, 107592.	6.4	11
3200	Investigating spatial convergence of diagnosed dementia, depression and type 2 diabetes prevalence in West Adelaide, Australia. <i>Journal of Affective Disorders</i> , 2020, 277, 524-530.	4.1	2
3201	Improving Patient Safety by Increasing Patient Access to Blood Pressure Monitoring Kits and a Follow-Up Guide for Postpartum Patients. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S45.	0.5	0
3202	Image-Guided Peripheral Nerve Cryoneurolysis for Pain Relief in Calciphylaxis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1947-1949.	0.5	3
3203	Applying the servicescape model to understand student experiences of a Norwegian academic library. <i>Library and Information Science Research</i> , 2020, 42, 101051.	2.0	2
3204	Cuidados generales en el manejo del traumatismo craneoencefálico grave: consenso latinoamericano. <i>Medicina Intensiva</i> , 2020, 44, 500-508.	0.7	9

3207	First open label study to investigate the use, safety and tolerability of octaplaslg® in patient blood management in two cardiac surgery centres in France. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, S44-S45.	1.3	0
3209	Cuidemos nuestro futuro. Cirug�a Espa�ola, 2020, 98, 431-432.	0.2	2
3210	The distribution of mutations and hotspots in transcription regulators of resistance-nodulation-cell division efflux pumps in tigecycline non-susceptible Acinetobacter baumannii in China. International Journal of Medical Microbiology, 2020, 310, 151464.	3.6	11
3211	Occurrence and characteristics of microplastics in the coral reef, sea grass and near shore habitats of Rameswaram Island, India. Marine Pollution Bulletin, 2020, 160, 111674.	5.0	36
3212	Risk of postoperative bleeding following dental extractions in patients on antithrombotic treatment. Saudi Dental Journal, 2021, 33, 511-517.	1.6	3
3213	��Mitochondrial Toolbox�� A Review of Online Resources to Explore Mitochondrial Genomics. Frontiers in Genetics, 2020, 11, 439.	2.3	3
3214	Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling. British Journal of Cancer, 2020, 123, 126-136.	6.4	12
3215	Molecular subtyping reveals immune alterations in <scp><i>IDH</i></scp> wild-type lower-grade diffuse glioma. Journal of Pathology, 2020, 251, 272-283.	4.5	42
3216	Role of molecular biomarkers in glioma resection: a systematic review. Chinese Neurosurgical Journal, 2020, 6, 18.	0.9	9
3217	MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. American Journal of Neuroradiology, 2020, 41, 874-881.	2.4	15
3218	Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning. Scientific Reports, 2020, 10, 7733.	3.3	66
3219	Molecular characteristics and clinical features of multifocal glioblastoma. Journal of Neuro-Oncology, 2020, 148, 389-397.	2.9	25
3220	Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. Advanced Science, 2020, 7, 1902971.	11.2	95
3221	Pathways of 4-Hydroxy-2-Nonenal Detoxification in a Human Astrocytoma Cell Line. Antioxidants, 2020, 9, 385.	5.1	7
3222	Epigenetic dynamics in cancer stem cell dormancy. Cancer and Metastasis Reviews, 2020, 39, 721-738.	5.9	26
3223	Contrast-enhanced T1-weighted image radiomics of brain metastases may predict EGFR mutation status in primary lung cancer. Scientific Reports, 2020, 10, 8905.	3.3	34
3224	Pediatric Low-Grade Gliomas. Cancers, 2020, 12, 1152.	3.7	26

#	ARTICLE	IF	CITATIONS
3225	Mitochondria Targeting as an Effective Strategy for Cancer Therapy. International Journal of Molecular Sciences, 2020, 21, 3363.	4.1	131
3226	A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes. Laboratory Investigation, 2020, 100, 1330-1344.	3.7	12
3227	Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism. Frontiers in Endocrinology, 2020, 11, 189.	3.5	8
3228	The biological and clinical basis for early referral of low grade glioma patients to a surgical neuro-oncologist. Journal of Clinical Neuroscience, 2020, 78, 20-29.	1.5	3
3229	A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma. Journal of Cellular and Molecular Medicine, 2020, 24, 7504-7514.	3.6	14
3230	Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know. Acta Neurochirurgica, 2020, 162, 1929-1939.	1.7	10
3231	Adult Glioma WHO Classification Update, Genomics, and Imaging. Topics in Magnetic Resonance Imaging, 2020, 29, 71-82.	1.2	38
3232	IDH-Mutant Gliomas. , 2020, , .		4
3233	Lower Grade Gliomas. Current Neurology and Neuroscience Reports, 2020, 20, 21.	4.2	68
3234	Tailoring drug and gene codelivery nanosystems for glioblastoma treatment. , 2020, , 141-182.		1
3235	Emerging strategies to target cancer metabolism and improve radiation therapy outcomes. British Journal of Radiology, 2020, 93, 20200067.	2.2	15
3236	Heme Oxygenase-1 in Central Nervous System Malignancies. Journal of Clinical Medicine, 2020, 9, 1562.	2.4	23
3237	Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406.	1.6	167
3238	New strategies for managing adult gliomas. Journal of Neurology, 2021, 268, 3666-3674.	3.6	14
3239	The epigenetics of brain tumors and its modulation during radiation: A review. Life Sciences, 2020, 256, 117974.	4.3	8
3240	Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma. Journal of Neuro-Oncology, 2020, 148, 473-480.	2.9	2
3241	Analysis of MRI Data in Diagnostic Neuroradiology. Annual Review of Biomedical Data Science, 2020, 3, 365-390.	6.5	5
3242	Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma. Frontiers in Oncology, 2020, 10, 798.	2.8	26

#	ARTICLE	IF	CITATIONS
3243	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5232-5245.	7.0	52
3244	Return to work following diagnosis of low-grade glioma. <i>Neurology</i> , 2020, 95, e856-e866.	1.1	21
3245	Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. <i>Blood</i> , 2020, 136, 1507-1519.	1.4	57
3246	Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 792.	2.8	24
3247	Landscape of Genomic Alterations in IDH Wild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic Factor. <i>JCO Precision Oncology</i> , 2020, 4, 575-584.	3.0	15
3248	Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. <i>JCO Precision Oncology</i> , 2020, 4, 593-613.	3.0	21
3249	A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 87.	5.2	24
3250	Increased Tau Expression Correlates With IDH Mutation in Infiltrating Gliomas and Impairs Cell Migration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 493-499.	1.7	2
3251	Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 802.	2.4	28
3252	Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 978-997.	3.4	14
3253	SIRT-Independent IDH1 deacetylation inhibits colorectal cancer and liver metastases. <i>EMBO Reports</i> , 2020, 21, e48183.	4.5	67
3254	Amide Proton Transfer Imaging in Predicting Isocitrate Dehydrogenase 1 Mutation Status of Grade II/III Gliomas Based on Support Vector Machine. <i>Frontiers in Neuroscience</i> , 2020, 14, 144.	2.8	16
3255	Role of Isocitrate Dehydrogenase 2 on DNA Hydroxymethylation in Human Airway Smooth Muscle Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 36-45.	2.9	12
3256	Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction. <i>European Radiology</i> , 2020, 30, 3834-3842.	4.5	45
3257	Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis. <i>European Radiology</i> , 2020, 30, 4664-4674.	4.5	24
3258	Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review. <i>Acta Histochemica Et Cytochemica</i> , 2020, 53, 1-10.	1.6	23
3259	Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 96-103.	3.8	6
3260	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1693-1701.	1.6	86

#	ARTICLE	IF	CITATIONS
3261	Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. <i>Molecules</i> , 2020, 25, 1471.	3.8	33
3262	A comprehensive overview on the molecular biology of human glioma: what the clinician needs to know. <i>Clinical and Translational Oncology</i> , 2020, 22, 1909-1922.	2.4	21
3263	Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. <i>Expert Review of Vaccines</i> , 2020, 19, 407-417.	4.4	8
3264	Pediatric low-grade glioma in the era of molecular diagnostics. <i>Acta Neuropathologica Communications</i> , 2020, 8, 30.	5.2	172
3265	Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 89.	2.8	14
3266	Intracranial Metastases Originating From Pediatric Primary Spinal Cord Glioblastoma Multiforme: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 99.	2.8	9
3267	Extracellular Vesicles Involvement in the Modulation of the Glioblastoma Environment. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	9
3268	TERT, a promoter of CNS malignancies. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa025.	0.7	22
3269	MicroRNA-144 represses gliomas progression and elevates susceptibility to Temozolomide by targeting CAV2 and FGF7. <i>Scientific Reports</i> , 2020, 10, 4155.	3.3	15
3270	Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma. <i>Molecular Neurobiology</i> , 2020, 57, 3827-3845.	4.0	18
3271	CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. <i>Scientific Reports</i> , 2020, 10, 10768.	3.3	31
3272	Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs. <i>Cancers</i> , 2020, 12, 1696.	3.7	7
3273	The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma. <i>Translational Oncology</i> , 2020, 13, 100819.	3.7	9
3274	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz060.	0.7	8
3275	Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. <i>Cancers</i> , 2020, 12, 1817.	3.7	43
3276	Robust detection of oncometabolic aberrations by ^1H - ^{13}C heteronuclear single quantum correlation in intact biological specimens. <i>Communications Biology</i> , 2020, 3, 328.	4.4	3
3277	Characterization of serial hyperpolarized ^{13}C metabolic imaging in patients with glioma. <i>NeuroImage: Clinical</i> , 2020, 27, 102323.	2.7	42
3278	A Common Rule for Resection of Glioblastoma in the Molecular Era. <i>JAMA Oncology</i> , 2020, 6, 503.	7.1	3

#	ARTICLE	IF	CITATIONS
3279	Survival after reoperation for recurrent glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 73, 118-124.	1.5	14
3280	Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 378-387.	1.9	75
3281	Publication Landscape Analysis on Gliomas: How Much Has Been Done in the Past 25 Years?. <i>Frontiers in Oncology</i> , 2019, 9, 1463.	2.8	20
3282	Bone Morphogenetic Protein 4 Targeting Glioma Stem-Like Cells for Malignant Glioma Treatment: Latest Advances and Implications for Clinical Application. <i>Cancers</i> , 2020, 12, 516.	3.7	14
3283	Heme Oxygenase-1 and Carbon Monoxide Regulate Growth and Progression in Glioblastoma Cells. <i>Molecular Neurobiology</i> , 2020, 57, 2436-2446.	4.0	25
3284	Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. <i>Neuro-Oncology</i> , 2020, 22, 1018-1029.	1.2	37
3286	From astrocytoma to glioblastoma: a clonal evolution study. <i>FEBS Open Bio</i> , 2020, 10, 744-751.	2.3	7
3287	HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival. <i>BMC Neurology</i> , 2020, 20, 59.	1.8	17
3288	Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns. <i>Medicine (United States)</i> , 2020, 99, e19123.	1.0	10
3289	DNA inhibitors for the treatment of brain tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 195-207.	3.3	3
3290	Tumor antigens in glioma. <i>Seminars in Immunology</i> , 2020, 47, 101385.	5.6	34
3291	Predictors of Postoperative Seizure Outcome in Low Grade Glioma: From Volumetric Analysis to Molecular Stratification. <i>Cancers</i> , 2020, 12, 397.	3.7	26
3292	The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically. <i>Oncogene</i> , 2020, 39, 3163-3178.	5.9	31
3293	A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 579-591.	2.5	4
3294	Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 325-332.	1.3	26
3295	Diseases of the Brain, Head and Neck, Spine 2020â€“2023. <i>IDKD Springer Series</i> , 2020, , .	0.8	17
3296	MR image phenotypes may add prognostic value to clinical features in IDH wild-type lower-grade gliomas. <i>European Radiology</i> , 2020, 30, 3035-3045.	4.5	6
3297	Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching. <i>Clinical Neurology and Neurosurgery</i> , 2020, 191, 105712.	1.4	11

#	ARTICLE	IF	CITATIONS
3298	Glioblastome Multiforme: A Bibliometric Analysis. World Neurosurgery, 2020, 136, 270-282.	1.3	65
3299	The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Science Translational Medicine, 2020, 12, .	12.4	46
3300	Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. International Journal of Molecular Sciences, 2020, 21, 685.	4.1	18
3301	Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 1612-1623.	6.4	76
3302	Germline cancer predisposition variants and pediatric glioma: a population-based study in California. Neuro-Oncology, 2020, 22, 864-874.	1.2	24
3303	Enabling Precision Oncology Through Precision Diagnostics. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 97-121.	22.4	50
3304	Concurrence of multiple sclerosis, oligodendroglioma, and autosomal recessive cerebellar ataxia with spasticity in the same patient: A challenging diagnosis. Multiple Sclerosis and Related Disorders, 2020, 40, 101945.	2.0	3
3305	A robust two-gene signature for glioblastoma survival prediction. Journal of Cellular Biochemistry, 2020, 121, 3593-3605.	2.6	7
3306	Is the anatomical distribution of low-grade gliomas linked to regions of gliogenesis?. Journal of Neuro-Oncology, 2020, 147, 147-157.	2.9	11
3307	Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2 -wildtype astrocytomas. Brain Pathology, 2020, 30, 653-660.	4.1	3
3308	Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. Molecules, 2020, 25, 490.	3.8	31
3309	Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration. Biochemical and Biophysical Research Communications, 2020, 524, 224-230.	2.1	8
3310	Metformin as Potential Therapy for High-Grade Glioma. Cancers, 2020, 12, 210.	3.7	52
3311	DNA methylation in Schwann cells and in oligodendrocytes. Glia, 2020, 68, 1568-1583.	4.9	10
3312	Potential implications of hydrogen peroxide in the pathogenesis and therapeutic strategies of gliomas. Archives of Pharmacal Research, 2020, 43, 187-203.	6.3	12
3313	Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Journal of Neuro-Oncology, 2020, 147, 1-14.	2.9	18
3314	Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Medicinal Chemistry Letters, 2020, 11, 101-107.	2.8	99
3315	Prospects of biological and synthetic pharmacotherapies for glioblastoma. Expert Opinion on Biological Therapy, 2020, 20, 305-317.	3.1	16

#	ARTICLE	IF	CITATIONS
3316	Metabolic changes related to the IDH1 mutation in gliomas preserve TCA cycle activity: An investigation at the protein level. <i>FASEB Journal</i> , 2020, 34, 3646-3657.	0.5	23
3317	Advances in histone demethylase KDM4 as cancer therapeutic targets. <i>FASEB Journal</i> , 2020, 34, 3461-3484.	0.5	81
3318	T2 mapping of molecular subtypes of WHO grade II/III gliomas. <i>BMC Neurology</i> , 2020, 20, 8.	1.8	22
3319	Targeting Glutamine Addiction in Gliomas. <i>Cancers</i> , 2020, 12, 310.	3.7	59
3320	Approaches to PET Imaging of Glioblastoma. <i>Molecules</i> , 2020, 25, 568.	3.8	42
3321	The Magnifying GLASS: Longitudinal Analysis of Adult Diffuse Gliomas. <i>Cell</i> , 2020, 180, 407-409.	28.9	2
3322	Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1004-1009.	2.2	16
3323	Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential. <i>Journal of Neuro-Oncology</i> , 2020, 146, 427-437.	2.9	14
3324	Recent Trends of microRNA Significance in Pediatric Population Glioblastoma and Current Knowledge of Micro RNA Function in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3046.	4.1	17
3326	Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF- κ B1 Target SerpinE1 in Aggressive Glioblastoma Tumors. <i>Cancers</i> , 2020, 12, 1081.	3.7	22
3327	Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A as a Diagnostic and Prognostic Biomarker in Gliomas. <i>Frontiers in Oncology</i> , 2020, 10, 250.	2.8	7
3328	Expression and prognostic value of mRNAs in lower grade glioma with MGMT promoter methylated. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 45-51.	1.5	7
3329	Prognostic impact of distinct genetic entities in pediatric diffuse glioma <sc>WHO</sc> grade <sc>II</sc> Report from the German/Swiss <sc>SIOP</sc> <sc>LGG</sc> 2004 cohort. <i>International Journal of Cancer</i> , 2020, 147, 2159-2175.	5.1	8
3330	Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. <i>Neuroradiology</i> , 2020, 62, 803-813.	2.2	23
3331	Radiomics in gliomas: clinical implications of computational modeling and fractal-based analysis. <i>Neuroradiology</i> , 2020, 62, 771-790.	2.2	32
3332	Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 327-338.	3.8	7
3333	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. <i>Cancer Cell</i> , 2020, 37, 569-583.e5.	16.8	244
3334	Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 720-725.	0.8	33

#	ARTICLE	IF	CITATIONS
3335	Does the expression of glial fibrillary acid protein (GFAP) stain in glioblastoma tissue have a prognostic impact on survival?. <i>Neurochirurgie</i> , 2020, 66, 150-154.	1.2	17
3336	Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer. <i>Oncogene</i> , 2020, 39, 3980-3996.	5.9	38
3337	Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields. <i>Frontiers in Oncology</i> , 2020, 10, 477.	2.8	7
3338	Image Analysis Reveals Microstructural and Volumetric Differences in Glioblastoma Patients with and without Preoperative Seizures. <i>Cancers</i> , 2020, 12, 994.	3.7	4
3339	The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e35-e46.	3.8	5
3340	Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes. <i>American Journal of Neuroradiology</i> , 2020, 41, 815-821.	2.4	14
3341	Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas. <i>Diagnostics</i> , 2020, 10, 247.	2.6	12
3342	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
3343	Integrating Genomic Data with Transcriptomic Data for Improved Survival Prediction for Adult Diffuse Glioma. <i>Journal of Cancer</i> , 2020, 11, 3794-3802.	2.5	5
3344	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro-Oncology</i> , 2020, 22, 1851-1861.	1.2	64
3345	The association between 11C-methionine uptake, IDH gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas. <i>Clinical Radiology</i> , 2020, 75, 622-628.	1.1	4
3346	Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma. <i>BioMed Research International</i> , 2020, 2020, 1-8.	1.9	5
3347	Imaging-Based Algorithm for the Local Grading of Glioma. <i>American Journal of Neuroradiology</i> , 2020, 41, 400-407.	2.4	9
3348	World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. <i>Radiology</i> , 2020, 296, 111-121.	7.3	62
3349	EMT Factors and Metabolic Pathways in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 499.	2.8	205
3350	Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2759.	4.1	40
3352	Rare occurrence of IDH2 mutation in adolescent oligodendroglioma with 1p/19q co-deletion: a case report. <i>Child's Nervous System</i> , 2020, 36, 3109-3113.	1.1	0
3353	Enhanced fatty acid oxidation provides glioblastoma cells metabolic plasticity to accommodate to its dynamic nutrient microenvironment. <i>Cell Death and Disease</i> , 2020, 11, 253.	6.3	67

#	ARTICLE	IF	CITATIONS
3354	Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9964-9972.	7.1	85
3355	Educational Case: Histologic and Molecular Features of Diffuse Gliomas. Academic Pathology, 2020, 7, 2374289520914021.	1.1	2
3356	The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. PLoS ONE, 2020, 15, e0231470.	2.5	10
3357	Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells. Cell Communication and Signaling, 2020, 18, 55.	6.5	9
3358	Cullin-7 (CUL7) is overexpressed in glioma cells and promotes tumorigenesis via NF- κ B activation. Journal of Experimental and Clinical Cancer Research, 2020, 39, 59.	8.6	41
3359	The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathologica Communications, 2020, 8, 40.	5.2	51
3360	mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma. Cancers, 2020, 12, 787.	3.7	22
3361	Fumarate Upregulates Surface Expression of ULBP2/ULBP5 by Scavenging Glutathione Antioxidant Capacity. Journal of Immunology, 2020, 204, 1746-1759.	0.8	4
3362	IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. British Journal of Cancer, 2020, 122, 1580-1589.	6.4	301
3363	Mouse Models of Myeloid Malignancies. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a035535.	6.2	3
3364	Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. Journal of Cellular Physiology, 2021, 236, 507-522.	4.1	28
3365	Anti-angiogenic therapies in the management of glioblastoma. Chinese Clinical Oncology, 2021, 10, 37-37.	1.2	11
3366	A colorimetric method for screening α -glucosidase inhibitors from flavonoids using 3,3',5,5'-tetramethylbenzidine as a chromogenic probe. Colloids and Surfaces B: Biointerfaces, 2021, 197, 111400.	5.0	24
3367	Subacute combined degeneration of the cervical and dorsal spinal cord in a 40-year-old male patient: A case report. Radiology Case Reports, 2021, 16, 13-17.	0.6	5
3368	Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188458.	7.4	34
3369	Pharmacovigilance in the era of social media: Discovering adverse drug events cross-relating Twitter and PubMed. Future Generation Computer Systems, 2021, 114, 394-402.	7.5	14
3370	Green emission and laser properties of Ho ³⁺ doped titano lead borate (TLB) glasses for colour display applications. Journal of Solid State Chemistry, 2021, 293, 121793.	2.9	17
3371	Effects of acoustical descriptors on speech intelligibility in Hong Kong classrooms. Applied Acoustics, 2021, 171, 107678.	3.3	11

#	ARTICLE	IF	CITATIONS
3372	The distribution of isocitrate dehydrogenase mutations, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p/19q codeletion in different glioma subtypes and their correlation with glioma prognosis in Taiwanese population: A single center study. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 23, 100922.	0.3	0
3374	Enabling improved cycling stability of hollow SnO ₂ /C composite anode for lithium-ion battery by constructing a built-in porous carbon support. <i>Applied Surface Science</i> , 2021, 537, 148052.	6.1	17
3375	Buckling analysis of gusset plates with bolted connections using finite element modeling. <i>Journal of Constructional Steel Research</i> , 2021, 176, 106420.	3.9	3
3376	Exploring urban travel patterns using density-based clustering with multi-attributes from large-scaled vehicle trajectories. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2021, 561, 125301.	2.6	23
3377	General principle of primary and secondary plant metabolites: Biogenesis, metabolism, and extraction. , 2021, , 3-23.		6
3379	Tenâ€Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wildâ€™type Isocitrate Dehydrogenase 1. <i>Hepatology</i> , 2021, 73, 1747-1763.	7.3	20
3380	Fully automated hybrid approach to predict the <i>IDH</i> mutation status of gliomas via deep learning and radiomics. <i>Neuro-Oncology</i> , 2021, 23, 304-313.	1.2	114
3381	Targeted nextâ€™generation sequencing of adult gliomas for retrospective prognostic evaluation and upâ€™front diagnostics. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 108-126.	3.2	10
3382	Sirtuin activation targets IDH-mutant tumors. <i>Neuro-Oncology</i> , 2021, 23, 53-62.	1.2	15
3383	Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 447-456.	1.2	8
3384	Chemotherapy toxicities and geriatric syndromes in older patients with malignant gliomas. <i>Journal of Geriatric Oncology</i> , 2021, 12, 134-138.	1.0	6
3385	Computational and systems biology of cancer. <i>Computational and Systems Oncology</i> , 2021, 1, e1005.	1.5	0
3386	Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. <i>Modern Pathology</i> , 2021, 34, 688-700.	5.5	25
3387	Metabolic Coordination of Cell Fate by Î±-Ketoglutarate-Dependent Dioxygenases. <i>Trends in Cell Biology</i> , 2021, 31, 24-36.	7.9	63
3388	Linking epigenetic signature and metabolic phenotype in <i>IDH</i> mutant and <i>IDH</i> wildtype diffuse glioma. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 379-393.	3.2	4
3389	Narrative review of palliative hypofractionated radiotherapy for high grade glioma. <i>Annals of Palliative Medicine</i> , 2021, 10, 846-862.	1.2	5
3391	CFD study of multiphase flow in aerated grit tank. <i>Journal of Water Process Engineering</i> , 2021, 39, 101698.	5.6	7
3392	SARS-CoV-2 RNA detection and persistence in wastewater samples: An experimental network for COVID-19 environmental surveillance in Padua, Veneto Region (NE Italy). <i>Science of the Total Environment</i> , 2021, 760, 143329.	8.0	75

#	ARTICLE	IF	CITATIONS
3393	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e5-235.e14.	1.6	8
3394	Characteristics of IDH-mutant gliomas with non-canonical IDH mutation. <i>Journal of Neuro-Oncology</i> , 2021, 151, 279-286.	2.9	21
3395	Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 609-620.	12.0	48
3396	Random and multi-super-ellipsoidal variables hybrid reliability analysis based on a novel active learning Kriging model. <i>Computer Methods in Applied Mechanics and Engineering</i> , 2021, 373, 113555.	6.6	11
3397	Influence of planes of anisotropy on physical and mechanical properties of freshwater limestone (Mudstone). <i>Construction and Building Materials</i> , 2021, 268, 121174.	7.2	8
3398	Non-orthogonal stagnation point flow of Maxwell nano-material over a stretching cylinder. <i>International Communications in Heat and Mass Transfer</i> , 2021, 120, 105043.	5.6	17
3399	Performance degradation due to anodic failure mechanisms in lithium-ion batteries. <i>Journal of Power Sources</i> , 2021, 502, 229145.	7.8	33
3400	Ketogenic diet as a potential intervention for lipedema. <i>Medical Hypotheses</i> , 2021, 146, 110435.	1.5	28
3401	Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan. <i>Annals of Human Genetics</i> , 2021, 85, 73-79.	0.8	0
3402	The presence of TIMP3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. <i>Brain Pathology</i> , 2021, 31, e12921.	4.1	5
3403	Nanotherapy for Brain Tumor Drug Delivery. <i>Neuromethods</i> , 2021, , .	0.3	2
3404	Automated MRI based pipeline for segmentation and prediction of grade, IDH mutation and 1p19q co-deletion in glioma. <i>Computerized Medical Imaging and Graphics</i> , 2021, 88, 101831.	5.8	38
3405	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. <i>Blood</i> , 2021, 137, 2103-2113.	1.4	57
3406	Demystifying demethylator sensitivity in gliomas: role for TERT and DNMT1. <i>Neuro-Oncology</i> , 2021, 23, 7-8.	1.2	0
3407	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	7.2	194
3408	Achieving sustainable operation for hypersaline membrane distillation applications: A novel strategy based on the critical Reynolds number. <i>Desalination</i> , 2021, 499, 114833.	8.2	14
3409	NAD ⁺ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation. <i>Free Radical Biology and Medicine</i> , 2021, 162, 514-522.	2.9	6
3410	Performance and emission characteristics analysis of <i>Elaeocarpus Ganitrus</i> biodiesel blend using CI engine. <i>Fuel</i> , 2021, 288, 119611.	6.4	13

#	ARTICLE	IF	CITATIONS
3411	Si@Cu ₃ Si nano-composite prepared by facile method as high-performance anode for lithium-ion batteries. <i>Journal of Alloys and Compounds</i> , 2021, 851, 156854.	5.5	22
3412	Blood biomarker algorithms for the diagnosis of mycoplasma pneumoniae respiratory infections. <i>Journal of Immunological Methods</i> , 2021, 489, 112908.	1.4	5
3413	Global zircon analysis records a gradual rise of continental crust throughout the Neoproterozoic. <i>Earth and Planetary Science Letters</i> , 2021, 554, 116654.	4.4	29
3414	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100.	7.7	52
3415	Electropolishing of pure metallic titanium in a deep eutectic solvent. <i>Arabian Journal of Chemistry</i> , 2021, 14, 102906.	4.9	16
3416	Sources of inefficient power generation by coal-fired thermal power plants in China: A metafrontier DEA decomposition approach. <i>Renewable and Sustainable Energy Reviews</i> , 2021, 138, 110562.	16.4	70
3417	Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis. <i>NeuroMolecular Medicine</i> , 2021, 23, 315-326.	3.4	8
3419	Uniting homeostatic plasticity and exosome biology: A revision of the conceptual framework for drug discovery in neurodegenerative diseases?. <i>Advances in Pharmacology</i> , 2021, 90, 277-306.	2.0	0
3420	Influence of polyaniline on the photocatalytic properties of metal nanocomposites: A review. <i>Colloids and Interface Science Communications</i> , 2021, 40, 100339.	4.1	41
3421	A basic review on systemic treatment options in WHO grade II-III gliomas. <i>Cancer Treatment Reviews</i> , 2021, 92, 102124.	7.7	44
3422	Ultra-stable soybean oil-in-water emulsions stabilized by a polymeric surfactant derived from soybean oil. <i>Industrial Crops and Products</i> , 2021, 160, 113093.	5.2	7
3423	Mechanical, electronic and optical properties of K ₂ TeX ₆ (X=Cl, Br, I) perovskite derivatives using density functional theory. <i>Materials Science in Semiconductor Processing</i> , 2021, 123, 105579.	4.0	6
3424	Application of microdosimetric concepts in CaCO ₃ :Ce ³⁺ /Dy ³⁺ for megalevel radiation dosimetry. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2021, 487, 12-24.	1.4	2
3425	A review on synthesis, characterization and application of nanoencapsulated phase change materials for thermal energy storage systems. <i>Applied Thermal Engineering</i> , 2021, 185, 116326.	6.0	69
3426	Heat transfer analysis of tokamak in-vessel coil water-cooling channel joint. <i>Fusion Engineering and Design</i> , 2021, 162, 112106.	1.9	0
3427	A modeling study on utilizing ultra-thin inorganic HTLs in inverted p-n homojunction perovskite solar cells. <i>Solar Energy</i> , 2021, 213, 1-12.	6.1	30
3428	Full-thickness cartilage graft myringoplasty combined with topical application of bFGF for repair of perforations with extensive epithelialization. <i>Auris Nasus Larynx</i> , 2021, 48, 601-608.	1.2	1
3429	Exploring the complex relationships and drivers of ecosystem services across different geomorphological types in the Beijing-Tianjin-Hebei region, China (2000-2018). <i>Ecological Indicators</i> , 2021, 121, 107116.	6.3	32

#	ARTICLE	IF	CITATIONS
3430	A simple solution for prefabricated vertical drain with surcharge preloading combined with vacuum consolidation. <i>Geotextiles and Geomembranes</i> , 2021, 49, 304-322.	4.6	22
3431	Simulating two-phase flow and geomechanical deformation in fractured karst reservoirs based on a coupled hydro-mechanical model. <i>International Journal of Rock Mechanics and Minings Sciences</i> , 2021, 137, 104543.	5.8	17
3432	Single-pixel imaging for dynamic targets via a non-diffracting beam. <i>Optics and Lasers in Engineering</i> , 2021, 139, 106450.	3.8	6
3433	Chromophoric dissolved organic matter in inland waters: Present knowledge and future challenges. <i>Science of the Total Environment</i> , 2021, 759, 143550.	8.0	79
3434	Sorting hidden patterns in nanoparticle performance for glioblastoma using machine learning algorithms. <i>International Journal of Pharmaceutics</i> , 2021, 592, 120095.	5.2	6
3436	Theoretical versus empirical secular change in zircon composition. <i>Earth and Planetary Science Letters</i> , 2021, 554, 116660.	4.4	17
3437	Experimental determination of cooling and spray characteristics of the water electrospray. <i>International Communications in Heat and Mass Transfer</i> , 2021, 120, 105046.	5.6	24
3438	Design and synthesize hollow spindle Ni-doped Co ₉ S ₈ @ZnS composites and their enhanced cycle performance. <i>Journal of Alloys and Compounds</i> , 2021, 853, 157118.	5.5	13
3439	The study of Canadian Arctic freshwater system toward radioactive contamination - status in 1999. <i>Journal of Environmental Radioactivity</i> , 2021, 226, 106454.	1.7	1
3440	Isolation of clinically significant microorganisms from prosthetic joint tissue using BacT/ALERT paediatric blood culture bottles compared with solid culture media and enrichment broth. <i>Pathology</i> , 2021, 53, 515-519.	0.6	0
3441	Integrated multi-omics profiling of nonfunctioning pituitary adenomas. <i>Pituitary</i> , 2021, 24, 312-325.	2.9	6
3443	Transfer learning and SE-ResNet152 networks-based for small-scale unbalanced fish species identification. <i>Computers and Electronics in Agriculture</i> , 2021, 180, 105878.	7.7	41
3444	Foreword. <i>Clinics in Podiatric Medicine and Surgery</i> , 2021, 38, xi-xii.	0.6	0
3445	Experimental study on the spontaneous imbibition characteristics of accumulated coal grains. <i>Fuel</i> , 2021, 288, 119634.	6.4	12
3446	One-pot synthesis of supported Ni@Al ₂ O ₃ catalysts with uniform small-sized Ni for hydrogen generation via ammonia decomposition. <i>International Journal of Hydrogen Energy</i> , 2021, 46, 4045-4054.	7.1	45
3447	Surface quality of cemented tungsten carbide finished by direct cutting using diamond-coated carbide end mill. <i>Journal of Manufacturing Processes</i> , 2021, 61, 83-99.	5.9	11
3448	Adhesion of spider cribellate silk enhanced in high humidity by mechanical plasticization of the underlying fiber. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2021, 114, 104200.	3.1	10
3449	Aged-based differences in spatial language skills from 6 to 10 years: Relations with spatial and mathematics skills. <i>Learning and Instruction</i> , 2021, 73, 101417.	3.2	15

#	ARTICLE	IF	CITATIONS
3450	Experimental and CFD investigation of spiral tube heat exchanger. Materials Today: Proceedings, 2021, 37, 3689-3696.	1.8	6
3451	7-T Magnetic Resonance Imaging in the Management of Brain Tumors. Magnetic Resonance Imaging Clinics of North America, 2021, 29, 83-102.	1.1	6
3452	Sink production and grain-filling ability of a new high-yielding rice variety, Kitagenki. Field Crops Research, 2021, 260, 107991.	5.1	9
3453	Investigating the effect of heat treatment on B4C reinforced aluminum metal matrix composites. Materials Today: Proceedings, 2021, 45, 100-104.	1.8	0
3454	Advancing Imaging to Enhance Surgery. Neurosurgery Clinics of North America, 2021, 32, 31-46.	1.7	7
3455	A numerical differentiation method based on legendre expansion with super order Tikhonov regularization. Applied Mathematics and Computation, 2021, 393, 125811.	2.2	2
3456	Self-destructive barite filter cake in water-based and oil-based drilling fluids. Journal of Petroleum Science and Engineering, 2021, 197, 107963.	4.2	9
3457	Effects of organic additives on calcium hydroxide crystallisation during lime slaking. Cement and Concrete Research, 2021, 139, 106254.	11.0	18
3458	Utilization of PET bottles and plastic granules in geopolymer concrete. Materials Today: Proceedings, 2021, 42, 444-449.	1.8	11
3459	Capacity credit evaluation of wind energy using a robust secant method incorporating improved importance sampling. Sustainable Energy Technologies and Assessments, 2021, 43, 100892.	2.7	7
3460	Enchondromatosis and Growth Plate Development. Current Osteoporosis Reports, 2021, 19, 40-49.	3.6	8
3461	TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation. International Journal of Biochemistry and Cell Biology, 2021, 130, 105885.	2.8	5
3462	Genome-wide translation patterns in gliomas: An integrative view. Cellular Signalling, 2021, 79, 109883.	3.6	4
3463	Understanding the epigenetic landscape and cellular architecture of childhood brain tumors. Neurochemistry International, 2021, 144, 104940.	3.8	2
3464	Applying behavioral economics to reduce broken dental appointments. Journal of the American Dental Association, 2021, 152, 3-7.	1.5	1
3465	Alteration of soil rhizobial populations by rabbit latrines could impair symbiotic nitrogen fixation in the insular alpine ecosystem of Teide National Park. Applied Soil Ecology, 2021, 160, 103850.	4.3	5
3466	Clinical phenotype associated with TANGO2 gene mutation. Archives De Pediatrie, 2021, 28, 80-86.	1.0	14
3467	The Anterolateral Ligament of the Knee: An Updated Systematic Review of Anatomy, Biomechanics, and Clinical Outcomes. Arthroscopy - Journal of Arthroscopic and Related Surgery, 2021, 37, 1654-1666.	2.7	38

#	ARTICLE	IF	CITATIONS
3468	Highly sensitive and stable self-powered biosensing for exosomes based on dual metal-organic frameworks nanocarriers. <i>Biosensors and Bioelectronics</i> , 2021, 176, 112907.	10.1	130
3469	Reactive oxygen species-responsive and scavenging polyurethane nanoparticles for treatment of osteoarthritis in vivo. <i>Chemical Engineering Journal</i> , 2021, 409, 128147.	12.7	31
3470	Analyzing magnetic resonance imaging data from glioma patients using deep learning. <i>Computerized Medical Imaging and Graphics</i> , 2021, 88, 101828.	5.8	23
3471	Commodity anti-counterfeiting decision in e-commerce trade based on machine learning and Internet of Things. <i>Computer Standards and Interfaces</i> , 2021, 76, 103504.	5.4	6
3472	The association between antidepressant use and assisted reproductive technology (ART) treatment in Danish women: A national registry-based cohort study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 258, 401-408.	1.1	3
3473	Differences of bacterial communities in two full-scale A2/O municipal wastewater treatment plants and their effects on effluent total nitrogen removal. <i>Environmental Technology and Innovation</i> , 2021, 21, 101317.	6.1	8
3475	Cancer patients' experience of oncology services in Assam, India. <i>Journal of Cancer Policy</i> , 2021, 27, 100267.	1.4	5
3476	Research Techniques Made Simple: Experimental Methodology for Imaging Mass Cytometry. <i>Journal of Investigative Dermatology</i> , 2021, 141, 467-473.e1.	0.7	9
3477	Non-structural carbohydrates coordinate tree peony flowering both as energy substrates and as sugar signaling triggers, with the bracts playing an essential role. <i>Plant Physiology and Biochemistry</i> , 2021, 159, 80-88.	5.8	11
3482	RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties. <i>Translational Oncology</i> , 2021, 14, 100884.	3.7	7
3483	Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. <i>Modern Pathology</i> , 2021, 34, 62-77.	5.5	42
3484	Glioma stem cells and their roles within the hypoxic tumor microenvironment. <i>Theranostics</i> , 2021, 11, 665-683.	10.0	89
3485	Controllable synthesis and luminescence properties of one-dimensional La ₂ O ₃ and La ₂ O ₃ :Ln ³⁺ (Ln = Er, Tm) nanorods. <i>Journal of Materials Chemistry C</i> , 2021, 9, 10000.	3.1	8
3486	Remote handling systems for the ISAC and ARIEL high-power fission and spallation ISOL target facilities at TRIUMF. <i>Nuclear Engineering and Technology</i> , 2021, 53, 1378-1389.	2.3	7
3487	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. <i>Neuro-Oncology</i> , 2021, 23, 240-250.	1.2	31
3488	lncRNA LINC01057 promotes mesenchymal differentiation by activating NF- κ B signaling in glioblastoma. <i>Cancer Letters</i> , 2021, 498, 152-164.	7.2	34
3489	Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates. <i>European Radiology</i> , 2021, 31, 749-763.	4.5	6
3490	Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies. <i>Clinical Cancer Research</i> , 2021, 27, 383-388.	7.0	12

#	ARTICLE	IF	CITATIONS
3491	Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS : A Prospective Study. Journal of Magnetic Resonance Imaging, 2021, 53, 416-426.	3.4	6
3492	Survival in patients with glioblastoma at a first progression does not correlate with <i>isocitrate dehydrogenase (IDH)1</i> gene mutation status. Japanese Journal of Clinical Oncology, 2021, 51, 45-53.	1.3	16
3493	Association of Clinicopathological Features With Outcome in Chondrosarcomas of the Head and Neck. Otolaryngology - Head and Neck Surgery, 2021, 164, 807-814.	1.9	9
3494	Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review. Neuroradiology, 2021, 63, 353-362.	2.2	33
3495	A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy. Journal of Radiotherapy in Practice, 2021, 20, 83-98.	0.5	7
3496	Perfusion CT and MR Imaging of the Brain. , 2021, , 203-225.		0
3497	SIRT7â€SREBP1 restrains cancer cell metabolic reprogramming by upregulating IDH1. Genome Instability & Disease, 2021, 2, 126-137.	1.1	5
3498	Preventing phenotypic plasticity in cancer to mitigate therapy resistance. , 2021, , 119-160.		0
3500	The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation. BMC Cancer, 2021, 21, 36.	2.6	8
3501	Hippo Signaling Pathway in Gliomas. Cells, 2021, 10, 184.	4.1	58
3502	Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma. Journal of Computer Assisted Tomography, 2021, 45, 110-120.	0.9	10
3503	Overview of glioblastoma biological hallmarks and molecular pathology. , 2021, , 1-15.		0
3504	Glutamine Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2021, 1311, 17-38.	1.6	43
3505	Clinical utility of solid tumor epigenetics. , 2021, , 425-446.		0
3506	Evidence-based approaches to chemotherapy for gliomas. , 2021, , 38-52.		0
3507	Approach to the low-grade glioma patient. , 2021, , 136-152.		0
3508	Molecular Mechanisms of Distinct Diseases. , 0, , .		0
3509	Machine learning classifiers for predicting 3-year progression-free survival and overall survival in patients with gliomas after surgery. Journal of Cancer, 2021, 12, 1604-1615.	2.5	1

[illegible]

#	ARTICLE	IF	CITATIONS
3530	Epigenetics and Metabolism. Learning Materials in Biosciences, 2021, , 179-201.	0.4	2
3531	The Role of Molecular Genetics of Glioblastoma in the Clinical Setting. Molecular Pathology Library, 2021, , 21-33.	0.1	0
3532	Immunohistochemical Surrogates for Molecular Pathology. Molecular Pathology Library, 2021, , 175-195.	0.1	0
3533	Histopathology of Adult and Pediatric Glioblastoma. Molecular Pathology Library, 2021, , 67-89.	0.1	1
3534	Molecular Stratification of Adult and Pediatric High Grade Gliomas. Molecular Pathology Library, 2021, , 123-151.	0.1	0
3535	Wild-type IDH1 inhibits the tumor growth through degrading HIF-1 α in renal cell carcinoma. International Journal of Biological Sciences, 2021, 17, 1250-1262.	6.4	6
3536	Targeting epigenetic alterations in the treatment of glioma. MGM Journal of Medical Sciences, 2021, 8, 194.	0.1	1
3537	Past and present drug treatments for glioblastoma. , 2021, , 17-29.		0
3538	The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET. BMC Cancer, 2021, 21, 83.	2.6	9
3539	Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF- β 2 and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab058.	0.7	13
3540	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances, 2021, 3, vdab017.	0.7	6
3541	Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma. Scientific Reports, 2021, 11, 695.	3.3	21
3542	Metabolic control of cancer progression as novel targets for therapy. Advances in Cancer Research, 2021, 152, 103-177.	5.0	5
3543	Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discovery, 2021, 11, 575-590.	9.4	193
3544	MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells. Frontiers in Oncology, 2020, 10, 600762.	2.8	3
3545	A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opinion on Therapeutic Targets, 2021, 25, 87-100.	3.4	9
3546	SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes. Pathology and Oncology Research, 2021, 27, 594931.	1.9	2
3547	Machine Learning Analytics of Resting-State Functional Connectivity Predicts Survival Outcomes of Glioblastoma Multiforme Patients. Frontiers in Neurology, 2021, 12, 642241.	2.4	11

#	ARTICLE	IF	CITATIONS
3548	Concomitant KIAA1549-BRAF fusion and IDH mutation in Pediatric spinal cord astrocytoma: a case report and literature review. Brain Tumor Pathology, 2021, 38, 132-137.	1.7	3
3550	Reoperation for recurrent glioblastomas: What to expect?. , 2021, 12, 42.		3
3551	Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective. Leukemia and Lymphoma, 2021, 62, 779-790.	1.3	1
3552	Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics, 2021, 11, 252.	2.6	2
3553	Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas. Annals of Nuclear Medicine, 2021, 35, 493-503.	2.2	12
3554	A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2373-2383.	2.5	2
3555	High Hepatic leukemia factor expression indicates a favorable survival in glioma patients. Medicine (United States), 2021, 100, e23980.	1.0	2
3556	New molecular prognostic factors of adult diffuse lower-grade gliomas in post-2016 molecular era: a retrospective analysis from single center. British Journal of Neurosurgery, 2021, , 1-8.	0.8	0
3558	Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. International Journal of Molecular Sciences, 2021, 22, 1831.	4.1	37
3559	Sequential filtering for clinically relevant variants as a method for clinical interpretation of whole exome sequencing findings in glioma. BMC Medical Genomics, 2021, 14, 54.	1.5	0
3560	Loss of 5-Hydroxymethylcytosine as an Epigenetic Signature That Correlates With Poor Outcomes in Patients With Medulloblastoma. Frontiers in Oncology, 2021, 11, 603686.	2.8	4
3561	Cancer metabolism and intervention therapy. Molecular Biomedicine, 2021, 2, 5.	4.4	20
3562	Leveraging the replication-competent avian-like sarcoma virus/tumor virus receptor-A system for modeling human gliomas. Glia, 2021, 69, 2059-2076.	4.9	7
3563	Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report. Genes, 2021, 12, 220.	2.4	1
3565	Magnetic resonance spectroscopy for the study of cns malignancies. Progress in Nuclear Magnetic Resonance Spectroscopy, 2021, 122, 23-41.	7.5	19
3566	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. Diagnostics, 2021, 11, 342.	2.6	15
3567	The Roles of 2-Hydroxyglutarate. Frontiers in Cell and Developmental Biology, 2021, 9, 651317.	3.7	59
3568	The Metabolic Fates of Pyruvate in Normal and Neoplastic Cells. Cells, 2021, 10, 762.	4.1	56

#	ARTICLE	IF	CITATIONS
3569	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. <i>Modern Pathology</i> , 2021, 34, 1245-1260.	5.5	21
3570	Impact of Artificial Intelligence in the field of Health Care. <i>Journal of Physics: Conference Series</i> , 2021, 1831, 012006.	0.4	2
3571	Fluid attenuation in nonâ€contrastâ€enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 523-531.	2.9	13
3572	A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , 2021, 592, 463-468.	27.8	232
3573	The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response. <i>Frontiers in Oncology</i> , 2021, 11, 619300.	2.8	12
3574	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	1.4	13
3575	Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts. <i>Journal of Immunology</i> , 2021, 206, 1483-1492.	0.8	0
3576	Multifaceted microglia â€” key players in primary brain tumour heterogeneity. <i>Nature Reviews Neurology</i> , 2021, 17, 243-259.	10.1	27
3577	Current paradigms in epigenetic anticancer therapeutics and future challenges. <i>Seminars in Cancer Biology</i> , 2022, 83, 422-440.	9.6	26
3578	R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. <i>Molecular Cell</i> , 2021, 81, 922-939.e9.	9.7	157
3579	The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). <i>Neuro-Oncology</i> , 2021, 23, 1765-1776.	1.2	21
3580	Favorable role of <i>IDH</i>1/2 mutations aided with <i>MGMT</i> promoter gene methylation in the outcome of patients with malignant glioma. <i>Future Science OA</i> , 2021, 7, FSO663.	1.9	10
3581	Evaluation of gliomas peritumoral diffusion and prediction of IDH1 mutation by IVIM-DWI. <i>Aging</i> , 2021, 13, 9948-9959.	3.1	5
3582	Assessment of Isocitrate Dehydrogenase 1 Mutation by Immunohistochemistry in Egyptian Patients with High-grade Gliomas. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 157-163.	0.2	0
3583	Immunohistochemical characterisation and histopathology of astrocytic neoplasms at a tertiary Nigerian hospital. <i>International Journal of Clinical Practice</i> , 2021, 75, e14094.	1.7	0
3584	Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2960.	4.1	4
3585	Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. <i>Journal of Biomedical Science</i> , 2021, 28, 18.	7.0	42
3586	Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. <i>Diagnostics</i> , 2021, 11, 481.	2.6	5

#	ARTICLE	IF	CITATIONS
3587	TERT Promoter Alterations in Glioblastoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 1147.	3.7	31
3588	Proteogenomics of glioblastoma associates molecular patterns with survival. <i>Cell Reports</i> , 2021, 34, 108787.	6.4	31
3589	Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. <i>Breast Cancer</i> , 2021, 28, 915-926.	2.9	10
3590	Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , 2021, 11, 6933.	3.3	9
3591	TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas. <i>Cancer Cell International</i> , 2021, 21, 148.	4.1	5
3592	Targeting glioma-initiating cells via the tyrosine metabolic pathway. <i>Journal of Neurosurgery</i> , 2021, 134, 721-732.	1.6	23
3593	MYD88 Is a Potential Prognostic Gene and Immune Signature of Tumor Microenvironment for Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 654388.	2.8	13
3594	Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 644857.	2.8	11
3595	Improving performance and generalizability in radiogenomics: a pilot study for prediction of IDH1/2 mutation status in gliomas with multicentric data. <i>Journal of Medical Imaging</i> , 2021, 8, 031905.	1.5	5
3596	High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma. <i>Chinese Neurosurgical Journal</i> , 2021, 7, 22.	0.9	3
3597	Drug target ranking for glioblastoma multiforme. <i>BMC Biomedical Engineering</i> , 2021, 3, 7.	2.6	5
3598	IDH Inhibitors in AML—Promise and Pitfalls. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 207-217.	2.3	33
3599	Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite. <i>Cancers</i> , 2021, 13, 1756.	3.7	8
3600	Proteogenomic and metabolomic characterization of human glioblastoma. <i>Cancer Cell</i> , 2021, 39, 509-528.e20.	16.8	327
3601	Glutaminolysis dynamics during astrocytoma progression correlates with tumor aggressiveness. <i>Cancer & Metabolism</i> , 2021, 9, 18.	5.0	14
3602	Isotope tracing reveals glycolysis and oxidative metabolism in childhood tumors of multiple histologies. <i>Med</i> , 2021, 2, 395-410.e4.	4.4	21
3603	Discovery and Optimization of 2-H ¹ -Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4913-4946.	6.4	12
3604	Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas. <i>Scientific Reports</i> , 2021, 11, 7927.	3.3	3

#	ARTICLE	IF	CITATIONS
3605	Brain Tumor Vaccines. Neurosurgery Clinics of North America, 2021, 32, 225-234.	1.7	4
3606	Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1. Bioorganic and Medicinal Chemistry, 2021, 36, 116095.	3.0	8
3607	A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning. Biomolecules, 2021, 11, 565.	4.0	10
3608	Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution. Frontiers of Medicine, 2021, 15, 551-561.	3.4	39
3609	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. Journal of Neurochemistry, 2021, 158, 522-538.	3.9	18
3610	Advances in epigenetic therapeutics with focus on solid tumors. Clinical Epigenetics, 2021, 13, 83.	4.1	53
3611	Pediatric Glial Tumors. Pediatric and Developmental Pathology, 2021, , 109352662110091.	1.0	3
3612	SH3BGR2 functions as a crucial tumor suppressor in glioblastoma tumorigenesis. Biochemical and Biophysical Research Communications, 2021, 547, 148-154.	2.1	2
3613	Glioblastoma Primary Cells Retain the Most Copy Number Alterations That Predict Poor Survival in Glioma Patients. Frontiers in Oncology, 2021, 11, 621432.	2.8	2
3614	R-2-HG in AML—friend or foe?. Blood Science, 2021, 3, 62-63.	0.9	0
3615	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery, 2021, 89, 129-132.	1.1	5
3616	State of Radiomics in Glioblastoma. Neurosurgery, 2021, 89, 177-184.	1.1	15
3617	Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches. International Journal of Molecular Sciences, 2021, 22, 4732.	4.1	12
3619	Can artificial intelligence overtake human intelligence on the bumpy road towards glioma therapy?. Medical Oncology, 2021, 38, 53.	2.5	8
3620	Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. NAR Cancer, 2021, 3, zcab018.	3.1	17
3621	SGPNet: A Three-Dimensional Multitask Residual Framework for Segmentation and IDH Genotype Prediction of Gliomas. Computational Intelligence and Neuroscience, 2021, 2021, 1-9.	1.7	4
3622	Hypoxia and Microvascular Alterations Are Early Predictors of IDH-Mutated Anaplastic Glioma Recurrence. Cancers, 2021, 13, 1797.	3.7	2
3623	Detection of Isocitrate Dehydrogenase Mutated Glioblastomas Through Anomaly Detection Analytics. Neurosurgery, 2021, 89, 323-328.	1.1	6

#	ARTICLE	IF	CITATIONS
3624	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559.	1.2	34
3625	Identification of CRYAB+ KCNN3+ SOX9+ Astrocyte-Like and EGFR+ PDGFRA+ OLIG1+ Oligodendrocyte-Like Tumoral Cells in Diffuse IDH1-Mutant Gliomas and Implication of NOTCH1 Signalling in Their Genesis. <i>Cancers</i> , 2021, 13, 2107.	3.7	9
3626	Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. <i>Cancer Research and Treatment</i> , 2021, 53, 367-377.	3.0	13
3627	Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA. <i>Nature Metabolism</i> , 2021, 3, 558-570.	11.9	58
3628	The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy. <i>Neuroradiology</i> , 2021, 63, 1823-1830.	2.2	10
3629	Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. <i>Acta Neurochirurgica</i> , 2021, 163, 1883-1894.	1.7	11
3630	High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas. <i>World Neurosurgery</i> , 2021, 148, e436-e449.	1.3	4
3631	Texture Enhanced Generative Adversarial Network For Stain Normalisation In Histopathology Images. , 2021, , .		6
3632	An integrative analysis of the age-associated multi-omic landscape across cancers. <i>Nature Communications</i> , 2021, 12, 2345.	12.8	54
3633	Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM. <i>Journal of Personalized Medicine</i> , 2021, 11, 290.	2.5	30
3634	Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs. <i>Acta Neuropathologica Communications</i> , 2021, 9, 69.	5.2	23
3635	Magnetic Resonance Imaging Parameters for Noninvasive Prediction of Epidermal Growth Factor Receptor Amplification in Isocitrate Dehydrogenase-Wild-Type Lower-Grade Gliomas: A Multicenter Study. <i>Neurosurgery</i> , 2021, 89, 257-265.	1.1	11
3636	The Predictive Value of Monocytes in Immune Microenvironment and Prognosis of Glioma Patients Based on Machine Learning. <i>Frontiers in Immunology</i> , 2021, 12, 656541.	4.8	34
3637	Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report. <i>Frontiers in Nutrition</i> , 2021, 8, 682243.	3.7	13
3638	Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. <i>Molecular and Clinical Oncology</i> , 2021, 15, 150.	1.0	5
3639	Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. <i>World Neurosurgery</i> , 2021, 149, e894-e912.	1.3	5
3640	Chondrosarcoma-from Molecular Pathology to Novel Therapies. <i>Cancers</i> , 2021, 13, 2390.	3.7	31
3641	The Evolving Role of Targeted Therapies in Primary Central Nervous System Tumors. <i>Advances in Oncology</i> , 2021, 1, 203-212.	0.2	1

#	ARTICLE	IF	CITATIONS
3642	Neuroimaging in the Era of the Evolving WHO Classification of Brain Tumors, From the AJR Special Series on Cancer Staging. American Journal of Roentgenology, 2021, 217, 1-13.	2.2	7
3644	From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy. International Journal of Molecular Sciences, 2021, 22, 5574.	4.1	6
3645	Immunotherapy and radiation for high-grade glioma: a narrative review. Translational Cancer Research, 2021, 10, 2537-2570.	1.0	6
3646	Radiogenomics of Gliomas. Radiologic Clinics of North America, 2021, 59, 441-455.	1.8	7
3648	From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells, 2021, 10, 1225.	4.1	17
3649	Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clinical Cancer Research, 2021, 27, 4101-4108.	7.0	24
3650	Altered corticospinal microstructure and motor cortex excitability in gliomas: an advanced tractography and transcranial magnetic stimulation study. Journal of Neurosurgery, 2021, 134, 1368-1376.	1.6	10
3651	Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping. Journal of Neuro-Oncology, 2021, 153, 361-372.	2.9	16
3652	Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence. Cancers, 2021, 13, 2408.	3.7	24
3653	Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker. Cancers, 2021, 13, 2338.	3.7	5
3654	Metabolomics in cancer research and emerging applications in clinical oncology. Ca-A Cancer Journal for Clinicians, 2021, 71, 333-358.	329.8	267
3655	Brainstem Infiltration Predicts Survival in Patients With High-grade Gliomas Treated With Chemoradiotherapy. Anticancer Research, 2021, 41, 2583-2589.	1.1	4
3656	Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics. Biomolecules, 2021, 11, 740.	4.0	3
3657	Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma. , 0, , 61-78.		5
3658	Mitochondrial DNA variation and cancer. Nature Reviews Cancer, 2021, 21, 431-445.	28.4	98
3659	IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. Pathology Research and Practice, 2021, 221, 153445.	2.3	6
3660	Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells, 2021, 10, 1226.	4.1	40
3661	Prolonged survival after laser interstitial thermal therapy in glioblastoma. , 2021, 12, 228.		7

#	ARTICLE	IF	CITATIONS
3662	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. <i>Cancers</i> , 2021, 13, 2474.	3.7	13
3663	Molecular Diagnostics of Adult Gliomas in Neuropathological Practice. <i>Acta Medica Academica</i> , 2021, 50, 29.	0.8	5
3664	Spectral fitting strategy to overcome the overlap between 2- ¹³ C-hydroxyglutarate and lipid resonances at 2.25 ppm. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1818-1828.	3.0	7
3665	The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 670145.	3.7	4
3666	A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study. <i>BMC Surgery</i> , 2021, 21, 238.	1.3	13
3667	Construction of a SUMOylation regulator-based prognostic model in low-grade glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5434-5442.	3.6	5
3668	5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.7	19
3669	The Acidic Brain Glycolytic Switch in the Microenvironment of Malignant Glioma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5518.	4.1	24
3670	Metabolic reprogramming and epigenetic modifications on the path to cancer. <i>Protein and Cell</i> , 2022, 13, 877-919.	11.0	179
3671	Imaging Findings of New Entities and Patterns in Brain Tumor. <i>Radiologic Clinics of North America</i> , 2021, 59, 305-322.	1.8	2
3672	Molecular and Metabolic Reprogramming: Pulling the Strings Toward Tumor Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 656851.	2.8	9
3673	MRI Imaging Characteristics of Glioblastoma with Concurrent Gain of Chromosomes 19 and 20. <i>Tomography</i> , 2021, 7, 228-237.	1.8	0
3674	Estimation of the occurrence rates of <i>IDH1</i> and <i>IDH2</i> mutations in gliomas and the reconsideration of <i>IDH</i>-wildtype anaplastic astrocytomas: an institutional experience. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110192.	1.0	5
3676	Novel Strategies for Disrupting Cancer-Cell Functions with Mitochondria-Targeted Antitumor Drug-Loaded Nanoformulations. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 3907-3936.	6.7	31
3677	Molecular Classification of Diffuse Gliomas. , 0, , .		0
3678	A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas. <i>Frontiers in Oncology</i> , 2021, 11, 652133.	2.8	4
3679	Purine synthesis as a target for radiation resistance in molecular glioblastoma. <i>Journal of the Neurological Sciences</i> , 2021, 425, 117439.	0.6	0
3680	Contrasts in Glioblastoma Venous Thromboembolism versus Bleeding Risk. <i>Cells</i> , 2021, 10, 1414.	4.1	5

#	ARTICLE	IF	CITATIONS
3681	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 631037.	2.8	10
3682	Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 691246.	2.8	13
3683	Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018. <i>Journal of Neurology</i> , 2022, 269, 861-872.	3.6	9
3684	Gemistocytes in newly diagnosed glioblastoma multiforme: Clinical significance and practical implications in the modern era. <i>Journal of Clinical Neuroscience</i> , 2021, 88, 120-127.	1.5	2
3686	DNA Repair Mechanisms and Therapeutic Targets in Glioma. <i>Current Oncology Reports</i> , 2021, 23, 87.	4.0	16
3687	Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 41-54.	2.7	8
3688	Bioinformatic Analyses Identify a Prognostic Autophagy-Related Long Non-coding RNA Signature Associated With Immune Microenvironment in Diffuse Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 694633.	3.7	10
3689	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 457-473.	3.8	19
3690	Predicting cancer malignancy and proliferation in glioma patients: intra-subject inter-metabolite correlation analyses using MRI and MRSI contrast scans. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2721-2732.	2.0	1
3691	Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma. <i>Cancer Medicine</i> , 2021, 10, 4644-4657.	2.8	3
3692	Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview. <i>Cancer Science</i> , 2021, 112, 2984-2992.	3.9	20
3693	Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?. <i>Journal of Neuro-Oncology</i> , 2021, 153, 537-545.	2.9	3
3694	In Regard to Tibbs et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 611-612.	0.8	1
3695	TERT and its binding protein: overexpression of GABPA/B in high grade gliomas. <i>Oncotarget</i> , 2021, 12, 1271-1280.	1.8	2
3696	Therapeutic targeting of chromatin: status and opportunities. <i>FEBS Journal</i> , 2022, 289, 1276-1301.	4.7	10
3697	Advances in the management of glioblastoma. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1103-1111.	1.9	58
3698	Metabolic Reprogramming and Molecular Rewiring in Cancer: Therapeutic Opportunities. <i>Indonesian Biomedical Journal</i> , 2021, 13, 114-39.	0.3	3
3699	A vaccine for glioma. <i>Nature Cancer</i> , 2021, 2, 584-586.	13.2	5

#	ARTICLE	IF	CITATIONS
3700	PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival. <i>Journal of Personalized Medicine</i> , 2021, 11, 624.	2.5	11
3701	An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor. <i>Cancers</i> , 2021, 13, 2813.	3.7	40
3702	RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma. <i>Scientific Reports</i> , 2021, 11, 11836.	3.3	13
3703	In Reply to Bunevicius etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 612.	0.8	0
3704	Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines. <i>BioMed Research International</i> , 2021, 2021, 1-11.	1.9	2
3705	Molecular Landscape for Malignant Transformation in Diffuse Astrocytoma. <i>Global Medical Genetics</i> , 2021, 08, 116-122.	0.9	1
3706	The implications of IDH mutations for cancer development and therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 645-661.	27.6	155
3707	Clinical outcomes and a therapeutic indication of intramedullary spinal cord astrocytoma. <i>Spinal Cord</i> , 2022, 60, 216-222.	1.9	10
3708	2-HG modulates glioma macrophages via Trp metabolism. <i>Nature Cancer</i> , 2021, 2, 677-679.	13.2	2
3709	Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. <i>European Radiology</i> , 2022, 32, 101-111.	4.5	12
3710	Clinical implications of molecular analysis in diffuse glioma stratification. <i>Brain Tumor Pathology</i> , 2021, 38, 210-217.	1.7	6
3711	Perioperative clinical trials for glioma: Raising the bar. <i>Journal of Clinical Neuroscience</i> , 2021, 89, 144-150.	1.5	5
3712	Pharmacological strategies for improving the prognosis of glioblastoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2019-2031.	1.8	8
3713	Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas. <i>Frontiers in Oncology</i> , 2021, 11, 696214.	2.8	3
3714	Foundations of Neuro-Oncology: A Multidisciplinary Approach. <i>World Neurosurgery</i> , 2021, 151, 392-401.	1.3	5
3715	Additional mutations in IDH1/2â€ mutated patients with acute myeloid leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1483-1490.	1.3	5
3716	Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma. <i>Cancer Science</i> , 2021, 112, 3699-3710.	3.9	13
3717	CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 722916.	2.8	64

#	ARTICLE	IF	CITATIONS
3718	BICD Cargo Adaptor 1 (BICD1) Downregulation Correlates with a Decreased Level of PD-L1 and Predicts a Favorable Prognosis in Patients with IDH1-Mutant Lower-Grade Gliomas. <i>Biology</i> , 2021, 10, 701.	2.8	0
3719	Targeted Therapies in Rare Brain Tumours. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7949.	4.1	4
3720	Multimodal Role of PACAP in Glioblastoma. <i>Brain Sciences</i> , 2021, 11, 994.	2.3	9
3721	Glioblastoma: clinical presentation, diagnosis, and management. <i>BMJ, The</i> , 2021, 374, n1560.	6.0	133
3722	Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas. <i>EJNMMI Research</i> , 2021, 11, 67.	2.5	1
3723	Glioblastoma Contains Topologically Distinct Proliferative and Metabolically Defined Subpopulations of Nestin- and Glut1-Expressing Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 674-684.	1.7	1
3724	Identification of the Prognostic Signatures of Glioma With Different PTEN Status. <i>Frontiers in Oncology</i> , 2021, 11, 633357.	2.8	15
3725	CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 675424.	3.7	6
3726	Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. <i>Cancer Research</i> , 2021, 81, 4861-4873.	0.9	7
3727	The impact of mitochondria on cancer treatment resistance. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 983-995.	4.4	15
3728	<i>IDH</i> Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. <i>Advanced Science</i> , 2021, 8, e2101230.	11.2	26
3729	Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA. <i>Scientific Reports</i> , 2021, 11, 14408.	3.3	12
3730	Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles. <i>Neuro-Oncology</i> , 2022, 24, 197-209.	1.2	21
3731	Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL. <i>Cancer Research</i> , 2021, 81, 5033-5046.	0.9	7
3732	Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. <i>Biochemistry</i> , 2021, 60, 2275-2284.	2.5	2
3733	Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas—A Single-Institution, Nine-Year Data. <i>World Neurosurgery</i> , 2021, 151, e217-e233.	1.3	4
3734	Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103372.	4.4	19
3735	Immunometabolism: A “Hot” Switch for “Cold” Pediatric Solid Tumors. <i>Trends in Cancer</i> , 2021, 7, 751-777.		8

#	ARTICLE	IF	CITATIONS
3736	Radiation Therapy for Grade 3 Gliomas: Correlation of MRI Findings With Prognosis. <i>Cureus</i> , 2021, 13, e16887.	0.5	1
3737	Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence. <i>Molecular Cancer Research</i> , 2021, 19, 1878-1888.	3.4	2
3738	Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain. <i>Cancer Discovery</i> , 2022, 12, 172-185.	9.4	19
3739	The Crucial Roles of Intermediate Metabolites in Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6291-6307.	1.9	5
3740	Multicenter DSCâ€“MRI-Based Radiomics Predict IDH Mutation in Gliomas. <i>Cancers</i> , 2021, 13, 3965.	3.7	25
3741	Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients. <i>Journal of Translational Medicine</i> , 2021, 19, 372.	4.4	3
3742	iGlioSub: an integrative transcriptomic and epigenomic classifier for glioblastoma molecular subtypes. <i>BioData Mining</i> , 2021, 14, 42.	4.0	7
3743	Joint application of biochemical markers and imaging techniques in the accurate and early detection of glioblastoma. <i>Pathology Research and Practice</i> , 2021, 224, 153528.	2.3	1
3744	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 302-310.	1.2	29
3745	Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system. <i>European Radiology</i> , 2021, 31, 7374-7385.	4.5	14
3747	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 5669-5680.	7.0	4
3748	Age is associated with unfavorable neuropathological and radiological features and poor outcome in patients with WHO gradeÂ2 and 3 gliomas. <i>Scientific Reports</i> , 2021, 11, 17380.	3.3	8
3749	Tumours of the central nervous system. <i>Surgery</i> , 2021, 39, 479-485.	0.3	0
3750	IDH mutation status and the development of venous thromboembolism in astrocytoma patients. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117538.	0.6	4
3751	The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results. <i>Chinese Clinical Oncology</i> , 2021, 10, 38-38.	1.2	5
3754	Case of multifocal glioblastoma with four fusion transcripts of ALK, FGFR2, NTRK2, and NTRK3 genes stresses the need for tumor tissue multisampling for transcriptomic analysis. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006100.	1.2	8
3755	Primary Extra-axial Glioblastoma: Case Report and Literature Review. <i>Brazilian Neurosurgery</i> , 2021, 40, e368-e373.	0.1	0
3756	Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8289.	4.1	10

#	ARTICLE	IF	CITATIONS
3757	Primary Cilia-Related Pathways Moderate the Development and Therapy Resistance of Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 718995.	2.8	5
3758	Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. <i>Oncogene</i> , 2021, 40, 5880-5892.	5.9	15
3759	Molecular investigation of brain tumors progressing during pregnancy or postpartum period: the association between tumor type, their receptors, and the timing of presentation. <i>Clinical Neurology and Neurosurgery</i> , 2021, 207, 106720.	1.4	4
3760	Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation. <i>Scientific Reports</i> , 2021, 11, 16489.	3.3	1
3761	Analysis of <i>ALK</i> , <i>IDH1</i> , <i>IDH2</i> and <i>MMP8</i> somatic mutations in differentiated thyroid cancers. <i>Molecular and Clinical Oncology</i> , 2021, 15, 210.	1.0	4
3762	Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma. <i>Cells</i> , 2021, 10, 2116.	4.1	8
3763	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 703764.	2.8	27
3764	A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database. <i>Cancers</i> , 2021, 13, 4299.	3.7	20
3766	Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images. <i>Scientific Reports</i> , 2021, 11, 16849.	3.3	34
3767	Combination of the Distance From Tumor Edge to Subventricular Zone and IDH Mutation Predicts Prognosis of Patients With Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 693693.	2.8	0
3768	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. <i>Molecular Cell</i> , 2021, 81, 3833-3847.e11.	9.7	10
3769	D-2-Hydroxyglutarate in Glioma Biology. <i>Cells</i> , 2021, 10, 2345.	4.1	26
3770	Control of topoisomerase II activity and chemotherapeutic inhibition by TCA cycle metabolites. <i>Cell Chemical Biology</i> , 2022, 29, 476-489.e6.	5.2	10
3771	Characterization of METTL7B to Evaluate TME and Predict Prognosis by Integrative Analysis of Multi-Omics Data in Glioma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 727481.	3.5	11
3772	SOCS3 is Related to Cell Proliferation in Neuronal Tissue: An Integrated Analysis of Bioinformatics and Experiments. <i>Frontiers in Genetics</i> , 2021, 12, 743786.	2.3	6
3773	Molecular Pathology of Gliomas. <i>Surgical Pathology Clinics</i> , 2021, 14, 379-386.	1.7	18
3774	An insertion variant of MGMT disrupts a STAT1 binding site and confers susceptibility to glioma. <i>Cancer Cell International</i> , 2021, 21, 506.	4.1	1
3775	The Big Picture of Glioblastoma Malignancy: A Meta-Analysis of Glioblastoma Proteomics to Identify Altered Biological Pathways. <i>ACS Omega</i> , 2021, 6, 24535-24544.	3.5	6

#	ARTICLE	IF	CITATIONS
3776	Construction of Novel Methylation-Driven Gene Model and Investigation of PARVB Function in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 705547.	2.8	5
3777	Driver Genetic Mutations in Spinal Cord Gliomas Direct the Degree of Functional Impairment in Tumor-Associated Spinal Cord Injury. <i>Cells</i> , 2021, 10, 2525.	4.1	6
3778	Moving pan-cancer studies from basic research toward the clinic. <i>Nature Cancer</i> , 2021, 2, 879-890.	13.2	40
3779	A map of the altered glioma metabolism. <i>Trends in Molecular Medicine</i> , 2021, 27, 1045-1059.	6.7	18
3780	The Evolving Molecular Landscape of High-Grade Gliomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 337-343.	2.0	5
3781	Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. <i>BMC Cancer</i> , 2021, 21, 1025.	2.6	6
3782	Activity of Wnt/PCP Regulation Pathway Classifies Patients of Low-Grade Glioma Into Molecularly Distinct Subgroups With Prognostic Difference. <i>Frontiers in Oncology</i> , 2021, 11, 726034.	2.8	3
3783	Biologic Pathways Underlying Prognostic Radiomics Phenotypes from Paired MRI and RNA Sequencing in Glioblastoma. <i>Radiology</i> , 2021, 301, 654-663.	7.3	38
3784	Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 694490.	4.8	25
3785	SOHO State of the Art Updates and Next Questions: IDH Inhibition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 567-572.	0.4	0
3786	Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development. <i>Frontiers in Immunology</i> , 2021, 12, 738435.	4.8	13
3787	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 953-966.	4.2	8
3788	Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. <i>Molecular Cancer Research</i> , 2021, 19, 2057-2067.	3.4	10
3789	Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: The diagnostic challenges. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	7
3790	Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 717601.	3.7	6
3791	A Radiomics Model for Predicting Early Recurrence in Grade II Gliomas Based on Preoperative Multiparametric Magnetic Resonance Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 684996.	2.8	4
3792	Atomic Force Microscope Nanoindentation Analysis of Diffuse Astrocytic Tumor Elasticity: Relation with Tumor Histopathology. <i>Cancers</i> , 2021, 13, 4539.	3.7	6
3794	Establishment of an Endocytosis-Related Prognostic Signature for Patients With Low-Grade Glioma. <i>Frontiers in Genetics</i> , 2021, 12, 709666.	2.3	4

#	ARTICLE	IF	CITATIONS
3795	Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T. <i>Frontiers in Neurology</i> , 2021, 12, 718423.	2.4	9
3796	A diagnostic tree for differentiation of adult pilocytic astrocytomas from high-grade gliomas. <i>European Journal of Radiology</i> , 2021, 143, 109946.	2.6	5
3797	Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH<i>wt</i> glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab127.	0.7	5
3798	Mutant IDH1 inhibitors activate pSTAT3-Y705 leading to an increase in BCAT1 and YKL-40 levels in mutant IDH1-expressing cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119114.	4.1	9
3799	Lectin isolated from <i>Abelmoschus esculentus</i> induces caspase mediated apoptosis in human U87 glioblastoma cell lines and modulates the expression of circadian clock genes. <i>Toxicon</i> , 2021, 202, 98-109.	1.6	9
3800	Next generation sequencing impacts the classification and management of primary brain tumours. <i>Pathology</i> , 2021, 53, 780-782.	0.6	2
3801	G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. <i>Science Advances</i> , 2021, 7, eabh3243.	10.3	53
3802	Antioxidant responses related to temozolomide resistance in glioblastoma. <i>Neurochemistry International</i> , 2021, 149, 105136.	3.8	17
3803	Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1. <i>Cancer Letters</i> , 2021, 517, 35-45.	7.2	15
3804	SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 139, 106054.	2.8	17
3805	Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. <i>Cells</i> , 2021, 10, 2621.	4.1	4
3806	Glioblastoma with primitive neuronal component: An immunohistochemical study and review of literature. <i>Journal of Clinical Neuroscience</i> , 2021, 93, 130-136.	1.5	3
3807	Determination of intracellular 2-hydroxyglutarate enantiomers using two-dimensional liquid chromatography. <i>Journal of Chromatography Open</i> , 2021, 1, 100005.	2.2	3
3808	Markers for bone sarcomas. , 2022, , 543-577.		0
3809	Applied cancer immunogenomics in glioblastoma. , 2022, , 19-38.		0
3810	Genetic Architectures and Cell-of-Origin in Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 615400.	2.8	26
3812	Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 153-162.	2.9	5
3813	IDH Mutation Status Prediction by Modality-Self Attention Network. <i>Smart Innovation, Systems and Technologies</i> , 2021, , 51-57.	0.6	2

#	ARTICLE	IF	CITATIONS
3814	Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining ^{18}F -fluorodeoxyglucose Positron Emission Tomography with Arterial Spin Labeling. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 367-375.	2.2	13
3815	Brain Neoplasm. , 2021, , 521-625.		1
3816	Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 453-460.	2.2	1
3817	Pathology, Molecular Biology and Classification of Gliomas. , 2021, , 37-55.		0
3818	Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses. <i>Life</i> , 2021, 11, 69.	2.4	66
3819	A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. <i>Journal of Neuro-Oncology</i> , 2021, 151, 103-112.	2.9	10
3820	TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers. <i>Neurology India</i> , 2021, 69, 126.	0.4	2
3821	Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours. <i>Journal of Neuro-Oncology</i> , 2021, 151, 123-133.	2.9	9
3822	MRI Features May Predict Molecular Features of Glioblastoma in IDH1 Wild-Type Lower-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2021, 42, 448-456.	2.4	34
3823	Gliomas - An experience based on molecular markers. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1341.	0.9	2
3824	The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vda050.	0.7	5
3825	Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. <i>Neuro-Oncology Advances</i> , 2021, 3, vda065.	0.7	12
3826	Proteins moonlighting in tumor metabolism and epigenetics. <i>Frontiers of Medicine</i> , 2021, 15, 383-403.	3.4	12
3827	Mitochondrial sirtuins at the crossroads of energy metabolism and oncogenic transformation. , 2021, , 103-126.		2
3828	Very long-chain acyl-CoA synthetase 3 mediates onco-sphingolipid metabolism in malignant glioma. <i>Medical Research Archives</i> , 2021, 9, .	0.2	5
3829	Mitochondrial metabolism and carcinogenesis. , 2021, , 119-163.		0
3830	Low expression of CDHR1 is an independent unfavorable prognostic factor in glioma. <i>Journal of Cancer</i> , 2021, 12, 5193-5205.	2.5	12
3831	BRAF ^{V600E} Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF ^{V600E} . <i>Frontiers in Oncology</i> , 2020, 10, 531968.	2.8	8

#	ARTICLE	IF	CITATIONS
3832	The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Computational and Structural Biotechnology Journal, 2021, 19, 4603-4618.	4.1	81
3833	IDH1 mutations induce organelle defects via dysregulated phospholipids. Nature Communications, 2021, 12, 614.	12.8	44
3834	Identification of an epigenetic prognostic signature for patients with lower-grade gliomas. CNS Neuroscience and Therapeutics, 2021, 27, 470-483.	3.9	16
3835	Predictive value of MGMT promoter methylation on the survival of TMZ treated <i>IDH</i>-mutant glioblastoma. Cancer Biology and Medicine, 2021, 18, 271-282.	3.0	31
3836	Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma. Neuro-Oncology Advances, 2021, 3, vda011.	0.7	10
3837	Anti-angiogenic therapy for high-grade glioma. The Cochrane Library, 2018, 2018, CD008218.	2.8	81
3838	In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients. Magnetic Resonance in Medicine, 2020, 84, 1152-1160.	3.0	11
3839	The Cytogenetics of Solid Tumors. , 2013, , 371-411.		2
3840	Endothelial Cell Tumor Prevention with Berry Extracts: Clinical Problems, Molecular Mechanisms and Therapeutic Opportunities. , 2011, , 117-130.		1
3841	Dynamics of DLGG and Clinical Implications. , 2013, , 249-262.		1
3842	Proteomic Studies in Low-Grade Gliomas: What Have They Informed About Pathophysiology?. , 2013, , 117-136.		1
3843	Introduction to Basic Neuropathology. , 2013, , 89-106.		1
3844	Understanding Cancer Metabolism Through Global Metabolomics. , 2012, , 177-190.		6
3845	Adult High-Grade (Diffuse) Glioma. Molecular Pathology Library, 2015, , 77-93.	0.1	2
3846	Assessing Neuronal Bioenergetic Status. Methods in Molecular Biology, 2011, 758, 215-235.	0.9	13
3847	CEST, pH, and Glucose Imaging as Markers for Hypoxia and Malignant Transformation. , 2020, , 161-172.		1
3848	MRS for D-2HG Detection in IDH-Mutant Glioma. , 2020, , 173-189.		1
3849	Radiomics and Machine Learning. , 2020, , 241-249.		2

#	ARTICLE	IF	CITATIONS
3850	Exploring Cancer Metabolism: Applications of Metabolomics and Metabolic Phenotyping in Cancer Research and Diagnostics. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1219, 367-385.	1.6	7
3851	Immunotherapy for Neuro-Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 183-203.	1.6	10
3852	Clinical MR Biomarkers. <i>Recent Results in Cancer Research</i> , 2020, 216, 719-745.	1.8	2
3853	Tenascin-C Function in Glioma: Immunomodulation and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1272, 149-172.	1.6	23
3854	Glioblastoma in the Elderly. <i>Cancer Treatment and Research</i> , 2015, 163, 159-170.	0.5	2
3855	Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas. <i>Cancer Treatment and Research</i> , 2015, 163, 117-142.	0.5	5
3856	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. , 2017, , 73-100.		2
3858	Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients?. , 2010, , 133-157.		2
3859	Gliomatosis Cerebri: Implications of Genetic Findings. <i>Tumors of the Central Nervous System</i> , 2014, , 85-92.	0.1	1
3861	DNA Methylation and Carcinogenesis: Current and Future Perspectives. , 2019, , 153-171.		4
3862	New Emerging Molecules in Cancer Research Which Hold Promise in Current Era. , 2019, , 539-583.		1
3863	The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 23.	4.2	9
3864	Cancer and the Nervous System. , 2008, , 1313-1333.		1
3865	Cancer and the Nervous System. , 2008, , 1357-1383.		1
3866	Brain Tumors in Childhood. , 2011, , 1746-1753.e1.		1
3867	Cancer of the Central Nervous System. , 2014, , 938-1001.e16.		1
3868	The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. <i>Academic Radiology</i> , 2021, 28, e189-e198.	2.5	17
3869	IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation. <i>European Journal of Radiology</i> , 2020, 128, 109031.	2.6	20

#	ARTICLE	IF	CITATIONS
3870	IDH1 and IDH2 Mutations in Gliomas. Yearbook of Neurology and Neurosurgery, 2009, 2009, 119-120.	0.0	23
3871	Cancer metabolism. , 0, , 295-308.		1
3872	A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma. Nature Biomedical Engineering, 2021, 5, 26-40.	22.5	38
3873	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics, 2018, 50, 62-72.	21.4	137
3874	An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity. Biochemical Journal, 2020, 477, 2999-3018.	3.7	8
3875	Expanding the scope of candidate prognostic marker IGFBP2 in glioblastoma. Bioscience Reports, 2019, 39, .	2.4	8
3876	<i>In silico</i> identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma. Bioscience Reports, 2020, 40, .	2.4	12
3877	Monocytes carrying GFAP detect glioma, brain metastasis and ischaemic stroke, and predict glioblastoma survival. Brain Communications, 2021, 3, fcaa215.	3.3	11
3878	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	1.2	23
3879	Malignant clinical features of anaplastic gliomas without IDH mutation. Neuro-Oncology, 2015, 17, 136-144.	1.2	16
3880	Adult precision medicine: learning from the past to enhance the future. Neuro-Oncology Advances, 2021, 3, vdaa145.	0.7	11
3881	Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression. Neuro-Oncology Advances, 2021, 3, vdaa162.	0.7	3
3882	IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management. American Journal of Surgical Pathology, 2020, 44, 396-405.	3.7	44
3897	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Science, 2020, 111, 1739-1749.	3.9	11
3898	Rise of Raman spectroscopy in neurosurgery: a review. Journal of Biomedical Optics, 2020, 25, 1.	2.6	39
3899	Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning. Journal of Medical Imaging, 2019, 6, 1.	1.5	23
3900	The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-14.	4.0	69
3901	Mitochondrial Alteration: A Major Player in Carcinogenesis. Cell Biology, 2015, 3, 8.	0.2	3

#	ARTICLE	IF	CITATIONS
3902	Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas. JCI Insight, 2020, 5, .	5.0	22
3903	Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. Journal of Clinical Investigation, 2018, 128, 3682-3691.	8.2	59
3904	Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma. Journal of Clinical Investigation, 2020, 130, 5782-5799.	8.2	16
3905	Oncometabolites: linking altered metabolism with cancer. Journal of Clinical Investigation, 2013, 123, 3652-3658.	8.2	334
3906	Isocitrate dehydrogenase mutations in leukemia. Journal of Clinical Investigation, 2013, 123, 3672-3677.	8.2	59
3907	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. Journal of Clinical Investigation, 2015, 125, 593-606.	8.2	35
3908	How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?. Hematology American Society of Hematology Education Program, 2012, 2012, 28-34.	2.5	30
3909	A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. EJNMMI Research, 2020, 10, 42.	2.5	11
3910	Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification. EJNMMI Research, 2020, 10, 44.	2.5	15
3911	2016 World Health Organization Classification of Central Nervous System Tumors. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1531-1547.	0.8	95
3912	Low-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1564-1579.	0.8	17
3913	High-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1548-1563.	0.8	49
3914	Adult Gliomas. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1452-1475.	0.8	8
3915	IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. Medical Science Monitor, 2014, 20, 247-254.	1.1	10
3916	Advances in treating glioblastoma. F1000prime Reports, 2014, 6, 46.	5.9	42
3917	Epigenetics in Cancer: A Hematological Perspective. PLoS Genetics, 2016, 12, e1006193.	3.5	77
3918	The Temporal Order of Genetic and Pathway Alterations in Tumorigenesis. PLoS ONE, 2011, 6, e27136.	2.5	99
3919	Fine Mapping of a Region of Chromosome 11q23.3 Reveals Independent Locus Associated with Risk of Glioma. PLoS ONE, 2012, 7, e52864.	2.5	17

#	ARTICLE	IF	CITATIONS
3920	High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models. PLoS ONE, 2013, 8, e56185.	2.5	25
3921	Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma Multiforme. PLoS ONE, 2013, 8, e61035.	2.5	39
3922	Modulation of HJURP (Holliday Junction-Recognizing Protein) Levels Is Correlated with Glioblastoma Cells Survival. PLoS ONE, 2013, 8, e62200.	2.5	41
3923	Genetic and Epigenetic Alterations in Primary Progressive Paired Oligodendroglial Tumors. PLoS ONE, 2013, 8, e67139.	2.5	6
3924	Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival. PLoS ONE, 2013, 8, e67421.	2.5	25
3925	IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis. PLoS ONE, 2013, 8, e68782.	2.5	96
3926	Acetate Supplementation Induces Growth Arrest of NG2/PDGFR α -Positive Oligodendroglioma-Derived Tumor-Initiating Cells. PLoS ONE, 2013, 8, e80714.	2.5	19
3927	Analysis of TET Expression/Activity and 5mC Oxidation during Normal and Malignant Germ Cell Development. PLoS ONE, 2013, 8, e82881.	2.5	80
3928	Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma. PLoS ONE, 2014, 9, e91216.	2.5	76
3929	SOCS3 Promoter Hypermethylation Is a Favorable Prognosticator and a Novel Indicator for G-CIMP-Positive GBM Patients. PLoS ONE, 2014, 9, e91829.	2.5	21
3930	An Axis Involving SNAI1, microRNA-128 and SP1 Modulates Glioma Progression. PLoS ONE, 2014, 9, e98651.	2.5	48
3931	A Unique Four-Hub Protein Cluster Associates to Glioblastoma Progression. PLoS ONE, 2014, 9, e103030.	2.5	24
3932	Single Arginine Mutation in Two Yeast Isocitrate Dehydrogenases: Biochemical Characterization and Functional Implication. PLoS ONE, 2014, 9, e115025.	2.5	7
3933	Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach. PLoS ONE, 2014, 9, e115687.	2.5	24
3934	A Novel Class of Mitochondria-Targeted Soft Electrophiles Modifies Mitochondrial Proteins and Inhibits Mitochondrial Metabolism in Breast Cancer Cells through Redox Mechanisms. PLoS ONE, 2015, 10, e0120460.	2.5	11
3935	A Novel Type II NAD $^{+}$ -Specific Isocitrate Dehydrogenase from the Marine Bacterium <i>Congregibacter litoralis</i> KT71. PLoS ONE, 2015, 10, e0125229.	2.5	10
3936	Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. PLoS ONE, 2015, 10, e0130872.	2.5	28
3937	PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas. PLoS ONE, 2015, 10, e0142750.	2.5	10

#	ARTICLE	IF	CITATIONS
3938	On the Utility of Short Echo Time (TE) Single Voxel 1Hâ€“MRS in Nonâ€“Invasive Detection of 2â€“Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. PLoS ONE, 2016, 11, e0147794.	2.5	10
3939	MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. PLoS ONE, 2016, 11, e0156422.	2.5	16
3940	Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform. Histology and Histopathology, 2016, 31, 269-83.	0.7	7
3941	Diagnostic markers for glioblastoma. Histology and Histopathology, 2011, 26, 1327-41.	0.7	16
3942	Beyond Alkylating Agents for Gliomas: Quo Vadimus?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 175-186.	3.8	7
3943	The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis. Journal of Clinical Medicine Research, 2016, 8, 29-39.	1.2	13
3944	Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1. Journal of Cancer Prevention, 2015, 20, 78-83.	2.0	6
3945	Pediatric Glioblastoma. , 0, , 297-312.		10
3946	Epidemiology and Outcome of Glioblastoma. , 0, , 143-153.		252
3947	IDH1 mutations in a Brazilian series of Glioblastoma. Clinics, 2011, 66, 163-165.	1.5	26
3949	The History of Neuroscience and Neurosurgery in Japan. International Neuroscience Journal, 2015, 1, 31-40.	0.4	5
3950	In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation. Cancer Research Frontiers, 2016, 2, 311-329.	0.2	7
3951	A Glioblastoma Genomics Primer for Clinicians. Medical Research Archives, 2020, 8, .	0.2	10
3952	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography, 2015, 1, 37-43.	1.8	12
3953	Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER. Tomography, 2016, 2, 94-105.	1.8	22
3954	Anti-senescence role of heterozygous fumarate hydratase gene knockout in rat lung fibroblasts in vitro. Aging, 2019, 11, 573-589.	3.1	7
3955	IDH mutation-specific radiomic signature in lower-grade gliomas. Aging, 2019, 11, 673-696.	3.1	51
3956	Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas. Aging, 2019, 11, 6252-6272.	3.1	32

#	ARTICLE	IF	CITATIONS
3957	EFEMP2 indicates assembly of M0 macrophage and more malignant phenotypes of glioma. Aging, 2020, 12, 8397-8412.	3.1	30
3958	Neutrophil depletion enhances the therapeutic effect of PD-1 antibody on glioma. Aging, 2020, 12, 15290-15301.	3.1	11
3959	RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma. Aging, 2020, 12, 16155-16171.	3.1	8
3960	Identification of a cullin5-RING E3 ligase transcriptome signature in glioblastoma multiforme. Aging, 2020, 12, 17380-17392.	3.1	8
3961	Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer. Oncoscience, 2015, 2, 483-486.	2.2	16
3962	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. Oncotarget, 2016, 7, 55169-55180.	1.8	45
3963	Annexin 2A sustains glioblastoma cell dissemination and proliferation. Oncotarget, 2016, 7, 54632-54649.	1.8	29
3964	GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget, 2016, 7, 69466-69478.	1.8	27
3965	Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget, 2016, 7, 69518-69535.	1.8	51
3966	Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. Oncotarget, 2016, 7, 80091-80100.	1.8	2
3967	Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging. Oncotarget, 2016, 7, 69606-69615.	1.8	11
3968	Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Oncotarget, 2016, 7, 73971-73983.	1.8	22
3969	TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection. Oncotarget, 2016, 7, 81512-81526.	1.8	49
3970	IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget, 2017, 8, 191-202.	1.8	30
3971	Integrated genomic analyses identify ERFF1 and TACC3 as glioblastoma-targeted genes. Oncotarget, 2010, 1, 265-277.	1.8	96
3972	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 2013, 4, 1737-1747.	1.8	141
3973	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	1.8	213
3974	Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget, 2017, 8, 13223-13239.	1.8	30

#	ARTICLE	IF	CITATIONS
3975	Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. <i>Oncotarget</i> , 2017, 8, 17763-17770.	1.8	37
3976	PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. <i>Oncotarget</i> , 2017, 8, 15827-15837.	1.8	14
3977	Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival. <i>Oncotarget</i> , 2017, 8, 50117-50123.	1.8	80
3978	MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with <i>IDH1</i> R132H mutations. <i>Oncotarget</i> , 2017, 8, 25345-25361.	1.8	19
3979	IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. <i>Oncotarget</i> , 2017, 8, 28865-28879.	1.8	23
3980	Genetic landscape of extreme responders with anaplastic oligodendroglioma. <i>Oncotarget</i> , 2017, 8, 35523-35531.	1.8	8
3981	Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. <i>Oncotarget</i> , 2017, 8, 49123-49132.	1.8	23
3982	Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas. <i>Oncotarget</i> , 2017, 8, 45888-45897.	1.8	43
3983	Mutations in <i>IDH1</i> , <i>IDH2</i> , and in the <i>TERT</i> promoter define clinically distinct subgroups of adult malignant gliomas. <i>Oncotarget</i> , 2014, 5, 1515-1525.	1.8	237
3984	Autophagy-related gene expression is an independent prognostic indicator of glioma. <i>Oncotarget</i> , 2017, 8, 60987-61000.	1.8	28
3985	ATRX mRNA expression combined with <i>IDH1/2</i> mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples. <i>Oncotarget</i> , 2014, 5, 2551-2561.	1.8	61
3986	Targeting Metabolic Remodeling in Glioblastoma Multiforme. <i>Oncotarget</i> , 2010, 1, 552-562.	1.8	178
3987	Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and <i>IDH1</i> , <i>IDH2</i> , and <i>TERT</i> mutation status. <i>Oncotarget</i> , 2017, 8, 57134-57148.	1.8	17
3988	Remote intracranial recurrence of <i>IDH</i> mutant gliomas is associated with <i>TP53</i> mutations and an 8q gain. <i>Oncotarget</i> , 2017, 8, 84729-84742.	1.8	9
3989	The molecular classification of astrocytic tumors. <i>Oncotarget</i> , 2017, 8, 96340-96350.	1.8	9
3990	WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of <i>IDH2</i> gene expression. <i>Oncotarget</i> , 2017, 8, 106352-106368.	1.8	4
3991	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , 2014, 5, 8083-8092.	1.8	55
3992	Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. <i>Oncotarget</i> , 2014, 5, 7342-7356.	1.8	19

#	ARTICLE	IF	CITATIONS
3993	T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma. <i>Oncotarget</i> , 2018, 9, 7782-7795.	1.8	8
3994	SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. <i>Oncotarget</i> , 2018, 9, 9400-9414.	1.8	8
3995	Multidimensional analysis of gene expression reveals TGFB11-induced EMT contributes to malignant progression of astrocytomas. <i>Oncotarget</i> , 2014, 5, 12593-12606.	1.8	36
3996	IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment. <i>Oncotarget</i> , 2018, 9, 35100-35113.	1.8	9
3997	Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas. <i>Oncotarget</i> , 2018, 9, 37097-37111.	1.8	4
3998	Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. <i>Oncotarget</i> , 2019, 10, 3641-3653.	1.8	1
3999	High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma. <i>Oncotarget</i> , 2015, 6, 4901-4919.	1.8	29
4000	D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. <i>Oncotarget</i> , 2015, 6, 8606-8620.	1.8	46
4001	Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. <i>Oncotarget</i> , 2015, 6, 7318-7324.	1.8	40
4002	Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. <i>Oncotarget</i> , 2015, 6, 12505-12519.	1.8	81
4003	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. <i>Oncotarget</i> , 2015, 6, 12279-12296.	1.8	53
4004	Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. <i>Oncotarget</i> , 2015, 6, 15871-15881.	1.8	9
4005	Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. <i>Oncotarget</i> , 2015, 6, 17354-17365.	1.8	51
4006	The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 14832-14842.	1.8	33
4007	Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models. <i>Oncotarget</i> , 2012, 3, 67-77.	1.8	16
4008	Neoplastic cells are a rare component in human glioblastoma microvasculature. <i>Oncotarget</i> , 2012, 3, 98-106.	1.8	79
4009	<i>TERT</i> promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. <i>Oncotarget</i> , 2015, 6, 16663-16673.	1.8	100
4010	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. <i>Oncotarget</i> , 2015, 6, 30295-30305.	1.8	113

#	ARTICLE	IF	CITATIONS
4011	TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. <i>Oncotarget</i> , 2015, 6, 24871-24883.	1.8	34
4012	Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. <i>Oncotarget</i> , 2015, 6, 29456-29468.	1.8	23
4013	IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. <i>Oncotarget</i> , 2015, 6, 30232-30238.	1.8	77
4014	The radiosensitivity index predicts for overall survival in glioblastoma. <i>Oncotarget</i> , 2015, 6, 34414-34422.	1.8	100
4015	Biomarker-based prognostic stratification of young adult glioblastoma. <i>Oncotarget</i> , 2016, 7, 5030-5041.	1.8	45
4016	Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas. <i>Oncotarget</i> , 2015, 6, 38257-38269.	1.8	11
4017	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. <i>Oncotarget</i> , 2015, 6, 40896-40906.	1.8	116
4018	Mutant IDH1 is required for IDH1 mutated tumor cell growth. <i>Oncotarget</i> , 2012, 3, 774-782.	1.8	37
4019	Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3' shore. <i>Oncotarget</i> , 2015, 6, 37647-37662.	1.8	27
4020	Mitochondrial mass and DNA repair in breast cancer stem cells. <i>Oncotarget</i> , 2015, 6, 38442-38443.	1.8	2
4021	Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. <i>Oncotarget</i> , 2012, 3, 1194-1203.	1.8	241
4022	Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells. <i>Oncotarget</i> , 2016, 7, 9907-9924.	1.8	18
4023	Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling. <i>Oncotarget</i> , 2016, 7, 15200-15214.	1.8	30
4024	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. <i>Oncotarget</i> , 2016, 7, 21556-21569.	1.8	24
4025	KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4. <i>Oncotarget</i> , 2016, 7, 24646-24655.	1.8	33
4026	Current perspectives between metabolic syndrome and cancer. <i>Oncotarget</i> , 2016, 7, 38959-38972.	1.8	86
4027	IDH-1R132H mutation status in diffuse glioma patients: implications for classification. <i>Oncotarget</i> , 2016, 7, 31393-31400.	1.8	28
4028	Validation of a multi-omics strategy for prioritizing personalized candidate driver genes. <i>Oncotarget</i> , 2016, 7, 38440-38450.	1.8	6

#	ARTICLE	IF	CITATIONS
4029	Exomic Sequencing of Four Rare Central Nervous System Tumor Types. <i>Oncotarget</i> , 2013, 4, 572-583.	1.8	69
4030	Prognostic value and their clinical implication of 89-gene signature in glioma. <i>Oncotarget</i> , 2016, 7, 51237-51250.	1.8	11
4031	A four-gene signature-derived risk score for glioblastoma: prospects for prognostic and response predictive analyses. <i>Cancer Biology and Medicine</i> , 2019, 16, 595-605.	3.0	53
4032	Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients. <i>Annals of Translational Medicine</i> , 2019, 7, 541-541.	1.7	39
4033	IDH mutational status and the immune system in gliomas: a tale of two tumors?. <i>Translational Cancer Research</i> , 2017, 6, S1253-S1256.	1.0	13
4034	(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas. <i>Translational Cancer Research</i> , 2019, 8, S167-S170.	1.0	22
4035	MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS. <i>Siberian Journal of Oncology</i> , 2019, 18, 34-44.	0.3	3
4036	Glutamine, Glucose and other Fuels for Cancer. <i>Current Pharmaceutical Design</i> , 2014, 20, 2557-2579.	1.9	29
4037	Targeting Tumor Suppressor Networks for Cancer Therapeutics. <i>Current Drug Targets</i> , 2014, 15, 2-16.	2.1	69
4038	Potential Therapeutic Agents Against Par-4 Target for Cancer Treatment: Where Are We Going?. <i>Current Drug Targets</i> , 2019, 20, 635-654.	2.1	5
4039	Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?. <i>Current Molecular Medicine</i> , 2016, 16, 447-464.	1.3	7
4040	Malignant Intracranial High Grade Glioma and Current Treatment Strategy. <i>Current Cancer Drug Targets</i> , 2019, 19, 101-108.	1.6	13
4041	Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. <i>Current Cancer Drug Targets</i> , 2020, 20, 490-500.	1.6	14
4042	Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. <i>Letters in Drug Design and Discovery</i> , 2019, 16, 861-867.	0.7	2
4043	Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer. <i>Medicinal Chemistry</i> , 2018, 14, 715-724.	1.5	5
4044	Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy. <i>Current Molecular Imaging</i> , 2013, 2, 107-116.	0.7	1
4045	The management of low-grade gliomas in adults. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 450-457.	0.6	49
4046	Glioblastoma: from volumetric analysis to molecular predictors. <i>Journal of Neurosurgical Sciences</i> , 2022, 66, .	0.6	9

#	ARTICLE	IF	CITATIONS
4047	Early growth response 1 promoted the invasion of glioblastoma multiforme by elevating HMGB1. Journal of Neurosurgical Sciences, 2023, 67, .	0.6	7
4048	Targeted variant detection using unaligned RNA-Seq reads. Life Science Alliance, 2019, 2, e201900336.	2.8	14
4049	Karnofsky Performance Scale and Neurological Assessment of Neuro-Oncology Scale as Early Predictor in Glioma. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3387-3392.	1.2	11
4050	Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation. Asian Pacific Journal of Cancer Prevention, 2020, 21, 755-760.	1.2	3
4051	Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2287-2295.	1.2	10
4052	Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping. Journal of Neurosurgery, 2020, 132, 1017-1023.	1.6	5
4053	Maffucci syndrome complicated by three different central nervous system tumors sharing an IDH1 R132C mutation: case report. Journal of Neurosurgery, 2019, 131, 1829-1834.	1.6	6
4054	Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. Journal of Neurosurgery, 2020, 133, 1010-1019.	1.6	29
4055	Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. Journal of Neurosurgery, 2020, , 1-10.	1.6	20
4056	Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. Neurosurgical Focus, 2020, 49, E11.	2.3	4
4057	Molecular Biomarkers of Brain and Spinal Cord Astrocytomas. Acta Naturae, 2019, 11, 17-27.	1.7	9
4058	Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma. Journal of Korean Neurosurgical Society, 2013, 54, 489.	1.2	12
4059	Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases. Journal of Korean Neurosurgical Society, 2015, 59, 44.	1.2	4
4060	Pleiotropic Role of Tenascin-C in Central Nervous System Diseases: From Basic to Clinical Applications. Frontiers in Neurology, 2020, 11, 576230.	2.4	7
4061	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. Journal of Immunotherapy and Precision Oncology, 2020, 3, 157-164.	1.4	2
4062	Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors. World Journal of Gastroenterology, 2020, 26, 5074-5089.	3.3	15
4063	Nuclei Isolation from Fresh Frozen Brain Tumors for Single-Nucleus RNA-seq and ATAC-seq. Journal of Visualized Experiments, 2020, , .	0.3	7
4064	IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1-mutant tumor cells. Molecular Medicine Reports, 2019, 20, 1893-1900.	2.4	4

#	ARTICLE	IF	CITATIONS
4065	Wild-type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells. <i>Molecular Medicine Reports</i> , 2020, 22, 1949-1957.	2.4	13
4066	IDH1 R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR. <i>Oncology Letters</i> , 2020, 19, 1322-1330.	1.8	10
4067	EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	3
4068	Treatment of malignant glioma using hyperthermia. <i>Neural Regeneration Research</i> , 2013, 8, 2775-82.	3.0	25
4069	Cancer stem cells in glioma: challenges and opportunities. <i>Translational Cancer Research</i> , 2013, 2, 429-441.	1.0	28
4070	Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. <i>Annals of Translational Medicine</i> , 2015, 3, 95.	1.7	85
4071	Current trends in the surgical management and treatment of adult glioblastoma. <i>Annals of Translational Medicine</i> , 2015, 3, 121.	1.7	163
4072	Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma. , 2015, 6, 295.		1
4073	Evaluation of rs1957106 Polymorphism of NF- κ B1 in Glioblastoma Multiforme in Isfahan, Iran. <i>Advanced Biomedical Research</i> , 2019, 8, 9.	0.5	3
4074	Diffuse low-grade glioma – Changing concepts in diagnosis and management: A review. <i>Journal of Innovative Optical Health Sciences</i> , 2019, 14, 356-363.	1.0	33
4075	A contemporary molecular view of diffuse gliomas with implications for diagnosis. <i>Glioma (Mumbai)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	8.1	1
4076	IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. , 2018, 9, 29.		13
4077	IDH Mutation Analysis in Ewing Sarcoma Family Tumors. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 257-261.	1.1	7
4078	Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 298-307.	1.1	2
4079	Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 165-170.	1.1	1
4080	Telomere Maintenance Mechanisms: Prognostic and Therapeutic Implications for the Pathologist and Oncologist. <i>Open Journal of Pathology</i> , 2013, 03, 10-20.	0.2	2
4081	Novel diagnostic and therapeutic approaches to malignant glioma. <i>Swiss Medical Weekly</i> , 2011, 141, w13210.	1.6	46
4082	Ion Channels in Glioblastoma. <i>ISRN Neurology</i> , 2011, 2011, 1-7.	1.5	62

#	ARTICLE	IF	CITATIONS
4083	Resection and Immunotherapy for Recurrent Grade III Glioma. ISRN Immunology, 2012, 2012, 1-9.	0.7	8
4084	Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. , 2012, 31, 206-209.		8
4085	Clinical neuropathology practice guide 1-2013: Molecular subtyping of glioblastoma: ready for clinical use?. , 2013, 32, 5-8.		3
4086	Neuropathological biomarker candidates in brain tumors: key issues for translational efficiency. , 2010, 29, 41-54.		13
4087	Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Reports, 2011, 44, 158-164.	2.4	53
4088	Molecular Diagnostics of Gliomas. Archives of Pathology and Laboratory Medicine, 2011, 135, 558-568.	2.5	67
4089	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1537-1570.	4.9	253
4090	Molecular Investigation of Isocitrate Dehydrogenase Gene (IDH) Mutations in Gliomas: First Report of IDH2 Mutations in Indian Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7261-7264.	1.2	16
4091	IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo. Asian Pacific Journal of Cancer Prevention, 2014, 15, 427-432.	1.2	38
4092	Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. ELife, 2017, 6, .	6.0	17
4093	Identification of gene expression and DNA methylation of SERPINA5 and TIMP1 as novel prognostic markers in lower-grade gliomas. PeerJ, 2020, 8, e9262.	2.0	8
4094	The alerting expression of microRNA-411 predicts clinical prognosis and regulates tumor progression of glioblastoma. Bioengineered, 2021, 12, 8650-8657.	3.2	3
4095	Application of Cluster Analysis of Time Evolution for Magnetic Resonance Imaging -Derived Oxygen Extraction Fraction Mapping: A Promising Strategy for the Genetic Profile Prediction and Grading of Glioma. Frontiers in Neuroscience, 2021, 15, 736891.	2.8	6
4096	Detección de la mutación de la enzima isocitrato deshidrogenasa en gliomas difusos grados II, III y IV. Medicina Y Laboratorio, 2021, 25, 709-719.	0.1	0
4097	Phospholipase C β 1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients. Laboratory Investigation, 2022, 102, 143-153.	3.7	14
4098	Role of Energy Metabolism in the Progression of Neuroblastoma. International Journal of Molecular Sciences, 2021, 22, 11421.	4.1	4
4099	Mitochondrial matrix protein C14orf159 attenuates colorectal cancer metastasis by suppressing Wnt/ β -catenin signalling. British Journal of Cancer, 2021, 125, 1699-1711.	6.4	1
4100	Pharmacoresistant seizures and IDH mutation in low-grade gliomas. Neuro-Oncology Advances, 2021, 3, vdab146.	0.7	5

#	ARTICLE	IF	CITATIONS
4101	Organic Bioelectronic Devices for Metabolite Sensing. <i>Chemical Reviews</i> , 2022, 122, 4581-4635.	47.7	55
4102	Synthesis and Evaluation of 3-(Indol-3-yl)-4-(Pyrazolo[3,4-c]Pyridazin-3-yl)-Maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors. <i>Pharmaceutical Chemistry Journal</i> , 2021, 55, 655-664.	0.8	0
4103	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 155, 297-306.	2.9	5
4104	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. <i>Neuro-Oncology</i> , 2021, 23, iii1-iii105.	1.2	804
4105	IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. <i>Neuro-Oncology</i> , 2022, 24, 809-820.	1.2	13
4106	Prognostic Factors Associated With Survival in Patients With Diffuse Astrocytoma. <i>Frontiers in Surgery</i> , 2021, 8, 712350.	1.4	3
4107	A szemÁlyre szabott terÁpia legÁjobb lehetÁsÁgei a molekulÁris onkolÁgiÁban. <i>Scientia Et Securitas</i> , 2021, 2, 191-199.	0.2	0
4108	T2-FLAIR mismatch sign: a roadmap of pearls and pitfalls. <i>British Journal of Radiology</i> , 2022, 95, 20210825.	2.2	7
4109	Development of a 3 RNA Binding Protein Signature for Predicting Prognosis and Treatment Response for Glioblastoma Multiforme. <i>Frontiers in Genetics</i> , 2021, 12, 768930.	2.3	0
4110	Update on Radiation Therapy for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 77-93.	2.2	5
4111	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 95-111.	2.2	6
4112	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. <i>Cancer</i> , 2022, 128, 47-58.	4.1	132
4113	Impact of awake mapping on overall survival and extent of resection in patients with adult diffuse gliomas within or near eloquent areas: a retrospective propensity score-matched analysis of awake craniotomy vs. general anesthesia. <i>Acta Neurochirurgica</i> , 2022, 164, 395-404.	1.7	9
4114	SYDE1 Acts as an Oncogene in Glioma and has Diagnostic and Prognostic Values. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 714203.	3.5	5
4115	Germline mutations among Polish patients with acute myeloid leukemia. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 42.	1.5	2
4116	USP29 coordinates MYC and HIF1Î± stabilization to promote tumor metabolism and progression. <i>Oncogene</i> , 2021, 40, 6417-6429.	5.9	19
4117	Tyrosine phosphorylation of DEPTOR functions as a molecular switch to activate mTOR signaling. <i>Journal of Biological Chemistry</i> , 2021, 297, 101291.	3.4	8
4118	Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours. <i>Lancet Neurology</i> , The, 2021, 20, 943-955.	10.2	47

#	ARTICLE	IF	CITATIONS
4121	Molecular Markers of Gliomas. , 2009, , 157-177.		0
4122	Recent Advances in Biological Research on Malignant Glioma and Their Therapeutic Relevance(<SPECIAL ISSUE>Progress in Treatment for Malignant Gliomas). Japanese Journal of Neurosurgery, 2010, 19, 880-886.	0.0	1
4123	High-Grade Astrocytomas. , 2011, , 195-232.		0
4124	Low-Grade Gliomas. , 2011, , 173-194.		0
4126	Malignant Gliomas: Present and Future Therapeutic Drugs. , 2011, , 207-214.		0
4127	Glioblastoma: Germline Mutation of TP53. , 2011, , 31-38.		0
4129	Atypical Pilocytic Astrocytoma in Adult: A Case Report. Japanese Journal of Neurosurgery, 2011, 20, 841-846.	0.0	0
4130	Hirntumoren. , 2011, , 687-721.		0
4132	Progrès récents dans la génomique et dans le traitement médical des gliomes cérébraux. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 11-21.	0.0	0
4135	Biomarker Discovery, Validation and Clinical Application for Patients Diagnosed with Glioma. , 0, , .		0
4136	Genetic Diversity of Glioblastoma Multiforme: Impact on Future Therapies. , 0, , .		0
4137	Molecular Etiology of Glioblastomas: Implication of Genomic Profiling From the Cancer Genome Atlas Project. , 0, , .		0
4138	Diagnostic Evaluation of Diffuse Gliomas. , 0, , .		1
4139	Bone Marrow-Derived Cells Support Malignant Transformation of Low-Grade Glioma. , 0, , .		0
4140	Genomic Abnormalities in Gliomas. , 0, , .		0
4141	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.		0
4142	Pediatric Low-Grade Gliomas: Advantage of Using Lower Doses of Cisplatin/Etoposide. Pediatric Cancer, 2012, , 309-320.	0.0	0
4143	Cancer and the Nervous System. , 2012, , 1116-1136.		0

#	ARTICLE	IF	CITATIONS
4144	Cancer and the Nervous System. , 2012, , 1158-1181.		0
4145	High-Grade Gliomas. , 2012, , 461-472.		0
4146	Techniques d'analyse du g�nome et de son expression : applications m�dicales. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 151-171.	0.0	3
4147	Children Are Not Small Adults: Importance of Molecular Analysis for Diagnosis, Prognosis, and Treatment of Pediatric CNS Tumors. , 2012, , 125-140.		0
4148	Supratentorial Primitive Neuroectodermal Tumor: Biology. , 2012, , 77-83.		0
4149	Genetic and epigenetic alterations in colorectal tumors and its clinical implications. Seibutsu Butsuri Kagaku, 2012, 56, 15-18.	0.1	1
4151	The Potential and Challenges of siRNA-Based Targeted Therapy for Treatment of Patients with Glioblastoma. , 0, , .		0
4155	Is Gliomatosis Cerebri a Diffuse Low-Grade Glioma?. , 2013, , 45-59.		0
4156	Genetic Alterations Involving the Progression of Human Gliomas. Japanese Journal of Neurosurgery, 2013, 22, 582-589.	0.0	0
4157	Suppression of Cellular Senescence in Glioblastoma: Role of Src Homology Domain-Containing Phosphatase 2. , 2013, , 249-259.		1
4158	TYPES OF DNA DAMAGE. , 2013, , 115-118.		0
4159	Colorectal Cancer Genome and Its Implications. , 2013, , 247-265.		0
4160	Animal Models for Low-Grade Gliomas. , 2013, , 165-175.		0
4161	Bridging Science and Clinical Practice: How to Use Molecular Markers When Caring for a Patient with Brain Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 108-113.	3.8	0
4162	Molecular Diagnosis of Cancer. , 2014, , 249-346.		1
4163	Genetic Basis for the Development of Adult Gliomas. Japanese Journal of Neurosurgery, 2014, 23, 532-540.	0.0	2
4164	Metabolic Adaptation in Reprogrammed Cancer Cells. Cancer Drug Discovery and Development, 2014, , 157-180.	0.4	0
4165	Molecular Testing in CNS tumors. , 2014, , 243-255.		0

#	ARTICLE	IF	CITATIONS
4166	Emerging Anti-cancer Targets in Mitochondria. , 2014, , 265-290.		0
4167	Aberrant DNA Methylation. , 2014, , .		0
4168	Metabolic Enzymes: The Novel Targets for Cancer Stem Cells. Journal of Stem Cell Research & Therapy, 2014, 04, .	0.3	0
4169	Expression of IDH1 Mutant Protein R132H and SDHB in Adult and Pediatric Gliomas. International Journal of Neuropathology, 0, , .	0.0	0
4170	Modern molecular approaches to diagnosis and treatment of high-grade brain gliomas. Zhurnal Voprosy Neirokhirurgii Imeni N N Burdenko, 2014, 78, 85.	0.2	0
4171	How Our Practice of Histopathology, Especially Tumour Pathology has Changed in the Last Two Decades: Reflections from a Major Referral Center in Pakistan. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3829-3849.	1.2	3
4174	Novel Strategies in Chemotherapy for Gliomas. Japanese Journal of Neurosurgery, 2015, 24, 386-398.	0.0	0
4175	Fighting Fire with Fire in Cancer. , 2015, , 39-49.		1
4176	CIC Mutation as Signature Alteration in Oligodendroglioma. , 2015, , 423-440.		0
4177	Pathogenesis and Mutations of Myeloproliferative Neoplasms: An Overview. British Journal of Medicine and Medical Research, 2015, 9, 1-24.	0.2	0
4178	Refined Glioma Classification based on Molecular Pathology. Japanese Journal of Neurosurgery, 2015, 24, 366-377.	0.0	0
4180	Signalling Pathways in Glioma-Propagating Cells. Cell Biology: Research & Therapy, 0, s1, .	0.2	0
4181	Acute Myeloid Leukemia. , 2016, , 527-559.		0
4182	IDH1 and IDH2 Mutations. , 2016, , 3-30-3-31.		0
4183	Oligodendroglioma. , 2016, , 54-61.		0
4184	Gliomas. , 2016, , 507-514.		0
4185	Hirntumoren. Springer-Lehrbuch, 2016, , 311-365.	0.0	1
4186	Updates in Genetic Molecular Targeted Therapy for Glioblastoma. Cancer and Oncology Research, 2016, 4, 1-15.	0.2	0

#	ARTICLE	IF	CITATIONS
4187	Widening the concept of oncogene. Aging, 2016, 8, 2262-2263.	3.1	1
4188	Title is missing!. , 2017, , .		0
4189	Synthesis and Application of Cell-Permeable Metabolites for Modulating Chromatin Modifications Regulated by α -Ketoglutarate-Dependent Enzymes. Methods in Pharmacology and Toxicology, 2017, , 63-79.	0.2	0
4190	Molecular Epidemiology of Diffuse Low-Grade Glioma. , 2017, , 55-72.		0
4191	How to understand the Results of Basic Glioma Genome Sequence Data. Japanese Journal of Neurosurgery, 2017, 26, 806-816.	0.0	2
4192	THE IMPACT OF THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMOURS OF THE CENTRAL NERVOUS SYSTEM UPON DIAGNOSIS AND PROGNOSIS. Australasian Medical Journal, 2017, 10, .	0.1	0
4193	Molecular Pathogenesis of Bone Tumours. , 2017, , 41-63.		0
4194	3.0T Imaging of Brain Gliomas. , 2017, , 271-319.		0
4195	An Update on the Genome, Epigenome, and Transcriptome in Gliomas. Japanese Journal of Neurosurgery, 2017, 26, 798-805.	0.0	0
4196	Molecular Carcinogenesis of Glial Brain Tumors. , 2017, , 115-136.		0
4197	Molecular Testing for Glioblastoma. , 2017, , 339-347.		0
4198	Dynamics of DLGG and Clinical Implications. , 2017, , 287-306.		0
4199	Molecular Imaging of Diffuse Low Grade Glioma. , 2017, , 173-195.		0
4200	Exam 5 Questions. , 2017, , 189-233.		0
4201	Pediatric Radiotherapy: Background and Current Paradigms. , 2017, , 1-31.		0
4202	Modulated radiotherapy with concurrent and adjuvant temozolomide for anaplastic gliomas: Indian single-center data. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 495.	0.2	0
4205	Cancer Metabolism. , 2018, , 129-154.		0
4207	Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival. Anticancer Research, 2017, 37, 6639-6648.	1.1	5

#	ARTICLE	IF	CITATIONS
4208	Neuropathologie kindlicher ZNS-Tumoren. , 2018, , 357-378.		0
4209	High-Grade Gliomas. , 2018, , 580-585.e2.		0
4210	Glioblastoma treatment: Where to now?. Integrative Cancer Science and Therapeutics, 2018, 5, .	0.1	0
4211	Be cautious to bid farewell to GBMO: evidence from a propensity score analysis. Glioma (Mumbai,) Tj ETQq1 1 0.784314 rgBT ₀ /Overlook	0.1	0
4212	Tumor Necrosis Factor-Alpha (TNF- α -308 G>A) Polymorphism in High-grade Gliomas. In Vivo, 2018, 32, 287-289.	1.3	1
4213	Outcomes of Treatment for Glioblastoma Multiforme in Adult Patients: A Single Institution Experience from the Eastern Black Sea Region of Turkey. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2018, 28, 30-35.	0.1	2
4217	Survival as a Function of Nonsteroidal Anti-inflammatory Drug Use in Patients with Glioblastoma. Cureus, 2018, 10, e3277.	0.5	2
4220	Awake Craniotomy: Cortical and Subcortical Mapping for Glioma Resection. , 2019, , 137-145.		0
4222	Genomic Applications in Brain Tumors. , 2019, , 289-308.		0
4223	Therapeutic Strategy for Glioma Grade â€¦. Japanese Journal of Neurosurgery, 2019, 28, 699-704.	0.0	0
4224	Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-Hydroxyglutarate. , 2019, , .		1
4225	Metabolic Plasticity of IDH1- <i>Mutant</i> Glioma Cell Lines Is Responsible for Low Sensitivity to Glutaminase Inhibition. SSRN Electronic Journal, 0, , .	0.4	1
4227	Primary Brain Tumors in Adults. , 2019, , 869-889.		0
4228	Quantitative Proteomics Reveals Global Reduction of Endocytic Machinery Components in Gliomas. SSRN Electronic Journal, 0, , .	0.4	0
4229	Oligodendroglioma WHO Grade II-â€œAnaplastic Oligodendroglioma WHO Grade III. , 2019, , 1439-1459.		0
4230	Molecular Diagnosis in WHO Classification of Tumours of the Central Nervous System 2016 : A Domestic Survey and Perspectives. Japanese Journal of Neurosurgery, 2019, 28, 674-685.	0.0	0
4231	Comparison of immunogenetic properties of glial tumors with advanced magnetic resonance imaging findings. Turkish Neurosurgery, 2019, 30, 422-427.	0.2	0
4232	The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01. Brain Tumor Research and Treatment, 2019, 7, 63.	1.0	8

#	ARTICLE	IF	CITATIONS
4233	Gliome. Springer Reference Medizin, 2019, , 1-14.	0.0	0
4234	Metabolic Deregulations Affecting Chromatin Architecture: One-Carbon Metabolism and Krebs Cycle Impact Histone Methylation. RNA Technologies, 2019, , 573-606.	0.3	1
4235	Glioblastoma with a primitive neuronal component in a long-term surviving patient. Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	0
4237	Patterns of local failure in patients with high-grade glioma after postoperative radiotherapy with or without chemotherapy. Translational Cancer Research, 2019, 8, 985-991.	1.0	0
4241	Ki67 labeling in CNS tumours. Indian Journal of Pathology and Oncology, 2019, 6, 586-592.	0.1	0
4243	Gliome. Springer Reference Medizin, 2020, , 1-14.	0.0	0
4244	The Basic Molecular Genetics and the Common Mutations of Brain Tumors. , 2020, , 93-104.		0
4245	Genome Medicine for Brain Tumors: Current Status and Future Perspectives. Neurologia Medico-Chirurgica, 2020, 60, 531-542.	2.2	5
4247	Integrative transcriptome analysis identified a BMP signaling pathwayâ€regulated lncRNA AC068643.1 in IDH mutant and wildâ€type glioblastomas. Oncology Letters, 2020, 20, 75-84.	1.8	3
4249	IMMUNOHISTOCHEMICAL STUDY OF PROTEINS PROX1, CD133 AND CD38 IN GLIOBLASTOMAS OF THE VENTRICULARSUBVENTRICULAR ZONE AND THEIR EFFECT ON THE LIFE EXPECTANCY OF PATIENTS. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2020, 27, 75-85.	0.2	0
4251	Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy. Current Medicinal Chemistry, 2020, 27, 2814-2825.	2.4	1
4252	Expression, association with clinicopathological features and prognostic potential of CEP55, pâ€Akt, FoxM1 and MMPâ€2 in astrocytoma. Oncology Letters, 2020, 20, 1685-1694.	1.8	0
4256	The influence of subventricular zone involvement in extent of resection and tumor growth pattern of glioblastoma. Innovative Surgical Sciences, 2021, 5, 127-132.	0.7	1
4257	TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. Cancers, 2021, 13, 5362.	3.7	13
4258	Primary intraventricular tumors - Imaging characteristics, post-treatment changes and relapses. Clinical Imaging, 2021, 82, 38-52.	1.5	0
4259	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. Hematology/Oncology Clinics of North America, 2021, 36, 113-132.	2.2	2
4260	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 770561.	2.8	51
4261	Evidence for ageâ€related contributions of DNA damage and epigenetics in brain tumorigenesis. International Journal of Experimental Pathology, 2021, 102, 232-241.	1.3	3

#	ARTICLE	IF	CITATIONS
4263	Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. Communications Biology, 2021, 4, 1243.	4.4	12
4264	The Role of Succinic Acid Metabolism in Ovarian Cancer. Frontiers in Oncology, 2021, 11, 769196.	2.8	14
4265	Imbalanced GSH/ROS and sequential cell death. Journal of Biochemical and Molecular Toxicology, 2022, 36, e22942.	3.0	118
4266	Metabolic Changes and Their Characterization. , 2020, , 35-70.		1
4267	Primäre Hirntumoren: Grundlagen. Springer Reference Medizin, 2020, , 1-9.	0.0	0
4268	Cerebral Neoplasms. IDKD Springer Series, 2020, , 37-44.	0.8	0
4270	Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk). Neuro-Oncology Advances, 2020, 2, iv22-iv34.	0.7	12
4271	Chemotherapy for Brain Tumors. , 2021, , 357-383.		0
4272	Establishing Orthotopic Xenograft Glioblastoma Models for Use in Preclinical Development. Neuromethods, 2021, , 281-296.	0.3	0
4273	CKAP2L Knockdown Exerts Antitumor Effects by Increasing miR-4496 in Glioblastoma Cell Lines. International Journal of Molecular Sciences, 2021, 22, 197.	4.1	11
4274	Radiotherapy in Brain Tumors. , 2021, , 313-334.		1
4275	Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicines. Neuromethods, 2021, , 1-61.	0.3	1
4276	Transcriptional and epigenetic regulatory mechanisms in glioblastoma stem cells. , 2020, , 231-255.		1
4277	Diagnostic and prognostic implications of molecular status in Chinese adults with diffuse glioma: An observational study. Glioma (Mumbai, India), 2020, 3, 168.	0.1	0
4278	Gliome. Springer Reference Medizin, 2020, , 997-1010.	0.0	0
4279	Pathology, Epidemiology, and WHO Classification of Brain Tumors. , 2020, , 3-13.		1
4280	Pediatric Radiotherapy: Background and Current Paradigms. , 2020, , 185-208.		0
4281	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0

#	ARTICLE	IF	CITATIONS
4282	Diffuse Astrocytic and Oligodendroglial Tumors. , 2020, , 15-72.		0
4284	Radiomics and Radiogenomics with Deep Learning in Neuro-oncology. Lecture Notes in Computer Science, 2020, , 199-211.	1.3	0
4285	Automated Acquisition Planning for Magnetic Resonance Spectroscopy in Brain Cancer. Lecture Notes in Computer Science, 2020, 12267, 730-739.	1.3	0
4286	Metabolic Pathways of Eukaryotes and Connection to Cell Mechanics. Biological and Medical Physics Series, 2020, , 825-891.	0.4	1
4290	Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). Cancer Research and Treatment, 2020, 52, 505-515.	3.0	9
4292	A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 452-460.	7.0	29
4293	Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation. Cancer Research, 2022, 82, 497-509.	0.9	13
4294	The existence of a nonclassical TCA cycle in the nucleus that wires the metabolic-epigenetic circuitry. Signal Transduction and Targeted Therapy, 2021, 6, 375.	17.1	34
4295	Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas. Frontiers in Cell and Developmental Biology, 2021, 9, 756005.	3.7	7
4299	Intracranial Mass Lesions. , 2021, , 377-389.		0
4300	LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma. Biochemistry and Cell Biology, 2020, 98, 556-564.	2.0	7
4301	Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population. PLoS ONE, 2020, 15, e0242793.	2.5	1
4302	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. American Journal of Translational Research (discontinued), 2011, 3, 251-8.	0.0	1
4304	Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. International Journal of Clinical and Experimental Pathology, 2011, 4, 651-60.	0.5	32
4305	Glioblastoma genetics: in rapid flux. Discovery Medicine, 2010, 9, 125-31.	0.5	11
4307	Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. American Journal of Blood Research, 2012, 2, 254-64.	0.6	39
4308	Gene mutations and molecularly targeted therapies in acute myeloid leukemia. American Journal of Blood Research, 2013, 3, 29-51.	0.6	36
4310	Molecular biology of gliomas: present and future challenges. Translational Medicine @ UniSa, 2014, 10, 29-37.	0.5	33

#	ARTICLE	IF	CITATIONS
4311	Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. International Journal of Clinical and Experimental Pathology, 2014, 7, 8627-36.	0.5	24
4312	Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. International Journal of Clinical and Experimental Pathology, 2015, 8, 5327-35.	0.5	13
4314	Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation. American Journal of Cancer Research, 2015, 5, 2745-55.	1.4	2
4315	TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. International Journal of Clinical and Experimental Pathology, 2015, 8, 11485-94.	0.5	11
4316	Identifying the genes regulated by IDH1 via gene-chip in glioma cell U87. International Journal of Clinical and Experimental Medicine, 2015, 8, 18090-8.	1.3	2
4317	Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. American Journal of Cancer Research, 2016, 6, 577-86.	1.4	18
4318	IDH1 Mutations in Glioma: Considerations for Radiotracer Development. , 2016, 2, .		1
4319	Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors. Asian Pacific Journal of Cancer Prevention, 2016, 17, 5195-5201.	1.2	8
4321	Management and treatment recommendations for World Health Organization Grade III and IV gliomas. International Journal of Health Sciences, 2017, 11, 54-62.	0.4	4
4322	Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment. American Journal of Cancer Research, 2019, 9, 122-133.	1.4	3
4323	Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing. Journal of Oncology Research and Therapy, 2019, 5, .	0.0	2
4324	Divide et Impera: Drp1-mediated Mitochondrial Fission in Glioma Malignancy. Yale Journal of Biology and Medicine, 2019, 92, 423-433.	0.2	7
4325	C6 cell line: the gold standard in glioma research. Hippokratia, 2018, 22, 105-112.	0.3	29
4326	Clinicopathologic changes and molecular finding of epithelioid pleomorphic xanthoastrocytoma: a case report. International Journal of Clinical and Experimental Pathology, 2018, 11, 5144-5148.	0.5	0
4327	Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas. International Journal of Clinical and Experimental Pathology, 2020, 13, 230-238.	0.5	5
4328	Overexpression of EP300-interacting inhibitor of differentiation 3 predicts poor prognosis in patients with glioblastoma multiforme. International Journal of Clinical and Experimental Pathology, 2020, 13, 979-988.	0.5	2
4329	Epigenetic mechanisms and the hallmarks of cancer: an intimate affair. American Journal of Cancer Research, 2020, 10, 1954-1978.	1.4	21
4330	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. Oncology Letters, 2020, 20, 351.	1.8	0

#	ARTICLE	IF	CITATIONS
4331	Synergistic regulation of methylation and SP1 on MAGE-D4 transcription in glioma. American Journal of Translational Research (discontinued), 2021, 13, 2241-2255.	0.0	0
4332	T2-FLAIR, DWI and DKI radiomics satisfactorily predicts histological grade and Ki-67 proliferation index in gliomas. American Journal of Translational Research (discontinued), 2021, 13, 9182-9194.	0.0	0
4333	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-Oncology, 2022, 24, 1020-1028.	1.2	12
4334	Oncometabolites as Regulators of DNA Damage Response and Repair. Seminars in Radiation Oncology, 2022, 32, 82-94.	2.2	3
4335	Genomic and molecular features distinguish young adult cancer from later-onset cancer. Cell Reports, 2021, 37, 110005.	6.4	21
4336	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Journal of Neuro-Oncology, 2021, 155, 363-372.	2.9	11
4337	Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene, 2022, 41, 613-621.	5.9	29
4338	PODN1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma. International Journal of Molecular Sciences, 2021, 22, 12572.	4.1	9
4339	Handheld Mass Spectrometer with Intelligent Adaptability for On-Site and Point-of-Care Analysis. Analytical Chemistry, 2021, 93, 15607-15616.	6.5	13
4340	Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of “False-Positive” Cases. Diagnostics, 2021, 11, 2129.	2.6	4
4341	An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach. Clinical and Translational Oncology, 2022, 24, 742-756.	2.4	2
4342	Identifying the Predictive Role of Oxidative Stress Genes in the Prognosis of Glioma Patients. Medical Science Monitor, 2021, 27, e934161.	1.1	8
4343	Heme Oxygenase-1 Predicts Risk Stratification and Immunotherapy Efficacy in Lower Grade Gliomas. Frontiers in Cell and Developmental Biology, 2021, 9, 760800.	3.7	3
4344	Hypoxia: The Cornerstone of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 12608.	4.1	62
4345	Lentiviral-Induced Spinal Cord Gliomas in Rat Model. International Journal of Molecular Sciences, 2021, 22, 12943.	4.1	3
4347	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers, 2021, 13, 5722.	3.7	17
4348	The Clinical Significance and Transcription Regulation of a DNA Damage Repair Gene, SMC4, in Low-Grade Glioma via Integrated Bioinformatic Analysis. Frontiers in Oncology, 2021, 11, 761693.	2.8	7
4349	In Situ Sprayed Starvation/Chemodynamic Therapeutic Gel for Post-Surgical Treatment of IDH1 (R132H) Glioma. Advanced Materials, 2022, 34, e2103980.	21.0	67

#	ARTICLE	IF	CITATIONS
4350	Immunohistochemical surrogates for molecular alterations for the classification and grading of gliomas. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 78-83.	1.5	1
4351	Subtyping non-small cell lung cancer by histology-guided spatial metabolomics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 351-360.	2.5	20
4352	Clinical Applications of Artificial Intelligence, Machine Learning, and Deep Learning in the Imaging of Gliomas: A Systematic Review. <i>Cureus</i> , 2021, 13, e19580.	0.5	11
4353	Comment on Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)â€”Experience at Two Specialized Centers. <i>Cancers</i> 2021, 13, 2540. <i>Cancers</i> , 2021, 13, 5634.	3.7	2
4354	A Ferroptosis-Related Prognostic Risk Score Model to Predict Clinical Significance and Immunogenic Characteristics in Glioblastoma Multiforme. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-30.	4.0	18
4355	DNA methylation-based classification of malformations of cortical development in the human brain. <i>Acta Neuropathologica</i> , 2022, 143, 93-104.	7.7	18
4356	GammaTile Brachytherapy Combined With External Beam Radiation Therapy for the Treatment of a Partially Resected Secondary Glioblastoma (WHO Grade 4 IDH-Mutant Astrocytoma): Matching External Beam Dose Gradient to Brachytherapy Dose Fall-Off. <i>Cureus</i> , 2021, 13, e19717.	0.5	2
4357	Differential impact of IDH1² mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	5.2	17
4358	Prognostic value of preoperative inflammatory markers among different molecular subtypes of lower-grade glioma. <i>Journal of Clinical Neuroscience</i> , 2022, 96, 180-186.	1.5	3
4359	Application of Multiplex Ligand-Activated Probe Amplification (MLPA) and Low Pass Whole Genome Sequencing (LP-WGS) to the Classification/Characterisation of Low Grade Glioneuronal Tumours. <i>Pathology Research and Practice</i> , 2021, 229, 153724.	2.3	2
4360	Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 711-723.	1.2	5
4361	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. <i>Neuro-Oncology</i> , 2022, 24, 770-778.	1.2	28
4362	Mutant IDH Inhibits IFNÎ³â€”TET2 Signaling to Promote Immune evasion and Tumor Maintenance in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 812-835.	9.4	55
4363	Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , 2022, 39, 165-177.	2.9	11
4364	Radiomics: Artificial Intelligence-Based Radiogenomic Diagnosis of Gliomas. , 2022, , 367-371.		0
4365	Cysteine is a limiting factor for glioma proliferation and survival. <i>Molecular Oncology</i> , 2022, 16, 1777-1794.	4.6	7
4366	Comprehensive Genomic Subtyping of Glioma Using Semi-Supervised Multi-Task Deep Learning on Multimodal MRI. <i>IEEE Access</i> , 2021, 9, 167900-167910.	4.2	6
4367	TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas. <i>Cancer Gene Therapy</i> , 2022, 29, 1117-1129.	4.6	14

#	ARTICLE	IF	CITATIONS
4368	Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma. Journal of Neuro-Oncology, 2022, 156, 353-363.	2.9	3
4369	D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment. Molecular Therapy, 2022, 30, 1188-1200.	8.2	19
4370	Post-translational modifications on mitochondrial metabolic enzymes in cancer. Free Radical Biology and Medicine, 2022, 179, 11-23.	2.9	20
4371	Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study. Radiotherapy and Oncology, 2022, 167, 1-6.	0.6	3
4372	Clinical development of IDH1 inhibitors for cancer therapy. Cancer Treatment Reviews, 2022, 103, 102334.	7.7	18
4373	Mitochondrial superoxide targets energy metabolism to modulate epigenetic regulation of NRF2-mediated transcription. Free Radical Biology and Medicine, 2022, 179, 181-189.	2.9	4
4374	Detection of IDH mutations in cerebrospinal fluid: A discussion of liquid biopsy in neuropathology. Archives of Pathology and Clinical Research, 2020, 4, 011-023.	0.4	0
4375	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. Oncology Letters, 2020, 20, 1-1.	1.8	2
4376	Immunotherapy for Neuro-oncology. Advances in Experimental Medicine and Biology, 2021, 1342, 233-258.	1.6	4
4377	NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis. ELife, 2021, 10, .	6.0	13
4378	Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology, 2022, 29, 551-564.	2.2	6
4379	MR Fingerprintingâ€”A Radiogenomic Marker for Diffuse Gliomas. Cancers, 2022, 14, 723.	3.7	9
4380	Intratumor morphologic and molecular genetic heterogeneity in astrocytomas of different grade of malignancy in the material from the first operation. Siberian Journal of Oncology, 2022, 20, 55-68.	0.3	0
4381	Epigenetic Drugs and Their Immune Modulating Potential in Cancers. Biomedicines, 2022, 10, 211.	3.2	5
4382	Markedly prolonged disease course, with breakthrough seizures, in a glioma with an isolated IDH1 mutation. Neuro-Oncology Advances, 2022, 4, vda004.	0.7	1
4383	The influence of the bloodâ€”brain barrier in the treatment of brain tumours. Journal of Internal Medicine, 2022, 292, 3-30.	6.0	23
4384	Meta-analysis of whole-genome gene expression datasets assessing the effects of IDH1 and IDH2 mutations in isogenic disease models. Scientific Reports, 2022, 12, 57.	3.3	3
4385	A Pyroptosis-Related Gene Prognostic Index Correlated with Survival and Immune Microenvironment in Glioma. Journal of Inflammation Research, 2022, Volume 15, 17-32.	3.5	15

#	ARTICLE	IF	CITATIONS
4386	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac002.	0.7	3
4387	Prognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme “ Data from a national neuro-oncology registry. <i>Journal of Clinical Neuroscience</i> , 2022, 95, 142-150.	1.5	2
4388	Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report. <i>Neuroradiology Journal</i> , 2022, , 197140092110674.	1.2	2
4389	Metabolomic Phenotyping of Gliomas: What Can We Get with Simplified Protocol for Intact Tissue Analysis?. <i>Cancers</i> , 2022, 14, 312.	3.7	11
4390	Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 3, .	0.3	5
4391	Relationship between molecular characteristics of glioblastoma multiforme and the subventricular zone. <i>British Journal of Neurosurgery</i> , 2022, , 1-8.	0.8	0
4392	The clinical characteristics and outcomes of incidentally discovered glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 551-557.	2.9	4
4393	Multidisciplinary Treatment for Glioblastoma. <i>Japanese Journal of Neurosurgery</i> , 2022, 31, 11-19.	0.0	0
4394	Integrative Multiomics Evaluation of IDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	1.3	0
4395	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 812422.	3.7	5
4396	Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1096.	4.1	17
4397	Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures. <i>ACS Omega</i> , 2022, 7, 3568-3578.	3.5	5
4398	A Novel 16-Genes Signature Scoring System as Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma. <i>Biomedicines</i> , 2022, 10, 317.	3.2	11
4399	Glioblastoma vaccine tumor therapy research progress. <i>Chinese Neurosurgical Journal</i> , 2022, 8, 2.	0.9	22
4400	Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy. <i>BMC Neurology</i> , 2022, 22, 24.	1.8	2
4402	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	3.7	2
4403	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	1.6	67
4404	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	32

#	ARTICLE	IF	CITATIONS
4405	The immunology of low-grade gliomas. <i>Neurosurgical Focus</i> , 2022, 52, E2.	2.3	20
4406	In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas. <i>Neurosurgical Focus</i> , 2022, 52, E3.	2.3	2
4407	Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. <i>Neurosurgical Focus</i> , 2022, 52, E6.	2.3	10
4408	Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas. <i>Neurospine</i> , 2022, , .	2.9	11
4409	Clinical factors and conventional MRI may independently predict progression-free survival and overall survival in adult pilocytic astrocytomas. <i>Neuroradiology</i> , 2022, 64, 1529-1537.	2.2	3
4410	Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas. , 0, 79, .		11
4411	Current Immunotherapeutic Approaches for Malignant Gliomas. <i>Brain Tumor Research and Treatment</i> , 2022, 10, 1.	1.0	5
4412	Distinct metabolic hallmarks of WHO classified adult glioma subtypes. <i>Neuro-Oncology</i> , 2022, 24, 1454-1468.	1.2	26
4413	The potential of advanced MR techniques for precision radiotherapy of glioblastoma. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2022, 35, 127-143.	2.0	5
4414	The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma. <i>PLoS ONE</i> , 2022, 17, e0257725.	2.5	2
4416	Put in a Ca^{2+} -to Acute Myeloid Leukemia. <i>Cells</i> , 2022, 11, 543.	4.1	3
4417	Newly Diagnosed Glioblastoma in Elderly Patients. <i>Current Oncology Reports</i> , 2022, 24, 325-334.	4.0	3
4418	A fully automatic multiparametric radiomics model for differentiation of adult pilocytic astrocytomas from high-grade gliomas. <i>European Radiology</i> , 2022, 32, 4500-4509.	4.5	10
4419	The epigenetic dysfunction underlying malignant glioma pathogenesis. <i>Laboratory Investigation</i> , 2022, 102, 682-690.	3.7	4
4420	Connections between metabolism and epigenetic modifications in cancer. <i>Medical Review</i> , 2021, 1, 199-221.	1.2	7
4421	DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis. <i>Genomics</i> , 2022, 114, 110289.	2.9	3
4423	Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?. <i>Current Molecular Medicine</i> , 2016, , .	1.3	2
4424	microRNAs and metabolism. , 2022, , 63-76.		0

#	ARTICLE	IF	CITATIONS
4425	The Integrated Histopathologic and Molecular Approach to Adult-type Diffuse Astrocytomas: Status of the Art, Based on the 2021 WHO Classification of Central Nervous System Tumors. <i>Oncologie</i> , 2022, 24, 51-63.	0.7	0
4426	YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. <i>Advances in Cancer Research</i> , 2022, , 283-317.	5.0	4
4427	Yippee Like 1 Suppresses Glioma Progression and Serves as a Novel Prognostic Factor. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 256, 141-150.	1.2	4
4428	Simultaneous brain tumor segmentation and molecular profiling using deep learning and T2w magnetic resonance images. , 2022, , 57-79.		0
4429	Noninvasive differentiation of molecular subtypes of adult nonenhancing glioma using MRI perfusion and diffusion parameters. <i>Neuro-Oncology Advances</i> , 2022, 4, vda023.	0.7	8
4431	Glioblastoma Microenvironment and Cellular Interactions. <i>Cancers</i> , 2022, 14, 1092.	3.7	28
4432	Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed <i>IDH1/2</i> â€”Mutant Acute Myeloid Leukemia. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 429-441.	1.6	3
4433	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 165-180.	2.0	15
4434	Overcoming Radiation Resistance in Gliomas by Targeting Metabolism and DNA Repair Pathways. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2246.	4.1	8
4435	Systemic Therapy for Chondrosarcoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 199-209.	3.0	6
4436	Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations. <i>Cancers</i> , 2022, 14, 1125.	3.7	10
4437	Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124.	3.7	3
4439	Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma. <i>Scientific Reports</i> , 2022, 12, 3200.	3.3	2
4440	Immunotherapeutic Approaches for Glioblastoma Treatment. <i>Biomedicines</i> , 2022, 10, 427.	3.2	6
4441	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 547-574.	2.5	25
4442	HSPA6 is Correlated With the Malignant Progression and Immune Microenvironment of Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 833938.	3.7	4
4443	Deciphering specific miRNAs in brain tumors: a 5-miRNA signature in glioblastoma. <i>Molecular Genetics and Genomics</i> , 2022, 297, 507-521.	2.1	9
4444	LMO1 Plays an Oncogenic Role in Human Glioma Associated With NF- κ B Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 770299.	2.8	3

#	ARTICLE	IF	CITATIONS
4445	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. <i>Neurology</i> , 2022, 98, .	1.1	2
4446	Radiomics Profiling Identifies the Incremental Value of MRI Features beyond Key Molecular Biomarkers for the Risk Stratification of High-Grade Gliomas. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-12.	0.8	3
4447	Surgical Neuro-Oncology. <i>Neurologic Clinics</i> , 2022, 40, 437-453.	1.8	6
4448	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2440-2448.	7.0	3
4449	Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival. <i>Frontiers in Oncology</i> , 2022, 12, 829524.	2.8	4
4450	Epidemiology, risk factors, and prognostic factors of gliomas. <i>Clinical and Translational Imaging</i> , 2022, 10, 467-475.	2.1	16
4451	Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 734-741.	2.8	1
4452	Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas. <i>Frontiers in Immunology</i> , 2022, 13, 824586.	4.8	6
4454	Recent Advances of Pyridinone in Medicinal Chemistry. <i>Frontiers in Chemistry</i> , 2022, 10, 869860.	3.6	20
4455	Assessing Nordihydroguaiaretic Acid Therapeutic Effect for Glioblastoma Multiforme. <i>Sensors</i> , 2022, 22, 2643.	3.8	2
4456	Construction and Validation of an Immune-Related Risk Score Model for Survival Prediction in Glioblastoma. <i>Frontiers in Neurology</i> , 2022, 13, 832944.	2.4	2
4457	Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. <i>Laboratory Investigation</i> , 2022, 102, 741-752.	3.7	8
4458	IDH mutation status prediction by a radiomics associated modality attention network. <i>Visual Computer</i> , 0, , 1.	3.5	0
4459	Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. <i>Brain Pathology</i> , 2022, 32, e13062.	4.1	53
4460	The emerging role of deubiquitylating enzymes as therapeutic targets in cancer metabolism. <i>Cancer Cell International</i> , 2022, 22, 130.	4.1	3
4461	<i>LRRFIP1</i> , an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 873-883.	3.9	1
4462	Comprehensive analysis of pyroptosis regulation patterns and their influence on tumor immune microenvironment and patient prognosis in glioma. <i>Discover Oncology</i> , 2022, 13, 13.	2.1	3
4463	Prospective genomically guided identification of early/evolving and undersampled IDH-wildtype glioblastoma leads to improved clinical outcomes. <i>Neuro-Oncology</i> , 2022, 24, 1749-1762.	1.2	10

#	ARTICLE	IF	CITATIONS
4464	Metabolic profile of the Warburg effect as a tool for molecular prognosis and diagnosis of cancer. Expert Review of Molecular Diagnostics, 2022, 22, 439-447.	3.1	12
4465	Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression. Cell Death and Disease, 2022, 13, 293.	6.3	20
4466	In-Depth Matrisome and Glycoproteomic Analysis of Human Brain Glioblastoma Versus Control Tissue. Molecular and Cellular Proteomics, 2022, 21, 100216.	3.8	22
4467	External Validation of a Convolutional Neural Network for IDH Mutation Prediction. Medicina (Lithuania), 2022, 58, 526.	2.0	2
4468	Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. Translational Oncology, 2022, 18, 101368.	3.7	2
4469	Cell Trafficking at the Intersection of the Tumorâ€“Immune Compartments. Annual Review of Biomedical Engineering, 2022, 24, 275-305.	12.3	9
4470	The epigeneticâ€“metabolic interplay in gliomagenesis. Open Biology, 2022, 12, 210350.	3.6	2
4471	Non-Canonical NF-Î³B Signaling Stratifies LGG into Subtypes with Distinct Molecular and Cellular Characteristic and Survival Expectancy. International Journal of General Medicine, 2022, Volume 15, 3677-3686.	1.8	0
4472	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. Journal of Neuro-Oncology, 2022, 157, 499-510.	2.9	2
4473	Applications of chemical exchange saturation transfer magnetic resonance imaging in identifying genetic markers in gliomas. NMR in Biomedicine, 2023, 36, e4731.	2.8	13
4474	Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review. Current Oncology, 2022, 29, 2550-2563.	2.2	3
4475	Development and validation of a novel survival prediction model for newly diagnosed lower-grade gliomas. Neurosurgical Focus, 2022, 52, E13.	2.3	4
4476	TDABNet: Three-directional attention block network for the determination of IDH status in low- and high-grade gliomas from MRI. Biomedical Signal Processing and Control, 2022, 75, 103574.	5.7	2
4477	Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies. Cancer Letters, 2022, 533, 215603.	7.2	6
4478	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia, 2022, 28, 100790.	5.3	5
4479	Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. Cell Reports Medicine, 2021, 2, 100469.	6.5	21
4480	An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. Journal of Oncology, 2021, 2021, 1-19.	1.3	2
4481	Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1077-1085.	2.8	2

#	ARTICLE	IF	CITATIONS
4482	Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?. <i>Journal of Neuro-Oncology</i> , 2022, 156, 317-327.	2.9	5
4483	Retinol binding protein 1â€dependent activation of NFâ€B signaling enhances the malignancy of nonâ€glioblastomatous diffuse gliomas. <i>Cancer Science</i> , 2022, 113, 517-528.	3.9	9
4484	GammaTile® brachytherapy in the treatment of recurrent glioblastomas. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab185.	0.7	10
4485	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion. <i>Frontiers in Immunology</i> , 2021, 12, 800928.	4.8	6
4486	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 200.	5.2	10
4487	Single-Tube qPCR Detection and Quantitation of Hotspot Mutations Down to 0.01% Variant Allele Fraction. <i>Analytical Chemistry</i> , 2022, 94, 934-943.	6.5	10
4488	IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 178-183.	1.2	6
4489	Clinical, Morphological, and Molecular Study of Diffuse WHO Grade II and III Astrocytomas: A Retrospective Analysis from a Single Tertiary Care Institute. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 569-576.	0.2	0
4490	ELK3: A New Molecular Marker for the Diagnosis and Prognosis of Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 608748.	2.8	9
4491	Clinical Use of PET/MR in Oncology: An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 356-364.	4.6	18
4492	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 358-383.	1.2	1
4493	The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13382.	4.1	14
4494	Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment. <i>Cells</i> , 2021, 10, 3529.	4.1	16
4495	Association of <i>MGMT</i> Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type <i>IDH</i> Glioblastoma. <i>Anticancer Research</i> , 2022, 42, 335-341.	1.1	5
4496	IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 83-97.	2.5	10
4497	A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration. <i>BMC Cancer</i> , 2021, 21, 1311.	2.6	20
4498	Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma. <i>Acta Neuropathologica Communications</i> , 2021, 9, 191.	5.2	4
4499	Functional clustering analysis identifies specific subtypes of aldehyde dehydrogenase associated with glioma immunity. <i>Translational Cancer Research</i> , 2021, 10, 5052-5064.	1.0	1

#	ARTICLE	IF	CITATIONS
4500	Brain location and tumor biological markers in high and low grade gliomas: our experience. Journal of Neurosurgical Sciences, 2020, , .	0.6	0
4502	Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma. BioMed Research International, 2022, 2022, 1-19.	1.9	2
4503	Early repeat resection for residual glioblastoma: decision-making among an international cohort of neurosurgeons. Journal of Neurosurgery, 2022, 137, 1618-1627.	1.6	4
4504	Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics. Cancer Imaging, 2022, 22, 19.	2.8	9
4505	Measurement of Full Diffusion Tensor Distribution Using High-Gradient Diffusion MRI and Applications in Diffuse Gliomas. Frontiers in Physics, 2022, 10, .	2.1	1
4506	Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nature Reviews Cardiology, 2022, 19, 414-425.	13.7	23
4507	Introduction to Pathologic Techniques. , 0, , 23-39.		0
4508	The central nervous system. , 0, , 3185-3317.		0
4592	SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Research, 2022, 32, 638-658.	12.0	19
4593	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro-Oncology, 2022, 24, 1989-2000.	1.2	27
4594	PET With 11C-Methyl-L-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. Clinical Nuclear Medicine, 2022, 47, 569-574.	1.3	3
4595	Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series. Tumori, 2012, 98, 756-61.	1.1	4
4597	Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 659-665.	0.4	2
4598	Characterization of the Ferroptosis-Related Genes for Prognosis and Immune Infiltration in Low-Grade Glioma. Frontiers in Genetics, 2022, 13, 880864.	2.3	1
4599	Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes. Journal of the National Cancer Institute, 2022, 114, 1072-1094.	6.3	9
4600	Rare and misincorporated DNA N6-methyladenine is a hallmark of cytotoxic stresses for selectively stimulating the stemness and proliferation of glioblastoma cells. Cell Discovery, 2022, 8, 39.	6.7	12
4601	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. Frontiers in Oncology, 2022, 12, 839302.	2.8	3
4602	Genetic Alteration Analysis of IDH1, IDH2, CDKN2A, MYB and MYBL1 in Pediatric Low-Grade Gliomas. Frontiers in Surgery, 2022, 9, 880048.	1.4	2

#	ARTICLE	IF	CITATIONS
4603	Modulation of Tumor Immune Microenvironment and Prognostic Value of Ferroptosis-Related Genes, and Candidate Target Drugs in Glioblastoma Multiforme. <i>Frontiers in Pharmacology</i> , 2022, 13, 898679.	3.5	7
4604	Targeting IDH-Mutant Glioma. <i>Neurotherapeutics</i> , 2022, 19, 1724-1732.	4.4	13
4605	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. <i>Cancers</i> , 2022, 14, 2393.	3.7	8
4606	Molecular and clinical characteristics of <scp>IDH</scp> mutations in Chinese <scp>NSCLC</scp> patients and potential treatment strategies. <i>Cancer Medicine</i> , 2022, , .	2.8	1
4607	Chirality in Lightâ€Matter Interaction. <i>Advanced Materials</i> , 2023, 35, e2107325.	21.0	43
4608	Targeted metabolomics analyses for brain tumor margin assessment during surgery. <i>Bioinformatics</i> , 2022, 38, 3238-3244.	4.1	3
4609	Long Term Survivals in Aggressive Primary Brain Malignancies Treated With an Adjuvant Ketogenic Diet. <i>Frontiers in Nutrition</i> , 2022, 9, 770796.	3.7	4
4610	Radiation-induced contrast enhancement following proton radiotherapy for low-grade glioma depends on tumor characteristics and is rarer in children than adults. <i>Radiotherapy and Oncology</i> , 2022, 172, 54-64.	0.6	9
4611	Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. <i>Human Pathology</i> , 2022, 126, 63-76.	2.0	5
4612	Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study. <i>Neuroradiology Journal</i> , 2023, 36, 49-58.	1.2	3
4613	LncRNAs and CircRNAs in cancer. <i>MedComm</i> , 2022, 3, e141.	7.2	18
4614	Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	7
4615	Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 403-412.	2.5	1
4616	Elevated RECQL1 expression predicts poor prognosis and associates with tumor immune infiltration in low-grade glioma. <i>Translational Cancer Research</i> , 2022, 11, 1552-1564.	1.0	2
4617	Chromatin dynamics orchestrates DNA repair mechanisms in glioblastoma. <i>International Journal of Neurooncology</i> , 2021, 4, 38.	0.1	0
4619	Recent Molecular and Genetic Findings in Intramedullary Spinal Cord Tumors. <i>Neurospine</i> , 2022, 19, 262-271.	2.9	6
4620	Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options. <i>Biochemical Pharmacology</i> , 2022, 201, 115090.	4.4	12
4621	Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?. <i>Cancers</i> , 2022, 14, 2416.	3.7	13

#	ARTICLE	IF	CITATIONS
4622	IDH mutation and cancer stem cell. <i>Essays in Biochemistry</i> , 2022, 66, 413-422.	4.7	6
4623	Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	13
4624	Developing dietary interventions as therapy for cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 452-466.	28.4	52
4625	Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics</i> , 2022, 19, 1705-1723.	4.4	26
4626	A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma. <i>Current Medical Science</i> , 2022, 42, 650-657.	1.8	3
4627	TRP Family Genes Are Differently Expressed and Correlated with Immune Response in Glioma. <i>Brain Sciences</i> , 2022, 12, 662.	2.3	2
4628	Glioblastoma: two immune subtypes under the surface of the cold tumor. <i>Aging</i> , 2022, 14, 4357-4375.	3.1	3
4629	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. <i>Neuro-Oncology</i> , 2023, 25, 199-210.	1.2	6
4630	Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5787.	4.1	3
4631	In vivo brain MR spectroscopy in gliomas: clinical and pre-clinical chances. <i>Clinical and Translational Imaging</i> , 2022, 10, 495-515.	2.1	6
4632	Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning. <i>Cancers</i> , 2022, 14, 2762.	3.7	3
4633	Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma. <i>Modern Pathology</i> , 2022, 35, 1636-1643.	5.5	1
4634	Patterns of care in adult histone mutant gliomas: results of an international survey. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	0
4635	Comprehensive Analyses of Ferroptosis-Related Alterations and Their Prognostic Significance in Glioblastoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.5	9
4636	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	1
4637	The Identification of Necroptosis-Related Subtypes, the Construction of a Prognostic Model, and the Characterization of the Tumor Microenvironment in Gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
4638	The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It Complicated. <i>Cancers</i> , 2022, 14, 2793.	3.7	28
4640	Deep learning for prediction of isocitrate dehydrogenase mutation in gliomas: a critical approach, systematic review and meta-analysis of the diagnostic test performance using a Bayesian approach. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 4033-4046.	2.0	6

#	ARTICLE	IF	CITATIONS
4641	CÄlenÄj IÄ©Äba mutovanÄ© formy isocitrÄjt dehydrogenÄjzy 1 u akutnÄ-myeloidnÄ-leukemie - pÄ™ÄbÄh ivosidenibu. Onkologie (Czech Republic), 2021, 14, 295-298.	0.1	0
4642	Cancer metabolism regulation by phytonutrients. , 2022, , 237-290.		0
4644	Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Journal of Cancer Research and Therapeutics, 2022, .	0.9	0
4645	Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma. Cancer Genomics and Proteomics, 2022, 19, 390-414.	2.0	9
4646	Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro-Oncology, 2023, 25, 146-156.	1.2	23
4648	Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma. Frontiers in Immunology, 0, 13, .	4.8	9
4649	Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas and meningiomas. Modern Pathology, 2022, 35, 1551-1561.	5.5	13
4651	Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications. Frontiers in Oncology, 0, 12, .	2.8	0
4652	Germ cell tumors with neuroglial differentiation do not show molecular features akin to their central nervous system counterpart: experience from extra-gynecological sites. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	2.8	1
4654	Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma. Neuroscience Bulletin, 2022, 38, 1069-1084.	2.9	6
4655	Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nature Reviews Neurology, 2022, 18, 515-529.	10.1	100
4656	Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma. Frontiers in Oncology, 0, 12, .	2.8	4
4657	Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas. Diagnostics, 2022, 12, 1444.	2.6	3
4658	The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro-Oncology, 2023, 25, 326-336.	1.2	23
4659	Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. Neuro-Oncology Advances, 2022, 4, .	0.7	4
4660	Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours. Molecules, 2022, 27, 3766.	3.8	2
4661	Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine. Cancers, 2022, 14, 2860.	3.7	38
4663	Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches. , 2022, 39, .		8

#	ARTICLE	IF	CITATIONS
4664	Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2022, 159, 43-52.	2.9	6
4665	The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. <i>Molecular Neurobiology</i> , 2022, 59, 5326-5365.	4.0	13
4667	Multi-omics data integration for subtype identification of Chinese lower-grade gliomas: A joint similarity network fusion approach. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3482-3492.	4.1	2
4668	Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211096.	1.9	9
4669	i-Modern: Integrated multi-omics network model identifies potential therapeutic targets in glioma by deep learning with interpretability. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3511-3521.	4.1	13
4670	A Comprehensive Clinical Review of Adult-Type Diffuse Glioma Incorporating the 2021 World Health Organization Classification. <i>Neurographics</i> , 2022, 12, 43-70.	0.1	3
4671	FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	1.3	2
4672	Survival Outcomes and Prognostic Factors in Glioblastoma. <i>Cancers</i> , 2022, 14, 3161.	3.7	33
4673	Certain aspects of radiomics and radiogenomics in glioblastoma: what the images hide?. <i>Translational Medicine</i> , 2022, 9, 70-80.	0.4	0
4674	A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas. <i>Journal of Clinical Medicine</i> , 2022, 11, 3802.	2.4	2
4675	Magnetic Resonance Spectroscopy in Diagnosis and Follow-Up of Gliomas: State-of-the-Art. <i>Cancers</i> , 2022, 14, 3197.	3.7	6
4676	The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK. <i>Marine Drugs</i> , 2022, 20, 418.	4.6	4
4677	Targeting Wnt/ β -Catenin Signaling by TET1/FOXO4 Inhibits Metastatic Spreading and Self-Renewal of Cancer Stem Cells in Gastric Cancer. <i>Cancers</i> , 2022, 14, 3232.	3.7	8
4678	Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas. <i>Cancers</i> , 2022, 14, 2891.	3.7	8
4679	Widespread redundancy in -omics profiles of cancer mutation states. <i>Genome Biology</i> , 2022, 23, .	8.8	5
4680	Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. <i>Cancers</i> , 2022, 14, 3203.	3.7	23
4681	Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	1
4682	Racial and ethnic disparities in brain tumour survival by age group and tumour type. <i>British Journal of Neurosurgery</i> , 2022, 36, 705-711.	0.8	2

#	ARTICLE	IF	CITATIONS
4683	Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status. <i>European Radiology</i> , 2022, 32, 8089-8098.	4.5	4
4684	Computational study on novel natural compound inhibitor targeting IDH1_R132H. <i>Aging</i> , 2022, 14, 5478-5492.	3.1	2
4686	Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	6
4687	Noncanonical (Non-R132H) IDH-Mutated Gliomas. , 0, , .		0
4688	IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas. <i>Journal of Neuro-Oncology</i> , 2022, 159, 261-270.	2.9	6
4689	Characterization of Fatty Acid Metabolism-Related Genes Landscape for Predicting Prognosis and Aiding Immunotherapy in Glioma Patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	14
4690	Integrative Genomic and Transcriptomic Analysis of Primary Malignant Gliomas Revealed Different Patterns Between Grades and Somatic Mutations Related to Glioblastoma Prognosis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	1
4691	Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays. <i>Nature Communications</i> , 2022, 13, .	12.8	9
4692	Using AI-Based Evolutionary Algorithms to Elucidate Adult Brain Tumor (Glioma) Etiology Associated with IDH1 for Therapeutic Target Identification. <i>Current Issues in Molecular Biology</i> , 2022, 44, 2982-3000.	2.4	1
4693	Targeting mitochondrial metabolism for precision medicine in cancer. <i>Cell Death and Differentiation</i> , 2022, 29, 1304-1317.	11.2	71
4694	Brain Gliomas and Ollier Disease: Molecular Findings as Predictive Risk Factors?. <i>Cancers</i> , 2022, 14, 3464.	3.7	3
4695	Tumors of the nervous system. , 2023, , 203-228.		1
4696	The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas. <i>Medicine (United States)</i> , 2022, 101, e29668.	1.0	1
4697	Identifying $\hat{I}\pm$ -KG-dependent prognostic signature for lower-grade glioma based on transcriptome profiles. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
4698	Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8171.	4.1	10
4699	The Tropomyosin Family as Novel Biomarkers in Relation to Poor Prognosis in Glioma. <i>Biology</i> , 2022, 11, 1115.	2.8	4
4700	Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	1
4701	Atypical imaging features of the primary spinal cord glioblastoma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 7950-7959.	0.8	2

#	ARTICLE	IF	CITATIONS
4702	Identification of EMT-Related Genes and Prognostic Signature With Significant Implications on Biological Properties and Oncology Treatment of Lower Grade Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	1
4703	Continuing maintenance temozolomide therapy beyond 12Âcycles confers no clinical benefit over discontinuation at 12Âcycles in patients with <i>IDH1/2</i>-wildtype glioblastoma. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	0
4704	Prognostic Model and Nomogram Construction and Validation With an Autophagy-Related Gene Signature in Low-Grade Gliomas. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
4705	Basic premises: searching for new targets and strategies in diffuse gliomas. <i>Clinical and Translational Imaging</i> , 0, , .	2.1	2
4706	Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas. <i>Brain Tumor Pathology</i> , 0, , .	1.7	0
4707	Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 707-716.	1.7	0
4708	Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	12
4710	Chromobox 7/8 serve as independent indicators for glioblastoma via promoting proliferation and invasion of glioma cells. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	6
4711	An Epigenetic Role of Mitochondria in Cancer. <i>Cells</i> , 2022, 11, 2518.	4.1	57
4712	Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification. <i>Journal of Neuro-Oncology</i> , 2022, 159, 695-703.	2.9	9
4713	Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	1
4714	Synthetic lethality in personalized cancer therapy. <i>Genome Instability & Disease</i> , 0, , .	1.1	0
4715	Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma. <i>IScience</i> , 2022, , 104918.	4.1	1
4716	Cytidine deaminase deficiency in tumor cells is associated with sensitivity to a naphthol derivative and a decrease in oncometabolite levels. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	2
4717	National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. <i>Neuro-Oncology</i> , 2023, 25, 799-807.	1.2	24
4718	Novel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patients. <i>PeerJ</i> , 0, 10, e13860.	2.0	1
4719	Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in Astrocytomas Stratified by IDH Mutation Status. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9507.	4.1	1
4720	The Brain Protein Atlas: A conglomerate of proteomics datasets of human neural tissue. <i>Proteomics</i> , 2022, 22, .	2.2	8

#	ARTICLE	IF	CITATIONS
4721	Bevacizumab combined with re-irradiation in recurrent glioblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
4722	Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	8
4723	Recent Progress in Analysis of Intermediary Metabolism by <i>ex vivo</i> ¹³ C NMR. <i>NMR in Biomedicine</i> , 0, , .	2.8	2
4724	Emerging immune-based technologies for high-grade gliomas. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 957-980.	2.4	1
4725	Current Considerations in the Treatment of Grade 3 Gliomas. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1219-1232.	3.0	3
4726	Identification of the Prognostic Signatures for Isocitrate Dehydrogenase Mutant Glioma. , 2022, , .		0
4727	Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
4728	Chromosomal instability in adult-type diffuse gliomas. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	7
4729	Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. <i>Neuro-Oncology</i> , 2023, 25, 28-36.	1.2	7
4730	Multiparametric MR radiomics in brain glioma: models comparison to predict biomarker status. <i>BMC Medical Imaging</i> , 2022, 22, .	2.7	8
4732	MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression. <i>JCI Insight</i> , 2022, 7, .	5.0	15
4733	The Association of Preoperative Frailty and Neighborhood-Level Disadvantage with Outcome in Patients with Newly Diagnosed High Grade Glioma. <i>World Neurosurgery</i> , 2022, 166, e949-e957.	1.3	4
4734	A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2090-2103.	3.9	9
4735	Sphingosine-1-phosphate lyase deficiency affects glucose metabolism in a way that abets oncogenesis. <i>Molecular Oncology</i> , 2022, 16, 3642-3653.	4.6	4
4736	Pathway-based Approach Reveals Differential Sensitivity to E2F1 Inhibition in Glioblastoma. <i>Cancer Research Communications</i> , 2022, 2, 1049-1060.	1.7	1
4737	World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas. <i>JAMA Oncology</i> , 2022, 8, 1493.	7.1	76
4738	Brain Tumor Characterization Using Radiogenomics in Artificial Intelligence Framework. <i>Cancers</i> , 2022, 14, 4052.	3.7	24
4740	Genetic, metabolic and immunological features of cancers with <i>NRF2</i> addiction. <i>FEBS Letters</i> , 2022, 596, 1981-1993.	2.8	5

#	ARTICLE	IF	CITATIONS
4741	Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. <i>Nature Communications</i> , 2022, 13, .	12.8	18
4742	Evaluation of two new highly multiplexed <scp>PCR</scp> assays as an alternative to next-generation sequencing for <i> <scp>IDH1</scp> /2 </i> mutation detection. <i>Molecular Oncology</i> , 0, , .	4.6	0
4743	Exploring the relationship between age and prognosis in glioma: rethinking current age stratification. <i>BMC Neurology</i> , 2022, 22, .	1.8	8
4744	Inhibition of the pseudokinase MLKL alters extracellular vesicle release and reduces tumor growth in glioblastoma. <i>IScience</i> , 2022, 25, 105118.	4.1	6
4745	Identification of upregulated genes in glioblastoma and glioblastoma cancer stem cells using bioinformatics analysis. <i>Gene</i> , 2023, 848, 146895.	2.2	4
4746	Metabolic dysregulation in cancer progression. , 2022, , 1-39.		0
4747	Aberrant Protein Glycosylation in Brain Cancers, with Emphasis on Glioblastoma. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 39-70.	1.6	3
4748	Imaging of malignant astrocytomas. , 2022, , 503-520.		0
4749	Novel Cancer Treatment Using Oncolytic Virus Therapy. , 2022, , 1-43.		0
4750	Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	2
4751	Diagnostic Applications of Nuclear Medicine: Brain Tumors. , 2022, , 569-605.		0
4752	Metabolomics in High Grade Gliomas. <i>RAS Oncology & Therapy</i> , 2022, 3, .	0.1	0
4753	Predicting Isocitrate Dehydrogenase Mutation Status in Glioma Using Structural Brain Networks and Graph Neural Networks. <i>Lecture Notes in Computer Science</i> , 2022, , 140-150.	1.3	2
4754	Oncometabolites, epigenetic marks, and DNA repair. , 2022, , 191-202.		0
4755	An Intra- and Inter-Modality Fusion Model Using MR Images for Prediction of Glioma Isocitrate Dehydrogenase (IDH) Mutation. , 2022, , .		0
4756	Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies. <i>Cancers</i> , 2022, 14, 4222.	3.7	10
4757	A genetic model for central chondrosarcoma evolution correlates with patient outcome. <i>Genome Medicine</i> , 2022, 14, .	8.2	9
4759	Co-amplified with <scp>PDGFRA</scp> , <scp>IGFBP7</scp> is a prognostic biomarker correlated with the immune infiltrations of glioma. <i>Cancer Medicine</i> , 0, , .	2.8	1

#	ARTICLE	IF	CITATIONS
4760	Protein Quality Control in Glioblastoma: A Review of the Current Literature with New Perspectives on Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9734.	4.1	1
4761	Identification of Shared Neoantigens in BRCA1-Related Breast Cancer. <i>Vaccines</i> , 2022, 10, 1597.	4.4	3
4762	Cellular Density in Adult Glioma, Estimated with MR Imaging Data and a Machine Learning Algorithm, Has Prognostic Power Approaching World Health Organization Histologic Grading in a Cohort of 1181 Patients. <i>American Journal of Neuroradiology</i> , 2022, 43, 1411-1417.	2.4	1
4763	Sequence-structure functional implications and molecular simulation of high deleterious nonsynonymous substitutions in IDH1 revealed the mechanism of drug resistance in glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	5
4764	Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 4253-4267.	2.5	3
4765	Integrated genomic, transcriptomic, and epigenetic analyses identify a leukotriene synthesis-related M2 macrophage gene signature that predicts prognosis and treatment vulnerability in gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
4766	Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	1.3	0
4767	Predicting the true extent of glioblastoma based on probabilistic tractography. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	3
4768	Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
4769	Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas. <i>Neuro-Oncology Practice</i> , 2023, 10, 132-139.	1.6	3
4770	A novel risk score model based on fourteen chromatin regulators-based genes for predicting overall survival of patients with lower-grade gliomas. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
4772	Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10037.	4.1	37
4773	The Evolving Role of Next-Generation Sequencing in Pediatric Neurosurgery: A Call for Action for Research, Clinical Practice, and Optimization of Care. <i>World Neurosurgery</i> , 2022, 168, 232-242.	1.3	1
4774	Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
4775	Synthesis of <i>N</i> -(4-chlorophenyl) substituted pyrano[2,3- <i>c</i>]pyrazoles enabling PKB ¹ /AKT2 inhibitory and <i>in vitro</i> anti-glioma activity. <i>Annals of Medicine</i> , 2022, 54, 2548-2560.	3.8	16
4777	Identification and validation of ferroptosis-related lncRNA signatures as a novel prognostic model for glioma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
4778	Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis. <i>Current Oncology</i> , 2022, 29, 6893-6907.	2.2	9
4780	U-Net Based Segmentation and Characterization of Gliomas. <i>Cancers</i> , 2022, 14, 4457.	3.7	10

#	ARTICLE	IF	CITATIONS
4781	An analysis of prognostic factors in a cohort of low-grade gliomas and degree of consistency between RTOG and EORTC scores. Scientific Reports, 2022, 12, .	3.3	0
4782	N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas. Exploration of Targeted Anti-tumor Therapy, 0, , 553-569.	0.8	1
4783	Predicting IDH subtype of grade 4 astrocytoma and glioblastoma from tumor radiomic patterns extracted from multiparametric magnetic resonance images using a machine learning approach. Frontiers in Oncology, 0, 12, .	2.8	5
4784	Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods. Neuro-Oncology, 2023, 25, 234-247.	1.2	9
4785	Ethics of Transitioning from Curative Care to Palliative Care: Potential Conflicts of Interest Using the Example of Neurosurgery. World Neurosurgery, 2022, 168, 139-145.	1.3	1
4786	Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States. Neuro-Oncology Practice, 0, , .	1.6	1
4787	The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. Frontiers in Oncology, 0, 12, .	2.8	12
4788	A Composite Bioinformatic Analysis to Explore Endoplasmic Reticulum Stress-Related Prognostic Marker and Potential Pathogenic Mechanisms in Glioma by Integrating Multiomics Data. Journal of Oncology, 2022, 2022, 1-28.	1.3	1
4789	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015â€“2019. Neuro-Oncology, 2022, 24, v1-v95.	1.2	385
4790	Altered Extracellular Matrix as an Alternative Risk Factor for Epileptogenicity in Brain Tumors. Biomedicines, 2022, 10, 2475.	3.2	3
4791	Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Gliomaâ€”A Case Report and Systematic Review. Current Issues in Molecular Biology, 2022, 44, 5117-5125.	2.4	4
4792	Next-Generation Sequencing Comparative Analysis of DNA Mutations between Blood-Derived Extracellular Vesicles and Matched Cancer Tissue in Patients with Grade 4 Glioblastoma. Biomedicines, 2022, 10, 2590.	3.2	0
4793	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology, 2023, 25, 4-25.	1.2	45
4794	The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Current Treatment Options in Oncology, 2022, 23, 1566-1589.	3.0	1
4795	Cytoskeletal Protein Palladin in Adult Gliomas Predicts Disease Incidence, Progression, and Prognosis. Cancers, 2022, 14, 5130.	3.7	0
4799	Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma. Cancers, 2022, 14, 4942.	3.7	2
4800	Chromatin as a sensor of metabolic changes during early development. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	1
4801	Basement-Membrane-Related Gene Signature Predicts Prognosis in WHO Grade II/III Gliomas. Genes, 2022, 13, 1810.	2.4	4

#	ARTICLE	IF	CITATIONS
4802	Construction and Verification of a Novel Pyroptosis-Related lncRNA Signature Associated with Immune Landscape in Gliomas. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	1.3	0
4804	Identification of potential driver mutations in glioblastoma using machine learning. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	9
4808	TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. <i>Neuro-Oncology</i> , 2023, 25, 1031-1043.	1.2	7
4809	Cytogenetic and Molecular Characterization of IDH-Wildtype Glioblastomas and Grade 4 IDH-Mutant Astrocytomas with Unusual Histology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 996-1001.	1.7	0
4810	Identification and verification of the prognostic value of CUL7 in colon adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
4811	The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities. <i>Neuroscience Bulletin</i> , 2023, 39, 393-408.	2.9	2
4812	Elevated ETV6 Expression in Glioma Promotes an Aggressive In Vitro Phenotype Associated with Shorter Patient Survival. <i>Genes</i> , 2022, 13, 1882.	2.4	0
4813	The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13034.	4.1	2
4814	Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	0
4816	Conventional MRI-Derived Biomarkers of Adult-Type Diffuse Glioma Molecular Subtypes: A Comprehensive Review. <i>Biomedicines</i> , 2022, 10, 2490.	3.2	3
4817	Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. <i>Cancer Discovery</i> , 2023, 13, 170-193.	9.4	6
4818	Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs. <i>Pathology Research and Practice</i> , 2022, 239, 154172.	2.3	2
4819	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
4820	Resistance to targeted therapies in acute myeloid leukemia. <i>Clinical and Experimental Metastasis</i> , 2023, 40, 33-44.	3.3	3
4821	The Role of DNA Methylation and DNA Methyltransferases in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 317-348.	1.6	7
4822	Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211392.	2.1	0
4823	An Attention-Guided CNN Framework for Segmentation and Grading of Glioma Using 3D MRI Scans. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, 20, 1890-1904.	3.0	4
4824	Targeting IDH1/IDH2 mutations in gliomas. <i>Current Opinion in Neurology</i> , 2022, 35, 787-793.	3.6	8

#	ARTICLE	IF	CITATIONS
4825	Two independent variants of epidermal growth factor receptor associated with risk of glioma in a Korean population. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
4826	Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas. <i>Cancer Biology and Medicine</i> , 2022, 19, 1477-1486.	3.0	3
4827	A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status. <i>European Radiology</i> , 2023, 33, 2871-2880.	4.5	3
4828	Applying MAP-MRI to Identify the WHO Grade and Main Genetic Features of Adult-type Diffuse Gliomas: A Comparison of Three Diffusion-weighted MRI Models. <i>Academic Radiology</i> , 2023, 30, 1238-1246.	2.5	7
4829	Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000â€“2014 (CONCORD-3). <i>Neuro-Oncology</i> , 2023, 25, 580-592.	1.2	10
4830	Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors. <i>Genes</i> , 2022, 13, 2075.	2.4	2
4831	Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	1
4833	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
4834	Mutant IDH1 attenuates hepatic lipogenesis through PTEN dependent pathway. <i>Biochemical and Biophysical Research Communications</i> , 2022, 637, 254-258.	2.1	0
4835	Probabilistic model checking of cancer metabolism. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
4836	Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011â€“2017): a multicenter retrospective study from CGGA. <i>Cancer Biology and Medicine</i> , 2022, 19, 1460-1476.	3.0	17
4837	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
4839	Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors. <i>Journal of Neuroimmunology</i> , 2023, 374, 578009.	2.3	0
4840	Less Common Triple-Negative Breast Cancers. , 2022, , 463-573.		0
4841	Mitochondrial function and immune response-regulating factor-encoding gene promoters. , 2023, , 15-31.		0
4842	Epigenetic basis for PARP mutagenesis in glioblastoma: A review. <i>European Journal of Pharmacology</i> , 2023, 938, 175424.	3.5	1
4843	Glioblastoma: the current state of the problem. <i>Medical Herald of the South of Russia</i> , 2019, 10, 28-35.	0.4	3
4844	Low grade gliomas guide-lines elaborated by the tumor section of Spanish Society of Neurosurgery. <i>NeurocirugAa (English Edition)</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
4845	Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
4846	Cost Matrix of Molecular Pathology in Glioma”Towards AI-Driven Rational Molecular Testing and Precision Care for the Future. <i>Biomedicines</i> , 2022, 10, 3029.	3.2	1
4847	Bottlenecks and opportunities in immunotherapy for glioma: a narrative review. <i>Journal of Bio-X Research</i> , 0, Publish Ahead of Print, .	0.2	0
4848	Metabolic determinants of tumour initiation. <i>Nature Reviews Endocrinology</i> , 2023, 19, 134-150.	9.6	16
4849	Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations. <i>Cancers</i> , 2022, 14, 5679.	3.7	7
4850	Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy. <i>Journal of Molecular Modeling</i> , 2023, 29, .	1.8	2
4851	IDH2-Mutated Sinonasal Tumors: A Review. <i>Advances in Anatomic Pathology</i> , 2023, 30, 104-111.	4.3	5
4852	Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1-Mutated Cancer Cells. <i>Cancers</i> , 2022, 14, 6228.	3.7	2
4853	Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. <i>Biomedicines</i> , 2022, 10, 3205.	3.2	2
4854	Cancer epigenetics in clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 376-424.	329.8	43
4855	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). <i>Oncology Letters</i> , 2022, 25, .	1.8	7
4856	Recurrent IDH2 Mutations in Salivary Gland Striated Duct Adenoma Define an Expanded Histologic Spectrum Distinct From Canalicular Adenoma. <i>American Journal of Surgical Pathology</i> , 2023, 47, 333-343.	3.7	6
4857	Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. <i>Cancer Biomarkers</i> , 2023, 36, 117-131.	1.7	3
4858	Roadmap toward subtype-specific vulnerabilities in adult glioma. , 2022, 1, .		0
4859	A novel lncRNA MDHDH suppresses glioblastoma multiforme by acting as a scaffold for MDH2 and PSMA1 to regulate NAD+ metabolism and autophagy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	9
4861	A Novel Approach to Detect IDH Point Mutations in Gliomas Using Nanopore Sequencing. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 133-142.	2.8	4
4862	Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	10
4864	Molecular profile and clinical features of patients with gliomas using a broad targeted next generation”sequencing panel. <i>Oncology Letters</i> , 2022, 25, .	1.8	0

#	ARTICLE	IF	CITATIONS
4865	Noninvasive detection of brain gliomas using plasma cell-free <scp>DNA 5- <i>hydroxymethylcytosine</i> </scp> sequencing. <i>International Journal of Cancer</i> , 2023, 152, 1707-1718.	5.1	3
4867	Regulation and function of the mammalian tricarboxylic acid cycle. <i>Journal of Biological Chemistry</i> , 2023, 299, 102838.	3.4	53
4868	The sinuous, wave-like intratumoral-wall sign is a sensitive and specific radiological biomarker for oligodendrogliomas. <i>European Radiology</i> , 2023, 33, 4440-4452.	4.5	3
4869	Impact of epigenetic reprogramming on antitumor immune responses in glioma. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	15
4870	Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
4871	Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3. <i>Journal of Neuro-Oncology</i> , 2023, 162, 489-501.	2.9	2
4872	The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	1
4873	DUSP10 upregulation is a poor prognosticator and promotes cell proliferation and migration in glioma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
4874	Proteome-based insights for IDH-mutant glioma classification. <i>Cell Reports Medicine</i> , 2023, 4, 100909.	6.5	0
4875	The Recurrent-Specific Regulation Network of Prognostic Stemness-Related Signatures in Low-Grade Glioma. <i>Disease Markers</i> , 2023, 2023, 1-29.	1.3	0
4876	Chromatin and Cancer: Implications of Disrupted Chromatin Organization in Tumorigenesis and Its Diversification. <i>Cancers</i> , 2023, 15, 466.	3.7	4
4877	Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status. <i>Cell Reports Medicine</i> , 2023, 4, 100877.	6.5	5
4878	Integrated analysis of genome-wide DNA methylation and cancer-associated fibroblasts identified prognostic biomarkers and immune checkpoint blockade in lower grade gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
4879	Melanoma and Glioblastoma—Not a Serendipitous Association. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	4.3	0
4880	Apparent Diffusion Coefficient as Imaging Biomarker for Identifying <scp>IDH</scp> Mutation, 1p19q Codeletion, and <scp>MGMT</scp> Promoter Methylation Status in Patients With Glioma. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 732-738.	3.4	4
4881	NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 12-20.	4.9	44
4882	D-2-Hydroxyglutarate Inhibits Calcineurin Phosphatase Activity to Abolish NF-AT Activation and IL-2 Induction in Stimulated Lymphocytes. <i>Journal of Immunology</i> , 2023, 210, 504-514.	0.8	2
4883	Identification of therapeutic targets and prognostic biomarkers among frizzled family genes in glioma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	1

#	ARTICLE	IF	CITATIONS
4884	An immune and epithelialâ€“mesenchymal transition-related risk model and immunotherapy strategy for grade II and III gliomas. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
4885	PRMT1 driven PTX3 regulates ferritinophagy in glioma. <i>Autophagy</i> , 2023, 19, 1997-2014.	9.1	9
4886	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
4887	Upstaging and Downstaging in Gliomasâ€“Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System. <i>Diagnostics</i> , 2023, 13, 197.	2.6	1
4888	Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. <i>Neuro-Oncology</i> , 2023, 25, 1085-1097.	1.2	11
4889	Ferroptosis-related NFE2L2 and NOX4 Genes are Potential Risk Prognostic Biomarkers and Correlated with Immunogenic Features in Glioma. <i>Cell Biochemistry and Biophysics</i> , 2023, 81, 7-17.	1.8	3
4890	The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 51-72.	1.6	0
4891	Chromatin mutations in pediatric high grade gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
4892	Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 265-275.	5.1	1
4893	Improved Prediction of MGMT Methylation Status in Glioblastoma using a Deep Attention Network. , 2022, , .		0
4894	Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	1
4895	Nomogram Model for Predicting the Prognosis of High-Grade Glioma in Adults Receiving Standard Treatment: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 196.	2.4	1
4896	Application of Intraoperative Rapid Molecular Diagnosis in Precision Surgery for Glioma: Mimic the World Health Organization CNS5 Integrated Diagnosis. <i>Neurosurgery</i> , 2023, 92, 762-771.	1.1	8
4897	Machine learning can aid in prediction of IDH mutation from H&E-stained histology slides in infiltrating gliomas. <i>Scientific Reports</i> , 2022, 12, .	3.3	8
4898	Cerebellar High-Grade Glioma: A Translationally Oriented Review of the Literature. <i>Cancers</i> , 2023, 15, 174.	3.7	1
4899	Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study. <i>Korean Journal of Radiology</i> , 2023, 24, 133.	3.4	9
4900	T cell exhaustion in malignant gliomas. <i>Trends in Cancer</i> , 2023, 9, 270-292.	7.4	23
4901	Nonâ€“Contact Microfluidic Analysis of the Stiffness of Single Large Extracellular Vesicles from IDH1â€“Mutated Glioblastoma Cells. <i>Advanced Materials Technologies</i> , 2023, 8, .	5.8	2

#	ARTICLE	IF	CITATIONS
4902	Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6719-6741.	2.5	14
4903	Preclinical Models of Low-Grade Gliomas. Cancers, 2023, 15, 596.	3.7	4
4904	Natural Course and Prognosis of Primary Spinal Glioblastoma. Neurology, 2023, 100, .	1.1	2
4905	Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Communications, 2023, 14, .	12.8	7
4906	Cancer Registration, Molecular Marker Status, and Adherence to the WHO 2016 Classification of Pathology Reports for Glioma Diagnosed during 2017–2019 in Belgium. Pathobiology, 2023, 90, 365-376.	3.8	0
4907	Mechanisms driving the immunoregulatory function of cancer cells. Nature Reviews Cancer, 2023, 23, 193-215.	28.4	40
4908	Updates on the WHO diagnosis of IDH-mutant glioma. Journal of Neuro-Oncology, 2023, 162, 461-469.	2.9	9
4909	Tumour DNA Sequencing. , 2023, , 81-99.		0
4910	Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT). Journal of Cancer, 2023, 14, 417-433.	2.5	0
4912	Análisis de la codelección 1p19q en pacientes con diagnóstico de oligodendroglioma y oligoastrocitoma por técnica de CISH. , 2023, 17, .		0
4913	Detection of Isocitrate Dehydrogenase (IDH-1), Epidermal Growth Factor Receptor (EGFR), P53 and C-erbB2/HER2 Mutation in Glial Tumour. , 2022, 18, 111-119.		0
4914	Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Targeted Oncology, 2023, 18, 51-76.	3.6	2
4915	TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas. Applied Immunohistochemistry and Molecular Morphology, 2023, 31, 288-294.	1.2	1
4916	A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments. Frontiers in Pharmacology, 0, 14, .	3.5	2
4917	Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution. Human Pathology, 2023, 136, 63-74.	2.0	2
4918	Local and systemic effects of IDH mutations on primary glioma patients. Immunology, 2023, 169, 503-514.	4.4	2
4919	Imidazole and Biphenyl Derivatives as Anti-cancer Agents for Glioma Therapeutics: Computational Drug Repurposing Strategy. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 1085-1101.	1.7	2
4920	Pharmacological targeting of MTHFD2 suppresses NSCLC via the regulation of ILK signaling pathway. Biomedicine and Pharmacotherapy, 2023, 161, 114412.	5.6	2

#	ARTICLE	IF	CITATIONS
4921	Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features. <i>Journal of Molecular Neuroscience</i> , 2023, 73, 269-286.	2.3	0
4925	Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance. <i>Clinical Cancer Research</i> , 2023, 29, 1763-1782.	7.0	3
4926	Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma. <i>Cancer Research Communications</i> , 2023, 3, 192-201.	1.7	2
4927	Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients. <i>International Journal of General Medicine</i> , 0, Volume 16, 393-403.	1.8	1
4928	D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase. <i>Cell Reports</i> , 2023, 42, 112067.	6.4	3
4929	Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. <i>PLoS ONE</i> , 2023, 18, e0281166.	2.5	5
4930	The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1438-1466.	12.0	3
4931	MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas. <i>Cancers</i> , 2023, 15, 951.	3.7	8
4932	Sex-specific radiomic features of L-[S-methyl-11C] methionine PET in patients with newly-diagnosed gliomas in relation to IDH1 predictability. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	4
4933	Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	5.2	2
4934	Entering a new era of molecular classification of brain tumors: An update of 2021 World Health Organization classification in adult gliomas. <i>Formosan Journal of Surgery</i> , 2023, 56, 43-46.	0.2	0
4935	Characterization of an IDH1 R132H Rabbit Monoclonal Antibody, MRQ-67, and Its Applications in the Identification of Diffuse Gliomas. <i>Antibodies</i> , 2023, 12, 14.	2.5	0
4936	Cytohesin-4 Upregulation in Glioma-Associated M2 Macrophages Is Correlated with Pyroptosis and Poor Prognosis. <i>Journal of Molecular Neuroscience</i> , 0, , .	2.3	2
4937	Prognostic RNA-editing signature predicts immune functions and therapy responses in gliomas. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	0
4938	Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
4939	Epilepsy and brain tumors: Two sides of the same coin. <i>Journal of the Neurological Sciences</i> , 2023, 446, 120584.	0.6	5
4940	Current Status and Challenges of Vaccination Therapy for Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 435-446.	4.1	3
4942	Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. <i>Animal Cells and Systems</i> , 2023, 27, 19-28.	2.2	5

#	ARTICLE	IF	CITATIONS
4944	Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors. <i>BJR Open</i> , 2023, 5, .	0.6	1
4945	DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. <i>Cancers</i> , 2023, 15, 1342.	3.7	13
4946	A Mitochondrial Perspective on Noncommunicable Diseases. <i>Biomedicines</i> , 2023, 11, 647.	3.2	1
4947	Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. <i>Nature Medicine</i> , 2023, 29, 615-622.	30.7	46
4948	PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas. <i>Npj Genomic Medicine</i> , 2023, 8, .	3.8	1
4949	Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
4950	Comparative survey of mitochondrial ultrastructure in <i>IDH1</i>-mutant astrocytoma and <i>IDH1</i>-wildtype glioblastoma (GBM). <i>Ultrastructural Pathology</i> , 2023, 47, 116-121.	0.9	2
4951	Molecular Markers: Indispensable Tools for Diagnosing Central Nervous System Tumors. , 2023, , 1-17.		0
4952	The Role of Reprogrammed Glucose Metabolism in Cancer. <i>Metabolites</i> , 2023, 13, 345.	2.9	4
4953	Capturing the Dynamic Conformational Changes of Human Isocitrate Dehydrogenase 1 (IDH1) upon Ligand and Metal Binding Using Hydrogenâ€Deuterium Exchange Mass Spectrometry. <i>Biochemistry</i> , 2023, 62, 1145-1159.	2.5	3
4954	Epidemiology and risk stratification of low-grade gliomas in the United States, 2004-2019: A competing-risk regression model for survival analysis. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
4957	Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenaseâ€Mutant Glioblastoma: A Multicenter Study. <i>Journal of Computer Assisted Tomography</i> , 0, Publish Ahead of Print, .	0.9	1
4958	High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
4959	MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.7	4
4960	Key events in cancer: Dysregulation of SREBPs. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	7
4961	Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence. <i>Brain Tumor Pathology</i> , 2023, 40, 109-123.	1.7	0
4962	Integrative analysis to screen novel pyroptosis-related LncRNAs for predicting clinical outcome of glioma and validation in tumor tissue. <i>Aging</i> , 0, , .	3.1	0
4963	Regulatory Issues: PMDA â€ Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Tesperaturev) for Malignant Glioma. <i>Oncologist</i> , 2023, 28, 664-670.	3.7	7

#	ARTICLE	IF	CITATIONS
4965	Mechanisms of cancer-associated thrombosis. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100123.	2.3	4
4966	Quinolate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPAR γ signaling axis. Nature Communications, 2023, 14, .	12.8	9
4967	Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology. Journal of Neuro-Oncology, 2023, 162, 525-533.	2.9	2
4968	Supratentorial multifocal gliomas associated with Ollier disease harboring <scp> <i>IDH1</i> R132H </scp> mutation: A case report. Neuropathology, 0, , .	1.2	0
4969	Clinicopathologic Features of<i>IDH2</i>R172â€“Mutated Myeloid Neoplasms. American Journal of Clinical Pathology, 0, , .	0.7	0
4970	Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors. Journal of Medicinal Chemistry, 2023, 66, 5279-5288.	6.4	2
4971	Vasari Scoring System in Discerning between Different Degrees of Glioma and IDH Status Prediction: A Possible Machine Learning Application?. Journal of Imaging, 2023, 9, 75.	3.0	2
4972	Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas. Molecules, 2023, 28, 2890.	3.8	3
4973	Cyclin-Dependent Kinase Inhibitor 2A/B Homozygous Deletion Prediction and Survival Analysis. Brain Sciences, 2023, 13, 548.	2.3	1
4974	Exam 2: Section 3. , 2023, , 183-207.		0
4975	N7-methylguanosin regulators-mediated methylation modification patterns and characterization of the immune microenvironment in lower-grade glioma. European Journal of Medical Research, 2023, 28, .	2.2	3
4976	Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report. Frontiers in Oncology, 0, 13, .	2.8	2
4977	NAGS, CPS1, and SLC25A13 (Citrin) at the Crossroads of Arginine and Pyrimidines Metabolism in Tumor Cells. International Journal of Molecular Sciences, 2023, 24, 6754.	4.1	1
4978	SASG-GCN: Self-Attention Similarity Guided Graph Convolutional Network for Multi-Type Lower-Grade Glioma Classification. IEEE Journal of Biomedical and Health Informatics, 2023, 27, 3384-3395.	6.3	2
4980	Rapid detection of isocitrate dehydrogenase 1 mutation status in glioma based on Crispr-Cas12a. Scientific Reports, 2023, 13, .	3.3	0
4981	Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma. Cancer Cell International, 2023, 23, .	4.1	4
4982	Proteomic analysis reveals microvesicles containing NAMPT as mediators of radioresistance in glioma. Life Science Alliance, 2023, 6, e202201680.	2.8	7
4985	Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. Metabolites, 2023, 13, 543.	2.9	2

#	ARTICLE	IF	CITATIONS
4986	Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. International Journal of Molecular Sciences, 2023, 24, 7076.	4.1	3
4988	Metabolic Rewiring in Adult-Type Diffuse Gliomas. International Journal of Molecular Sciences, 2023, 24, 7348.	4.1	2
4990	Extended Application of Genomic Selection to Screen Multi-Omics Data for the Development of Novel Pyroptosis-Immune Signatures and Predicting Immunotherapy of Glioma. Frontiers in Pharmacology, 0, 13, .	3.5	1
4992	An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?. Frontiers in Oncology, 0, 13, .	2.8	2
4993	A novel gene, TARDBP, and the protein it encodes can predict glioma patient prognosis and establish a prediction model. BMC Neurology, 2023, 23, .	1.8	0
4994	Differentiated chondrosarcoma, variants of transformation of the sarcomatous component of the tumor. Sarkomy Kosteji, Mâċgkih Tkanej I Opuholi KoÅ³i, 2023, 15, 44-56.	0.2	0
4995	Therapies for IDH-Mutant Gliomas. Current Neurology and Neuroscience Reports, 2023, 23, 225-233.	4.2	3
4996	Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat. Tomography, 2023, 9, 942-954.	1.8	2
4997	Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment. Cell Communication and Signaling, 2023, 21, .	6.5	8
4999	Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of Glioblastoma. Antioxidants and Redox Signaling, 0, , .	5.4	1
5000	Expression of IL-13RÎ±2 and FUS in glioma: clinicopathological and prognostic correlation. BMC Neurology, 2023, 23, .	1.8	0
5001	lncRNA TRHDE-AS1 Correlated with Genomic Landscape and Clinical Outcome in Glioma. Genes, 2023, 14, 1052.	2.4	0
5002	Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Fundersâ€™ Collaborative Consortium (EORTC 1419). European Journal of Cancer, 2023, 189, 112913.	2.8	8
5003	Impact of redox-related genes on tumor microenvironment immune characteristics and prognosis of high-grade gliomas. Frontiers in Cellular Neuroscience, 0, 17, .	3.7	0
5004	Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma. European Journal of Medicinal Chemistry, 2023, 257, 115464.	5.5	1
5005	p53-independent tumor suppression by cell-cycle arrest via CREB/ATF transcription factor OASIS. Cell Reports, 2023, 42, 112479.	6.4	3
5006	Chemical Exchange Saturation Transfer (CEST) Imaging. , 2023, , 293-308.		0
5007	An on-line heart-cutting two-dimensional liquid chromatography method for intracellular 2-hydroxyglutarate enantiomers. Analytical Methods, 2023, 15, 2833-2838.	2.7	1

#	ARTICLE	IF	CITATIONS
5008	Magnetic Resonance Spectroscopy: Clinical Applications. , 2023, , 241-292.		0
5009	Radiomics and Radiogenomics in Glioma. , 2023, , 1313-1321.		0
5010	Nanobiotechnology-based treatment strategies for malignant relapsed glioma. Journal of Controlled Release, 2023, 358, 681-705.	9.9	8
5011	Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario. Biomedicines, 2023, 11, 1520.	3.2	5
5012	Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status. Journal of Neuro-Oncology, 2023, 163, 339-344.	2.9	2
5013	Non-coding RNAs in glioblastoma at a glance. , 2023, , 477-504.		0
5014	Racial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort study. Cancer, 2023, 129, 3010-3022.	4.1	2
5015	Forging a path to the use of liquid biopsy in the diagnosis of gliomas. , 2023, , 55-80.		0
5016	Practice guidelines for the diagnosis of glioblastoma. , 2023, , 11-32.		0
5017	Optimizing the role of immunotherapy for the treatment of glioblastoma. , 2023, , 553-591.		1
5018	The prognostic impact of subclonal IDH1 mutation in grade 2-4 astrocytomas. Neuro-Oncology Advances, 2023, 5, .	0.7	0
5019	Personalized Treatment of Glioblastoma: Current State and Future Perspective. Biomedicines, 2023, 11, 1579.	3.2	5
5020	Focusing on scRNA-seq-Derived T Cell-Associated Genes to Identify Prognostic Signature and Immune Microenvironment Status in Low-Grade Glioma. Mediators of Inflammation, 2023, 2023, 1-17.	3.0	0
5021	Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas. Genes, 2023, 14, 1201.	2.4	0
5022	RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma. World Neurosurgery, 2023, , .	1.3	0
5023	Arginine deprivation as a treatment approach targeting cancer cell metabolism and survival: A review of the literature. European Journal of Pharmacology, 2023, 953, 175830.	3.5	1
5024	Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. New England Journal of Medicine, 2023, 389, 589-601.	27.0	90
5026	The Interplay between Dysregulated Metabolism and Epigenetics in Cancer. Biomolecules, 2023, 13, 944.	4.0	1

#	ARTICLE	IF	CITATIONS
5027	Impact of IDH Mutations, the 1p/19q Co-Deletion and the G-CIMP Status on Alternative Splicing in Diffuse Gliomas. International Journal of Molecular Sciences, 2023, 24, 9825.	4.1	0
5028	Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study. Applied Immunohistochemistry and Molecular Morphology, 0, Publish Ahead of Print, .	1.2	0
5029	Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction. BMC Cancer, 2023, 23, .	2.6	1
5030	FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response. Aging, 0, .	3.1	0
5031	Inmunopatología del Glioblastoma Multiforme y su importancia en el Ámbito clínico. Revista Ciencias Biomédicas (cartagena), 2022, 11, 163-178.	0.0	0
5032	Simple and Ultrasensitive Detection of Glioma-Related ctDNAs in Mice Serum by SERS-Based Catalytic Hairpin Assembly Signal Amplification Coupled with Magnetic Aggregation. International Journal of Nanomedicine, 0, Volume 18, 3211-3230.	6.7	4
5033	Extramedullary skeletal muscle metastasis of glioblastoma: A case report and literature review âĖ. , 2016, 2, 189-193.		0
5034	Watching the clock in glioblastoma. Neuro-Oncology, 2023, 25, 1932-1946.	1.2	1
5035	Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas. Communications Biology, 2023, 6, .	4.4	2
5036	Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas. Cell Reports Medicine, 2023, 4, 101082.	6.5	2
5037	CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review. Current Issues in Molecular Biology, 2023, 45, 5276-5292.	2.4	3
5038	Development and validation of a predictive model in diagnosis and prognosis of primary glioblastoma patients based on Homeobox A family. Discover Oncology, 2023, 14, .	2.1	1
5039	Prediction of IDH1 gene mutation by a nomogram based on multiparametric and multiregional MR images. Clinics, 2023, 78, 100238.	1.5	0
5040	Clinical cases in neuro-oncology. , 2023, , 467-698.		0
5041	P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients. Neuro-Oncology Advances, 0, .	0.7	0
5042	Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenaseâ€“mutant Astrocytic and Oligodendroglial Tumors. Clinical Cancer Research, 2023, 29, 4863-4869.	7.0	2
5043	Oligodendrocyte Transcription Factor 2 as a Potential Prognostic Biomarker of Glioblastoma: Kaplan-Meier Analysis and the Development of a Binary Predictive Model Based on Visually Accessible Rembrandt Image and Magnetic Resonance Imaging Radiomic Features. Journal of Computer Assisted Tomography, 0, Publish Ahead of Print, .	0.9	0
5044	The impact of survivorship bias in glioblastoma research. Critical Reviews in Oncology/Hematology, 2023, 188, 104065.	4.4	8

#	ARTICLE	IF	CITATIONS
5045	The complexities underlying epilepsy in people with glioblastoma. <i>Lancet Neurology</i> , The, 2023, 22, 505-516.	10.2	5
5046	Adult diffuse gliomas: What the neuroradiologist needs to know. <i>Neuroradiology Journal</i> , 0, , 197140092311731.	1.2	0
5047	Mutational landscape of primary spinal cord astrocytoma. <i>Journal of Pathology</i> , 2023, 260, 317-328.	4.5	0
5048	Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 367-388.	5.9	0
5049	Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies. <i>Cancers</i> , 2023, 15, 2556.	3.7	1
5050	Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients. <i>Medeniyet Medical Journal</i> , 2023, 38, 102-110.	0.7	0
5051	Development and validation of an immune infiltration/tumor proliferation-related Notch3 nomogram for predicting survival in patients with primary glioblastoma. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	0
5052	Dissecting Intra-tumor Heterogeneity in the Glioblastoma Microenvironment Using Fluorescence-Guided Multiple Sampling. <i>Molecular Cancer Research</i> , 0, , OF1-OF13.	3.4	0
5053	Combining methionineâ€PET and MRI fluidâ€attenuated inversionâ€recovery mismatch to determine glioma molecular subtype. <i>Journal of Neuroimaging</i> , 2023, 33, 652-660.	2.0	1
5054	Advances in Mapping Tumor Progression from Precancer Atlases. <i>Cancer Prevention Research</i> , 0, , OF1-OF9.	1.5	0
5055	Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.7	0
5056	From Theory to Practice: Implementing the WHO 2021 Classification of Adult Diffuse Gliomas in Neuropathology Diagnosis. <i>Brain Sciences</i> , 2023, 13, 817.	2.3	1
5057	Association of <i>MGMT</i> Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. <i>JAMA Oncology</i> , 2023, 9, 919.	7.1	10
5058	Tyrosine metabolic reprogramming coordinated with the tricarboxylic acid cycle to drive glioma immune evasion by regulating PDâ€L1 expression. , 2023, 9, 133-147.		2
5059	Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors. <i>Journal of Neuro-Oncology</i> , 2023, 162, 457-459.	2.9	1
5060	Neuroimaging of Brain Tumors in the Era of Radiogenomics. , 2023, , 1275-1311.		0
5061	Mutant IDH in Gliomas: Role in Cancer and Treatment Options. <i>Cancers</i> , 2023, 15, 2883.	3.7	3
5062	The impact of RNA binding proteins and the associated long non-coding RNAs in the TCA cycle on cancer pathogenesis. <i>RNA Biology</i> , 2023, 20, 223-234.	3.1	3

#	ARTICLE	IF	CITATIONS
5063	Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy. Biomarker Research, 2023, 11, .	6.8	1
5064	Bibliometric Analysis of Studies on the Energy Metabolism Enzyme Isocitrate Dehydrogenase. Mersin Âœniversitesi TÃ±p FakÃ¼ltesi Lokman Hekim TÃ±p Tarihi Ve Folklorik TÃ±p Dergisi, 2023, 13, 437-444.	0.7	0
5065	Mitochondrial-Encoded Complex I Impairment Induces a Targetable Dependency on Aerobic Fermentation in HÃ¼rthle Cell Carcinoma of the Thyroid. Cancer Discovery, 2023, 13, 1884-1903.	9.4	4
5066	Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics. Cellular Signalling, 2023, 109, 110738.	3.6	0
5067	Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications. International Journal of Molecular Sciences, 2023, 24, 10546.	4.1	1
5068	Gliomes avec mutation dâ€™un gÃªne <i>IDH</i>. Medecine/Sciences, 2023, 39, 499-501.	0.2	0
5069	Understanding the molecular profiling of diffuse gliomas classification: A brief overview. Surgical Neurology International, 0, 14, 225.	0.2	0
5071	Expression of intra-tumoral necrosis-associated cytokine pattern correlated with prognosis and immune status in glioma. Frontiers in Molecular Neuroscience, 0, 16, .	2.9	0
5072	Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection. Journal of Translational Medicine, 2023, 21, .	4.4	1
5073	Advances in glioma models using in vivo electroporation to hijack neurodevelopmental processes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188951.	7.4	0
5074	Impact of Timing of Surgery and Adjuvant Treatment on Survival of Adult IDHâ€œwild-type Glioblastoma: A Single-center Study of 392 Patients. World Neurosurgery, 2023, 177, e785-e792.	1.3	1
5075	Use Test of Automated Machine Learning in Cancer Diagnostics. Diagnostics, 2023, 13, 2315.	2.6	2
5076	Recent advances in understanding brain cancer metabolomics: a review. , 2023, 40, .		0
5077	Identification of predictive markers in the cerebrospinal fluid of patients with glioblastoma. Uspehi Molekularnoj Onkologii, 2023, 10, 117-125.	0.3	0
5078	A Preliminary Study Indicating Improvement in the Median Survival Time of Glioblastoma Multiforme Patients by the Application of Deuterium Depletion in Combination with Conventional Therapy. Biomedicines, 2023, 11, 1989.	3.2	0
5079	Benign Glioma. Advances in Experimental Medicine and Biology, 2023, , 31-71.	1.6	0
5080	Malignant Glioma. Advances in Experimental Medicine and Biology, 2023, , 1-30.	1.6	8
5081	Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation. Human Cell, 0, , .	2.7	0

#	ARTICLE	IF	CITATIONS
5082	Malignant Spinal Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 565-581.	1.6	1
5083	Cellular senescence in glioma. <i>Journal of Neuro-Oncology</i> , 2023, 164, 11-29.	2.9	4
5084	A new era for glioma therapy “targeting mutant IDH. <i>Nature Reviews Clinical Oncology</i> , 0, , .	27.6	0
5085	Vascular differences between <i>IDH</i>wildtype glioblastoma and astrocytoma <i>IDH</i>mutant grade 4 at imaging and transcriptomic levels. <i>NMR in Biomedicine</i> , 0, , .	2.8	0
5086	The Role of Artificial Intelligence in Neuro-oncology Imaging. <i>Neuromethods</i> , 2023, , 963-976.	0.3	0
5087	Modeling epigenetic lesions that cause gliomas. <i>Cell</i> , 2023, 186, 3674-3685.e14.	28.9	10
5088	Pathology of the Tumors of the Central Nervous System. , 2023, , 71-110.		0
5089	Extracellular-Vesicle-Based Cancer Panels Diagnose Glioblastomas with High Sensitivity and Specificity. <i>Cancers</i> , 2023, 15, 3782.	3.7	0
5090	2-hydroxyglutarate rides the cancer-immunity cycle. <i>Current Opinion in Biotechnology</i> , 2023, 83, 102976.	6.6	1
5091	Intracellular spatiotemporal metabolism in connection to target engagement. <i>Advanced Drug Delivery Reviews</i> , 2023, , 115024.	13.7	0
5092	A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	3.2	1
5093	The Evolving Landscape of Monocyte/Macrophage System in Glioma. , 2023, , .		0
5094	The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12037.	4.1	0
5095	NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
5096	A texture-based method for predicting molecular markers and survival outcome in lower grade glioma. <i>Applied Intelligence</i> , 2023, 53, 24724-24738.	5.3	3
5097	Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal. <i>Cancer Investigation</i> , 0, , 1-10.	1.3	0
5098	Epigenetic activation of secretory phenotypes in senescence by the FOXQ1-SIRT4-GDH signaling. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	1
5099	Outcomes of Fluorescence-Guided vs White Light Resection of Glioblastoma in a Single Institution. <i>Cureus</i> , 2023, , .	0.5	0

#	ARTICLE	IF	CITATIONS
5100	Decoding the prognostic significance of integrator complex subunit 9 (INTS9) in glioma: links to TP53 mutations, E2F signaling, and inflammatory microenvironments. Cancer Cell International, 2023, 23, .	4.1	0
5101	Nuclear transport surveillance of p53 by nuclear pores in glioblastoma. Cell Reports, 2023, 42, 112882.	6.4	2
5102	Breast cancers as ecosystems: a metabolic perspective. Cellular and Molecular Life Sciences, 2023, 80, .	5.4	2
5103	Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series. Journal of Neuro-Oncology, 2023, 164, 55-64.	2.9	2
5104	Targeting IDH in Low-Grade Glioma. New England Journal of Medicine, 2023, 389, 655-659.	27.0	1
5105	ASCO 2023: new treatment options in CNS tumors. Memo - Magazine of European Medical Oncology, 0, , .	0.5	1
5106	Prognostic value of integrative genomic approaches for IDH-mutant gliomas. Neuro-Oncology, 0, , .	1.2	0
5107	The impact of interaction between verteporfin and yes-associated protein 1/transcriptional coactivator with PDZ-binding motif-TEA domain pathway on the progression of isocitrate dehydrogenase wild-type glioblastoma. Journal of Central Nervous System Disease, 2023, 15, .	1.9	2
5108	Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies. Cancers, 2023, 15, 4213.	3.7	1
5109	The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic TÂcell function. Cell Reports, 2023, 42, 113013.	6.4	0
5110	Somatic mutation effects diffused over microRNA dysregulation. Bioinformatics, 0, , .	4.1	1
5111	Tumour-treating fields for high-grade glioma. The Cochrane Library, 2023, 2023, .	2.8	0
5112	The Correlation of In Vivo MR Spectroscopy and Ex Vivo 2-Hydroxyglutarate Concentration for the Prediction of Isocitrate Dehydrogenase Mutation Status in Diffuse Glioma. Diagnostics, 2023, 13, 2791.	2.6	1
5113	Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era. Neuro-Oncology, 0, , .	1.2	0
5114	Mechanisms Involved in the Therapeutic Effect of Cannabinoid Compounds on Gliomas: A Review with Experimental Approach. Current Protein and Peptide Science, 2024, 25, 27-43.	1.4	0
5115	Prognosis of overall and disease-free survival in patients with grade 3 astrocytomas (anaplastic) Tj ETQq1 1 0.784314rgBT /Overlock 100,2	0.2	0
5116	Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis. Journal of Neuro-Oncology, 2023, 164, 31-41.	2.9	3
5117	Predicting survival in glioblastoma with multimodal neuroimaging and machine learning. Journal of Neuro-Oncology, 2023, 164, 309-320.	2.9	1

#	ARTICLE	IF	CITATIONS
5118	GradWise: A Novel Application of a Rank-Based Weighted Hybrid Filter and Embedded Feature Selection Method for Glioma Grading with Clinical and Molecular Characteristics. <i>Cancers</i> , 2023, 15, 4628.	3.7	1
5119	Novel immune checkpoint-related gene model to predict prognosis and treatment responsiveness in low-grade gliomas. <i>Heliyon</i> , 2023, 9, e20178.	3.2	1
5120	Liquid biopsy: creating opportunities in brain space. <i>British Journal of Cancer</i> , 2023, 129, 1727-1746.	6.4	1
5121	Distinct aneuploid evolution of astrocytoma and glioblastoma during recurrence. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	0
5122	Asleep-awake-asleep versus hypnosis for low-grade glioma surgery: long term follow-up outcome. <i>Neurochirurgie</i> , 2023, 69, 101494.	1.2	0
5123	Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI. <i>Cancers</i> , 2023, 15, 4453.	3.7	0
5124	Role of Non-Coding RNAs in TGF- β^2 Signalling in Glioma. <i>Brain Sciences</i> , 2023, 13, 1376.	2.3	1
5125	D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 921-933.	1.7	1
5126	An integrative computational approach for the identification of dual inhibitors of isocitrate dehydrogenase 1 and 2 from phytochemicals of <i>Phyllanthus amarus</i> . <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-17.	3.5	1
5127	MRI-Based Deep Learning Method for Classification of IDH Mutation Status. <i>Bioengineering</i> , 2023, 10, 1045.	3.5	1
5128	Use, Access, and Initial Outcomes of Off-Label Ivosidenib in Patients with IDH1 Mutant Glioma. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	0
5129	Clinical trial links oncolytic immunoactivation to survival in glioblastoma. <i>Nature</i> , 2023, 623, 157-166.	27.8	15
5130	Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review. <i>Cancer Reports</i> , 2023, 6, .	1.4	2
5131	Neuropathologist-level integrated classification of adult-type diffuse gliomas using deep learning from whole-slide pathological images. <i>Nature Communications</i> , 2023, 14, .	12.8	1
5132	Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
5133	Combination Drug Therapy of Glioblastoma: Lessons from 3D In Vitro Models and the Roadmap for Future Research. <i>Advanced Therapeutics</i> , 0, , .	3.2	0
5134	Overcoming EGFR inhibitor resistance in glioblastoma by targeting co-amplified genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	0
5135	Chromosome 2, , 2023, , 28-51.		0

#	ARTICLE	IF	CITATIONS
5136	Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma. <i>Neuro-Oncology</i> , 2023, 25, 2028-2041.	1.2	1
5137	Genome-guided discovery of cancer therapeutic targets. <i>Cell Reports</i> , 2023, 42, 112978.	6.4	3
5138	Natural language processing to predict isocitrate dehydrogenase genotype in diffuse glioma using MR radiology reports. <i>European Radiology</i> , 2023, 33, 8017-8025.	4.5	2
5140	Spinal cord motor disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 3-42.	1.8	0
5141	Deep learning based on dynamic susceptibility contrast MR imaging for prediction of local progression in adult-type diffuse glioma (grade 4). <i>Scientific Reports</i> , 2023, 13, .	3.3	0
5142	Brain tumour genetic network signatures of survival. <i>Brain</i> , 2023, 146, 4736-4754.	7.6	1
5143	Nuclear mitochondria-related genes-based molecular classification and prognostic signature reveal immune landscape, somatic mutation, and prognosis for glioma. <i>Heliyon</i> , 2023, 9, e19856.	3.2	0
5145	Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis. <i>Journal of Neuro-Oncology</i> , 2023, 164, 461-471.	2.9	0
5146	Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy. <i>Radiology</i> , 2023, 308, .	7.3	3
5147	Systematic Review of WHO Grade 4 Astrocytoma in the Cerebellopontine Angle: The Impact of Anatomic Corridor on Treatment Options and Outcomes. <i>Journal of Neurological Surgery Reports</i> , 2023, 84, e129-e139.	0.6	0
5148	The prognostic power of [11C]methionine PET in IDH-wildtype diffuse gliomas with lower-grade histological features: venturing beyond WHO classification. <i>Journal of Neuro-Oncology</i> , 2023, 164, 473-481.	2.9	2
5149	Tumor radiogenomics in gliomas with Bayesian layered variable selection. <i>Medical Image Analysis</i> , 2023, 90, 102964.	11.6	0
5151	Development and validation of a personalized classifier to predict the prognosis and response to immunotherapy in glioma based on glycolysis and the tumor microenvironment. <i>PeerJ</i> , 0, 11, e16066.	2.0	0
5152	Platycodin D inhibits glioblastoma cell proliferation, migration, and invasion by regulating DEPDC1B-mediated epithelial-to-mesenchymal transition. <i>European Journal of Pharmacology</i> , 2023, 958, 176074.	3.5	0
5153	High-Grade Gliomas in Early Adulthood: A Case-Based Review of Current Molecular Diagnostic Considerations. <i>AJSP Review and Reports</i> , 2020, 25, 63-68.	0.1	0
5154	The prognostic value of tumor-associated macrophages in glioma patients. <i>Medicine (United States)</i> , 2023, 102, e35298.	1.0	1
5155	IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
5156	Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia. , 2023, , 61-89.		0

#	ARTICLE	IF	CITATIONS
5157	Hypoxic regulation of extracellular vesicles: Implications for cancer therapy. Journal of Controlled Release, 2023, 363, 201-220.	9.9	2
5158	Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM. Clinical Cancer Research, 2024, 30, 283-293.	7.0	5
5160	Molecular Profiling and Targeted Therapies in Gliomas. Current Neurology and Neuroscience Reports, 2023, 23, 627-636.	4.2	2
5161	Metabolic remodeling in astrocytes: Paving the path to brain tumor development. Neurobiology of Disease, 2023, 188, 106327.	4.4	1
5162	The Signaling of Neuregulin-Epidermal Growth Factor Receptors and Its Impact on the Nervous System. Neuroglia (Basel, Switzerland), 2023, 4, 253-274.	0.9	0
5163	BTN2A2, a new biomarker and therapeutic target for glioma. Aging, 0, , .	3.1	1
5164	Added prognostic value of 3D deep learning-derived features from preoperative MRI for adult-type diffuse gliomas. Neuro-Oncology, 2024, 26, 571-580.	1.2	1
5165	Molecular testing for gliomas. , 2024, , 385-396.		0
5166	The disulfidptosis-related signature predicts prognosis and immune features in glioma patients. Scientific Reports, 2023, 13, .	3.3	0
5167	Molecular testing in acute myeloid leukemia. , 2024, , 597-615.		0
5168	Mitochondrial response of glioma cells to temozolomide. Experimental Cell Research, 2023, 433, 113825.	2.6	0
5169	Morphogenetic characteristics of glial tumors in adults per the WHO classifications of 2007, 2016, 2021. Changes in the classifications and their significance for clinical practice. Russian Journal of Neurosurgery, 2023, 25, 135-148.	0.2	0
5170	Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas. , 2023, 11, .	2.3	0
5171	Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas. Cell Reports Medicine, 2023, 4, 101249.	6.5	1
5172	Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis, 2023, 12, .	4.9	3
5173	Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues. International Journal of Molecular Sciences, 2023, 24, 16316.	4.1	1
5174	Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing. Journal of Neuro-Oncology, 2023, 165, 209-218.	2.9	0
5175	Mining cancer genomes for change-of-metabolic-function mutations. Communications Biology, 2023, 6, .	4.4	0

#	ARTICLE	IF	CITATIONS
5176	MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Scientific Reports, 2023, 13, .	3.3	1
5177	Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51, 1085-1096.	6.4	1
5178	Inferring mitochondrial and cytosolic metabolism by coupling isotope tracing and deconvolution. Nature Communications, 2023, 14, .	12.8	1
5179	IDH1R132H mutation increases radiotherapy efficacy and a 4-gene radiotherapy-related signature of WHO grade 4 gliomas. Scientific Reports, 2023, 13, .	3.3	0
5180	Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma. Acta Neuropathologica Communications, 2023, 11, .	5.2	0
5181	Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (<i>IDH1/2</i>) Mutant Cholangiocarcinoma. Molecular Cancer Therapeutics, 2024, 23, 394-399.	4.1	0
5182	Advances in molecular and imaging biomarkers in lower-grade gliomas. Expert Review of Neurotherapeutics, 2023, 23, 1217-1231.	2.8	1
5183	The value of multiparametric MRI radiomics in predicting IDH genotype in glioma before surgery. Frontiers in Oncology, 0, 13, .	2.8	0
5184	Differential metabolic alterations in IDH1 mutant vs. wildtype glioma cells promote epileptogenesis through distinctive mechanisms. Frontiers in Cellular Neuroscience, 0, 17, .	3.7	0
5185	Microgravity as an Anti-Metastatic Agent in an In Vitro Glioma Model. Biophysica, 2023, 3, 636-650.	1.4	0
5186	Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma. Clinical Cancer Research, 0, , OF1-OF10.	7.0	1
5187	Animal models and age-related diseases. , 2023, , .		0
5188	Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains. Neuro-Oncology Advances, 2023, 5, .	0.7	1
5189	Investigating the value of radiomics stemming from DSC quantitative biomarkers in IDH mutation prediction in gliomas. Frontiers in Neurology, 0, 14, .	2.4	1
5190	Clinical impact of molecular profiling in rare brain tumors. Current Opinion in Neurology, 2023, 36, 579-586.	3.6	0
5191	Artificial intelligence in neuroimaging of brain tumors: reality or still promise?. Current Opinion in Neurology, 2023, 36, 549-556.	3.6	0
5192	Treatment of glioblastoma in Greenlandic patients. International Journal of Circumpolar Health, 2023, 82, .	1.2	0
5193	<i>IDH1</i>-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with <i>MGMT</i> methylation and serrated-type dysplasia. Histopathology, 2024, 84, 515-524.	2.9	0

#	ARTICLE	IF	CITATIONS
5194	Targeting Mutant <i>IDH</i> to Treat Low-grade Glioma. Touch Reviews in Oncology & Haematology, 2023, 19, 3.	0.2	0
5195	11C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11C-Methionine PET/CT in Glioma Classification and Survival Prediction. Clinical Nuclear Medicine, 0, , .	1.3	0
5198	Biomarkers in Adult-Type Diffuse Gliomas: Elevated Levels of Circulating Vesicular Heat Shock Protein 70 Serve as a Biomarker in Grade 4 Glioblastoma and Increase NK Cell Frequencies in Grade 3 Glioma. Biomedicines, 2023, 11, 3235.	3.2	0
5199	Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies. Genome Biology, 2023, 24, .	8.8	1
5201	Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies. Brain Sciences, 2023, 13, 1700.	2.3	4
5202	Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play. Pathology, 2024, 56, 158-169.	0.6	1
5203	Adult-type Diffuse Gliomas. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 1662-1679.	0.8	0
5204	2021 World Health Organization Classification of Brain Tumors. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 1638-1661.	0.8	0
5205	Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndromeâ€refractory anemia by regulating the cell cycle. Experimental and Therapeutic Medicine, 2023, 26, .	1.8	0
5206	Mitochondrial metabolism as a dynamic regulatory hub to malignant transformation and anti-cancer drug resistance. Biochemical and Biophysical Research Communications, 2024, 694, 149382.	2.1	0
5207	Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive l-[methyl-11C] methionine cohort study with two PET scanners. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0
5208	Exploiting Iron Metabolism as a Therapeutic Vulnerability in Glioblastoma. Clinical Cancer Research, 0, , OF1-OF2.	7.0	0
5209	Identification of IDH and TERTp mutations using dynamic susceptibility contrast MRI with deep learning in 162 gliomas. European Journal of Radiology, 2024, 170, 111257.	2.6	0
5210	Neuro-oncology Treatment Strategies for Primary Glial Tumors. Seminars in Neurology, 2023, 43, 889-896.	1.4	0
5211	Research Progress on the Pathogenesis of Brain Tumor Related Epilepsy. Advances in Clinical Medicine, 2023, 13, 19265-19270.	0.0	0
5212	Role of Glycolytic and Glutamine Metabolism Reprogramming on the Proliferation, Invasion, and Apoptosis Resistance through Modulation of Signaling Pathways in Glioblastoma. International Journal of Molecular Sciences, 2023, 24, 17633.	4.1	0
5213	Methodological and analytical considerations for intra-operative microdialysis. Fluids and Barriers of the CNS, 2023, 20, .	5.0	0
5214	Identification of RP11â€770J1.4 as immuneâ€related lncRNA regulating the CTXN1â€cGASâ€STING axis in histologically lowerâ€grade glioma. MedComm, 2023, 4, .	7.2	0

#	ARTICLE	IF	CITATIONS
5215	Integrated analysis of necroptosis related gene signature to predict clinical outcomes, immune status and drug sensitivity in lower grade Glioma. Heliyon, 2024, 10, e23947.	3.2	0
5216	Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas. Journal of Neuropathology and Experimental Neurology, 2024, 83, 107-114.	1.7	0
5217	Genomic Landscape of NSCLC in the Republic ofÂIreland. JTO Clinical and Research Reports, 2024, 5, 100627.	1.1	0
5218	Dietary approaches for exploiting metabolic vulnerabilities in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2024, 1879, 189062.	7.4	0
5220	IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients. BMC Cancer, 2024, 24, .	2.6	0
5221	Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas. Cancer Imaging, 2024, 24, .	2.8	0
5222	Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction. American Journal of Neuroradiology, 2024, 45, 188-197.	2.4	0
5223	è¶...é«~æ,,ÿâ° ä»£è~â,âf;âf1/4â,âf3â,°â,'â®ÿç¾4âªªâ,â«•çš,,æ,âæ¥µæ³•. The Brain & Neural Networks, 2023, 30, 1791188.		0
5224	Glioma. , 2024, , 184-192.		0
5225	Multi-task Model for Glioma Segmentation and Isocitrate Dehydrogenase Status Prediction Using Global and Local Features. , 2023, , .		0
5226	D-mannose promotes the degradation of IDH2 through upregulation of RNF185 and suppresses breast cancer. Nutrition and Metabolism, 2024, 21, .	3.0	0
5227	Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?. Clinical Orthopaedics and Related Research, 0, , .	1.5	0
5228	Aggressive renal cell carcinoma with biphasic papillary and solid clear cell features harboring IDH2 (R172M) mutation. Pathology Research and Practice, 2024, 253, 155090.	2.3	0
5229	A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma. Journal of Neuropathology and Experimental Neurology, 2024, 83, 125-130.	1.7	0
5230	Extent of resection for low-grade gliomas â€“ Prognostic or therapeutic?. Clinical Neurology and Neurosurgery, 2024, 236, 108117.	1.4	0
5231	Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity. Heliyon, 2024, 10, e24454.	3.2	0
5233	Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma. Neuro-Oncology Advances, 2024, 6, .	0.7	0
5234	Diagnostic utility of genetic alterations in distinguishing <scp>IDH</scp>â€wildtype glioblastoma from lowerâ€grade gliomas: Insight from nextâ€generation sequencing analysis of 479 cases. Brain Pathology, 0, , .	4.1	0

#	ARTICLE	IF	CITATIONS
5235	TMEM64 aggravates the malignant phenotype of glioma by activating the Wnt/ β -catenin signaling pathway. International Journal of Biological Macromolecules, 2024, 260, 129332.	7.5	0
5236	IDH1 mutation inhibits differentiation of astrocytes and glioma cells with low oxoglutarate dehydrogenase expression by disturbing α -ketoglutarate-related metabolism and epigenetic modification. , 2024, 3, .		0
5237	Image-Based Subtype Classification for Glioblastoma Using Deep Learning: Prognostic Significance and Biologic Relevance. JCO Clinical Cancer Informatics, 2024, , .	2.1	0
5238	Targeting the Metabolic Paradigms in Cancer and Diabetes. Biomedicines, 2024, 12, 211.	3.2	0
5239	Genetic profiling of rat gliomas and cardiac schwannomas from life-time radiofrequency radiation exposure study using a targeted next-generation sequencing gene panel. PLoS ONE, 2024, 19, e0296699.	2.5	0
5240	Epigenetic dysregulation in brain tumors. , 2024, , 269-285.		0
5241	A New Systemic Disease Mouse Model for Glioblastoma Capable of Single-Tumour-Cell Detection. Cells, 2024, 13, 192.	4.1	0
5242	Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nature Reviews Nephrology, 2024, 20, 233-250.	9.6	0
5243	Forward Genetic Screens Identify Mechanisms of Resistance to Small-Molecule Lactate Dehydrogenase Inhibitors. ACS Chemical Biology, 2024, 19, 471-482.	3.4	0
5244	OCT4 Expression in Gliomas Is Dependent on Cell Metabolism. Current Issues in Molecular Biology, 2024, 46, 1107-1120.	2.4	0
5245	Added value of dynamic contrast-enhanced MR imaging in deep learning-based prediction of local recurrence in grade 4 adult-type diffuse gliomas patients. Scientific Reports, 2024, 14, .	3.3	0
5246	Consistency between Primary Uterine Corpus Malignancies and Their Corresponding Patient-Derived Xenograft Models. International Journal of Molecular Sciences, 2024, 25, 1486.	4.1	0
5247	Diagnostic and Theranostic Opportunities in Neuro-Oncology. Advances in Oncology, 2024, 4, 111-124.	0.2	0
5248	Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma. Clinical and Translational Medicine, 2024, 14, .	4.0	0
5249	Identifying IDH-mutant and 1p/19q noncodeleted astrocytomas from nonenhancing gliomas: Manual recognition followed by artificial intelligence recognition. Neuro-Oncology Advances, 2024, 6, .	0.7	0
5250	Brain injury drives optic glioma formation through neuron-glia signaling. Acta Neuropathologica Communications, 2024, 12, .	5.2	0
5251	Computational Pathology for Prediction of Isocitrate Dehydrogenase Gene Mutation from Whole Slide Images in Adult Patients with Diffuse Glioma. American Journal of Pathology, 2024, 194, 747-758.	3.8	0
5252	Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma. NAR Cancer, 2024, 6, .	3.1	0

#	ARTICLE	IF	CITATIONS
5253	Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas. Journal of Neuro-Oncology, 2024, 167, 133-144.	2.9	1
5254	Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings. Neuro-Oncology Advances, 2024, 6, .	0.7	0
5255	Cerebral Neoplasms. IDKD Springer Series, 2024, , 41-48.	0.8	0
5256	<scp>IDH</scp> mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient <scp>IDH</scp>â€mutant astrocytoma <scp>PMMRDIA</scp>: a systematic review. Molecular Oncology, 0, , .	4.6	0
5257	Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype. Journal of Neuro-Oncology, 2024, 167, 99-109.	2.9	0
5258	Cellular signaling in glioblastoma: A molecular and clinical perspective. International Review of Cell and Molecular Biology, 2024, , .	3.2	0
5259	The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma. Journal of Neuro-Oncology, 2024, 167, 75-88.	2.9	0
5261	Systematical identification of key genes and regulatory genetic variants associated with prognosis of esophageal squamous cell carcinoma. Molecular Carcinogenesis, 0, , .	2.7	0
5262	Adult-Type Diffuse Gliomas. , 2023, , 23-54.		0
5263	Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [18F]FET PET, and TSPO PET. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0
5264	TGIF2 is a potential biomarker for diagnosis and prognosis of glioma. Frontiers in Immunology, 0, 15, .	4.8	0
5265	Exploring the potential of nutraceutical to combat gliomas: focus on mIDH2 protein. Frontiers in Physics, 0, 12, .	2.1	0
5266	Proposed novel classification of circumscribed Lower-Grade Gliomas (cLGG) vs. infiltrating Lower-Grade Gliomas (iLGG): Correlations of radiological features and clinical outcomes. World Neurosurgery: X, 2024, 23, 100356.	1.1	0
5267	Metabolic basis of cardiac dysfunction in cancer patients. Current Opinion in Cardiology, 2024, 39, 138-147.	1.8	0
5268	Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations. Pharmaceuticals, 2024, 17, 336.	3.8	0
5269	DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma. Epigenetics, 2024, 19, .	2.7	0
5270	Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers. International Journal of Molecular Sciences, 2024, 25, 3040.	4.1	0
5273	The Impact of Mutational Hotspots on Cancer Survival. Cancers, 2024, 16, 1072.	3.7	0

#	ARTICLE	IF	CITATIONS
5274	Identification and Validation of a PEX5-Dependent Signature for Prognostic Prediction in Glioma. Biomolecules, 2024, 14, 314.	4.0	0
5275	Epigenetic regulation of tumor-immune symbiosis in glioma. Trends in Molecular Medicine, 2024, 30, 429-442.	6.7	0
5276	Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas. Frontiers in Oncology, 0, 14, .	2.8	0
5278	Diffusion- and Perfusion-Weighted MRI Radiomics for Survival Prediction in Patients with Lower-Grade Gliomas. Yonsei Medical Journal, 2024, 65, 283.	2.2	0
5280	IDH1/2 Mutation and MGMT Promoter Methylation â€” the Relevant Survival Predictors in Czech Patients with Brain Gliomas. Folia Biologica, 2016, 62, 194-202.	0.6	0
5281	Machine Learning-Based Prediction of Glioma IDH Gene Mutation Status Using Physio-Metabolic MRI of Oxygen Metabolism and Neovascularization (A Bicenter Study). Cancers, 2024, 16, 1102.	3.7	0
5282	Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Cancers, 2024, 16, 1202.	3.7	0
5283	Current approaches in glioblastoma multiforme immunotherapy. Clinical and Translational Oncology, 0, , .	2.4	0
5284	Identifying key factors for predicting O6-Methylguanine-DNA methyltransferase status in adult patients with diffuse glioma: a multimodal analysis of demographics, radiomics, and MRI by variable Vision Transformer. Neuroradiology, 2024, 66, 761-773.	2.2	0
5285	Motor seizures confer overall survival benefit in who grade 2 glioma. Epilepsia, 0, , .	5.1	0